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Most cancer research is performed with the aim of generating new knowledge 
that leads to benefits such as improved treatments, higher cure rates, and 
better cancer prevention. Evaluating these downstream effects of research, 
often referred to as research impact, is of increasing importance to all cancer 
research stakeholders. There is currently no consensus surrounding the optimal 
way to approach this evaluation. The work in this thesis aimed to address this 
gap by first identifying which approaches to impact assessment have been 
applied previously for cancer research, and in particular for cancer clinical 
trials, and secondly to test a number of these approaches within the context of a 
case study of one cancer clinical trial. The Short Course Oncology Treatment 
(SCOT) trial was chosen for the purposes of the case study.  
SCOT was a phase III randomised controlled trial (RCT) which tested the non-
inferiority of shortening adjuvant treatment for patients with colorectal cancer 
(CRC) from the standard of 6 months to 3 months of doublet chemotherapy. The 
trial met its pre-specified non-inferiority end-point but showed unexpected 
differences in outcome based on the treatment regimen used and stage of 
disease. Specifically, for patients receiving CAPOX (capecitabine and 
oxaliplatin), non-inferiority for 3 months versus 6 months of treatment was met, 
but this was not the case for those treated with FOLFOX (5-fluorouracil and 
oxaliplatin). Similarly, non-inferiority was met for patients with small tumours 
with a small nodal burden (low-risk stage III), but not for those with more 
extensive disease and/or a higher nodal burden (high-risk stage III disease). SCOT 
was the largest contributor to a collaboration of six trials addressing the same 
research question, called the International Duration Evaluation of Adjuvant 
therapy (IDEA).  
A systematic literature review was used to identify methods, frameworks, and 
categories of impact frequently used to perform research impact assessment 
(Chapter 3). This review was also used to identify previous impact assessments 
specific to cancer research. Fourteen empirical examples were identified, 
published between the years 1996 to 2015. These included assessment of 
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research at the cancer project, programme and research centre level. One 
example specifically assessed the impact of a phase III cancer RCT. The methods 
for impact analysis included across these examples included surveys, interviews, 
bibliometric searching of journals and clinical guidelines, economic approaches 
and documentary analysis. The categories of impact most commonly used were 
policy, clinical practice, health and economic impact. The Payback framework 
and the Canadian Academy of Health Sciences (CAHS) framework were utilised to 
collect data and communicate the results of impact assessment in two of these 
examples.   
A second approach was adopted to identify ways that have previously been used 
to assess the impact of cancer clinical trials in particular (Chapter 4). The 
research impact case studies submitted to the United Kingdom government’s 
research performance exercise for universities in 2014 were screened to find 
examples of assessments of the impact of cancer clinical trials. In total, 46 case 
studies describing 110 clinical trials were identified. Many of these trials were 
phase III trials that met their primary endpoint, but earlier phase trials and 
those with negative findings were also impactful. Policy impact was the most 
commonly described downstream effect. There was a gap within these case 
studies in the use of real world evidence to demonstrate the impact of cancer 
trials on clinical practices and health. 
A number of the approaches to impact assessment identified in the literature 
review and in the analysis of the REF 2014 case studies were then tested to 
evaluate the impact of the SCOT Trial. The methods used for this assessment 
included surveys of clinician prescribing practices (Chapter 5), economic 
evaluation of the budget impact of trial results implementation (Chapter 6), and 
interrogation of real world data to explore the clinical practice and potential 
health benefits attributable to the SCOT trial at both a local (Chapter 7) and 
national (Chapter 8) level.   
A clinician survey performed in April 2019 demonstrated a high level of 
awareness of SCOT trial results (Chapter 5), with 98% of those who were aware 
of the trial indicating they had changed their clinical practice based on the trial 
results. This impact on practice was driven mainly by shortening of treatment to 
3 months for patients with low-risk stage III CRC (SCOT non-inferiority met), 
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whereas most clinicians reported they still used 6 months of doublet 
chemotherapy for patients with high-risk stage III disease (SCOT non-inferiority 
not met). This finding aligned with the post-hoc subgroup analysis performed for 
both the SCOT trial and IDEA collaboration. When shortening treatment for this 
subgroup of patients, clinicians mainly used CAPOX, whereas there was a more 
even split between using CAPOX and FOLFOX when 6 months of treatment was 
still used. A follow up survey in August 2020 was performed using a subset of 
respondents to the first survey and showed an increase in the use of shorter (3 
months) treatment for patients with stage III disease with one high-risk feature, 
compared to responses in April 2019. 
The results of the first clinician survey were applied within a budget impact 
analysis (Chapter 6) to estimate the economic impact of implementing SCOT 
trial results in the six countries that recruited to the trial. It was estimated that 
implementation of SCOT trial findings could translate to over $150 million USD 
savings over five years for those 6 healthcare systems (Australia, Denmark, New 
Zealand, Spain, Sweden, UK). Adopting a societal perspective by including 
money lost because patients did not work when receiving longer treatment, as 
well as travel costs to hospital, increased this impact to $340 million USD. 
Adding the monetised quality adjusted life-year (QALY) gains from 
implementation to this calculation ($456 million USD) meant that the gains from 
implementation of SCOT were vastly in excess of the original investment to 
conduct the SCOT trial ($8.8 million USD).  
The final analysis conducted as part of the SCOT case study involved 
examination of individual patient level chemotherapy prescribing data. Using 
local (one health board in Scotland) level data, five different approaches were 
tested to evaluate the impact of the SCOT trial. In this instance, the change in 
practice was obvious even using simple descriptive statistics. Out of the other 
methods tested, interrupted time series analysis (ITSA) was the additional 
method that added the most value; the strengths of the ITSA were the ability to 
visualise the trends in prescribing pre and post-SCOT, as well as the 
counterfactual situation. Focusing on patients prescribed doublet chemotherapy 
(as per the SCOT trial), there was a significant decrease (85% to 31%) in the 
proportion of patients receiving over 3 months of treatment after the SCOT trial 
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results were published (ꭓ2 p<0.001) compared to before this time-point. There 
was no significant change in a comparator group of patients who received 
monotherapy (76% pre-SCOT versus 77% post-SCOT (ꭓ2 p=0.774)). 
In order to evaluate this impact at a national level, it was first necessary to 
establish, for the first time, linkage of chemotherapy prescribing data at a pan-
Scottish level. This process presented several challenges relating to data access, 
resource and infrastructure. Analysis of this data demonstrated a reduction in 
the proportion of patients receiving over 3 months of treatment across cancer 
networks in Scotland, although this change was less marked for patients treated 
in the Northern cancer network because 3 months of treatment was used 
proportionally more in the pre-SCOT period, compared to in the West or South-
East of the country. The change in practice across the country was driven by 
changes for patients receiving CAPOX specifically, rather than FOLFOX or 
monotherapy, again fitting with the SCOT and IDEA subgroup analyses. Change 
was also greater for patients with low-risk rather than high-risk stage III disease, 
mirroring the clinician survey results. Following these in-depth analyses across 
Chapters 5-8, results from the survey, economic evaluation and administrative 
data interrogation were combined and summarised using a number of different 
impact frameworks that had been identified in Chapter 3, including the Payback 
framework.  
This study has demonstrated how cancer research impact has been assessed in 
the past and has tested how impact analysis can be performed specifically for a 
cancer clinical trial. Evaluating the impact of the SCOT trial demonstrated its 
rapid and significant effects on new knowledge, future research, policy, clinical 
practice, and monetary savings for the health service. This assessment also 
allowed reflection on the pathway to these impacts occurring, as well as on how 
future trials could be designed to maximise impact. The study has highlighted 
challenges that currently exist to accessing real world data to investigate cancer 
trial impact. Further research to understand which impacts from clinical trials 
are meaningful to patients and trialists would be useful. More investment by 
funders and governments to support access to healthcare datasets that can be 
used to assess clinical practice change in response to trials would make impact 
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1 Chapter 1: Introduction 
1.1 Rationale 
Research to improve outcomes for patients with cancer and to prevent cancer 
occurring is a priority. Cancer is highly prevalent, with up to one in two people 
likely to have a diagnosis of malignancy in their lifetime (1, 2). Despite current 
treatments, mortality and morbidity remain high (1). Cancer research attracts 
substantial public and charity sector funding. The National Cancer Institute (NCI) 
in the United States of America (USA) had a 2020 budget of over $6 billion United 
States dollars (USD) for cancer research and the same organisation spends over 
$800 million each year specifically on developing and performing cancer trials (3). 
As well as public and charity funds, there is also huge financial investment into 
cancer research, and into cancer trials in particular, from private pharmaceutical 
companies, and the altruistic investment of time and effort from patients who 
participate in these clinical trials. In the United Kingdom (UK) in 2018, over 25,000 
patients were recruited to trials run by one charity (Cancer Research UK (CRUK)) 
alone (4). Many of these patients will experience adverse effects from novel 
treatments tested within trials, without gaining personal benefits in terms of 
improved outcomes (5).  
We live in an era of increasing austerity. In particular, the effect of the 
coronavirus-19 (COVID-19) pandemic on healthcare systems and economies 
worldwide means that now, more than ever, there is scrutiny around how public 
investments will benefit society; this scrutiny applies equally to investment in 
research. It is reasonable to question if research is leading to the real world 
benefits expected and to query the opportunity cost of not spending the same 
money directly within other public sectors such as health and social care, the 
environment, or education (6-8). These wider, real-life benefits from research on 
society are often referred to as ‘research impact’.  
In the UK, the concept of assessing the impact from research has been put under 
the spotlight within the academic community because of a government funding 
allocation process known as the Research Excellence Framework (REF)(9). The REF 
is an assessment exercise used by the UK government to allocate core funding to 
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universities. The demonstration of wider impacts from research the universities 
perform is a substantial component of that assessment. 
The impact from cancer research and cancer clinical trials in particular, will be 
important to patients who participate in these trials and the charities and 
companies who invest in them. It can be assumed that charities will want to 
understand why investment in research, rather than other endeavours such as 
direct care for the populations they support, is worthwhile. Even pharmaceutical 
companies will have a limited budget and will be mindful of the value of investing 
in one research endeavour over another. In light of the REF, cancer trial impact 
will also be of interest to universities who sponsor and support cancer clinical 
trials.  In order to understand the impact of any research, it is first necessary to 
know how to evaluate this impact. It is only with a clearer understanding of 
approaches to assessment that the impact of cancer research and cancer trials 
can be maximised.  
 
1.2 Research impact evaluation 
1.2.1 Definition of research  
Research can be defined as ‘systematic investigation or inquiry aimed at 
contributing to knowledge of a theory or topic by careful consideration, 
observation or study of a subject.’ (Oxford Dictionary (10)) 
Clinical trials performed within the field of oncology are a type of research and 
for the purposes of this thesis are referred to as cancer trials. Cancer trials are 
clinical trials using the recruitment of human subjects for the purposes of 
investigating the diagnosis or screening of malignancy, or treatment and 
management of individuals with a diagnosis of malignancy. 
1.2.2 History of research impact evaluation 
The interest in evaluating research impact has been rising, partly driven by the 
actions of national bodies and governments. Traditionally, assessments of 
research output and quality were directed at measuring scholarly and academic 
influence, and the ability to measure this aspect of research output was helped 
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by  the rise of bibliometrics in the 1960s and the discovery of the internet (11). In 
contrast to the concept of assessing scholarly merit alone, the term research 
impact, referring to the wider impact of research on society, emerged in the 1990s 
and 2000s (12).   
The academic community have been conducting research to explore which 
approaches are suitable for evaluating and communicating research impact 
outside government driven assessment exercises. Specifically, there has been a 
rise in academic literature investigating research impact assessment over the past 
decade. The results of the Definitions, Evidence and Structures to Capture 
Research Impacts and Benefits (DESCRIBE) (12) study identified that the research 
impact literature went through a rapid phase of development from 2010 onwards 
and entered the end of an initial phase of understanding the concepts around 
research impact assessment around 2013. This coincided with the formation of the 
International School of Research Impact Assessment (ISRIA), set up by a small 
network of researchers located in the UK, Canada and Spain. The purpose of ISRIA 
was to teach individuals to assess research investments and activities, with the 
aim of optimising returns from research. The organisation achieved this aim by 
holding a series of international workshops from 2013-2017 and published a set of 
guidelines in 2018 to summarise the findings from these workshops (13). Even in 
2018, the authors of this report recognised that the practice of research impact 
assessment was still in its formative stages, without any accepted standards or 
recommendations around how research impact assessment should be performed. 
Although the research evaluation community have been assessing research impact 
since the 1990s, it was not until the 2000s that the interest in assessing the wider 
impact of research on society arose, driven by national governments and research 
institutions. At that time, the Australian Government developed a Research 
Quality Framework (RQF) to assess the quality of research performed within 
academic institutions in Australia (14). This framework assessed both academic 
outputs and broader impact, defined as ‘the recognition by qualified end-users 
that quality research has been successfully applied.’ The plans for the RQF 
specified that research impact would be evaluated via impact statements 
generated by universities, which would be assessed by a panel of experts. 
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Although the RFQ was scheduled to be implemented in 2009, this was abandoned 
by a change in government in 2007.  
Although not implemented, the development of the RQF signalled a shift in focus 
by national institutions globally, with an increased emphasis on the returns to 
society from the research they were funding and performing. In the UK, the 
Research Assessment Exercise (RAE) had been used since 1986 to measure the 
quality of research performed by higher education institutions. The RAE focused 
on traditional measures of academic merit such as publications and the 
corresponding impact factors of the journals of publication, the university 
environment, and research infrastructure. In 2008, the UK government piloted an 
assessment of research impact, with the definition and the methods for evaluation 
explicitly influenced by the Australian RQF, as well as by work performed by UK 
academics (Brunel University) who were exploring ways to evaluate impact using 
a case-study approach (15). Formal adoption of impact assessment into the UK 
national evaluation in 2014 led to the establishment of what is now known as the 
REF (16).  
In the REF 2014, impact was evaluated using peer-reviewed case studies under 
four main disciplines of research. The first (panel A) included clinical medicine 
and biological sciences, the second (panel B) included physical and earth sciences, 
the third (panel C) included economics, law and politics, and the last (panel D) 
included the arts, languages, and music. The impact case studies generated by 
universities were read and scored from 1-4 by expert reviewers. The higher the 
score allocated to each impact case study, the more research funding that the 
higher education institution submitting the case study received from the 
government. Although the individual scores given to each impact case study have 
not been published, several institutions have analysed their own submissions to 
better understand the indicators of impact and approaches to impact evaluation 
that led to their case studies achieving higher scores (17-19). In 2014, impact case 
studies were worth 20% of £2 billion annual funding allocated to UK universities. 
The assessment is being repeated in 2021, with a higher proportion of funds (25%) 




Although their 2007 government rejected impact assessment, the Australian 
government recently performed its inaugural engagement and impact assessment 
(EI) (20). The main rationale behind the EI was to serve as a mechanism to show 
the government and the public how investment in university research in Australia 
is being translated into tangible benefits beyond academia, such as economic, 
environment, social, and cultural impacts. A major similarity between the EI and 
the REF is the use of impact narrative case studies that are scored by a panel of 
experts. In the EI, a score is allocated to the case study not only for the impact 
evidenced, but also for the efforts made by the university to translate their 
research to impact. Other countries have also made efforts to evaluate impact at 
a national level. For example, in Canada, the Canadian Academy of Health 
Sciences (CAHS) framework was developed in 2009 (21) by an expert panel and 
sponsored by multiple Canadian and international research foundations with the 
intention that it would be used by all funders of health research in Canada for 
evaluation of their health research impacts. More recently, a white paper from 
the Canadian Health Services and Policy Research Alliance (22) provided updated 
guidance on how research impact should be approached.   
Research impact is also important in other sectors. For example, private 
pharmaceutical companies prioritise the intellectual property rights associated 
with patent policy, market exclusivity to new medications, stakeholder 
investment, and drug sales as key drivers of their work and investment. As an 
example, the first line of the annual report from a well-known pharmaceutical 
company (AstraZeneca) in 2020 mentioned “double-digit revenue growth to 
leverage improved profitability and cash generation” (23). Despite this focus on 
monetary gains, the mission statement of the same pharmaceutical company 
states that their aim is to “create a meaningful difference in the lives of patients”. 
It is therefore clear that wider, longer terms impacts on health are important to 
the pharmaceutical industry. It is not yet clear how AstraZeneca, or other 
pharmaceutical companies, are evaluating their goal of improving health, or what 
other impacts they are prioritising.  
Third sector institutions such as charities are also facing increasing expectations 
to demonstrate the impact of their work and there are now several companies 
offering guidance and services to help charities with this endeavour (24, 25). 
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Despite this guidance, it is again not clear from looking at public facing 
information from charities, how or when this impact evaluation is being 
performed. A recent review of the academic literature on this topic identified 
only thirteen published examples of impact assessment of charity and public 
research investment (26). If these evaluations are not being communicated to 
either the public or the academic community, this raises the question as to 
whether they are being undertaken. Improved transparency in this regard would 
provide greater insight into how the third sector are approaching the topic of 
research impact evaluation. 
1.2.3 Rationale for conducting research impact evaluation 
Undertaking an assessment of research impact requires time and investment, 
therefore it is useful to consider why conducting such an assessment may be 
worthwhile. The purpose of any research impact assessment will also dictate the 
type of evaluation methodology that is used. The rationale for research impact 
assessment has commonly been divided into four main categories, known 
collectively as the “4 As” (27). These are: advocacy, accountability, analysis and 
allocation.  
First, research funders and providers may want to use research impact evaluation 
to advocate for ongoing or increased investment for their work. Secondly, 
researchers and institutions may want to show accountability to their stakeholders 
by demonstrating that research conducted using funder investment has been 
worthwhile and aligns with the mission statement for that investor. Another 
reason to perform impact evaluation is driven by a desire to analyse if, why and 
how, impact occurs. Finally, research impact assessment can be used to guide 
prospective allocation of funding for future research endeavours. Of course, these 
reasons for conducting impact assessment are not mutually exclusive and impact 
evaluation could be performed for more than one reason. 
1.2.4 Definition of research impact 
Although research impact is a term frequently used in the literature, to date there 
is no consensus around what this encompasses, and several definitions exist. 
Penfield et al (28) have identified that different definitions may be relevant 
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depending on the purpose of evaluating research impact, the target audience, and 
users of the research in question. In their review of the literature, Alla et al (29) 
found 108 definitions of research impact, most of which (76%) had been 
constructed by research institutions and funders. These definitions included those 
based on bibliometric evaluation and use-based definitions.  
Bibliometric based definitions identified by Alla et al (29) focused on quantifiable 
effects from research, usually related to how the research is cited in the academic 
literature. These definitions are often considered to reflect a narrow 
interpretation of research impact that aligns with a traditional concept of 
scholarly influence. The research governance definitions of research impact 
identified by Alla and colleagues mainly focused on the contribution or benefit of 
research to society and the economy. Examples included definitions from the 
Research Councils UK (RCUK) (30), and the UK REF assessment (31).  
The RCRUK (30) defines research impact as: 
        “Academic impact 
The demonstrable contribution that excellent research makes to 
academic advances, across and within disciplines, including significant 
advances in understanding, methods, theory, and application. 
Economic and societal impacts 
The demonstrable contribution that excellent research makes to 
society and the economy. Economic and societal impacts embrace all 
the extremely diverse ways in which research-related knowledge and 
skills benefit individuals, organisations, and nations by: 
fostering global economic performance, and specifically the economic 
competitiveness of the United Kingdom, 
increasing the effectiveness of public services and policy, 
enhancing quality of life, health and creative output.” 
The definition used for the purposes of the REF (31) is:  
"an effect on, change or benefit to the economy, society, culture, 





An important distinction between these two definitions is that the former includes 
academic influence from research whereas the REF definition specifically excludes 
academic impact and only includes wider, downstream changes. Secondly, the 
RCUK definition focuses on the contribution of research to impacts on society and 
the economy, whereas the REF definition focuses more on the outcomes or effects 
from that research (29). This demonstrates a difference in the importance placed 
on whether impact occurs and the extent of impact (REF), versus the process 
through which impact takes place and the efforts adopted by institutions and 
researchers to maximise that impact (RCUK). This also aligns with the different 
perspectives adopted by the UK versus Australian governments in their national 
research performance assessment exercises.  
Lastly, use-based definitions identified in Alla et al’s review focused on the way 
research is utilised and how research findings are adopted by stakeholders. In this 
context, Lavis et al (32) have provided a classification to explain how research 
can be used. They distil the use of research into three main processes: 
instrumental use, conceptual use, and symbolic use. Instrumental use describes 
acting on research findings in a specific way to solve a particular problem and 
often constitutes the most obvious example of research impact. Conceptual use is 
the indirect use of research as a form of enlightenment. Symbolic use of research 
is not to inform decision making, but instead to justify a position of action or 
inaction that has already been taken. Although all types of research use could 
contribute to research impact as defined by the RCUK and the REF, examples of 
instrumental use of research to produce specific impacts will most closely align 
with the outputs based definition from the REF. Indeed, a criticism of the REF 
definition is that it prioritises examples of direct impact over indirect processes, 
which may be symbolic or conceptual.  
1.2.5 Definitions relevant to research impact evaluation 
The ISRIA guidelines (13) include several terms that are used throughout the 
research impact literature and will be used in this thesis. These are outlined in 




Table 1-1 Terms relevant to the research impact literature 
Term Definition 
Indicator of impact A description of what is being evaluated to indicate research 
impact. For example, number of lives saved, influence on patient 
views and attitudes, improvement in health literacy. Indicators 
of impact can be quantitative or qualitative measures. The term 
impact metric is often used to describe purely quantitative 
indicators of impact.  
Methods for impact 
evaluation 
Ways to collect or analyse data for the purposes of a research 
impact evaluation. 
Categories  Types of impacts evaluated that are classified under common 
headings, for example, environmental impact or health impact. 
Domains Domains can be used as an alternative to categories of impact. 
Alla et al (29) use the term domains in a broader sense when they 
are describing definitions of research impact and the category of 
impact is just one of those domains. Other domains include the 
avenues of impact which are the processes through which 




A schema or structure that guides how to collect, analyse and 
communicate data for the purposes of a research impact 
assessment. The constituents of a framework will depend on the 
philosophical assumptions underlying the approach to knowledge, 
and how impact occurs.  
Outputs Often used to refer to the immediate results or direct benefits 
arising from research, for example, the results from a research 
project.  
Outcomes Often used to refer to benefits or changes resulting from research 
that do not occur immediately and imply a longer-term process.  
 
1.2.6 Overlap between implementation science and impact 
evaluation  
Implementation science can be defined as ‘the scientific study of methods to 
promote the systematic uptake of research findings and other evidence based 
practices into routine practice, and hence, to improve the quality and 
effectiveness of health services (33)’. The study of implementation has 
similarities to research impact evaluation, especially evaluation of the impact of 
health research, because a major part of how health research impacts society is 
through implementation of research findings (34). This is especially relevant for 
clinical trials that are an applied form of research. 
One of the major reasons for conducting both impact evaluation and 
implementation studies is to understand if the expected downstream effects 
from research and research funding are being realised. There will also be 
overlap between the two disciplines in terms of the methods. Where they differ 
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is that investigation of if, and how, research has been implemented may or may 
not be one component of an impact evaluation. In contrast, within 
implementation science, the core aim of any assessment is to evaluate in detail 
the barriers to and facilitators for the translation of evidence into practice. The 
funder of a research project may use impact assessment to understand the value 
of their investment whereas the stakeholder for an implementation study may 
be a healthcare provider who is trying to run a health service as efficiently as 
possible by ensuring practice is evidence based.  
This overlap between implementation science and the field of impact 
assessment was recently recognised formally at an international convention of 
researchers who are interested in impact assessment (35). The summit was 
called: ‘In the Trenches: Implementation to Impact International Summit’, and 
one of the key aims was to advance the science of implementation and impact 
by engaging in interdisciplinary dialogue. In the conference proceedings, the 
authors highlight that one way to achieve research impact is by implementation 
of research findings.  
1.2.7 Cancer research, clinical trials and research impact 
assessment 
Cancer research covers a vast array of activities, including basic laboratory 
studies, prospective or retrospective clinical projects at an individual patient 
level, or population based research. Cancer trials are an important example of 
applied, clinical research and as such, are an important mechanism through which 
new knowledge regarding the optimal management of patients will emerge.  
Cancer trials are commonly described by the phase of the trial, the types of 
intervention being evaluating or the funding source. Phase I trials describe the 
early investigation of the use of novel therapies in humans, whereas phase II trials 
investigate the efficacy of treatments in the relevant disease area. Phase III trials 
are often large, randomised trials that compare the efficacy of novel treatments 
compared to a standard of care, and phase IV trials investigate the effectiveness 
of a therapy in practice after it has been shown to be at least as efficacious as the 
current standard of care and approved for use in the patient population.  
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The primary outcome investigated within cancer trials will often align with the 
phase of the trial. For example, commonly assessed endpoints for a phase I trial 
include measurement of the safety of a novel drug or a recommended dose of the 
drug to take forward for further testing in phase II trials (36). In phase II trials, 
the primary outcome often relates to efficacy of a treatment in a particular 
patient population without a specific comparator treatment (36). Phase III trials, 
which nearly always randomly allocate patients to treatments, commonly have 
primary outcomes that compare the efficacy of a treatment to a recognised 
standard treatment. The endpoint of a phase III trial can assess whether the novel 
treatment being tested is better than the current standard, which may include no 
active treatment/placebo (superiority trial), if the new treatment is equivalent 
(equivalence trial) or if the new therapy is not significantly worse than the 
standard of care (non-inferiority trial).  
For superiority trials, the null hypothesis is that there is no difference between 
the treatments being tested. In equivalence trials, the difference between two 
treatments is pre-defined as “∆” and the objective of the trial is to demonstrate 
that the treatments are equivalent, with the difference in confidence intervals 
for the treatment effect not exceeding -∆ and +∆. For non-inferiority trials, the 
aim is to demonstrate that a treatment is not unacceptably worse than the 
standard of care. The treatment may be inferior, but as long as not unacceptably 
so. The acceptable margin of inferiority is defined in advance as ∆, and non-
inferiority can be claimed if the lower boundary of the confidence interval of the 
treatment effect does not exceed -∆ (37). Often the treatment being compared 
to the standard of care in a non-inferiority trial has other benefits such as shorter 
treatment and/or reduced toxicity or cost.  
The types of intervention being assessed in a cancer trial can vary from those 
directed at screening for malignancy, improved diagnostics, cancer treatments, 
assessment of the prevention of cancer, the natural history of how cancer 
develops, or improving the quality of life or palliation for patients with a diagnosis 
of malignancy (38). Cancer treatments can include investigational medicinal 
products, radiotherapy, surgery, or medical devices. Finally, the funding received 
to support trial set-up and delivery can, for example, be provided by 
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pharmaceutical companies, charities, academic institutions or a combination of 
these sources.   
Cancer research funders, such as charities and government bodies, have shown 
interest in evaluating the impact of cancer trials. In 2014, CRUK commissioned a 
project to estimate the return to the UK economy from the £15 billion spent on 
cancer research between the years 1970 to 2009 (39). The results of this report 
were disseminated specifically to Members of Parliament (40). Despite interest in 
the topic, there is minimal accompanying guidance from cancer funders into how 
the evaluation of the impact of cancer research can be performed on a routine 
basis. 
1.2.8 Summary 
In summary, several definitions of research impact exist and the approach to 
evaluation will depend on the definition used, the stakeholder conducting the 
evaluation, the type of research being assessed, and the rationale for conducting 
impact evaluation. Acknowledging this issue, for the purposes of this thesis, 
research impact includes academic and wider impacts, neutral (effect) or positive 
(benefit) impacts, and those occurring through direct or indirect processes.  
There is transparency needed in the methods used to assess impact in order for 
the value of the impact to be analysed and understood. Although research impact 
assessment has emerged formally as a recognised type of evaluation over the past 
decade, there is no standardised approach to assessment. One of the aims of this 
study is to reflect on approaches that may be suitably applied in particular to the 
evaluation of the impact of cancer trials. One large clinical trial (the Short Course 
Oncology Treatment (SCOT) trial, European Union Drug Regulating Authorities 
Clinical Trials Database (EudraCT) number 2007-003957-10 and National Clinical 
Trials (NCT) number 00749450) (41)) has been selected as a case study to explore 
and test various approaches to impact evaluation. This trial is discussed in more 
detail below.  
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1.3 The SCOT trial  
1.3.1 Background 
Although surgery is performed with curative intent in patients with stage II and 
stage III CRC, 40-50% of patients with stage III colorectal cancer (CRC) and at 
least 20% of patients with stage II CRC will experience disease relapse due to 
clinically occult micro metastatic disease present at the time of surgery (42). 
Adjuvant chemotherapy is used after surgery to reduce the risk of relapse, 
improve survival, and increase the chance of cure. The SCOT trial investigated 
the optimal duration of adjuvant chemotherapy for patients with a diagnosis of 
high-risk stage II or stage III CRC. Patients with stage II disease were defined as 
having high-risk disease if they had one or more of the following disease 
features: T4 disease, tumour obstruction with or without perforation of the 
primary tumour preoperatively, fewer than ten lymph nodes harvested, poorly 
differentiated histology, perineural invasion, or extramural venous or lymphatic 
vascular invasion. These features were in line with findings from the Multicenter 
international study of oxaliplatin/5-fluorouracil-LV in the adjuvant treatment of 
colon cancer (MOSAIC) trial (National Clinical Trial (NCT) number 00275210) (43), 
which identified a group of patients with stage II disease who benefited most 
from doublet chemotherapy in the adjuvant setting. Individuals included in the 
SCOT trial were fit (World Health Organisation (WHO) performance status 0 or 1) 
and aged over 18 years (44). 
1.3.2 Clinical trial evidence prior to SCOT 
1.3.2.1 Overview of previous studies 
At the time the SCOT trial was developed, 6 months of adjuvant fluoropyrimidine-
oxaliplatin doublet chemotherapy was a recognised standard of care for patients 
with CRC based on the results of several previous clinical trials (43, 45-58) which 
are summarised in Figure 1-1. The common medications and drug doses used 





Figure 1-1 Clinical trials investigating the optimal treatment for patients with CRC in the 
adjuvant setting Abbreviations: FU, fluorouracil; LEV, levasimole; CRC, colorectal cancer; 
DFS, disease free survival; OS, overall survival; vs, versus; MOF, 5-fluorouracil, vincristine 
and semustine chemotherapy; BCG, Bacillus Clamette-Guerin; FOLFOX, 5-fluorouracil and 
oxaliplatin chemotherapy; CAPOX, capecitabine and oxaliplatin chemotherapy; m, months; 
LV, leucovorin; NSABP, National Surgical Adjuvant Breast and Bowel Project; MOSAIC, Multi-
center International Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer, 
RFS, recurrence free survival, IMPACT, Multi-Center Pooled Analysis of Colon Cancer Trials; 
INT, intergroup; X-ACT, Xeloda in Adjuvant Colon Cancer Therapy; SAFFA, Short Adjuvant 
Fluorouraci and Folinic Acid; QUASAR, Quick And Simple And Reliable; GERCOR, Groupe 
Cooperateur Multidisciplinaire en Oncologie. 
  
 





1988 NSABPC-01Trial (Stage II/III Colon)45 
(Observation) vs (MOF chemotherapy) vs (BCG)  
Improved DFS and OS with chemotherapy vs 
observation. Improved OS, not DFS with BCG. 
  
1989 Laurie et al (Stage II/III CRC)46 
(Observation) vs (12m FU+LEV) vs (12m LEV)  
Reduced recurrence for patients in FU+LEV and LEV 
arms. Borderline OS benefit for stage III FU+LEV.  1990 INT-0035 Trial (Stage II/III Colon)47 
(Observation) vs (12m FU+LEV) vs (LEV)  
Stage III: FU+LEV reduced recurrence and death rate. 
Nil benefit LEV. Stage II:  reduced recurrence FU+LEV 
but no OS gain. 
1999 NSABPC-04 Trial (Stage II/III Colon)50 
(12m FU+LEV) vs (12m FU+ LV)vs(12mFU+LEV+LV) 
FU+LV increased 5 year DFS and increased OS vs 
FU+LEV. No difference in DFS/OS adding LEV. 
        1995 IMPACT (Stage II/III Colon)48 
                  (6m FU+LV) vs (observation) 
FU+LV provides DFS and OS benefit. 
       1998 O’Connell (Stage II/III Colon)49 
             (6m FU+LEV) vs (6m FU+LEV+LV)vs 
             (12m FU+LEV) vs (12m FU+LEV+LV) 
No benefit of 12m versus 6m. When 6m given, LEV only 
was inferior to LEV+LV. 
       2004 MOSAIC (Stage II/III Colon)43 
                  (6m FOLFOX) vs (6m FU+ LV) 
FOLFOX increased DFS. 
NCT00275210 
    2005 GERCOR C96 (Stage II/III Colon)57 
                 (6m FU bolus) vs (6m FU infusion)  
            vs (12m FU bolus) vs (12m FU infusion) 
Similar DFS for both regimens and durations 
       2007 QUASAR (Stage II/III CRC)55 
                  (6m FU + folinic acid) vs (observation) 
Recurrence and risk of death reduced with FOLFOX. 
NCT00005586 
       2005 SAFFA (Stage II/III CRC)51 
                  6m bolus FU vs 3m infusional FU 
No significant difference in OS. Trend to better OS and 
RFS for 3m infusional FU. 
       2005 X-ACT (Stage III Colon)53 
                  (6m capecitabine) vs (6m FU bolus) 
DFS and OS at least equivalent. Improved relapse free 
survival and less adverse events with capecitabine. 
       2005 INT-0089 (Stage II/III Colon)52 
                 Testing doses of LV with FU (6m) 
No significant difference in OS or DFS between arms. 
   2007 NSABP C-07 (Stage II/III Colon)54,56 
                         (6m FLOX) vs (FU) 
                   Improved DFS using FLOX. 
                                NCT00004931 
 
       2011 NO16968 (Stage III Colon)58 
                  (6m CAPOX) vs (bolus FU/LV) 





In the 1980s, several therapeutic agents were trialled in the adjuvant setting for 
treatment of CRC (59), and by the end of the decade, it had been demonstrated 
that one year of intravenous 5-fluorouracil (5-FU), in combination with levamisole, 
offered survival benefits compared to observation alone (47). In the 1990s, several 
trials demonstrated that 5-FU/low-dose leucovorin was as effective as 5-FU/high 
dose leucovorin (52), 6 months of 5-FU with folinic acid/leucovorin was at least 
as effective as one year of treatment (48, 49) and that adding levamisole did not 
confer any extra benefit (49, 50). 
During this time, bolus administration was used to deliver 5-FU and leucovorin, 
and monthly (Mayo) versus weekly (Roswell Park) bolus regimens were shown to 
be equally effective (59). In 2000, an oral form of fluoropyrimidine (capecitabine) 
was shown to be at least as effective as, and less toxic compared to bolus 5-FU 
when used in the adjuvant setting for treatment of colon cancer (53). Around the 
same time, there was increasing evidence that using two weekly infusional 
(FULV2), rather than bolus FU/LV, had comparable efficacy and less toxicity to 
the bolus regimens which had been traditionally used (57, 60).  
Lastly, an important trial in relation to the hypothesis tested in SCOT was the UK 
Short Adjuvant Fluorouracil and Folinic Acid (SAFFA) trial, which compared 3 
months of infusional 5-FU to 6 months of bolus Mayo clinic regimen (51). This trial 
was not large enough to test for non-inferiority but did suggest a trend for 
improved disease free survival (DFS) and overall survival (OS), and less toxicity, 
with the shorter infusional regimen. The authors of this trial concluded that the 
probability of 3 months of infusional 5-FU being inferior to 6 months of bolus 
treatment was highly unlikely and that the shorter duration of treatment merited 
further exploration.  
In the 2000s, additional agents, such as irinotecan, bevacizumab, and cetuximab, 
were added to fluoropyrimidine monotherapy, but failed to significantly improve 
survival outcomes (61). However, the addition of oxaliplatin to 6 months of 
fluoropyrimidine was tested in three trials with success (43, 54, 58, 62). Each of 
these trials demonstrated that using doublet fluoropyrimidine-oxaliplatin 
chemotherapy conferred DFS and OS benefits compared to fluoropyrimidine 
monotherapy alone for patients with stage III colon cancer.  
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1.3.2.2 Previous evidence specific to patients with stage II colon cancer 
The SCOT trial was set-up in the late 2000s. At that time, it was known that 
adjuvant fluoropyrimidine monotherapy conferred a survival benefit for patients 
with stage II and stage III colon cancer. Although it was also known that 6 months 
of fluoropyrimidine-oxaliplatin doublet treatment improved survival for patients 
with stage III disease, it was still not clear if doublet treatment conferred survival 
benefit for those with stage II disease; the long-term outcomes from important 
trials such as MOSAIC were awaited (56, 63). Whilst these trial results were still 
outstanding, patients with stage II disease were included within the SCOT trial. 
Subsequently, longer-term follow up from MOSAIC (reported in 2015) did not 
confirm a statistically significant 5-year DFS or 6-year OS improvement for patients 
with stage II disease with the addition of oxaliplatin versus fluoropyrimidine alone 
(63). 
1.3.2.3 Previous evidence specific to patients with rectal cancer 
In addition to patients with colon cancer, individuals with a diagnosis of rectal 
cancer were recruited to SCOT. A Cochrane review published in 2012, which 
pooled data from over 21 clinical trials (n>10,000), reported a significant DFS and 
OS benefit from giving fluoropyrimidine based adjuvant chemotherapy to patients 
with rectal cancer (64). Important limitations to this review included the 
heterogeneity of disease stages included and the fact that these trials were 
conducted over a long time-period, during which surgical resection for rectal 
cancer significantly improved. Also, several trials included in the Cochrane review 
combined adjuvant chemotherapy with radiotherapy, making it difficult to 
ascertain the benefit of chemotherapy treatment alone.  
1.3.2.4 Previous evidence specific to older patients 
There are no randomised trials specifically investigating the benefits of adjuvant 
chemotherapy for elderly patients with CRC. Pooled analyses of colon cancer 
trials have shown the same benefit from using adjuvant fluoropyrimidine 
monotherapy in patients above or below 70 years. A systematic review (65) 
which included the MOSAIC (66), NSABP C-07 (56) and XELOXA (62) trials 
demonstrated increased toxicity from doublet treatment, but no benefit from 
adding oxaliplatin to fluoropyrimidine therapy for patients over 70. In contrast, 
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other pooled analyses including more recent trials (67-69) have shown the 
benefit from adding oxaliplatin is present regardless of age, although less so for 
those aged 70 and over. Overall, the benefits for older patients receiving 
chemotherapy are similar to younger patients with regards time to recurrence, 
but are less for DFS and OS, implying that elderly patients may have the same 
recurrence reduction but cannot derive the benefit in terms of survival due to 
competing co-morbidities and poorer survival (70).  
1.3.3 SCOT: the clinical question and trial design 
The SCOT trial was a phase III, multi-centre, international, non-inferiority trial 
that compared 3 versus 6 months of adjuvant chemotherapy for patients with a 
diagnosis of colorectal cancer (CRC). When the SCOT trial was designed, it was 
recognised that the side effects of 6 months of treatment were often debilitating, 
and could be permanent. In particular, oxaliplatin chemotherapy caused sustained 
peripheral neuropathy in a substantial (>15%) proportion of patients, many of 
whom would be cured from their primary cancer (71-74). It was hypothesised that 
shorter treatment that is not unacceptably worse in terms of efficacy, may lead 
to reduced toxicity. As well as the clinical question, the trial included an economic 
analysis built into the study design to ensure that potential cost-effectiveness of 
the treatments tested were assessed. The full trial details are published in peer 
reviewed journals (41, 75, 76).  
The primary endpoint for SCOT was non-inferiority of 3-year DFS. DFS was defined 
as the time from randomisation to relapse, development of a new CRC, or death 
from any cause. The estimated 3-year DFS for the standard 6 months of treatment 
was 78%, based on the use of 6 months of 5-fluorouracil-oxaliplatin (FOLFOX) 
chemotherapy within the MOSAIC trial. The pre-defined 3-year DFS difference 
between the two treatments (assuming shorter treatment would have worse 
efficacy) that was deemed clinically acceptable was 2.5%, that is, 3 months would 
not be unacceptably worse if at least half of the benefit from adding oxaliplatin 
to fluoropyrimidine monotherapy demonstrated in the MOSAIC trial was 
maintained (3-year DFS for monotherapy was 73%). This maximally acceptable 
drop in efficacy corresponded to a hazard ratio for death of 1.13 and the planned 
recruitment was 9,500 patients. Secondary endpoints included OS, toxicity, and 
cost-effectiveness. The fluoropyrimidine-oxaliplatin doublet permitted was either 
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CAPOX (capecitabine-oxaliplatin) or mFOLFOX6, and the choice of which regimen 
to use was at the discretion of the treating clinician, on the assumption that there 
was no difference in efficacy between these two regimens that deliver the same 
drugs in different formulations (77).  
1.3.4 SCOT trial results 
1.3.4.1 Patient information 
The SCOT trial recruited 6,088 patients from 244 centres in six countries 
between March 2008 and November 2013. This was less than the target of 9,500 
patients due to slow accrual and therefore the study had 66% power rather than 
90% power for rejecting the null hypothesis. The majority of patients were 
recruited from the UK (n=5,244), followed by Denmark (n=311), Spain (n=237), 
Australia (n=197), Sweden (n=83) and New Zealand (n=16). Median follow up in 
both groups was 37 months (Inter quartile range (IQR) 36-49) and 787 patients 
had died at the time of cut-off for the primary analysis in December 2016. In 
total, 23 patients did not consent for their data to be used after randomisation, 
therefore analysis was conducted on 6,055 patients, 3,035 in the 3 month arm 
and 3,030 in the 6 month arm, on an intention to treat basis. Baseline 
demographics were balanced, with median age 65 years (IQR 58-70) and a 
female to male ratio of 39%:61% in both trial arms. Overall, approximately two 
thirds of patients received CAPOX and one third received FOLFOX according to 
clinician preference. 
1.3.4.2 Main effectiveness results 
The SCOT trial met its primary endpoint and demonstrated that 3 months of 
adjuvant doublet chemotherapy was non-inferior to using 6 months of treatment 
in the overall trial population. In the 3-month arm, 3-year DFS was 76.7% (95% 
confidence interval (CI) 75.1-78.2) compared to 77.1% (95% CI 75.6-78.6) in the 6-
month arm (0.4% absolute difference). The pre-specified non-inferiority margin of 
an upper CI of 1.13 was met (HR 1.006 (0.909-1.114)), test for non-inferiority 




Figure 1-2 Kaplan-Meier curve showing 3 year DFS by study group This diagram has been 
taken directly from the original SCOT trial results publication (41). 
1.3.4.3 Toxicity results 
Side effects for patients receiving 3 months of treatment were significantly 
reduced compared to patients in the 6-month arm. The frequency of grade 3–5 
diarrhoea (p=0.033), neutropenia (p=0.031), pain (p=0.014), hand-foot syndrome 
(p=0.031), and sensory neuropathy (p<0.0001) was significantly higher in the 6 
month group than in the 3 month group. In particular, the percentage of 
patients suffering from Grade 2 or greater peripheral neuropathy during and up 
to one month after treatment was less than half (25% vs 58%). Information from 
neuropathy specific questionnaires completed by patients throughout follow-up 
demonstrated that higher symptoms of neuropathy in the 6 versus 3-month arm 
lasted up to 5 years post-treatment (Figure 7 in (41)). 
1.3.4.4 Subgroup analysis   
Analysis of 3-year DFS by stratification factors (Figure 1-3) revealed unexpected 
heterogeneity in outcome dependent on the choice of chemotherapy regimen 




Figure 1-3 Forest plot showing DFS by stratification factors and timing of randomisation. 
This diagram has been taken directly from the original SCOT trial results publication (41). 
Consequently the authors performed a post-hoc analysis to investigate this 
difference. The Kaplan-Meier curves for DFS for patients who received CAPOX 
compared to those who received FOLFOX are shown in Figure 1-4. Non-inferiority 
using 3-months versus 6-months was demonstrated for CAPOX (p=0.0020) but not 
for FOLFOX. Explanations put forward for this unexpected difference include the 
different oxaliplatin doses and dose density of fluoropyrimidine used in the two 
regimens, (78) and/or intrinsic differences in the tumour microenvironment that 




Figure 1-4 Kaplan-Meier curves showing DFS by study group for patients receiving A CAPOX 
and B FOLFOX This diagram has been taken directly from the original SCOT trial results 
publication (41). 
A post-hoc analysis was also performed by separating stage III disease into two risk 
groups: low-risk (T1-3N1 disease) and high-risk (T4 or N2 or both). For patients in 
the low-risk group, 3 months of treatment was non-inferior to 6 months, but this 




Figure 1-5 Kaplan-Meier curves showing DFS by study group for patients receiving A T1-3N1 
disease and B T4N2 disease This diagram has been taken directly from the original SCOT trial 
results publication (41). 
Although not yet published in full, SCOT trial results specifically for patients 
with stage II disease with high-risk features were presented at a special session 
at ESMO 2019. Non-inferiority was not met for this subgroup in the overall 
population. The clinical difference in 3 year DFS for 3 versus 6 months of 
treatment was small when CAPOX was used (1.4% difference). Table 1-2 outlines 
the 3 year DFS results for the SCOT overall study group and for the subgroups 




Table 1-2 Three year DFS for overall SCOT trial study group and by regimen and stage 
subgroups *Non-inferiority of 3 versus 6 months met according to pre-specified boundary 
for the SCOT trial. NR: Not recorded.  















79.2% (76.6%-81.8%) 1.158  
(0.964-1.391) 
0.590 




84.0% (80.6%-87.5%) 0.908  
(0.750-1.098) 
0.012 




64.8% (62.0%-67.7%) 1.068  
(0.934-1.222) 
0.200 




82.9% (80.4%-85.5%) NR NR 




86.3% (83.0%-89.6%) NR NR 
CAPOX High-risk Stage III 
(T4 or N2) 
62.1% (58.6%-
65.6%) 
63.4% (59.9%-66.9%) NR NR 
FOLFOX  High-risk Stage 
III 
(T4 or N2) 
65.0% (60.0%-
69.9%) 
67.7% (62.9%-72.5%) NR NR 




86.1% (83.2-89.1%) 0.949  
(0.730-1.223) 
NR 




85.7% (82.2%-89.2%) 0.923  
(0.680-1.254) 
NR 








1.3.4.5 SCOT Cost-effectiveness analysis  
The cost-effectiveness of 3 versus 6 months of adjuvant chemotherapy for patients 
with CRC was explored in a within-trial analysis as part of the SCOT trial using 
patient level data (75). Compared to 6 months, 3 months was the dominant 
strategy by being cheaper and providing a (non-statistically significant) quality 
adjusted life year (QALY) gain. The incremental net monetary benefit (INMB) at a 
willingness to pay (WTP) threshold of £30,000 was £7246. Sub-group analysis 
revealed that whereas 3 months of CAPOX was cost-effective at a range of 
willingness to pay thresholds, there was more uncertainty regarding the cost-
effectiveness of 3 months versus 6 months of FOLFOX.  
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1.3.5 IDEA Collaboration  
The SCOT trial findings were not only reported independently, but they also made 
a significant contribution to the International Duration Evaluation of Adjuvant 
therapy (IDEA) collaboration (81). The IDEA collaboration was a pre-planned 
pooling of results from six international trials that all investigated the use of 
shorter duration of adjuvant doublet chemotherapy for patients with stage III 
colon cancer. Four of the trials, including SCOT, also recruited patients with stage 
II disease, and these results were also pooled and reported separately. Table 1-3 
(adapted from (81)) shows the details for each of the six trials. The primary 
endpoint for all six trials was DFS and the IDEA collaboration used a modified 
intention to treat method for the primary analysis. Assuming a 3-year DFS of 72% 
in the 6 month group and specifying a one-sided type 1 error rate of 0.025, the 




Table 1-3 Trials contributing data to IDEA Collaboration. Adapted from (81) Abbreviations: ACHIEVE, Adjuvant Chemotherapy for Colon Cancer with High 
Evidence; CALGB/SWOG, Cancer and Leukemia Group B/South-West Oncology Group; IDEA, International Duration Evaluation of Adjuvant Therapy; 
SCOT, Short Course Oncology Treatment; TOSCA, Three or Six Colon Adjuvant; HORG, Hellenic Oncology Research Group; NCT, National Clinical Trial 
number; UMIN, University Medical Information Network; EudraCT, European Clinical Trials database. 
Name of trial Clinical Trials 
Number 
























Japan III Colon CAPOX, 
FOLFOX 
CAPOX 75.1% 
FOLFOX    24.9% 
Yes 1291 No 0 
ACHIEVE 2  UMIN 
000013036 
Japan II  Colon CAPOX, 
FOLFOX 
CAPOX 84% 
FOLFOX          16% 







III Colon   FOLFOX  
(plus 
celecoxib) 
FOLFOX      100% Yes 2440 No 0 
HORG  NCT 
01308086 
Greece II/III Colon CAPOX, 
FOLFOX 
CAPOX 58.2% 
FOLFOX     41.8% 
Yes 708 Yes 413 
IDEA France EudraCT 
2009-010384-
16 
France III Colon CAPOX, 
FOLFOX 
CAPOX 10% 
FOLFOX          90% 















FOLFOX      33.5% 






NCT00646607 Italy II/III Colon CAPOX, 
FOLFOX 
CAPOX 35% 
FOLFOX         65% 





The stage III IDEA collaboration did not meet its pre-specified non-inferiority 
endpoint (HR 1.07, 95% CI 1.00-1.15, p=0.11 for non-inferiority of 3-month 
therapy, p=0.045 for superiority of 6-month therapy). Nevertheless, the clinical 
difference in 3-year DFS between 3 months vs 6 months was small (0.9%). The 3-
year DFS in the 3-month arm was 74.6% (95% CI 73.5%-75.7%) compared to 75.5% 
(95% CI 74.4%-76.7%) in the 6-month arm.  
As in the SCOT trial, toxicity was less for patients in the 3-month group, and the 
same regimen and disease stage differences that were reported in the SCOT trial 
were reported. Specifically, non-inferiority of 3 months versus 6 months of 
treatment was proven for patients with low-risk stage III colon cancer (regardless 
of regimen), those patients who were prescribed CAPOX chemotherapy, and 
subsequently for those individuals who were prescribed CAPOX and had low-risk 
disease. Overall, for patients receiving FOLFOX chemotherapy (regardless of risk 
stage) or for those with high-risk stage III disease (regardless of regimen used), 3 
months of treatment was inferior to 6 months of chemotherapy. For patients 
receiving FOLFOX who had low-risk disease specifically and for those receiving 
CAPOX who had high-risk disease specifically, non-inferiority of the shorter 
treatment duration was not proven. These regimen and disease risk subgroup 




Figure 1-6 Three year DFS for the IDEA stage III collaboration by regimen and disease risk 
stage This figure has been taken directly from the Supplementary material of the IDEA 
collaboration publication in the New England Journal of Medicine 2018 (81). 
 
The early response by the academic community to the IDEA collaboration finding 
was to recognise the complexity of the results and the unexpected difference 
between regimens that was revealed. In a special European Society for Medical 
Oncology (ESMO) plenary session in September 2017, a panel of eleven academics, 
including nine of the chief investigators from the IDEA trials, debated what they 
referred to as ‘hard road’ to interpret the data (78). At this plenary session, 
patient preference was discussed by referring to patients as having a ‘fighter’ or 
‘fatalist’ attitude to risk, with fighters more likely to accept small improvements 
in survival regardless of toxicity, whereas fatalists were less likely to accept 
longer, more toxic treatment if the additional benefit offered compared to shorter 
treatment was small. In general, there was a consensus that results relating to 
using 3 months of CAPOX for low-risk stage III disease were practice changing, 
whereas if using FOLFOX, then 6 months of treatment should remain the current 
standard when treating high-risk disease. The conclusions around using 3 months 
of CAPOX for high-risk disease and around continuing to use 6 months of FOLFOX 
for low-risk disease were less clear and in these situations, patient attitude to risk 
made the most difference to clinicians when making practice decisions. National 
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Comprehensive Cancer Network (NCCN) guidelines (USA), updated soon after 
publication of the IDEA results (82) allowed for a certain amount of flexibility and 
variability in practice depending on the risk of disease, regimen selected and 
patient preference.  
Updated survival analysis from the stage III IDEA analysis, presented at the virtual 
America Society of Clinical Oncology (ASCO) conference 2020 (83), showed very 
little difference in 5-year OS (0.4%) between using 3 versus 6 months of treatment 
in the overall trial population (see Kaplan-Meier 5-year OS curve below). 
 
Figure 1-7 Five-year overall survival with 3 versus 6 months of adjuvant treatment from the 
IDEA collaboration This diagram has been taken directly from the publication describing the 
updated IDEA collaboration stage III results (84). 5 year OS for 3 month arm was 82.4% (95% 
CI 81.4%-83.3%) versus 82.8% (95% CI 81.8%-83.8%) for the 6 month arm (HR 1.11 (0.95-1.11), 
non-inferiority p=0.058. 
Although the 95% non-inferiority HR margin met the IDEA pre-specified non-
inferiority boundary (1.11), the statistical conclusion was to reject the null 
hypothesis after a multiplicity adjustment.  Figure 1-8 shows a summary of the 
updated 5-year OS results for regime and disease risk subgroups in the IDEA 
collaboration. The general consensus following the presentation of these results 
was that the OS curves for 3 versus 6 months of treatment were virtually 
inseparable, with minimal clinical difference between the approaches, 
strengthening the argument to use shorter treatment for most patients (85, 86). 
The take home message was that 5-year OS was already very high for patients with 
stage III disease and using 3 versus 6 months was unlikely to make a significant 
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difference for most patients. The main rationale for still using 6 months of 
treatment would be when prescribing FOLFOX chemotherapy for patients with 
high-risk stage III disease.  
 
 
Figure 1-8 Subgroup analyses from the updated IDEA stage III collaboration This figure has 
been created using information from the updated IDEA stage III publication (84)  
The stage II IDEA collaboration results, combining data from the four trials which 
recruited patients with stage II disease (see Table 1-3), were presented at ASCO 
2019 (87) and reported in full in 2021 (88).  Five-year DFS was similar in both 
groups (80.7% in 3 month arm versus 83.9% in 6 month arm, 3.2% absolute 
difference), but the non-inferiority margin was not met statistically (HR 1.17, 80% 
CI 1.05-1.31, p=0.3851). Again, toxicity was significantly reduced for the shorter 
arm. Overall, grade 3-5 toxicity was reduced approximately by half (40% in 6 
month arm versus 26% in 3 month arm, p<0.0001) and grade 2-4 neurotoxicity was 
reduced by one third (36% versus 13%, p<0.0001). Between regimen differences in 
treatment effect were also demonstrated. Specifically, 5 year DFS was 81.7% in 
 
89.1% vs 89.4% 
∆ - 0.3%  




90.4% vs 88.1% 
∆ + 2.3%  




72.5% vs 75.3% 
∆ - 2.8%  
HR 1.12 (95% CI 
0.98-1.27) 
 
71.4% vs 72.4% 
 ∆ -1.0% 









IDEA secondary end-point: 5 year OS 
82.1% vs 81.2%  
∆ + 1.1%  
HR 0.96 (95% CI 
0.85-1.08) 
  
82.6% vs 83.8%  
∆ -1.2%  
HR 1.07 (95% CI 
0.97-1.18) 
  
89.6% vs 88.9%  
∆ + 0.7%  
HR 0.95 (95% CI 
0.84-1.08) 
  
 72.0% vs 74.1% 
       ∆ - 2.1%  





the 3 month arm versus 82.0% in the 6 month arm for patients receiving CAPOX. 
For patients receiving FOLFOX, 5 year DFS was 79.2% in the 3 month arm versus 
86.5% in the 6 month arm. 
1.3.6 Summary 
In summary, the SCOT trial illustrated that 3 months of adjuvant doublet 
chemotherapy is non-inferior (3 year-DFS), significantly less toxic, and more cost-
effective compared to 6 months of treatment. SCOT was the largest contributor 
to the IDEA collaboration and has contributed to novel findings for stage III, high-
risk stage II and both colon and rectal cancer patients.  
The SCOT trial was chosen as a case study for the purposes of this thesis because 
it was a large phase III trial that provided both clinical and health economic 
results. The preliminary results of SCOT (89) were reported 6 months prior to the 
commencement of this study, providing a good opportunity to evaluate early 
impact. The preliminary results indicated that the trial had met its primary 
endpoint and therefore there was a hypothesis that these findings had the 
potential to impact on clinical practice. In addition, the SCOT trial was developed 
and run by the Glasgow Clinical Trials Unit (CTU), which was supporting the 
Clinical Trials Fellowship associated with this research.  
1.4 Thesis aims and objectives 
The aim of this thesis was to explore existing approaches to research impact 
assessment, to identify which approaches have been used previously for cancer 
trial impact evaluation, and to test a number of these approaches within the 
context of a case study. To meet this aim, the specific objectives were: 
Part I: Exploring methods of research impact evaluation and identifying 
approaches relevant to cancer trials. 
 Identify approaches to impact assessment used across research disciplines, 
find examples of the application of these approaches to evaluate cancer 
research, and explore which of these approaches would be best suited to 
evaluate the impact of cancer clinical trials (Chapter 3).  
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 Analyse REF 2014 impact case studies to identify examples of the evaluation 
of cancer clinical trial impact and establish the methods used and the types 
of impacts evaluated in these case studies (Chapter 4). 
Part II: Case study of the SCOT trial to test approaches to impact assessment.  
Part IIa: An analysis of estimated impact of SCOT  
 Assess the impact of the SCOT trial findings on clinician attitudes and self-
reported prescribing practice change (Chapter 5). 
 Assess the potential economic impact of implementation of the SCOT trial 
findings on countries involved in SCOT (Chapter 6). 
Part IIb: An analysis of real world implementation of SCOT trial results 
 Evaluate real life practice change post-SCOT using local prescribing data 
(Chapter 7). 
 Assess the feasibility of using national data to assess practice change 
(Chapter 8). 
Chapter 2 outlines a number of the materials and methods developed and used 
throughout this study. The methods utilised to perform each specific part of the 
analysis are explained in detail within each chapter (Chapter 3-8). Chapter 9 
reflects on the work performed, considers how the findings can be used, and 
suggests how the results can help to direct future research in this field. 
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2 Chapter 2: Materials and methods  
Several distinct methods were used to achieve the aim of this thesis. This Chapter 
provides a description of a number of these methods, with signposting to good 
practice guidelines, and when relevant, describes the development of, or access 
to, materials and data required to perform the analyses. There is also a description 
of any regulatory approvals attained and software versions used. A more specific 
description of why specific methods were chosen and the details of the particular 
analyses that were performed are provided in each results chapter (Chapters 3-
8).  
2.1 Overview of reviews 
2.1.1 Description of approach used 
In Chapter 3, a systematic review of the literature was performed to identify 
approaches to assessment of research impact. An overview of reviews, also 
known as an umbrella review, was the approach taken, given the large number 
of studies and many reviews that have already been undertaken in this area over 
the past decade. Overviews of reviews are generally used to summarise broad 
issues and current knowledge on a topic, to signpost the reader to evidence, 
summarise existing research, and highlight where an absence of evidence may 
exist (90).  
In carrying out this overview of reviews, existing guidelines on the methodology 
for conducting an overview of previously published literature reviews were 
followed (91, 92). The approach taken aligned with guidance by using a clearly 
defined research question, adopting a systematic approach to searching for 
relevant review articles, and reporting results of the search using the Preferred 
Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) (93). The 
methodology for this overview differed from the guidelines for a traditional 
umbrella review by including both systematic and narrative reviews, rather than 
systematic reviews only (94).  
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2.1.2 Systematic review data extraction 
A data extraction form was designed to collect details for each review. 
Information on the year of publication, primary author location, relevant 
research discipline, aims of the review as detailed by the authors, and the 
search strategy used (if any) to review the literature were collected.  
A prior scoping review of the literature (unpublished) performed in the initial 
stages of this study revealed three themes that were relevant to describing 
approaches to impact assessment. Findings from each review were summarised 
under these themes. These were (i) categorisation of impact into different types 
depending on who or what is affected by the research (the individuals, 
institutions, or parts of society, the environment), and how they are affected 
(for example health, monetary gain, sustainability) (ii) methods of data 
collection and analysis for impact assessment, (iii) frameworks to organise and 
communicate research impact. There was also space available on the data 
extraction form to document other key findings.   
A separate data extraction form was developed to extract data from any 
empirical examples of cancer research impact assessment identified from the 
review articles. The information extracted included: year of publication, 
location of primary authors, research discipline, aims of the evaluation as 
described by the authors, research unit under assessment, and the rationale for 
impact evaluation. Data was extracted using the same three themes as outlined 
above, and the approaches used in these studies were compared to those 
identified from the literature reviews.  
2.2 Content Analysis  
2.2.1 Overview 
Content analysis (95) was the methodology used for the study reported in Chapter 
4. Content analysis is defined as ‘a research technique for making replicable and 
valid inferences from texts (or other meaningful matter) to the contexts of their 
use’ (Krippendorf 2004) (96). An earlier definition from Breleson (1952) describes 
content analysis as: ‘a research technique for the objective, systematic and 
quantitative description of the manifest content of communication (97).’ The data 
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analysed for the purposes of a content analysis is usually non-numerical and can 
be in the form of written, oral, or visual data. It is now generally accepted that 
content analysis can be used to analyse both the manifest content of a document, 
as well as the latent content. Manifest content refers to the inherent meaning 
that can be deduced directly from the text or other medium, whereas latent 
content refers to the interpretation of meanings that may be implied but not 
explicitly stated in the source (95).  
In order to perform a content analysis for the purposes of this study it was 
necessary to develop a coding manual. A coding manual is a statement of 
instructions to researchers that includes all the possible options for each 
dimension being coded (95). The content manual for this study was developed 
using the methodology outlined in the social sciences research methods primary 
text by Bryman (Fourth Edition) (95).  
2.2.2 Coding manual development 
2.2.2.1 Source documents for analysis 
The coding manual was developed to analyse the impact case studies from the 
REF exercise in 2014. A typical case study contained an initial section that 
included a title and information on the submitting institution, research subject 
area(s), the ‘Unit of Assessment’ and the ‘Summary Impact Type’. The Units of 
Assessment were 36 subject areas, each with a separate REF expert review panel. 
The Summary Impact Types were eight categories of impact, assigned to each case 
study by text analysis after submission to the REF. These categories were 
technological, economic, health, political, legal, cultural, societal and 
environmental (9). The next section within each case study was a short summary 
of the impact, a description of the underpinning research on which the impact 
described was based, and a list of references that representing the findings of 
that research. The main part of the case study in which the higher education 
institutions described the impact attributed to the research they listed was the 
‘Details of the impact’ section, followed by a reference list of sources to 
corroborate the claims made in this text. For the purposes of this study, the title 
section, list of research references and the ‘Details of the impact’ section were 
analysed. It was expected that the researcher using the coding manual would look 
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up the full publication for any clinical trials listed in the research references 
section. 
2.2.2.2 Units of analysis 
There were two main units of analysis and the coding manual was developed to 
allow coding of each unit separately. The first unit of analysis was the 
characteristics of the case studies and clinical trial(s) described in each case study 
and the second unit of analysis was the content of the case study itself (that is, 
the approaches to impact assessment used by universities).  
2.2.2.3 Dimensions used in the coding manual 
Dimensions for the first version of the coding manual were chosen by the primary 
researcher (CH). For the first unit of analysis (characteristics of case studies and 
clinical trials), these dimensions included the main headings within the case 
studies (university, type of research) as well as characteristics of clinical trials 
deemed important to the researcher (for example, type of malignancy 
investigated, funding source for trial). For the second unit of analysis (approaches 
to impact assessment used by universities), categories of impact and methods to 
evaluate impact were used based on results from Chapter 3 of the thesis.  
Each dimension within a case study could take a number of different pre-specified 
options; these options were the codes used for the purposes of the content 
analysis. These codes were initially populated using information from the previous 
literature (98-100), the researcher’s own experience, from information contained 
on the REF 2014 webpage, or from the results of Chapter 3 (Table 3-2 and Figure 
3-2).  
The initial aim was that all codes would apply to manifest messages included in 
the REF case studies to minimise any bias that may be introduced through 
subjective interpretation on the part of the coder. During development of the 
codes, it became clear that coding for some of the dimensions would require 
analysis of a latent message within the text. This was particularly relevant when 
coding categories of impact described by the higher education institutions. On 
occasions, there were sub-headings used within the text of case studies, such as 
‘impact on practice’ or ‘impact on clinical guidelines’ that manifest the message 
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being portrayed by the author of the case study. However, on many occasions, the 
case study text was not explicit regarding the type of impact being described and 
it was necessary for the researcher to make a judgement about the message being 
conveyed within the text. To reduce bias in this coding as much as possible, 
detailed examples and descriptions of categories of impact were developed 
through iteration of the coding manual.  
The first version of the coding manual was developed by the primary researcher 
(CH) alone. Although all dimensions for the initial coding manual were decided in 
advance of reading the case studies, some codes used in the final analysis were 
emergent from the data and finalised through the iterative process of coding 
manual development. For example, some of the pre-specified codes did not meet 
the criteria for being mutually exclusive and exhaustive, and were developed and 
refined by reading the case studies and ensuring all options were included and 
that no options were overlapping. The primary researcher read and re-read the 46 
case studies and adjusted the coding manual deductively so that is was fit for 
purpose.  
A second researcher (Lauren Gatting, (LG)) was involved in the coding manual 
development from this stage onward. LG is a PhD student at the Institute of Health 
and Wellbeing, University of Glasgow. The primary researcher (CH), having 
identified the need for this collaboration to meet the requirements of checking 
validity of coding for the purposes of content analysis, sought out, and initiated 
contact with LG. 
The primary researcher coded all case studies and LG coded two randomly 
selected case studies using the initial coding manual. Random number generation 
(Microsoft Excel®) was used to select case studies for double coding. Both 
researchers then discussed the ease of use of the manual and the appropriateness 
and relevance of the codes. After discussion, several changes were made; in 
particular, the manual was divided into ‘Part A’ (case study and trial 
characteristics) and ‘Part B’ (impact evaluation). More detailed descriptions and 
examples for each impact category relevant to cancer trials were also included. 
Version 2 of the coding manual was used for double coding of two further case 
studies. Again, the primary researcher manually coded all case studies and the 
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second researcher coded two randomly selected case studies. On this occasion, an 
inter-rater reliability score (101) was calculated as an indication of the agreement 
between coders using coding manual version 2. Rather than continuing with this 
coding manual, it was agreed by both researchers that a further iteration to the 
manual would be beneficial. The manual was changed from Microsoft Word® to 
Microsoft Excel®, with two separate spreadsheets for Part A and Part B. In Part B, 
indicators (see Table 1-1 Chapter 1 for definition) of impact were provided for 
each category to make coding more straightforward. These changes were made to 
produce the final version of the coding manual, which can be found at the 
following link: http://researchdata.gla.ac.uk/1135/.  
Throughout the process of manual development and content analysis, the primary 
researcher performed the first two stages of coding all case studies using paper 
copies of printed source data. The third and final stage of coding was performed 
using Nvivo®. The second researcher (LG) used Nvivo® software for all coding. 
The results of coding at each stage were transferred into a Microsoft Excel® for 
analysis. 
2.3 Survey Design 
A survey was used for the analysis reported in Chapter 5. General texts (95, 102-
105) on survey design were consulted in the development of the survey used. 
2.3.1 Search for previous surveys 
As per recognised good practice (105), a scoping review of the literature was 
performed to identify any existing, validated surveys that could be used to 
investigate clinicians attitudes and self-reported practice, in general or 
specifically in response to clinical trial evidence. No validated, pre-existing 
surveys were identified.   
2.3.2 Survey development 
In the development of survey content, a mixture of closed and open questions 
were used. More open questions were used in the pilot phases of the survey to 
get broad feedback from respondents on the face and content validity of the 
survey questions. Key open questions were kept in the final survey to allow 
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respondents to expand on answers about practice change where they felt 
appropriate.  
The final survey began with a statement of purpose, followed by a 
confidentiality statement (106). This was important to ensure proper 
understanding by the respondents of the rationale for the survey, and to inform 
participants how their personal data would be used. All participants confirmed 
at the start of the survey that they prescribed adjuvant CRC chemotherapy. 
Section 1 asked respondents about their awareness of clinical trials and 
guidelines. Section 2 asked about participants’ current practice, and how their 
practice may have changed in response to clinical trial findings. Section 3 used a 
Likert scale (107) to explore attitudes to using 3 months of doublet 
chemotherapy, and the final section asked about respondents their place of 
work and occupation. As per good practice guidelines, personal questions were 
left to the end of the so that respondents knew what information they had 
provided in the survey before entering more personal details (104).  
2.3.3 Survey validity  
Face validity (103), which assesses the extent to which a survey analyses what it 
has set out to achieve, was assessed in the pilot phase by asking respondents if 
they felt that the survey asked them about their current clinical practice, 
practice change in response to trials, and their attitudes to using shorter 
adjuvant treatment for CRC. Content validity (103), which assesses if there is 
sufficient content in the survey to explore the issue in question, was analysed by 
asking pilot respondents if the survey adequately addressed all relevant aspects 
of this topic. Finally, criterion (or concurrent) validity considers the extent to 
which questionnaire results agree with an independent or gold-standard measure 
of the same variable (103). As there was no gold standard for clinicians’ 
interpretation or opinion towards the results of the clinical trials, the possibility 
of testing the validity of the responses on current practice by assessing the 
chemotherapy prescribing records of five local clinicians who answered the pilot 
survey was considered. However, although this would have been technically 
possible, on further consideration, it was felt that this would be questioning the 
truthfulness of clinician’s responses and would raise issues about potential 
comparisons between clinicians. Also, if the respondents’ replies did not 
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correlate with their actual prescribing it would be difficult to know if this was an 
individual issue or if this would be mirrored when assessing a larger group of 
health care professionals. One measure of reliability is the internal consistency 
of the answers to the survey. This was addressed in the pilot survey by using 
questions that queried the same concept or opinion but used different wording. 
The aim was to test this in the final survey using Cronbach’s alpha statistic 
(108).  
2.3.4 Survey piloting 
Piloting was performed to test survey layout, wording and comprehension (109). 
The initial pilot survey was sent to a six colleagues, including clinicians who 
were representative of the intended sample of respondents, and five responses 
were received. One of the main pieces of feedback was that duplicate questions, 
which were included to assess internal consistency, were cumbersome, adding 
irrelevant length to the survey, and were likely to decrease response rate. On 
consultation with the expert in survey design, it was decided to omit this 
measure of reliability.  
Pilot 2 was sent to twenty individuals, including lay people, academics, and 
potential participants, four of whom had answered the first survey; thirteen 
people replied. The survey was piloted for a third and final time by emailing to 
seven potential participants, six of whom replied. Feedback from all pilot rounds 
and subsequent changes made are available at this link: 
http://researchdata.gla.ac.uk/1135/. The first pilot was written in Microsoft 
Word®, whereas versions 2 and 3 were constructed using OnlineSurveys®. The 
final survey is available to view at this link: https://glasgow-
research.onlinesurveys.ac.uk/uk-survey-adjuvant-treatment-for-patients-with-
colorectal-2  
2.3.5 Development of follow up survey 
If clinicians provided their email addresses for the purposes of sending them the 
study results or contacting them in the future with a follow up survey, this list of 
email addresses was downloaded separately and stored within a different file on 
a password protected, University of Glasgow One Drive account. 
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A second survey was developed with the aim of following-up responders to the 
first survey to explore if, and how, clinicians’ self-reported practice in response 
to clinical trials and their attitudes to using a shorter duration of adjuvant CRC 
chemotherapy had changed over time. A pilot for the second survey was sent to 
four individuals, two of whom replied. Both of these individuals were clinicians, 
one treated patients with CRC as part of their clinical duties. The second survey 




2.3.6 Survey analysis 
Descriptive statistics were used to analyse the survey results using Microsoft 
Excel® and STATA. Diagrams were drawn using Microsoft Excel®, Microsoft 
Word®, Online maps® and Google® Charts. Where appropriate, if comparing the 
proportions of different responses between group of clinicians, Chi-squared or 
Fisher’s exact tests were calculated (110).  
2.4 Cost-utility analysis 
For the purposes of the study reported in Chapter 6, one of the methods used to 
conduct the analysis was a within trial cost-utility analysis. Other types of 
economic evaluation and how they compare to a cost-utility analysis are outlined 
in Table 13-1 Appendix 4. This analysis adhered to good practice economic 
methodology (Consolidated Health Economic Evaluation Reporting Standards 
(CHEERS) (111) and the statistical code developed by researchers (Dr Jose 
Antonio Robles-Zurita and Dr Kathleen Anne Boyd) at the University of Glasgow 
for the initial SCOT study evaluation (75, 76) was adapted for this updated 
analysis. The rationale for repeating this analysis and the approaches to 
estimate outcomes and costs within the cost-utility calculation are outlined in 
Chapter 6.  
2.4.1 Cost-utility analysis from a multi-national perspective 
The objective of the cost-utility analysis reported in Chapter 6 was to conduct the 
analysis from the perspective of all six countries that recruited to SCOT. As 
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different countries’ regulatory bodies often set different requirements in their 
health technology assessments (HTAs), there is not one recognised approach for 
conducting an economic evaluation alongside a clinical trial that has recruited 
patients from multiple countries (112). Prior to commencing this analysis, the 
main features of each of the healthcare systems in these countries were reviewed 
and the HTA guidelines specific to each country were compared and contrasted 
(information available by following this link: 
http://researchdata.gla.ac.uk/1135/). 
Multi-country cost-effectiveness analyses can be described according to the source 
of the effectiveness data and resource data used (see Table 13-2 Appendix 4). 
Fully pooled analyses use patient level data on clinical effectiveness and resource 
use from all patients in the trial. Partially split analyses use clinical effectiveness 
estimates from patients in all countries but resource use data from only one 
country, or a selection of countries, (with unit costs from that country or selection 
of countries). Finally, analyses that are fully-split use clinical effectiveness and 
resource use estimates from the same group of patients in one country only. This 
has the advantage of maintaining the patient level link between clinical and cost-
effectiveness but small, country-specific patient numbers often limits the 
statistical robustness of this approach.  
Multi-country cost-effective analyses can also be defined by the method of costing 
used. Single country costing is when unit costs relevant to one country are applied 
to all patients in a trial regardless of the location for that patient. The alternative 
is multi-country costing, in which country specific costs are applied to patients 
from that specific country. The limitations and benefits of different combinations 
of approaches for pooling data and applying unit costs are provided in Table 13-3 
Appendix 4.   
2.4.2 Unit costs for multi-national cost-utility analysis 
Country specific unit costs were used within the cost-utility analysis to calculate 
the cost of resource use of interest. For chemotherapy unit costs, as far as 
possible, prices that reflected the drug tariff price were used. Figure 13-1 
Appendix 4 shows how the tariff price compares to other categories of unit costs 
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available. The source of chemotherapy medication costs used are shown in Table 
2-1.  
Gathering country specific information on hospital unit costs was challenging. Unit 
costs were often not available and when they were, they were only in the national 
language, which in many cases was not English. Often, resource allocation and 
pricing is at a regional rather than national level (Sweden, Spain) and these 
regional level unit costs were not publicly available (Sweden). When national unit 
costs were available they were often based on diagnosis-related codes (DRGs). 
Although DRGs are a commonly used method of calculating the cost of resource 
use based on the diagnosis of the individual patient, for the purposes of this 
analysis costs based on DRG coding were not applicable to the patient level data 
collected in the SCOT trial. Finally, although in several instances individual 
resource unit costs were found for a particular type of hospital stay and country, 
it was not clear how comparable these would be between countries in terms of 
the component costs included.  
For all of these reasons, one main source of unit cost information, the WHO 
CHOICE (CHOosing Interventions that are Cost-Effective) project, was used (113, 
114). The ratios of unit costs for each non-UK country as compared to those for 
the UK were calculated from the CHOICE study (113) (Table 2-1). The Scottish 
Information Services Division (ISD) cost book (2019) (115) unit costs for 
hospitalisation resource use were used as the source of UK costs which were 
adjusted for other countries using the WHO ratios. In order to calculate the unit 
cost per day or per night of stay, the total cost was divided by the average length 
of stay. WHO ratios for tertiary public hospital stays were used to adjust unit costs 
for ICU and oncology inpatient stays. Ratios for secondary public hospital stays 
were used to make adjustments for general medical stays, and outpatient unit 
costs were adjusted using ratios for public, tertiary hospital outpatient visits. A 
consumer price inflation (CPI) rate was used to convert unit costs from 2010 to 
2019 prices. Health specific purchasing power parity (PPP) was used to convert 
country specific currencies to USD (116). USD and 2019 were the currency and 
year used for the base case analysis.  
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Table 2-1 Unit costs used for this analysis
  AUSTRALIA DENMARK NEW ZEALAND SPAIN SWEDEN UK  
Medication unit costs ( 
all in USD)             
Oxaliplatin 0.3200 0.3504 0.3925 0.1135 0.5263 0.1164 
Capecitabine 0.0009 0.0006 0.0009 0.0006 0.0008 0.0005 
5-fluorouracil (bolus) 0.0150 0.0117 0.0051 0.0030 0.0031 0.0010 
5-fluorouracil 
(infusion) 0.0150 0.0117 0.0051 0.0033 0.0031 0.0010 
Information source www.pbs.gov.au  
Personal communication 
with Amgros December 
2019 (amgros.dk/en/) www.pharmac.govt.nz  
FU: https://es.vidal-
consult.com  (free trial 




Universitario de Valencia, 
Spain (Communication). 
Contacted in September 
23, 2020. Capecitabine: 
Framework agreement for 
the supply of the drug 
"capecitabine" to the 
hospitals of the Madrid 
Health Service, 2016. 
Consulted, September 
24th, 2020.  
www.tlv.se ("Decision 





costs (all in USD)             
Inpatient ratio 1.22 1.18 0.81 0.87 1.35 1.00 
Outpatient ratio 1.15 1.13 0.86 0.91 1.10 1.00 
ICU 4065 3938 2709 2917 4512 3340 
HDU 1739 1685 1159 1248 1931 1429 
GM 899 871 599 646 998 739 
IN_clinonc 1869 1811 1246 1342 2075 1536 
IN_clinonc_with_tx 1412 1443 993 1069 1654 1224 
OUT_clinonc 521 509 388 410 496 452 
DAY_clinonc 1566 1530 1166 1231 1489 1358 





2.5 Budget impact analysis 
Budget impact analysis was a second method used for the purposes of the study 
reported in Chapter 6. It is increasingly recognised that understanding not only 
the value of new treatments, but also the real world consequences of using these 
treatments in practice are important from a health technology and policy 
perspective, and therefore several countries have published country specific 
budget impact guidelines (117). Important information from these guidelines were 
summarised prior to embarking on this analysis, and this information is available 
by following this link: http://researchdata.gla.ac.uk/1135/. After comparing and 
contrasting these guidelines, a decision was made to use the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) guidelines (2014) (118) 
for the purposes of this study to ensure consistency of approach rather than 
following guidelines from one of the countries.  
In order to perform the budget impact analysis, a cost-calculator was built. This 
can be viewed at: http://researchdata.gla.ac.uk/1135/. Face validity of the 
calculator was checked by asking a clinician and a health economist from each 
country to review the approach used. The proformas used for these checks are 
available at the same link. 
2.6 Evaluation of chemotherapy prescribing data 
Chemotherapy prescribing data was assessed on a local (Greater Glasgow and 
Clyde (GG&C) health board) (Chapter 7) and national (Scotland) (Chapter 8) 
level. Below is a description of how these data sets were acquired. A description 
of how these datasets were analysed and the results of these analyses are 
provided in the relevant results chapters. 
2.6.1 Data access: Local 
2.6.1.1 Acquisition of datasets 
Acquisition of datasets for the purposes of analysis of local chemotherapy 
prescribing data is outlined in Figure 2-1. Extracting and linking most of the GG&C 
data was performed by a data analyst (Christine Crearie (CC)). GG&C 
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chemotherapy prescribing data was linked with additional, key data variables, 
such as disease staging. This linkage was possible because CC had access to a 
system called (Acute hospital discharges, Cancer Registrations, Death records and 
Mental health) AcaDME. ACaDMe is part of a National Health Service (NHS) 
National Services Scotland (NSS) data warehouse that stores information from the 
Scottish Medical Registry (SMR) for acute admissions (SMR01), mental health 
(SMR04) and cancer (SMR06), and NRS deaths. Demographic and staging data were 
provided to the primary researcher in a separate data file to the dataset 
containing drug dose data.  
Cancer quality performance data was acquired from a separate data provider. This 
data was extracted by a Quality Performance Indicator (QPI) data analyst (Finlay 
MacKay). The three datasets (chemotherapy drug dose, demographics from 
AcaDME, and QPI data) were linked by the primary researcher (CH) using a unique 
identifier called the Community Health Index (CHI) number, which was available 
for each patient. This unique identifier (CHI) has been assigned to every patient 
on first registration to the healthcare service in Scotland since the 1970s. A CHI 
number consists of a patient’s date of birth plus four additional digits.  
There were no direct research costs incurred to access this local data and the 
datasets were available within one month of approval to access the data. Patient 
identifiable information was sent to the primary researcher (CH) via NHS email 




Figure 2-1 Access and linkage of GG&C datasets 
 
2.6.2 Data access: National 
2.6.2.1 National data 
The data used for analysis at a national level represented the first example of a 
dataset that included granular chemotherapy prescribing data covering the 
Scottish population linked with other administrative datasets, which was made 
available to researchers. This dataset was acquired for the purposes of this study 
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(CRUK) funded COloRECTal Repository (CORECT-R), which is aiming to quantify 
the characteristics of, and any variation in, CRC and its management in the UK 
(119, 120). The data used within the study described in this thesis was a subset of 
the whole dataset that was acquired, but the PhD researcher (CH) was heavily 
involved in the process of acquiring data for both projects because of this overlap. 
The process of acquisition of the whole, larger dataset is described below, 
followed by a more specific focus on the datasets used for the purposes of this 
project. There were four main stages (Figure 2-2) in accessing and linking data on 




Figure 2-2 Flowchart outlining the main stages to access and link data  Abbreviations: NSH, 
National Safe Haven; eDRIS, electronic Data Research and Innovation Service; PHS, Public 
Health Scotland; QPI, Quality Performance Indicator; SICSAG, Scottish Intensive Care Society 
Audit Group; CHILIS, CHI Indexing and Linkage Service; SMR, Scottish Morbidity Record; 




Applications for data access 
 Discuss and define study requirements with eDRIS prior to 
PBPP application 
 PBPP application preparation 
 PBPP submission of application 
 PBPP review and decision 
 Resolve PBPP clarifications and approval 
 Request critical care data/approval by SICSAG Steering 
Committee 
Stage 2 
Clarification of specification, cohort generation, and 
data extraction  
 Transfer of ChemoCare patient CHI numbers to CHILIS by 
regional data providers 
 Transfer of SMR06 CHI numbers to CHILIS by PHS 
 Cohort generation by CHILIS using chemotherapy prescribing 
datasets and SMR06 dataset 
 Indexing of all datasets and creation of master index 
 Extraction and obtaining indexed data from data controllers: 
 Chemotherapy prescribing datasets 
 QPI datasets 
 SICSAG datasets 
 Other datasets to PHS, for example, PLICS and PIS data 
 PBBP amendment and revised approval 
Stage 3 
Data linkage 
 Data checking steps prior to data release 
 Linkage by eDRIS 
Stage 4 
Data release 
 Release to NSH for purposes of analysis 





The first stage in accessing data was to define the study requirements in order to 
apply to the Public Benefit and Privacy Panel (PBPP) for Health and Social Care in 
Scotland (121). PBPP have responsibility for weighing up the benefits to the public 
from granting access to healthcare data against the risk that the sharing of the 
data poses to an individual’s privacy. All applications to PBPP go to a Tier 1 panel 
for proportionate review. Some applications will be referred on for further review 
by a Tier 2 Committee.  
Separate PBPP applications for this project (PBPP reference number 1718-0263) 
and the CORECT-R project (PBPP reference number 1718-0026) were developed, 
but it was recognised in advance that this project would use a subset of data 
acquired for the larger initiative. The PBPP application for this project was written 
by the primary researcher (CH), whereas the PBPP application for the CORECT-R 
project was written by Dr Holly Ennis (CORECT-R project manager in Scotland) and 
Dr Peter Hall (CORECT-R principal investigator in Scotland). The primary 
researcher (CH) for this project was named on both applications. A list of the 
datasets requested for the larger application are outlined in Table 14-1 in 
Appendix 5.  
First contact with an eDRIS co-ordinator was made in January 2018 and both PBPP 
applications were submitted in parallel in April 2018.  PBPP approval was granted 
in June 2018 for this project and in October 2018 after Tier 2 review by a full 
panel of PBPP committee members for the CORECT-R submission. A substantial 
amendment for project 1718-0026 was necessary (written by Dr Holly Ennis) and 
this was approved by the PBPP committee in February 2020. 
Stage 2 
The second stage was acquisition of datasets for transfer into the National Safe 
Haven (NSH). The NSH is a research platform operated by Edinburgh Parallel 
Computing Centre (EPCC) on behalf of Public Health Scotland (PHS).  The NSH 
provides a secure analytical environment where data controllers can allow 
administrative data to be used for research purposes when it is not practical to 
obtain individual patient consent, whilst protecting patent privacy and identity. 
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eDRIS were the principal department of PHS responsible for overseeing data 
transfer.  
Datasets were divided into those held by PHS and those held by data controllers 
external to PHS (Table 14-1 in Appendix 5). Figure 2-3 shows the data transfer 
process that occurred to transfer data to the NSH. A trusted Third-Party indexing 
team (CHI Indexing and Linkage Service (CHILIS)) facilitated this transfer for the 
cohort generation and indexing of datasets. Specifically, this meant that no 
identifiable data was sent directly from data controllers external to PHS to the 
eDRIS team. Instead, patient identifiers were replaced with a unique patient 
identifier and the data was subsequently considered pseudonymised because the 
link between unique identifiers and CHI numbers was held by a Trusted Third Party 
(CHILIS). In addition, under the General Data Protection Regulation (GDPR), health 
data is considered sensitive category personal data and therefore cannot be 
considered fully anonymised. The cohort of patients included in the final dataset 
(Figure 2-3 “Master Cohort List”) was defined using a combination of Cancer 





Figure 2-3 Cohort definition and transfer of datasets to PHS  Abbreviations: PHS, Public 
Health Scotland; SMR, Scottish Morbidity Record; QPI, Quality Performance Indicator; 
CHILIS, CHI Indexing and Linkage Service; eDRIS, electronic Data Research and Innovation 
Service; CHI, Community Heath Index; SICSAG, Scottish Intensive Care Society Audit Group; 
PLICS, patient level information costing system. 
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Master Cohort list of identifiers. 
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Step 4: Row number, CHI and 
unique indexed ID from 
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from CHILIS to QPI analyst at 
each site (3 transfers) and 
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Step 5: Row number, CHI 
and unique ID from 
individual cohorts sent from 
CHILIS to ChemoCare 
analysts (5 transfers) 
Step 7: eDRIS link 
QPI, ChemoCare, 
SICSAG, SMR06 and 




Stage 2 involved initiating and continuing a dialogue and discussion with the 
relevant data controllers/data providers in the NHS Boards and other analytical 
teams in PHS. The primary researcher for this study (CH) played a major role in 
liaising with data providers from the five ChemoCare sites and three QPI locations, 
for the purposes of both projects (CORECT-R and this project). 
The transfer of ChemoCare and QPI datasets to PHS required the use of a secure 
transfer platform. In total, 28 successful secure transfers were performed to 
transfer data from external data providers to PHS. The final master cohort 
contained information on all patients aged 18+ who had a CRC diagnoses between 
January 2006 and April 2018 in Scotland.  
Stage 3 
Each dataset that was to be linked and subsequently released to the research team 
for analysis was checked by eDRIS to confirm it matched the approved 
specification. Deterministic linkage of pseudonymised datasets was performed by 
the eDRIS team within their NSH using individual unique identifiers. Essentially 
each of the unique indexed identifiers supplied in Step 4 of Figure 2-3 was 
replaced with the master index in Step 7 so each patient had the same unique 
identifier across all datasets. The linkage process, with the number of patients 
per dataset, is outlined in Figure 2-4 below. This outlines all of the datasets that 
were linked by December 2020.  
Stage 4 
After linkage was performed, the pseudonymised dataset was transferred to the 
researcher-facing NSH. Access to data within the NSH was limited to the project 
team named on the most recently approved PBPP application. Prior to accessing 
the data, each named person demonstrated up to date, approved information 
governance training, and completed an eDRIS User Agreement. 
The initial plan from eDRIS had been that the subset of data required and approved 
for this study would be identified by the primary researcher in the large project 
(CORECT-R) NSH space. This data would then be transferred by eDRIS to a separate 
NSH folder that could be accessed by the PhD student and supervisors. Due to 
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costs and time delays already incurred, a decision was made by eDRIS in November 
2020 not to proceed with a separate NSH transfer and instead all analysis was 
performed in the CORECT-R project space. A requirement for working with this 
linked data was that all outputs had to undergo a disclosure-controlled release, 





Figure 2-4 Datasets included in data release one and two  Abbreviations: ICD, International 
Classification of Disease; CRC, Colorectal cancer; WoSCAN, West of Scotland Cancer 
Network; SCAN, South East Scotland Cancer Network; NoSCAN, North of Scotland Cancer 
Network; SMR, Scottish Morbidity Record; QPI, Quality Performance Indicator; NRS, National 
Registry Scotland; SICSAG, Scottish Intensive Care Society Audit Group; PIS, Prescribing 
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Figure 2-5 summarises the steps involved in the process of national level data 
access and the times at which each step occurred.  
 
Figure 2-5 Timeline for transfer of datasets to PHS  As of January 2020, 32 individual data 
files were available. There was also a demographics file that contained all patients in the 
master cohort which was provided to research team with release one of the data. PIS datasets 
were provided as nine separate data files, one for each year (2010-2019). ChemoCare 
Grampian and Highlands data were provided each as three separate files. ChemoCare 
Grampian provided an additional file with information regarding body surface area, height, 
and weight. SICSAG information consisted of two files (episodes and daily information). 
Abbreviations: WoSCAN, West of Scotland Cancer Network; SCAN, South East Scotland 
Cancer Network; NoSCAN, North of Scotland Cancer Network; SMR, Scottish Morbidity 
Record; QPI, Quality Performance Indicator; NRS, National Registry Scotland; PIS, 
Prescribing Information System; A&E, Accident and Emergency; SAS, Scottish Ambulance 
Service; PLICS, Patient Level Information Costing System; GP OOH, General Practice Out of 




Estimated direct costs and resource use incurred during this process 
An estimation of the costs and resources required to achieve data access are 
outlined in Figure 2-6. These costs were linked with the number of datasets being 
linked and, in particular, the number of datasets external to PHS that were used. 
 
Figure 2-6 Direct costs and resource use  Abbreviations: eDRIS: electronic Data Research 
and Innovation Service, PhD: Doctor of Philosophy, QPI: Quality Performance Indicators, 
SICSAG: Scottish Intensive Care Society, CHILIS: CHI Indexing and Linkage Service, PHS: 
Public Health Scotland, PLICS: Patient Level Information Costing System, PBPP: Public 
Benefit and Privacy Panel for Health and Social Care. 
 
2.6.3 Description of the datasets used  
Below is a general description of the datasets used for the purposes of the 
analyses reported in Chapters 7 and 8. An outline of which datasets and 
variables were used for each specific study are provided in more detail in each 
results chapter.  
2.6.3.1 ChemoCare  
ChemoCare is an electronic chemotherapy prescribing platform which is used for 
the majority of systemic anticancer therapy prescriptions in Scotland. There are 
five separate instances of ChemoCare used in Scotland: one each for the West of 
Scotland Cancer Network (WoSCAN) and the South-East Scotland Cancer Network 
(SCAN) and three in the Northern Cancer Alliance (NCA) (Grampian, the Highlands, 
and Tayside). Reports from ChemoCare for audit and research purposes are 
generated by software called CRYSTAL and compiled in Microsoft Excel®.   
 Funders for data 
access 
 Research Personnel  Data access Personnel 
 
£42,180 CRUK CORECT-R 




funds to eDRIS for data 










PBPP panel/panel manager 
eDRIS data analyst 
3 x ChemoCare data controllers 
3 x QPI data controllers 
SICSAG data controller 
CHILIS staff 
PHS analyst from PLICS team 
Unscheduled care team 
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2.6.3.2 Quality Performance Indicators and Cancer Audit data 
QPI data collection has existed in Scotland since 2013. There are typically 10-15 
individual QPIs defined for each tumour type and these have been developed 
collaboratively by representatives from the three regional cancer networks, PHS, 
and Healthcare Improvement Scotland under the supervision of the National 
Cancer Quality Steering Group. NHS boards are required to report their activity 
against QPIs as part of a mandatory national cancer quality programme (122). Prior 
to 2013, a similar data collection process known as the Cancer Audit existed but 
unfortunately the availability of pre-2013 Cancer Audit data is not consistent 
across regional health boards.  
2.6.3.3 Scottish Morbidity Record 06: Scottish Cancer Registry 
SMR 06 collects patient level information relevant to the diagnosis and 
management of tumours. Cancer diagnoses are coded within the registry using the 
International Classification of Diseases, 10th edition (ICD-10). A patient may have 
two records within Registry if they have a diagnosis of more than one cancer. In 
1997, a new electronic system for data capture was launched alongside an 
expansion of the variables included within the dataset. Information on stage and 
grade of tumour, as well as treatment information is now available. This includes 
an indication of if the patient received chemotherapy and/or radiotherapy and 
the intention of that therapy, but does not include information on the individual 
names or doses of systemic therapy or radiotherapy. Data is collected annually.  
2.6.3.4 National Records of Scotland Deaths Data 
Death record collection within National Records of Scotland (NRS) contains 
information on date, cause, and place of death.  
2.6.3.5 SMR01: The General/Acute and Inpatient Daycase dataset 
The SMR 01 dataset comprises patient level episode data on hospital inpatient and 
day case discharges from acute specialities in Scotland. Each patient hospital 
admission creates a new SMR01 record and an individual patient can have several 
records for the same admission if they transfer between hospitals, treating 
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consultant or facility (such as an intensive care unit admission). Data is collected 
continuously throughout the year. 
2.6.3.6 Deprivation index and Charlson co-morbidity index 
Additional information was provided as derived variables included within a number 
of the above above-named datasets. An indication of the socio-economic 
demographic of each patient, based on their residential post-code, was provided 
using the Scottish Index of Multiple Deprivation (SIMD). SIMD is calculated using a 
patient’s postcode and a publicly available file, which has been developed by the 
Scottish ISD to identify over 6000 small area concentrations of multiple 
deprivation across Scotland in a consistent way. It combines 38 indicators of 
deprivation across seven domains: income, employment, health, education, skills 
and training, housing, geographic access and crime. The small data zones are 
grouped into bands (vigintiles, deciles and quintiles) with the first band, for 
example, quintile 1, representing the most deprived areas in Scotland. SIMD look 
up tables are updated approximately every four years. For the purposes of this 
analysis, SIMD quintiles were used based on SIMD codes from 2016.  
Information on patient co-morbidity was provided for the national dataset as the 
indicators required to calculate the Charlson co-morbidity index within SMR-01 
(123). The index was calculated by summing the total number of co-morbidities 
associated with hospital admissions (excluding cancer) from the year prior to 
diagnosis (QPI diagnosis) until the time of death or censoring. Quan weights (124) 
were applied to produce the final Charlson score for each patient. 
For the GG&C analysis, datasets to perform this analysis were all received as 
Microsoft Excel® 2016 files and Microsoft Access® was used for data linkage. All 
datasets were converted to STATA data files for analysis. For the national analysis, 
datasets were all received in the NSH as Microsoft Excel® files and were converted 
to STATA data files for analysis.  
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2.7 Ethics and governance approvals 
Ethical approval for using a survey to evaluate clinician practice was granted by 
the University of Glasgow Medical Veterinary and Life Sciences College Ethics 
Committee (project number 200180056).  
Approval to access and use records from patients within GG&C health board for 
research purposes was granted from the local Caldicott Guardian. Separate 
approval was granted to access data collected for quality performance purposes 
for patients who received adjuvant chemotherapy in GG&C.  
Approval from the Public Benefit and Privacy Panel for Health and Social Care 
(PBPP reference 1718-0263) was granted to perform the work reported in Chapter 
8. The primary researcher (CH) was also listed on a separate PBPP application 
(PBPP reference 1718-0026).  
Appendix 7 contains the approval letters for ethical approval that was 
specifically sought for the purposes of the work in this thesis.   
The original ethical approval to conduct the SCOT trial and to collect and 
analyse information for the purposes of clinical and economic outcomes for the 
trial was granted by the West Glasgow Research Ethics (REC) Committee in 
January 2008 (REC reference number 08/S0703/136). Approval was sought from 
the SCOT trial management group (TMG) to use the data for the purpose of the 
work performed in this thesis.   
2.8 Software used  
The following versions of software were used throughout this study: NVivo® 
version 11 (125), Microsoft Excel® 2016 (126), Microsoft Word® 2016 (127), 
STATA® version 14 (128), Google® Charts® 2020 (129)(used in results Chapter 5 




3 Chapter 3: Systematic review of the literature on 
approaches to research impact assessment 
3.1 Introduction 
Despite the contemporary interest in research impact assessment described in 
Chapter 1, knowledge of how best to perform assessments and the infrastructure 
for, and experience in doing so, are lacking (8, 131, 132). This lack of clarity 
extends to cancer research. The enthusiasm regarding research impact 
assessment from cancer funders and researchers (133) has not been 
accompanied by instruction or reflection on which approaches would be suited 
to assessing the impact of cancer research specifically. Being cognisant of the 
discipline specific nature of impact assessment, and understanding the 
uniqueness of cancer research in approaching such evaluations, underpins the 
rationale for the study reported in this chapter. 
In a 2016 survey of Australian cancer researchers, respondents indicated they felt 
a responsibility to deliver impactful research, but that evaluating and 
communicating this impact to stakeholders was difficult. In total, 80% of the 
respondents agreed that the researcher themselves should be contributing to 
doing an impact assessment, but acknowledged that this activity would take time 
away from research itself, teaching and writing. Respondents also suggested that 
the types of impact expected from research, and the approaches used, should be 
discipline specific (134). These results add weight to the rationale for this study, 
which was to consider approaches to impact assessment from a cancer research 
specific perspective.  
As already discussed in Chapter 1, there is no single definition of what research 
impact encompasses, with potential differences in the evaluation approach 
depending on the definition. For the purposes of this study, the definition of 
research impact given by the RCUK is used (see Chapter 1 Section 1.2.4). This 
definition was chosen because it takes a broad perspective, which incorporates 
academic, economic and societal perspectives of research impact (135).  
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The aim of this study was to explore approaches to research impact assessment 
across research disciplines, identify approaches that have been used previously 
for cancer research, to explore whether these approaches are adequately 
capturing impact, and to consider which are relevant to cancer clinical trials. 
For the purposes of this study, cancer research included both basic science and 
applied research, research into any malignant disease, concerning paediatric or 
adult cancer, and including but not limited to studies spanning nursing, medical 
and/or public health elements of cancer research.  
The study objectives were to: 
(i) Identify existing literature reviews that report approaches to research impact 
assessment and summarise these approaches.   
(ii) Use these same literature reviews to identify examples of cancer research 
impact evaluations, describe the approaches to evaluation used within these 
empirical examples, and compare them to those described in the broader 
literature.  
3.2 Methods  
This study was undertaken in two parts: (i) An overview of existing reviews of the 
literature on approaches to research impact assessment and (ii) A search of the 
reference lists of the reviews identified in part one to find empirical examples of 
the evaluation of the impact of cancer research.  
An overview of reviews (discussed in Chapter 2) was performed because a 
scoping review of the literature had identified that a large number of reviews on 
the topic of approaches to research impact already existed. Rather than 
duplicate previous work, the aim of identifying and synthesising evidence from 
existing reviews was to provide a summary of the important approaches to 
impact evaluation used. The choice to include both systematic and narrative 
reviews in the study was purposeful because it was felt that both types of 
reviews (94) would make a useful contribution to understanding the important 
themes on the topic of impact evaluation and help to identify previous 
evaluations of impact that have been carried out. 
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As research impact assessment is a field that has not been extensively developed 
in oncology, it was felt that to perform a primary review of empirical studies 
that have evaluated the impact of cancer trials, or those describing the 
methodology to assess research impact within the field of oncology, was too 
narrow. There have been ad hoc examples of evaluating specific aspects of the 
impact of cancer trials, for example, how a trial result has been incorporated 
into guidelines (136) or how it has changed clinician’s views (137) and practice 
(138-140). However, these studies are often not identified in the literature 
under the umbrella term of “impact” and it is rarely acknowledged how the 
outcomes sit within a wider analysis of all the potential impacts of that trial. A 
review of existing reviews was undertaken because of these anticipated 
challenges of conducting a primary review of empirical examples of cancer 
research impact evaluation, and to allow a critique of empirical studies in the 
context of lessons learnt from the wider literature.  
3.2.1 Part I: Data sources and search strategy 
For part one (overview of reviews), eleven publication databases and the grey 
literature (for example, reports not published in peer-reviewed journals) from 
January 1998 to May 2019 were searched to identify review articles that 
summarised approaches to research impact assessment.  
The electronic databases searched were Medline, Embase, Health Management 
and Policy Database, Education Resources Information Centre, Cochrane, 
Cumulative Index of Nursing and Allied Health Literature, Applied Social Sciences 
Index and Abstract, Social Services Abstracts, Sociological Abstracts, Health 
Business Elite and Emerald. These were chosen in collaboration with a Beatson 
West of Scotland Cancer Centre specialist librarian (Lorraine MacLeod, LMacL) 
with the aim of identifying review articles that spanned across research 
disciplines. The search strategy specified that article titles must contain the word 
‘impact’, as well as a second term indicating that the article described the 
evaluation of impact, such as ‘model’ or ‘measurement’ or ‘method’. The search 
terms used, and an example of the search performed for the Ovid Medline 
database are outlined in Appendix 2. 
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The grey literature was searched using a proforma that provided a list of online 
grey literature sources. Keywords were inserted into the search function of 
websites and the first fifty results were screened. Title searches were performed 
by either a specialist librarian (LMacL) or the primary researcher (CH). All further 
screening of records was performed by the primary researcher (CH).   
Articles were kept for final inclusion in the study by assessing each article against 
the following inclusion and exclusion criteria.  
The following criteria were used to select relevant review articles for inclusion 
in the overview of reviews: 
Inclusion criteria 
“Review” or “overview” mentioned in abstract or methods 
Review of methods to assess or evaluate the impact of research  
Publication date between the years 1998 to 2019 
Can include part of a document as long as that is a standalone review, for 
example a chapter in a PhD thesis or a literature review in a supplementary 
appendix  
Exclusion criteria 
Description of one framework for impact evaluation with no review of 
approaches to existing approaches to research impact evaluation 
Primary, empirical examples analysing research impact 
PowerPoint® presentations, visual or multimedia 
Editorials, blogs, short opinion pieces, workshops, books 
Instructions on how to use a specific impact assessment framework 
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Website address with no identifiable document  
Documents focusing on one country (Reviews of methods from several different 
countries to evaluate research impact are permitted) 
Articles only focusing on the definition of research impact  
Articles only focusing on “health impact assessment” (not the same as the 
impact of health research) 
Articles describing the development of a new framework with a brief mention of 
a scoping review in the methodology are excluded.  
To meet these criteria, an article had to be a review of approaches to evaluate 
the impact of research. No restrictions were placed on the discipline, field, or 
scope (national/global) of research for this part of the study.  Articles reviewing 
concepts and methodology of approaches to impact assessment were permitted, 
as well as reviews of empirical impact evaluations. If two articles drew primarily 
on the same review but contributed a different critique of the literature or 
methods to evaluate impact, both were kept. If a review article was part of a grey 
literature report, for example a thesis, but was also later published in a journal, 
the journal article only was kept. The reference list of final, included reviews 
were also searched to identify any additional, relevant articles. 
3.2.2 Part II: Data sources and search strategy 
For part two of the study, the reference lists from the literature reviews included 
in part one were manually screened (141) to identify empirical examples of 
assessment of the impact of cancer research using the inclusion and exclusion 
criteria outlined below. Summary tables and diagrams from the reviews were also 
searched using the words ‘cancer’, ‘oncology’ and ‘trial’.  
Inclusion criteria 
Empirical examples of research impact assessment. 




Clinical trials (one trial, multiple trials or a programme of trials), or  
Cancer trials 
Exclusion criteria 
Primary evaluations of research impact when the research may include cancer 
research or clinical trials, but this is not the primary focus of the research or 
research programme being evaluated.  
 
3.2.3 Data extraction and analysis 
A data extraction form (see Chapter 2) was used to summarise information from 
the review articles identified. These lists were tabulated or presented 
graphically. A separate data extraction form (see Chapter 2) was used to 
summarise information from empirical examples of cancer research impact 
assessment. A narrative approach (142) was used to synthesise and describe the 
results from both parts of this review and to compare and contrast the 
approaches to cancer research with the approaches identified from literature 
reviews in part one.    
3.3 Results 
3.3.1 Search results 
For part one, following an initial title screen, 800 abstracts were reviewed and 
140 selected for full review. Out of 140 articles read in full, 27 met the inclusion 
criteria. A further 13 relevant articles were found through reference list searching 
from the included reviews (141), giving an overall number of 40 reviews for 
inclusion in part one of the study. For part two, 4,479 titles were screened and 
after removal of duplicates, 57 full articles were read and fourteen were deemed 




Figure 3-1 PRISMA diagram for review 
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3.3.2 Part One: Identification and analysis of literature reviews 
describing approaches to research impact assessment 
3.3.2.1 Characteristics of included literature reviews 
The characteristics of the forty reviews of the literature on approaches to 
research impact assessment that met the pre-specified inclusion criteria are 
outlined in Table 3-1. A large proportion (20/40; 50%) were written by primary 
authors based in the UK, followed by the USA (5/40; 13%) and Australia (5/40; 
13%), with the remainder from Germany (3/40; 8%), Italy (3/40; 8%), the 
Netherlands (1/40; 3%), Canada (1/40; 3%), France (1/40; 3%) and Iran (1/40; 
3%). All reviews were published since 2003, despite the search strategy dating 
from 1998. Raftery et al 2016 (143) was an update to Hanney et al 2007 (144) 
and both were reviews of studies assessing research impact relevant to a 
programme of HTA research. The narrative review article by Greenhalgh et al 






Table 3-1 Literature reviews identified in overview of reviews 
ID Author/Year
/Location 






















1 Hanney et al 
2003 (146). 
UK. 
Review how health research is used in 
policy-making and the approaches to 
assess the policy impact of research. 
Not detailed NA Healthcare  1 0 1 1 
2 Buxton et al 
2004 (100). 
UK. 
Identify key studies that have estimated 
the economic value of the impact of 




Unknown Healthcare 1 0 0 1 
3 Coryn et al 
2007 (147). 
USA. 
Describe, classify, and evaluate national 
models and mechanisms used to evaluate 
research in 16 countries. 
Not detailed NA Not discipline 
specific 
0 0 1 0 




Review the literature describing the 
evaluation of the impact of programmes 







1990-2005 Healthcare 1 0 1 1 
5 Brutsher et 
al 2008 (Part 
1 of report) 
(148). UK 
Present and discuss five key elements of 
research evaluation.  
Not detailed.  NA Not discipline 
specific.  
1 1 1 0 




Review current practices of assessing the 
economic benefits of medical research. 
Not detailed.  NA Medical research 1 0 0 0 
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7 Boaz et al 
2009 (150). 
UK. 
Review methods for evaluating the 
impact of research on policy outcomes.  
Databases (10 in 
total), web 










1 0 1 0 
8 Marjanovic 
et al 2009 
(151). UK 
Historical overview of landmark studies 
in the research evaluation field to reflect 
on methodological developments.  
Not detailed.  NA Biomedical and 
health research.  
1 0 1 0 
9 Yazdizadeh 
et al 2010 
(152). Iran. 
Systematic review to identify methods 
used to assess the economic impact of 
healthcare research.  
Databases (8), 21 
relevant 
websites.  
Unknown.  Healthcare 1 0 1 0 
10 Banzi et al 
2011 (153). 
Italy. 
Review to identify the most common 
approaches to research impact 
assessment, categories of impact, and 





1990-2009 Not discipline 
specific.  
1 1 1 0 
11 Hanney et al 
2011 (154). 
UK. 
Review of studies that have assessed 
economic impacts from health research 





known to the 
authors.  
Unknown Healthcare 1 0 0 1 
12 Patel et al 
2011 (155). 
UK.   
Systematic review to identify indicators 





1950-2010 Healthcare 1 0 1 0 
13 Ruscio et al. 
2012 (156). 
USA. 
Evaluate 22 scholarly impact metrics.  Not detailed.  NA Not discipline 
specific.  
1 0 0 1 




Literature survey of existing research on 
practices employed in the assessment of 





Unknown Not discipline 
specific. 
1 0 1 1 
15 Guthrie et al 
2013 (158). 
UK 
Identify and review frameworks in use 
for research evaluation, to identify the 
research evaluation tools applied to 
those frameworks to provide a guide to 
Not detailed.  NA Not discipline 
specific. 
1 0 1 0 
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developing a research evaluation 
framework that can be used in a range of 
circumstances.  
16 Smith et al 
2013 (159). 
UK 
Review the methods of assessing 






NA Not discipline 
specific.  
1 0 1 0 
17 Carpenter et 
al 2014 
(160). USA 
Broad overview of widely available 
measures of academic productivity and 
impact using publication data and to 
highlight the uses of these metrics.  
Not detailed.  NA Science 1 0 0 0 
18 Penfield et 
al 2014 (28). 
UK 
Explore what is understood by the term 
research impact and provide a 
comprehensive overview of the literature 
to understand which methods and 
frameworks of impact assessment could 
be used for UK based impact assessment. 
Not detailed.  NA Not discipline 
specific 
1 0 1 0 
19 Milat et al 
2015 (161). 
Australia. 
Synthesise evidence that describes 
processes and conceptual models for 
assessing policy and practice impacts of 
public health research.  
Databases (6) 1990-2013 Healthcare 1 0 1 0 




Provide a broad overview of the wide 
array of metrics to assess research 
impact currently in use in academic and 
research.  
Not detailed NA Not discipline 
specific.  
1 1 1 0 




Identify a wide range of potential 
impacts of research, investigate different 
ways of classifying impacts, produce a 




on a limited set 
of key sources 
known to the 
study team.  
Unknown Not discipline 
specific 
0 1 1 0 
22 Thonon et al 
2015 (164). 
France.  
Identify indicators of impact that could 
be used to measure the output and 






1 1 0 0 
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23 Wouters et 
al 2015 
(165). UK 
Review literature of academic research 
looking at a range of impact indicators.  
Not detailed NA Not discipline 
specific 
1 0 0 0 
24 Agarwal et al 
2016 (166). 
USA 
Provide a broad overview of evaluation 
metrics currently used in academic and 
research.  
Not detailed NA Not discipline 
specific 
1 0 0 0 
25 Chikoore et 
al 2016 
(167). UK 
Explore the meaning of research impact, 
issues regarding how it can be evaluated, 
and challenges associated with 
assessment. 
Not detailed NA Not discipline 
specific 
1 0 1 0 
26 Raftery et al 
2016 (143). 
UK 
Review published research studies on 
tools and approaches to assessing the 
impact of programmes of health research 
and specifically to update the previous 











searches of other 
reviews and 
references. 
2005-2014 Healthcare 1 1 1 1 
27 Greenhalgh 
et al 2016 
(145). UK 
Review the strengths and limitations of 
six established approaches of measuring 
both the outcomes of research and the 
processes and activities through which 
this is achieved.  
Search strategy 
based on Raftery 
et al 2016.  
As above Not discipline 
specific 
1 0 1 1 
28 Wimmer et 
al 2016 
(168). USA 
Review both traditional and novel impact 
evaluation tools, the impact metrics they 
calculate and to explore if and why these 
tools are relevant to the field of nursing 
research.  
Not detailed.  NA Healthcare  1 0 0 0 




Review how impact is measured within 
science and beyond and the problems 
associated with impact evaluation.  
Databases (3 in 
total) and other 
literature 
reviews.  
Unknown Science 1 0 0 0 
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30 Cruz Rivera 
et al 2017 
(170). UK 
Identify existing methodological 
frameworks used to measure healthcare 
research impact and to summarise the 
common themes and metrics in an 
impact matrix.  







Unknown Healthcare 1 0 1 0 




List the stated objective for research 
impact frameworks, to identify existing 
frameworks and to evaluate whether 
these have the capabilities necessary to 
address pre-specified objectives.  
One database and 
grey literature 
2005-2015 Healthcare or 
medical 
1 0 1 0 
32 Peter et al 
2017 (172). 
Canada 
Identify approaches that have been used 
to understand the impacts of health 
research, identify ways that research 
impacts have been defined and 
measured, and provide recommendations 
for occupational science. 
Traditional 
databases, author 
search from the 
assessment tools 
that were 
mentioned in the 
included reviews 





analysis and a 
forward citation 
search in the 






1 0 1 0 
33 Reale et al 
2017 (173). 
Italy 
Understand how impact assessment 
methods are used in social sciences and 
humanities and how far these approaches 
attempt to apply methods and 
instruments that take into account the 
distinctive features of this discipline.  
Journal 
articles/database
s, books, reports, 
working papers, 
CORDIC database, 
EU FP17 Flash-it 
project 
2006-2012 Social sciences 
and humanities 
1 1 1 0 
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34 Newson et al 
2018 (174). 
Australia 
Review the extent and nature of studies 
measuring the impact of health research 
on policy and compare forward and 






1995-2016 Not discipline 
specific 
1 0 1 1 
35 Pedrini et al 
2018 (175). 
Italy 
Analyse the approaches to the 
assessment of healthcare research social 
impact with a focus on different 
stakeholders. 
Databases (3) 2000-2016 Healthcare 1 0 0 1 




Conduct a literature review to analyse 
how impacts of agricultural research are 
assessed. 
Databases 2008-2016 Agricultural 1 1 0 0 
37 Williams et 
al 2008 (14). 
UK 
Systematic review of the evolution of 
research impact assessment approaches 







Unknown Not discipline 
specific 
0 0 1 0 
38 Braithwaite 
et al 2019 
(177). UK 
Identify what is known about methods for 
assessing researchers’ achievements for 
the purposes of producing a new 
assessment model. 
Databases (all 
Web of Science) 
2007-2017 Not discipline 
specific 
1 0 0 0 
39 Gomes et al 
2019 (26) UK 
Review empirical impact evaluation to 
understand the impact generated by 
publicly and charity-funded health 






hand searching of 
specific journals 
2006-2017 Health research 1 0 1 1 
40 Heyeres et al 
2019 (178) 
Australia 
Systematic review of studies that used a 
case study approach to assess research 
impact. 
Databases (11), 
reference lists of 
impact case 
studies identified 
2000-2018 Not discipline 
specific 
1 0 1 1 
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Approximately half of the reviews identified (19/40; 48%) described approaches 
to evaluate research impact without focusing on a specific discipline and nearly 
the same amount (16/40; 40%) focused on evaluating the impact of health or 
biomedical research. Two reviews examined approaches to impact evaluation for 
environmental research and one focused on research within the social sciences 
and humanities. Finally, two reviews provided a critique of impact evaluation 
methods used by different countries at a national level (147, 148). None of these 
reviews focused specifically on cancer research.  
Twenty-five reviews (25/40; 63%) specified search criteria and eleven of these 
included a PRISMA diagram. The articles that did not outline a search strategy 
were often expert reviews of the approaches to research impact assessment and 
the authors stated they had chosen the articles in their reviews included based 
on their prior knowledge of the topic. Most reviews were found by searching 
traditional publication databases, however seven (7/40; 18%) were from the grey 
literature. These included four reports written by an independent, not-for-profit 
research institution (Research and Development (RAND) Europe) (148, 149, 151, 
158), one literature review which was part of a PhD thesis (167), a literature 
review informing a quantitative study (163), and a review that provided 
background information for a report to the UK government on the best use of 
impact metrics (165). 
3.3.2.2 Key findings from the reviews: Approaches to research impact 
evaluation  
(i) Categorisation of impact for the purpose of research impact 
assessment 
Nine reviews attempted to categorise the type of research impact being assessed 
according to who, or what, was affected by research, and how they were 
affected. In Figure 3-2, colour coding was used to identify overlap between 
impact types identified in these nine reviews to produce a summary list of seven 




Figure 3-2 Categories of impact identified from literature reviews of approaches to research impact assessment.  The 9 literature reviews have each been 
denoted with a letter A-I in this figure. A:Brutscher et al (2008) (148)  B:Banzi et al (2011) (153) C:Moed et al (2012) (162) D:Pollitt et al (2016) (Supplementary 
material) (163) E:Thonon et al (2015) (164) F: Raftery et al (2016) (143) G:Cruz Rivera (2017) (170) H:Real et al (2017) (173) I:Weisshuhn (2018) (176).  
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The first category of impact refers to the immediate knowledge produced from 
research and the second focuses on the contribution research makes to driving 
innovation and building capacity for future activities within research 
institutions. The former is synonymous with the academic impact of research, 
and applied to cancer trials specifically would traditionally refer to the results of 
the clinical trial and resultant publications. The latter may refer to the act of 
securing funding to perform future research, providing knowledge that allows 
development of later phase clinical trials, or training cancer researchers.  
The third category identified was the impact of research on policy. Three of the 
review articles included in this overview specifically focused on policy impact 
(146, 150, 174). In their review, Hanney et al (146) suggested that policy impact 
(of health research) falls into one of three sub-categories: impact on national 
health policies from the government, impact on clinical guidelines from 
professional bodies, and impact on local health service policies. Cancer clinical 
trials are often cited in clinical guidelines written by medical professional bodies 
and used as the evidence to support suggested guidance. Examples of such 
guidelines include those published by the National Institute for Health and Care 
Excellence (NICE) in the UK, or the National Comprehensive Cancer Network 
(NCCN) in the USA. Cruz Rivera and colleagues, in their review (170), specifically 
distinguished the impact of research on policy making from impact on clinical 
guidelines; they listed the latter under health impact. This shows that the lines 
between categories are subjective and will often blur.  
Impact on health was the next category, and several of the reviews 
differentiated impacts on the health sector from health gain. Both of these 
impact categories will be relevant when assessing the impact of cancer clinical 
trials, given that cancer is a major burden for both healthcare systems and the 
patients they treat. Economic impact of research was the sixth category. 
Relevant to cancer trials research, there is likely to be close overlap between 
healthcare system and economic impacts because of the high cost of cancer care 
for healthcare services globally.  
With regards to the economic impact of research, a key study identified from 
the previous literature was the review article authored by Buxton et al (100). 
The authors searched the literature for examples of studies that estimated the 
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value of the economic return on investment in health research and found four 
main approaches to perform these assessments, which were referenced in later 
reviews by other authors (149) (143, 152, 154). The four approaches were (i) 
measuring direct cost savings to the health-care system, (ii) estimating benefits 
to the economy from a healthy workforce, (iii) evaluating benefits to the 
economy from commercial development and, (iv) measuring the intrinsic value 
to society of the health gain from research. In a later review, (149) Buxton et al 
added an additional approach of estimating the ‘spillover’ contribution of 
research to the Gross Domestic Product (GDP) of a nation. The term ‘spillover’ is 
used by economists to describe how an organisational investment will not only 
benefit the organisation in question, but also other organisations in the same or 
other sectors of the economy, in the same or within other countries (179). 
The final impact category identified from these literature reviews was social and 
cultural impact. This term social impact was commonly used in a specific way to 
refer to research improving human rights, well-being, employment, education, 
and social inclusion (153, 170). Two of the reviews which included this category 
focused on the impact of non-health related research (social sciences and 
agriculture), indicating that this type of impact may be less relevant, or less 
obvious, for health related disciplines such as oncology. A related term, societal 
impact, was used in a distinct way in the literature to describe any wider impact 
from research that is external to traditional academic benefits (157, 175).  
Lastly, other categories of impact identified that did not show significant 
overlap between the review articles included technological, environmental and 
political impacts, amongst others.  
(ii) Methods for data collection and analysis  
In total, thirty-six (36/40, 90%) of the reviews of approaches to research impact 
assessment discussed methods to collect or analyse the data required to conduct 
an impact evaluation. The common methods described, with strengths and 
weaknesses of each approach, and how they may be applied to assessing cancer 








ID number of 
review (from Table 
1) 







Umbrella term referring to the 
use of documents and data to 
analyse research impact (See 
(146) Additional File 1: 
Elements of a protocol for 
documentary analysis.) 
Time efficient 
Likely to be cost-effective. 
Can be applied to a wide 
range of sources, e.g. 
publications, guidelines, 
conference proceedings, 
reports.   
No standard methodology 
for analysis.  
Relies on the quality of the 
primary document.  
Pre-existing documents/data that 
could be analysed to assess 
cancer trial impact may include 
national/international clinical 
guidelines, local treatment 
protocols, patient facing 
websites, funding information, 
drug or device patents, 
information on drug sales and 
research publications where the 
study was performed using 
information from the clinical trial 




Includes online, telephone and 
paper/postal surveys.  
Can be used for a wide range 
of stakeholders and across 
disciplines. 
Often cost effective.  
Can identify areas to focus on 
in an interview.  
Relies on robust response 
rate and access to 
respondents  
Burdensome to complete. 
Decreased accuracy if 
incomplete data.  
Response bias 
This method could be used to 
survey users of clinical trial 
information/results, such as 
clinicians, patients and policy 
makers. Alternatively, a survey 
could be used to ask the clinical 
trialists what impacts they 
perceive have arisen from their 




Can be structured, semi-
structured or unstructured and 
open-ended.  
Can be conducted face-to-face, 
over the telephone or via video 
link. (See (146) Additional File 
Provide personal perspectives 
from individuals e.g. 
researchers or users of 
research.  
Allow in depth analysis.  
Time consuming.  
Interviewers need to be 
skilled so as not to 
introduce bias.  
Results may not be 
generalisable.  
As for surveys, these could be 
directed to the direct users of 
clinical trials, or the trialists. 
Interviews are more likely to be 
useful if the aim of the 
assessment is to have an in depth 
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2: Draft interview schedule for 
assessing research utilisation in 
policy-making). 
understanding of how trial 
information/results are used, or, 
if interviewing trialists, to get a 
broad overview of potential 
impacts that are not pre-defined, 
as would be more common when 








A narrative description of the 
impact of research.  
Other methods may have been 
used to collect data that is used 
within the impact narrative.  
Narratives often offer a wide 
perspective of research 
impact. 
Can provide evidence of a 
pathway to and a context for 
the research impact 
described.  
Time consuming and 
costly.  
Case study selection may 
be biased towards only 
positive or high achieving 
research examples. 
Individual cancer clinical trials or 
a small collection of cancer 
clinical trials assessing the same 
research question are good 
candidates for a case study or 
impact narrative, as usually the 
trial is developed with a specific, 











Quantitative analysis of 
research activity, usually in the 
form of journal publications and 
citations.  
Low cost and burden 
 
Focus on outputs  
Not necessarily a measure 
of impact.  
Discriminate against 
researchers who have been 
active for less time. 
Not comparable between 
research disciplines. 
Often only considers 
citations in publication 
databases and does not 
include other data sources 
such as books or reports. 
Open to gaming.  
This method would include 
citation analysis of publications 
describing cancer clinical trial 
results. This is an 
approach/metric that focuses 
only on academic impact and 
does not evaluate cancer trial 
impact as per the wider 
definition. Bibliometric software 
can be adapted to analyse other 
data sources, such as policy 
documents and non-academic 
websites, which may provide a 
better indication of wider 





Quantitative analysis of 
research activity, usually based 
Captures different routes of 
research dissemination 
Disadvantages similar to 
bibliometrics.  
Examples of software to carry out 
this approach to assessment are 




related citations.  
compared to traditional 
bibliometrics.  
Can be analysed in an 
automated fashion with a high 
degree of accuracy.  
Mentions on social media 
or the lay new media may 
be more an indication of 
dissemination and 
influence than impact. 
Open to manipulation.  
These are tools that track and 
collect online activity relating to 
publications such as those which 
report the results from cancer 
clinical trials. They could be 
applied to one or several trials 
(or the outputs from a specific 
trialist). Similar to bibliometrics, 
these scores will not describe the 
wider impact of a cancer trial, 
but they may give an indication 
of how and by whom the original 
publication is being used and 
read. 




Relies on advisory service by 
experts in the field to assess 
the impact of the research in 
question. 
Material can be reviewed by a 
group of peers (allows 
discussion) or individuals. 
Credibility within the 
academic community.  
Can offer expert feedback for 
future improvement, flexible. 
Can be conducted at any time 
during an impact analysis.  
Subjective/not always 
transparent.  
May be costly, requires 
facilitation, can be slow.  
Peers may be expert in 
their field but may not be 
expert at assessing 
research impact. 
Impractical to assess broad 
research area given peers 
generally experts in one 
field.  
Issues with time/cost and 
reporting bias around how 
information presented for 
review.  
Peer/expert review could be 
used to assess the impact of a 
cancer clinical trial or group of 
trials. The limitation is that any 
expert review will be biased by 
the individual’s own research 
expertise and understanding of 
research impact. This type of 
analysis could be guided by using 
an impact framework to make 







An umbrella term that 
incorporates many methods e.g. 
cost-benefit analysis, cost-
utility analysis, cost-
Offers an estimation of the 
return on research investment 
which may be especially 
useful to funders.  
Challenging to monetise 
broad impacts such as 
health and to account for 
This method of impact 
assessment may be particularly 
relevant for funders of cancer 
trials. There is not one 
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effectiveness, proportion of 
GDP. 
A single monetary figure for 
the return on a specific 
research project means that a 
comparison with the return on 
the benefits from other 
research projects may be 
possible.   
all research costs and 
benefits.  
Rather than the final 
monetary value, important 
to detail the methodology 
for calculation of the 
return on investment to 
allow comparison with 
other impact assessments.  
recognised approach to evaluate 
the economic impact of cancer 
clinical trials and the impact may 
be positive or negative depending 
on the stakeholder perspective, 
for example, a pharmaceutical 
company (sales of drug) versus a 
public health service (cost of 
buying a drug). There may be 
economic benefits relating to the 
implementation of clinical trial 
results, but there may also be 
benefits if the clinical trial leads 
to future research 
investment/patients/drug sales.  
Using a scale  1 Using a scale to assess the 
extent of research use within a 
certain category. For example, 
using a scale to report the level 
of research utilisation in 
policymaking. (See 
(146)Additional File 3: Draft 
scales of the level of research 
utilisation in health policy-
making). 
Relatively easy to carry out.  Disadvantages of any 
quantitative metric. A 
scale provides a superficial 
indication of the use of 
research findings and may 
lack context.  
Problems with ensuring a 
fair comparison between 
research items could be 
decreased by using the 
same person or same team 
to score the research 
projects.  
A scale could be applied to 
cancer clinical trial but it is 
unlikely to provide worthwhile 
insight into the wider impact of a 
trial. A scale may be used in 
conjunction with other 
approaches to impact evaluation. 
Benchmarking  5,14, The act of comparing metrics, 
usually bibliometrics, in order 
to compare impact from 
different research studies.  
May be useful on an 
institutional level as a tool to 
encourage improved research 
productivity.  
Used alone this is not a 
measure of "impact". The 
benchmarking output 
requires careful 
interpretation in context.  
Benchmarking has important 
limitations and should only be 
used to assess and compare 
clinical trials if the metric being 
used is comparable between 
trials, which will often not be the 
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case. If the metrics being used 
are only bibliometric assessments 
of research publications, these 
are not a satisfactory measure of 
trial impact.  
Workshop or 
focus group 
 7,34,35,40 Discussion amongst a group of 
people, usually facilitated by a 
researcher.  
May be used as a tool to 
evaluate the impact of 
research on a group of 
stakeholders.  
Time and cost intensive to 
run and analyse.  
As for interviews, this approach 
could be used to ask research 
users, such as patients, or 
researchers, regarding their use 
of clinical trial information or 
their perception of the impact of 
a single or group of cancer 
clinical trials. Compared to 
interviews, individuals will be 
able to share and discuss their 
ideas with others. Compared to 
surveys, the topics for discussion 
and information gathering may 
deviate from a pre-defined list. 
In this way, unexpected impacts 
related to cancer trials may be 




 7,16,26,35,36,40 An overview of the literature.  Usually straightforward to 
perform.  
May be used to understand 
the impact of current 
research in the context of 
other evidence on the same 
topic.  
Measure of academic 
impact only.  
Cancer clinical trial results will 
often be reported in academic 
journals and therefore will be 
amenable to evaluate via a 
literature review or meta-
analysis. These are approaches 
focusing on scholarly impact 
only. 
User or expert 
testimony 
 7,8,16,18 A statement from the user of 
the research or an expert in the 
field, which describes the 
Straightforward to collect and 
demonstrates the impact of 
research directly from the 
stakeholder perspective.  
One perspective only. Applied to a cancer trial, the 
user or expert could be a patient 
or clinician. It is important to 
recognise the reason the 
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impact of the research from 
their perspective.  
testimony was given, and explore 
any bias, for example, was the 
expert involved in development 





A mixed methods approach to impact analysis was often advocated in these 
review articles, in particular the triangulation of surveys, interviews (of 
researchers or research users), and documentary analysis (144, 146, 150, 174). A 
large number of reviews cautioned against the use of quantitative metrics, 
specifically bibliometrics, alone (28, 146, 155, 156, 159, 160, 165, 166, 177, 
180). Concerns were that these metrics were not designed to be comparable 
between research programmes (162), their use incentivised researchers to focus 
on quantity rather than quality (156), and they could be gamed and used in the 
wrong context to make decisions about researcher funding, employment and 
promotion (180) (159, 160). 
Several reviews explained that the methods for data collection and analysis 
chosen for impact evaluation depended on the unit of research and the rationale 
(4 As, see Chapter 1) for the analysis (148, 150, 151, 154, 158, 161, 176). 
Regarding cancer research, the unit of analysis could be, for example, a single 
clinical trial or a programme of trials, research performed at a cancer centre, or 
research funded by a specific institution or charity.  
(iii) Using a framework within a research impact evaluation 
Applied to research impact evaluation, a framework (see Table 1-1 Chapter 1) 
provides a way of collecting and organising data, facilitating a more objective 
and structured evaluation than would be possible with an ad hoc analysis. In 
total, twenty-seven (68%) articles discussed the use of a framework in this 
context. Table 3-3 lists and provides a short description of the frameworks 
mentioned in three or more of the included reviews. Although several of the 
frameworks identified were designed to assess the impact of health research, 
none were specifically developed to assess the impact of cancer research. Table 
3-3 also outlines which of these frameworks may be relevant to assessing the 




Table 3-3 Examples of frameworks for research impact assessment Abbreviations: REF, Research Excellence Framework; RAE, Research Assessment 
Exercise; SIAMPI, Social Impact Assessment Methods for research; RIF, Research Impact Framework; RQF, Research Quality Framework; ERA, Excellence 
in Research Australia; MORIA, Measurement of Research Impact and Assessment; SEP, Strategy Evaluation Policy. 
Framework 
Main level intended for 
evaluation Description 
 
Relevance to cancer clinical trials 
Payback Framework Various 
Developed at Brunel University in 1990s to evaluate the 
impact of health services research.  
This framework has been applied to health 
research and could be used to assess the impact 
of a cancer trial or a programme of trials.  
Social Impact 
Assessments Methods 
for research (SIAMPI) 
and other frameworks 
Initial case studies aimed 
at a centre/institution 
level of assessment.  
Developed through a collaboration between the UK's 
Economic and Social Research Council and researchers in 
the Netherlands. The focus is on social impact and there 
is an assumption is that “productive interactions” 
between researchers and stakeholders are important. The 
aim of this framework is learning from research impact 
evaluations rather than accounting or judging impact.  
Applied to cancer trials, an assessment could be 
made of direct, indirect and funding productive 
interactions. Examples of direct impacts could 
include use of cancer trial results by clinicians or 
patients, indirect impacts could be citation in 
policy guidelines, and funding interactions could 
be increased funding for a trials unit, or for future 
trials that occurs because of the success of a 
previous cancer clinical trial. If using this 
framework, the aim of the assessment would be 
to learn about impact from previous trials to 
maximise trial impact going forward.  
Monetary/economic 
framework Various 
Any method that attempts to evaluate the opportunity 
costs of research and its outputs.  
Several review articles referred to using an 
economic framework but it is not clear how these 
could be applied to a cancer clinical trial. This is 
a gap in the current literature.  
Research Impact 
framework (RIF) 
Individual researcher or 
project 
Developed by researchers at the London School of 
Hygiene and Tropical Medicine for healthcare 
researchers. Includes four categories of impact with sub-
categories and indicators within each area. Based initially 
on a review of the literature and other assessment 
exercises and developed by interviewing researchers and 
applying the categories to research projects at their 
centre.  
A framework developed for health research, with 
categories and indicators of impact that are 
relevant, although not specific to, cancer clinical 
trials. This framework could be used at the level 
of evaluating a single clinical trial.  
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UK REF and RAE  
National frameworks to 
evaluate institutions 
Introduced by the UK government in 2014 to allocate 
funding to universities. The RAE was the previous national 
assessment effort by the UK government used prior to the 
REF; impact was not explicitly included. 
These frameworks were intended for a national 
funding allocation process. Alone, they could not 
be applied to a cancer trial because the approach 
relies on scoring and comparing many different 
impact case studies in order to allocate funding. 
The method of using a case study (see methods 
above) used within the REF framework would be 
applicable to a cancer trial but it is not clear how 
the scoring method used in the REF would 
compare between trials.  
Canadian Academy of 
Health Sciences 
(CAHS) Various 
Developed by a panel of experts to provide a framework 
for assessing Canadian healthcare research and based on 
the Payback Framework.  
There are four different versions/pillars of this 
framework (biochemical research, clinical 
research, health services research and 
public/population health research), with the 
applied clinical research framework being most 






of Research Impact 
and Assessment 
(MORIA)  National 
The aim of the RQF was to use it to assess the quality of 
publicly funded research using case studies and peer 
review to assess impact. The RQF was never employed. 
Instead, the ERA was introduced in Australia, with a focus 
on quantitative metrics. First used in 2010, then 2012, 
2015 and 2018. MORIA was developed for use at the grant 
review stage.   
These are national assessment exercises, designed 
to evaluate the impact of a large body of research 
at an institutional level. They are therefore less 
relevant to assessing individual cancer trials, but 
trials may be used as examples of research within 
these assessments.  
Weiss Logic model 
Various. Developed to 
assess medical research.  
Developed to assess medical research by psychiatrist 
Anthony Weiss.  
This framework focuses on implementation of 
clinical research findings and therefore is most 
relevant to later phase cancer clinical trials. It is 
also not clear how the framework would apply to 
any form of research that did not have findings 
that could be readily implemented into practice, 
for example, early phase clinical trials or trials 
that do not meet their primary endpoint.  
Netherlands Royal 




National, institution or 
programme level. Uses 
self-evaluation and 
intermittent external 
review of the institution 
Used to assess research performance generally, not just 
the impact of research. There is overlap with ERiC. SEP is 
the national assessment process but there was initially no 
framework or specific methodology specified to carry out 
the assessment; the ERiC was used for this purpose.  
This framework has been formulated to evaluate 
research units, rather than specific research 
projects. It could therefore by applied at the level 
of a cancer clinical trials unit. The framework 
relies on a group of experts to assess a research 
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at set intervals. Overlap 
with the SIAMPI approach.  
unit’s research over the previous 6 years. This 
framework has similarities to the assessments 
performed by cancer research funders for their 
clinical trials units (for example the quinquennial 
review of clinical trials units undertaken by 
CRUK).  
Lavis exchange model Various 
A conceptual model describing producer push, user pull, 
and the exchange model.  
This model focuses on knowledge exchange as a 
technical exercise that links research to action. 
The model describes the theory of how knowledge 
exchange occurs and is limited in the guidance 
offered on how to practically evaluate the impact 
of research. The theory of the exchange of 
knowledge between trialists and cancer trial 
users, such as clinicians or patients, could be used 




Various. Could be used at 
the project or individual 
researcher level.  
Focuses on the role of the researcher in creating impact 
from their research. The ladder consists of six stages from 
the transmission of research results to those results being 
used by others in a different context to that of the 
original research.  
This framework focuses on the researcher/clinical 
trialist and is most suitable to use if assessing the 
efforts made by trialists to increase the impact of 
their clinical trial, rather than providing a way to 
evaluate the overall impact of the trial in 
question.  
HTA Quebec model 
Programme of HTA 
research.  
Developed to assess the impact of research for the HTA 
programme in Quebec. Effectiveness of research is 
assessed by the ability to impact on decision makers. Uses 
case studies, documentary analysis, and interviews.  
This framework has been developed for health 
technology assessment purposes. Although it could 
be applied to assess the wider impact of cancer 
clinical trials, this was not the intended use of the 
framework. 
Becker model 
Focused at the research 
study level.  
Framework for tracking diffusion of research outputs and 
activities to locate indicators of impact that demonstrate 
evidence of biochemical research impact. The pathways 
of diffusion are: advancement of knowledge, clinical 
implementation, community benefit, legislation and 
policy, and economic benefit.  
This framework was developed to assess 
biomedical research generally. It is suitable for 
both basic and applied research. Although not 
specific to cancer clinical trials, the main strength 
is the list of impact indicators which could be 
used to assess the impact of a clinical trial.  
Banzi Various 
This approach to impact evaluation is based on their 2011 
umbrella literature review. They summarise indicators of 
impact under five main headings: advancing knowledge, 
capacity building, informing decision making, health 
There is overlap with the CAHS framework, from 
which the categories and indicators of impact are 
developed. These are not specific to cancer 
clinical trials, but could be applied to trials either 
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benefits, broad socio-economic benefits. The impact 
categories and relative indicators are adapted from the 
CAHS framework.  
using the Banzi publication or the original CAHS 
framework.  
Balanced scorecard Various 
A strategy performance management tool that is not 
specific to research impact. Focuses on financial 
dimensions, customer, business process, learning, and 
growth.  
This is more appropriately applied at the 
organisational level, rather than the individual 
clinical trial level.  
Canadian Institutes of 
Health Research 
framework (CIHR) Various 
Developed in 2005 by Canadian and international experts 
and based on the Payback framework. Pre-dated and 
provided a basis for the CAHS model.  
The CAHS model is a more up to date version that 
could be applied to cancer clinical trials (clinical 
research pillar).  
Program Assessment 
Rating Tool (PART) Research programme level 
This approach was developed for evaluating the research 
performance of all USA government research programmes 
during the time of the Bush administration (2003). It uses 
a survey format and focuses on impacts and efficiency.  
This is most suited to assessing research at the 
programme level, and therefore would be most 
relevant to a programme of cancer clinical trial 
work. The framework focuses on the strategy of 
the programme and is not specific to assessing the 





The most frequently described framework was the Payback Framework, 
developed by Buxton and Hanney in 1996 (181), and many of the other 
frameworks identified reported that they were developed by adapting key 
elements of the Payback framework. This framework was originally developed to 
evaluate the impact of health services research. It consists of a modified logic 
model that explains the process of how impact from research occurs, alongside 
five categories of impact. A logic model is a graphic or description that 
represents the theory of how the critical aspects of an intervention are arranged 
to show how the intervention produces change (182). Figure 3-3 is a 
diagrammatic representation taken from the original manuscript describing the 
Payback Framework (15). The authors explain that the Payback Framework is a 
research tool that can be used to inform surveys, interviews, or documentary 
analysis and may be particularly useful in structuring data collection when the 
impact of more than one research project or programme is being assessed to 
help with consistency and communication of the results of the evaluation.  
 
Figure 3-3 The Payback Framework logic model  Figure taken directly from (15). 
 
In the original Payback Framework, these impacts were described as benefits. 
However, iterations of the framework by other authors, for example by Klautzer 
et al (183) for use in the social sciences, have changed the term ‘benefits’ to 
‘impacts’ in order to signify that recognising both the positive and negative 
effects from research is important.  
(iv) Additional findings from the included reviews 
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The challenges of research impact evaluation were commonly discussed in these 
reviews. Several mentioned that the time lag (169) (28, 149, 152, 157, 158, 161, 
170, 172) between research completion and impact occurring will influence 
when an impact evaluation is carried out; too early and impact will not have 
occurred, too late and it is difficult to link impact to the research in question. 
This overlaps with the challenge of attributing impact to a particular piece of 
research (28, 100, 151-153, 157, 158, 161, 170, 173, 175). Many authors argued 
that the ability to show attribution in an assessment was inversely related to the 
time since the research was carried out (28, 149, 150, 158, 172).  
3.3.3 Part Two: Empirical examples of cancer research impact 
evaluation  
3.3.3.1 Study characteristics 
Fourteen empirical impact evaluations relevant to cancer research were 
identified by searching the reference lists of the review articles. These studies 
were published between the years 1994 to 2015 by primary authors located in 
the UK (7/14; 50%), USA (2/14; 14%), Italy (2/14; 14%), Canada (2/14; 14%), and 
Brazil (1/14; 14%). Table 3-4 lists these studies with the rationale for each 
assessment, the unit of analysis of cancer research evaluated, the main findings 
from each evaluation, if the research included cancer trials and/or how the 




Table 3-4 Empirical examples of cancer research impact assessment Abbreviations: QALY, Quality adjusted life year; UK, United Kingdom; USD, United 
State dollars; GDP, Gross Domestic Product; SIGN, Scottish Intercollegiate Guidelines Network; NICE, National Institute for Health and Care Excellence; 
BBC, British Broadcasting Agency; USA, United States of America; CAHS, Canadian Academy of Health Sciences; NBCF, National Breast Cancer 











assessed Methods used 
Frame
work Main findings Strengths Limitations 
 
 

















analysis followed by 
evaluation of the 
social return on 
research 
investment.  Human 
capital approach 
used to value return 
on investment.  Nil 
Cost-effectiveness of 
treatment estimated at 
$2094 USD per year of life 
saved. The net present 
value of the return on the 
$10.84 million investment 
in the trial estimated at 
$1.66 billion USD.  
The cost of conducting 
research incorporated 
into analysis of the 
value of the research 
investment.  Time-
period for assessment of 
the costs and benefits 




about adoption of 
trial results into 
practice rather than 
an assessment of 
actual practice 
change.  
Highly relevant given that 
the focus was on a 
programme of phase III 
RCTs assessing colorectal 
cancer treatments. This 
could be used by a 
funding or research 
institute to assess the 
impact of the clinical 
trials they fund/support 
to reflect on the impact 









centre Allocation Academic  
Bibliometric 
assessment using an 
journal impact 
factor based metric  Nil 
Most publications from 
the research centre that 
were identified and 
analysed scored highly (8-
10/10) on the normalised 
journal impact factor 
score.  
An early (1997) attempt 
to evaluate the 
academic impact of a 
cancer institute.  
Metric, quantitative 
based approach only 
looking at a narrow 
interpretation of 
impact. Using the 
impact factor of a 
journal to assess the 
quality of individual 
research articles and 
for allocation of 
resources.  
The journal impact factor 
is a misnomer with 
regards to assessing the 
wider impact of research. 
This approach would not 
be recommended to 
assess the impact of 



















using the number of 
occurrences of an 
oncological 
publication in a 
journal (by author 
country of origin) 
compared to 
country 
population/GDP and Nil 
The UK made the highest 
contribution to European 
cancer publication output 
(21.12%), whereas Sweden 
performed best in the 
metric of number of 
publication occurrences 
versus country population 
and the Netherlands was 
ranked first for the mean 
Comparison of two 
methods to understand 
how to assess the 
impact of cancer 
researchers' work.  
Quantitative metric 
used that does not 
assess the quality of 
the individual articles 
or the contribution of 
the authors to the 
work. The authors 
acknowledge the 
limitations of using 
bibliometrics alone. 
This approach is better 
suited to a large 
programme of research, 
rather than individual 
studies, such as clinical 
cancer trials. The main 
reason for performing an 
analysis using this 








the "mean impact 
factor" of the 
occurrences of the 
publication by 
author.  
impact factor of the 
occurrences.  
comparisons. The metric 
used is narrow and does 
not adequately address 
the wider impact of 
research; it would not be 
recommended as an 
approach to evaluate 
cancer trials.  










Assessment of “time 
to payback” for two 
alternative 
hypothetical cancer 
trials. This is the 
number of years 
until the returns 
from conducting a 
clinical trial 
outweigh the costs.  Nil 
An effectiveness clinical 
trial would be worthwhile 
to look for a 5% 
improvement in survival 
from more intensive 
follow up (if a 5% 
improvement is 
considered likely). An 
equivalence trial would 
not be a worthwhile 
investment.  
Ex-ante evaluation 
shows how impact 
assessment can prevent 
investment in cancer 
trials that are unlikely 
to be worthwhile.  
An evaluation of 
potential rather than 
realised impact. Any 
error in the 
assumptions made and 
results obtained in 
these types of analysis 
means that some 
potentially impactful 
trials will not be 
performed.  
This is highly relevant to 
cancer trials, however it 
is an approach to evaluate 
the potential impact of 
trials that are yet to be 
performed. The main 
rationale for using this 
approach would be to 
prioritise which cancer 
trials to develop based on 
cost-effectiveness of 
carrying out the trials. 
This approach would 
therefore be relevant to 
cancer trial funders who 
are making funding 












Identification of 43 
UK guidelines from 
NICE, SIGN and 
Clinical Evidence. 
Bibliometric 
software used to 
analyse guideline 
citations.  Nil 
UK papers were cited 
more frequently in cancer 
clinical guidelines than 
expected from their 
presence in the world 
oncology literature. The 
publications were 
generally more clinical 
than basic. 
Outlines and executes a 
method for evaluating 
the impact of cancer 
research on guidelines. 
Authors highlight that 
small clinical trials 
with negative 
outcomes are unlikely 
to be cited in 
guidelines, and 
discuss limitation of 
using clinical 
guideline impact as a 
surrogate for practice 
change. 
Although this analysis 
included both basic 
cancer research and 
applied research such as 
clinical trials, the authors 
showed that it is mainly 
clinical research that is 
cited in these guidelines. 
Consequently, this 
approach to impact 
evaluation would be 
relevant to assess the 
policy impact of a 
programme of specific 
trials. If evaluating one 
cancer clinical trial, this 
could be performed using 
manual analysis of the 
relevant guidelines rather 
than the software used in 










as cited in 
the media Analysis 
Media impact 
(dissemination) 




stories focusing on 
cancer compared 
with UK's burden of 
disease (WHO 2002). 
Journal/author, 
research level (basic 
versus clinical), 
potential citation 
rate, actual citation 
rate/ funding of any 
cited paper 
recorded.  Nil 
Research on breast, 
cervical and skin cancer 
are over-reported in the 
media compared to their 
burden of disease whereas 
lung cancer is under-
reported. New and 
improved drugs are the 
research topic most cited. 
UK research was over-
cited in the UK media 
compared to its place in 
world oncology research.  
Novel attempt to 
investigate the impact 
of research in the 
media. Methodology 
clearly explained.  
Only one media 
website archive used 
for analysis.  
This approach to 
assessment would be 
relevant to cancer trials, 
both early and late phase. 
It is likely the type of 
trials reported in the 
media will be those either 
deemed to be of 
contemporary interest or 
those actively 
disseminated by trialists 
or pharmaceutical/device 
companies, and any 
analysis must recognise 
this bias.   















of a sample of 
abstracts.  
Over 50% of abstracts 
were from the USA. 
Clinical trials were more 
likely than "other" types 
of research to be 
presented in poster or 
oral form (vs publication 
only).  
Analysed only a 
sample (10%) of all 
abstracts, no 
comparison between 
the two time periods 
sampled and no 
information on the 
abstracts that were 
submitted but 
rejected. 
This approach could be 
applied to clinical trials 
reported at a conference 
but it is assessing a 
narrow, academic 










country Analysis Academic 
Quantification of 





burden of cancer in 
Russia. Citation 
scores for Russian 
cancer publications 
compared with the 
citations to cancer 
papers worldwide in 
the same years.   Nil 
Russia publishes one sixth 
as many cancer papers as 
its wealth and disease 
burden suggest. 
Collaboration in cancer 
research is dominated by 
former socialist states. 
Russian cancer research is 
incorporated into UK 
clinical guidelines, but 
rarely into UK media.  
Multiple indicators used 
to map some important 
impacts of cancer 
research.  
Mainly quantitative 
indicators used. No 
assessment of broader 
aspects of societal 
impact. Only looked 
at the impact on UK 
clinical guidelines and 
media rather that in 
Russia (likely to be 
much higher).  
The aim of this analysis 
was to compare between 
country outputs for 
cancer research. This 
could be restricted to 
cancer clinical trials only 
from different countries, 
however this type of 
assessment focuses mainly 
on academic publications 
rather than downstream 















gains in cancer 
survival using 
willingness to pay 
estimates derived 
from the literature 
and a comparison 
with the cost in 
cancer spending.  Nil 
Cancer survival increased 
by 3.9 years from 1988-
2000; equates to 23 
million additional life 
years. Authors estimate 
that an average life year 
is worth 82,000 USD, 
therefore the value of this 
survival is monetised at 
1.9 trillion USD in social 
value. 18-year time lag 
from research investment 
to survival outcome 
attributable research 
used.  
Attempts to monetise a 
complex concept of 
willingness to pay for 
cancer survival. 
Detailed description of 
analysis. 
Complex methods, 
willingness to pay 
values from previous 
literature. The actual 
investment costs in 
different cancer types 
and different research 
types (basic versus 
trials) not outlined.  
This analysis would not be 
suitable to apply to a 
single clinical trial. Also, 
this top down approach is 
not transferrable to 
analysis of a pre-defined 
group of clinical trials 
alone because it relies 
initially on a population 
health change to have 
occurred, and then works 
down to identify the 
research (including 
clinical trials) that 
contributed to the health 
change. 
Montague 









Clinical version of 
the CAHS to guide 
impact evaluation. 
Indicators of impact 
taken from this 
logic model 
framework and 
combined with a 
Bennett’s hierarchy. 










chy   
Impacts in all categories 
of the CAHS can be 
identified for this trial. 
The authors produce an 
impact timeline to show 
the pathway to impact in 
chronological order.  
Use of conceptual 
framework means that 
impact of this cancer 
trial is communicated in 
a transparent and 
organised fashion. Use 
of the program chain of 
events helps 
demonstrate the 
processes through which 
impact has occurred. 
Incorporated the 
funding initially 
allocated to perform 
the cancer trial.  
The theory of action 
hierarchy makes 
assumptions that prior 
events influence 
events higher up the 
chain. No estimation 
of the economic 
consequences of 
conducting the trial. 
Mainly desk analysis 
used.  
This is highly relevant to 
cancer clinical trials and 
is a suitable approach to 
apply to a single clinical 
trial, as has been 
performed in this analysis. 
The use of a framework to 
report the results of the 
analysis is a strength of 
the evaluation.  
Sullivan R 











linked with cancer 











Calculation of the 
number of papers 
from UK cancer Nil 
UK cancer centres 
heterogeneous in terms of 
their overall research 
output and type of 
research performed. More 
focus on 
basic/fundamental 
research compared to 
applied research. 
Heterogeneity in 
proportion of papers from 
UK cancer centres that 
are cited in 
guidelines/media. Does 
not correlate with the 
size of centre or the 
The authors combine 
publication citation 
impact with other 
impacts (on guidelines 
and media) to give a 
broader overview of 
cancer centre research 
impact.  
Mainly quantitative 
measures of impact. 
The authors mention 
the potential future 
use of the Research 
Impact Framework 
but they do not use 
this or any other 
framework in their 
current analysis.  
This approach could be 
applied to academic 
cancer clinical trial 
publications but it is a 
narrow interpretation of 
research impact and 
therefore of limited 
usefulness if wanting to 
evaluate wider impact.  
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centres reported in 
UK guidelines and in 















Desk analysis of 
data held by the 
charity, survey of 
chief investigators, 
















153 responses to a survey 
sent to 242 NBCF-funded 
researchers showed the 
research performed had 
impacts on drug 
development, higher 
degree attainment, 
capacity building for 
future research, policy, 
and health gain. 
Differences in impact 
between basic and 
applied cancer research. 
Transparent 
methodology using a 
recognised framework 
and a mixture of 
quantitative and 
qualitative methods to 
gain in depth insight 
into impact of the 
research.  
No consideration of 
the economic value of 
the return on the 
investment. Impact 
from the perspective 




perceived impact of 
the funded research.  
This analysis assessed 
both basic and applied 
cancer research, but it 
could be applied to 
clinical trials alone. The 
approach would rely on 
the researchers 
responsible for developing 
and running the clinical 
trials answering a survey 
and being available to 
provide information on 
costs and potential 
outcomes from the trials. 
It would be less suitable 
to evaluate the impact of 
a single trial.  
Glover M 








estimated NMB using 
monetised value for  
QALY, estimated 
cost of delivering 
benefit, estimated 
the proportion of 
NMB attributable to 
UK research and 
time lapse between 
funding and health 
gain  and the 
internal rate of 
return from cancer 
research on health.  Nil 
Time lag between 
research spending and 
impact on health gain 
estimated as 15 years. 
Overall return on public 
spending on cancer 
research estimated as 
10.1%. 








nature of this 
assessment and 
accompanying case 
studies were performed 
(Guthrie et al, see 
below).  
Assumptions made to 
perform this economic 
analysis. The authors 
outline the difficulty 
in differentiating the 
impact of smoking 
cessation in their 
calculation of the 
impact of cancer 
research overall.  
This economic approach 
to evaluate impact uses a 
bottom up approach 
(versus the top down 
approach used by 
Lakdawalla) and therefore 
could be applied to a 
group of cancer clinical 
trials or a single trial. It 
could be improved by 
making a clearer link 
between the 
research/trials performed 
and the clinical practice 
and health changes 
attributed to the research 
in question.  
Guthrie S 
et al 2015 
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Individual narratives for 
each case study.  
The use of case studies 
enables the reader to 
understand the process 
through which impact 
has occurred and the 
time lines involved.  
Requires in depth 
documentary analysis 
to contextualise and 
explain case study 
specific impacts.  
This case study approach 
could be applied to one or 
a number of clinical 
cancer trials. It would be 
most useful when 
understanding the process 
of impact occurring is the 




3.3.3.2 Approaches to cancer research impact evaluation used in empirical 
studies 
(i) Categories of impact evaluated in cancer research impact assessments 
Several of the empirical studies focused on academic impact. For example, 
Ugolini and colleagues evaluated scholarly outputs from one cancer research 
centre in Italy (185) and in a second study looked at the academic impact of 
cancer research from European countries (186). Saed et al (190) used 
submissions to an international cancer conference (ASCO) to evaluate the 
dissemination of cancer research to the academic community, and Lewison and 
colleagues (188, 189, 191, 194) assessed academic, as well as policy impact and 
dissemination of cancer research findings to the lay media.  
The category of health impact was also commonly evaluated, with particular 
focus on the assessment of survival gains. Life years gained or deaths averted 
(184), life expectancy gains (187), years of extra survival (192) and QALYs were 
all used as indicators of the health impact attributable to cancer research. 
Lakdawalla and colleagues (192) considered the impact of research investigating 
both cancer screening and cancer treatments, and concluded that survival gains 
were 80% attributable to treatment improvement. In contrast, Glover and 
colleagues (39) acknowledged the importance of improved cancer therapies but 
also highlighted the significant advances from research around smoking 
cessation, as well as cervical cancer and bowel cancer screening. Several of 
these studies that assessed health impact, also used the information on health 
gains to assess the economic impact of the same research (39, 184, 187, 192). 
Finally, two studies (193, 195) performed multi-dimensional research impact 
assessments, which incorporated nearly all of the seven categories of impact 
identified from the previous literature (Figure 3-2). In their assessment of the 
impact of research funded by one breast cancer charity in Australia, Donovan 
and colleagues (195) evaluated academic, capacity building, policy, health, and 
wider economic impacts. Montague and Valentim (193) assessed the impact of 
one randomised clinical trial which investigated the use of a hormonal 
medication as an adjuvant treatment for patients with breast cancer. In their 
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study, they assessed the dissemination of research findings, academic impact, 
capacity building for future trials and international collaborations, policy 
citation, and the health impact of decreased breast cancer recurrence 
attributable to the clinical trial.   
(ii)      Methods for cancer research impact evaluation 
Methods of data collection and analysis for the purposes of research impact 
assessment used in these studies mostly aligned with the categories of impact 
that were being assessed. For example, studies assessing academic impact used 
traditional bibliometric searching of publication databases and associated 
metrics. In their evaluation, Ugolini et al (185) applied a normalised journal 
impact factor to publications from a cancer research centre as an indicator of 
the research quality and productivity. The journal impact factor is an index that 
reflects the yearly average number of citations for articles published in the 
previous two years by a given journal. This analysis was adjusted for the number 
of employees within each department and the scores were used to apportion 20% 
of future research funding. The same bibliometric method of analysis was used 
in a second study by the same authors to compare and contrast national level, 
cancer research efforts across Europe (186). They assessed the quantity and the 
mean impact factor of the journals for publications from each country and 
compared this to the location-specific population and GDP. A similar approach 
was used for the manual assessment of 10% of cancer research abstracts 
submitted to ASCO between 2001-2003 and 2006-2008 (190). These authors 
examined if the location of authors affected the likelihood of the abstract being 
presented orally, as a face-to-face poster or online only.  
Lewison and colleagues, who performed four of the studies identified, (188, 189, 
191, 194) used a different bibliometric method of publication citation count to 
analyse the dissemination, academic, and policy impact of cancer research. The 
authors also assigned a research level to publications to differentiate if the 
research was a basic science or clinical cancer study by coding the words in the 
title of each article or the journal in which the paper was published. The cancer 
research types assessed by these authors included cancer research at a national 
level for two different countries (UK and Russia) and research performed by 
cancer centres in the UK. 
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To assess policy impact these authors extracted journal publications from cancer 
clinical guidelines and for media impact they looked at publications cited in 
articles stored within an online repository from a well-known UK media 
organisation (British Broadcasting Corporation). Most of the cancer research 
publications contained in guidelines and cited in the UK media were clinical 
studies whereas a much higher proportion published by UK cancer centres were 
basic science studies. These authors also identified that funders of cancer 
research played an important role as commentators to explain the importance of 
the research in the lay media. The top ten most frequent commentators 
(commenting on >19 media articles out of 725) were all representatives from the 
charity CRUK.  
Within these empirical examples of cancer research impact evaluation, a 
combination of clinical trial findings and documentary analysis of large data 
repositories were used to estimate health system or health impact from cancer 
research. In their study, Montague and Valentim (193) cited the effect size for a 
decrease in cancer recurrence reported from a clinical trial and implied the 
same health gains would be expected in real life for patients with breast cancer 
living in Canada.  In their study of the impact of charitable and publicly funded 
cancer research in the UK, Glover et al (39) used CRUK and Office for National 
Statistics cancer incidence data. They also utilised national hospital databases 
listing episodes of radiotherapy delivered, the number of cancer surgeries 
performed, and systemic anti-cancer treatments prescribed, to evaluate changes 
in real world practice attributable to cancer research. In their USA perspective 
study, Lakdawalla et al (192) used the population-based Surveillance, 
Epidemiology and End Results Program (SEER) database to evaluate the number 
of patients likely to be affected by the implementation of cancer research 
findings (192). Survival calculations from clinical trials were also applied to 
population incidence estimates to predict the scale of survival gain attributable 
to cancer research (184, 192).  
The methods of data collection and analysis used for economic evaluations 
aligned with the categories of assessment identified by Buxton in their 2004 
literature review (100). For example, three studies (39, 187, 192) estimated 
direct healthcare cost savings from implementation of cancer research. This was 
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particularly relevant in one assessment of the potential impact of a clinical trial 
testing the equivalence of using less intensive follow up for patients following 
cancer surgery (187). These authors assessed the number of years it would take 
(“years to payback”) of implementing the hypothetical clinical trial findings to 
outweigh the money spent developing and running the trial. The return on 
investment calculation was performed by estimating direct cost savings to the 
healthcare system by using less intensive follow up without any detriment to 
survival. There was an implicit assumption that the direct healthcare cost 
savings would be a way of paying back investment a future clinical trial from a 
research funder, even if the investment and cost savings were not from the same 
budget. 
The second of Buxton’s categories was an estimation of productivity loss avoided 
from research using the human capital approach. As described in Chapter 2, this 
method uses the national average income to value survival gains from patients 
surviving longer who are of working age. This approach was used in two studies 
(184, 192) and in both, estimates of average income (USA) were utilised. 
Buxton’s fourth category, an estimation of an individual’s willingness to pay for 
a statistical life, was used in two assessments (187, 192), and Glover and 
colleagues (39) adapted this method, placing a monetary value on the 
opportunity cost of QALYs forgone in the UK health service within a fixed budget 
(197). One of the studies that used this method identified that there may be 
differences in how patients diagnosed with distinct cancer types value the 
impact of research on cancer specific survival (192). In particular, individuals 
with pancreatic cancer seemed to be willing to spend up to 80% of their annual 
income for the extra survival attributable to implementation of cancer research 
findings, whereas this fell to below 50% for breast cancer and CRC. Only one of 
the studies specifically calculated Buxton’s third category of benefits to the 
economy from commercial development (192). These authors assessed the gain 
to commercial companies from sales of on-patent pharmaceuticals and 
concluded that economic gains to commercial producers were small relative to 
gains from research experienced by cancer patients. Glover et al (39) did 
mention GDP spillover in their study but they did not carry out a cancer specific 
evaluation for this type of impact.  
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The cost estimates relevant to cancer treatments used in these impact 
evaluations came from documentary analysis, clinical trial publications, real-life 
data repositories, surveys, and population average income estimates. For 
example, in one study, cost information from a NCI trials database was 
supplemented by using a telephone phone survey to pharmacies, historical 
Medicare (USA national health insurance programme) documents and estimates 
of the average income from the 1986 US Bureau of the Census Consumer Income 
(184). In their study, Coyle et al (187) costed annual follow up and treatment for 
cancer recurrence based on the Ontario Health Insurance plan, a cost model 
relevant to an Ottawa hospital and cost estimates from Statistics Canada (198).  
The data used to calculate the cost of performing cancer research was usually 
from funding bodies and research institutions.  For example, charity reports and 
Canadian research institution documents were used to estimate that it costs the 
National Cancer Institute in Canada $1,500 per patient accrued to a clinical trial 
(187). Government research investment outgoings were used to calculate the 
$300 billion was spent on cancer research in the USA from 1971-2000, 25% of 
which was contributed by the NCI (192), and that the NCI spent over $10 million 
USD in the 1980s to generate the knowledge that adjuvant chemotherapy was 
beneficial to colorectal cancer patients (184). Charity and research institution 
spending reports, along with an estimation of the proportion of funds spent 
specifically on cancer research, were used to demonstrate £15 billion of UK 
charity and public money was spent on cancer research between the years 1970 
to 2009 (39). 
Lastly, the two studies (193, 195) which adopted a multi-category approach to 
impact assessment used the highest number and broadest range of methods 
identified from the previous literature (Table 3-2). These included surveys and 
semi-structured telephone interviews with clinicians, documentary analysis of 
funding and project reports, case studies, content analysis of media release, 
peer review, bibiliometrics, budget analysis, large data repository review, and 
observations of meetings.  
(iii)  Frameworks for cancer research impact evaluation 
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Only two of the empirical articles identified in this study used an impact 
framework. These were also the studies that performed a multi-category 
assessment and used the broadest range of methods within their analyses. 
Donovan et al (195) used the Payback framework to guide the questions asked in 
their researcher surveys and interviews when they evaluated the impact of 
research funded by the Australian National Breast Cancer Foundation. Montague 
and Valentim (193) used the Canadian Academy Health Services (CAHS) 
Framework. Rather than using the framework in it is original form, they arranged 
impact indicators from the CAHS framework within a hierarchy to illustrate 
impacts occurring over time. The authors distinguished short term, intermediate 
and longer-term changes resulting from one clinical cancer trial, aligning with 
the concept of categorising impacts based on when they occur, which was 
described in one of the literature review identified in part one of this study 
(170). 
(iv) Time-lags and impact attribution 
Lastly, the challenges of time lags and attribution of impact were identified and 
addressed by several of these empirical studies. Lewison and colleagues tracked 
the citation of over 3,000 cancer publications in UK cancer clinical guidelines 
over time, (188) and in their analysis Donovan et al (195) explicitly 
acknowledged that the short time frame between their analysis and funding of 
the research projects under evaluations was likely to under-estimate the impact 
achieved. Glover et al (39) used bibliometric analysis of citations in clinical 
cancer guidelines to estimate the average time from publication to clinical 
practice change (eight years). They added seven years to account for the time 
between funding allocation and publication of research results giving an overall 
time lag from funding cancer research to impact of 15 years. The challenge of 
attribution was addressed in one study by using a time-line to describe impacts 
occurring at different time-points but linking back to the original research in 
question (193). The difficultly of estimating time lags and attributing impact to 
cancer research were both specifically addressed in a companion study (196) to 
the one conducted by Glover and colleagues. In this study, instead of quantifying 
the return on cancer research investment, qualitative methods of assessment 
were used. This approach identified factors that enhanced and accelerated the 
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process of impact occurring and helped to provide a narrative to link impacts to 
research.  
3.4 Discussion 
This study identified existing reviews of approaches to evaluate the impact of 
research and empirical examples of the assessment of cancer research impact. 
The cancer research impact assessment examples were performed over three 
decades, and mostly evaluated research performed in high-income countries. 
The empirical examples of cancer research impact highlighted the huge 
investment into cancer research that currently exists, and the desire by many 
research organisations and funders to understand the return on that investment. 
These examples included studies supported or commissioned by the National 
Breast Cancer Charity in Australia , CRUK, the Wellcome Trust, the NIHR and 
Academy of Medical Sciences in the UK (39), the Chief Scientist Office in 
Scotland and the Medical Research Council (188), Genentech Ltd and the RAND 
Cooperation in the USA (192).  
Many of these evaluations acknowledged the contribution of both basic and 
applied cancer studies, and several studies categorised research publications 
based on this distinction. For example, Donovan and colleagues (195) 
successfully used the same approach to assess the impact of both basic and 
applied research. They found that basic research was more likely to have 
knowledge and product based impacts and to take longer to accrue impacts 
compared to applied, clinical studies that more frequently affected policy and 
health outcomes. 
Looking across the empirical examples identified, conclusions can also be drawn 
about what type of cancer studies were deemed most impactful by these 
authors. In their study (2008) on the impact of cancer research within the 
media, Lewison et al (189) found that the largest proportion of cancer studies 
cited in the media concerned novel treatments. The authors reflect that this is 
likely to be explained by the high research activity in the area of drug discovery 
and testing, and the advocacy of pharmaceutical and biotechnology companies 
that rely on media coverage to leverage support from their stakeholders. There 
were also studies cited in the media that focused on lifestyle choices preventing 
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cancer although no mention of research focusing on screening or cancer 
diagnosis. Breast cancer research also featured highly in several of these studies 
(39, 192, 193, 195), in particular, research on the treatment of breast cancer. 
Rather than concluding that breast cancer research per se is more impactful that 
research into other cancers, it is more likely this relates to the high incidence of 
breast cancer (most common cancer in women) and the new treatments that 
were tested clinically at the end of the 20th century.  
Looking at how the categories of impact assessed varied across the fourteen 
articles identified, academic, health/healthcare, policy and economic impacts 
were commonly assessed. The studies assessing academic impact only were all 
published in the 1990s, whereas those studies looking at how publications were 
being used in the media and in guidelines were performed in the 2000s. Both of 
the articles which adopted a multi-category approach to impact assessment and 
those focusing on the economic returns on cancer research that had been 
performed were conducted from 2010 onwards. These findings are likely to 
reflect the broadening in the concept of research impact over time, 
demonstrating how the field of impact assessment has evolved.  
Within the evaluations of health impact, there was a focus on survival, in 
particular in economic studies looking at the value of health gains. This reflects 
the high mortality rate of cancer as a disease entity and the importance of this 
as a measure of wider impact from cancer research specifically, contrasting with 
similar evaluations of musculoskeletal or mental health research, which have 
focused on improvements in morbidity (199, 200). Studies that analysed the 
number of patients diagnosed with cancer, or population-level survival gains, 
often used site-specific cancer incidence and other studies evaluated research 
relating to only one type of cancer (184, 187) (193, 195).  
Impact under the category of policy change from cancer research was also 
commonly evaluated and this was done using clinical practice guidelines. Policy 
citation was often used as an indicator of the time lag between research being 
performed and being used in clinical practice (39). Reflecting on this approach, 
using cancer guidelines as a surrogate for clinical practice change and health 
service impact does have drawbacks. For example, guidelines can often be 
outdated, irrelevant, or simply not used by cancer clinicians. Furthermore, local 
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hospitals often have their own local clinical guidelines, which may take 
precedence over national documents. Lewison and colleagues (188) identified 
that the location where research has been conducted has a strong influence on 
the likelihood of clinical guideline citation. Studies performed in a certain 
country were more likely to be cited in guidelines from the same location. This 
makes sense if we consider many of the ‘policy makers’ for clinical guidelines 
are clinicians and researchers who may be more aware of research being 
conducted in their vicinity. The other aspects of policy impact described in the 
broader literature (146), such as impact on policy agenda setting and 
implementation, were rarely assessed. 
The overview of reviews showed that the concept of valuing the economic return 
on research investment emerged as a field of study in the 1990s. Buxton’s review 
(100) of key studies that estimated the economic value of the impact of health 
research on society was performed in 2004 and commissioned by the WHO. This 
was closely followed by the formation of the UK Evaluation Forum (2004), which 
was initiated by the Academy of Medical Sciences, the Medical Research Council, 
and the Wellcome Trust. The aim of the UK Evaluation Forum was to co-ordinate 
activity in determining the socio-economic benefits of UK medical research, and 
it’s work led to one of the other literature reviews identified in this study (149) 
as well as informing the empirical example of estimating the value of cancer 
research performed by Glover et al (39). The other cancer specific studies which 
used this type of economic approach to evaluate impact that were identified in 
this study were performed by Ladawalla et al (192) and Brown et al (184) (see 
Table 3-4). All of these studies concluded that returns on medical research 
investment far exceeded expectations, with Glover and colleagues showing this 
was the case for UK cancer research specifically (39).  
Lastly, although several of the empirical examples of cancer research impact 
assessment did address numerous categories of impact, there were no specific 
examples of social, environmental, or cultural impacts arising from cancer 
research. This is not surprising considering these are potentially less expected 
impacts from cancer research, and more in keeping with impacts that would be 
expected from arts or social science research. Nevertheless, it raises the 
question of whether these impacts may exist if they were actively sought out, or 
137 
 
if they could exist if researchers thought about those impacts in the early phases 
of their research. Examples of these more unexpected impacts from cancer 
research could include research targeted at improving social inclusion regarding 
access to cancer screening and treatment, or identifying and reducing socio-
demographic inequalities where they exist. From a cultural point of view, cancer 
is a disease that affects all groups in society and there may be cultural 
differences with the approaches to care and treatment, especially around end of 
life care. There may also be an opportunity for cancer research to impact 
culture in terms of the arts, or for cancer researchers to work with those who 
work in the arts who may be able to disseminate cancer research findings in 
innovative ways so that it reaches a wider audience.  
In general, the categorisation of research impact will be useful when considering 
how to approach the impact of the SCOT trial, and the categories of health, 
policy and economic value would be reasonable to investigate in greater detail. 
Regarding health gain, the likely benefit from SCOT will be the reduction in 
peripheral neuropathy within a real world population after the SCOT trial results 
are implemented in practice. Policy impact could be investigated by focusing on 
clinical practice guidelines and economic impact may be approached by 
considering a form of monetisation of the benefits from implementing SCOT, 
drawing on lessons from Lakdawalla (192), Brown (184) and Glover et al (39).  
The methods of data collection and analysis (Table 3-2) commonly used in the 
empirical cancer research impact were bibliometrics, alternative metrics (media 
citation), documentary analysis, surveys, and economic approaches. All of these 
approaches may be suitable for assessing cancer trial impact, although if only 
bibliometrics or alternative metrics are used, the assessment is likely to provide 
information on academic impact alone. The method of collecting expert 
testimony from researchers was also utilised in the examples identified, but 
there were no obvious examples of testimony about the impact of cancer 
research from other stakeholders such as clinicians, cancer patients or their 
families.  
Methods less commonly adopted in the empirical cancer research impact 
assessments were interviews, using a scale, and focus groups. This may have 
been due to the time and resource implications of using qualitative techniques 
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and more in depth analysis. It would be most appropriate to use these types of 
methods applied to a cancer clinical trial if the rationale for conducting the 
assessment was to understand the process through which impact occurred, or to 
perform a more in depth analysis if barriers to impact occurring had been 
identified. An example of when this was done was in the study by Guthrie et al 
(201). Using interviews and documentary analysis, these authors constructed 
cases studies to assess the impact of specific cancer research studies or 
programmes of work. Adopting this approach, they were able to identify ways 
that the impact of cancer research could be maximised going forward. For 
example, across their case studies the authors learned that having infrastructure 
and networks between researchers and policymakers could speed up impact on 
policy. Having a champion for the research in question, for example, the chief 
investigator, who pushes the research findings to research users through 
dissemination activities can reduce the time lag to impact occurring.  
Despite the large number of framework examples identified from the previous 
literature (Table 3-3), only two of the empirical assessments, published after 
2010, used an impact framework (193, 195). The first example used the Payback 
Framework to assess the impact of a programme of cancer research.  This 
framework could be used to structure a survey or interviews with trialists or 
patients in order to understand the breadth and depth of impacts that are 
expected from a clinical cancer trial in development, or that have occurred from 
a completed cancer trial. In their review article, Hanney et al (146) provide a 
template for using the Payback Framework when conducting interviews, and 
there are previous examples of when the Payback Framework has been used to 
conduct surveys (195). The strengths of the Framework applied to cancer trial 
assessment are that it would encourage reflection on the original research 
question posed in the trial(s) in question, the inputs required to perform the 
trial(s), as well as the outputs and outcomes arising from the trial and its 
findings. The Framework also draws attention to the inevitable reservoir of 
knowledge that will exist whilst the clinical trial is being performed, which in 
turn influences the impact such a trial has on society. One drawback of the 
Payback Framework is that the list of categories and the logic model are 
separate entities, and do not overlap intuitively. 
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The second example of the use of a framework to assess cancer research impact 
identified from the overview of reviews was an iteration of the CAHS framework 
by Montague and Valentim (193). These authors provided a framework to 
structure the description of how impact from research is likely to occur, 
including a detailed list of impact categories and indicators. They authors chose 
a phase III cancer trial to demonstrate how their framework can be successfully 
applied, which is clearly very relevant when considering how to evaluate the 
impact of other cancer trials, such as SCOT.  
Other frameworks identified from the literature (Table 3-3) that may be 
appropriate for the assessment of cancer trials impact include Anthony Weiss’s 
logic model (202), the research impact framework (203), the research utilisation 
ladder (204) and the framework from Cruz Rivera et al (170). Their relevance to 
cancer trial assessment is discussed in more detail below. 
The research utilisation ladder (204) is relevant to cancer trials because it 
focuses on the application of research results in practice, with the researcher 
self-evaluating their own research. A limitation of any self-assessment approach 
is that it may lead to an over-estimation of the extent to which research has 
been used. Overall, despite its relevance, this framework lacks the breadth of 
impact categories and the structure to aid data collection and communication 
offered by other frameworks on this list. 
The Research Impact Framework (RIF) (99) consists of a comprehensive list of 
impact categories and indicators to evaluate the impact of health research. This 
has similarities to another of the frameworks identified (Table 3-3), the Becker 
model, although the latter was developed for biomedical research. There is no 
accompanying logic model or any indication of the how to prioritise the 
importance of the impacts described within the RIF. This could be seen as a 
disadvantage, however it also means there are no assumptions or restrictions 
regarding the process through which impact occurs, which may be direct or 
indirect. The categories and sub-categories of the RIF could be used to structure 
a cancer trial impact case study, to identify what type of data collection should 
occur and to build an impact narrative, either when a trial is being developed or 
once completed. It could also be performed for several trials simultaneously, 
which could then be qualitatively compared, for example, if making decisions 
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around trial investment or reflection on a collection of trials that have already 
been performed. This framework could also be applied to a survey or interview 
schedule to ask trialists, or users of cancer trial results, about the impact of that 
research. Overall, it is a good choice of framework to apply to cancer trial 
impact evaluation. 
Weiss’s medical research logic model (202) is highly relevant to the evaluation of 
the impact of cancer trials and is particularly well suited to evaluate the impact 
of a phase III trial that has met its primary endpoint. It is less obvious how it 
would be used to assess the impact of a trial that did not demonstrate efficacy 
or non-inferiority of an experimental treatment regimen, as the premise of the 
model is that the results of the trial are integrated into practice. In addition, it 
is not particularly relevant for the purposes of evaluating basic cancer research 
or earlier phase trials that are not expected to change practice. This model 
could be embedded or used alongside a wider impact evaluation framework that 
considers impacts that do not always rely on implementation of research 
findings.  
Lastly, Cruz Rivera et al (170) have produced a comprehensive impact matrix 
that merges several aspects of both the Payback Framework and the RIF. Their 
matrix uses a linear model to order the impact categories, providing an 
indication of when different impacts may occur over time, alongside indicators 
of impact that can be utilised within each category. The limitations of the 
frameworks are that the indicators are not provided in any form of easily 
accessible list and there is no indication as to whether the research inputs and 
activities form part of this pathway. Finally, it is not straightforward to pick 
apart the distinction between their categories of health and health systems 
versus health related impacts. Improved health outcomes are grouped under a 
sub-category describing quality of care and service delivery, which are not 
necessarily synonymous. Overall, it is not clear that this matrix offers a better 
approach to impact assessment over that would be achieved by using the RIF or 
CAHS impact indicators alongside the Payback Framework or Montague and 
Valentim’s framework.  
This process of comparing and contrasting impact frameworks has indicated 
which components of these frameworks would be useful to assess cancer trial 
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impact. A modified logic model, such as the Payback or CAHS Framework, is a 
useful platform which could be used to structure data collection and build an 
impact narrative. The Payback Framework can be adapted to make it more 
relevant to cancer trial research by inserting additional categories of impact 
within the logic model, such as the seven identified from the overview of 
reviews. Putting this idea into action, below is a diagram of an adapted Payback 
Framework. It is recommended that a list of impact indicators, such as those in 
the RIF or the Becker model, are used alongside this type of logic model to 
provide specific examples of the types of impacts that can be evaluated within 
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Reflecting on the findings from this overview of reviews and the examples of 
cancer research impact assessment that have been identified, Table 3-5 lists 
suggestions of how these findings can be used to guide the assessment of cancer 
research impact assessment in future, alongside an indication of how this advice 
could apply to assessing the impact of the SCOT trial in particular, to help guide 




Table 3-5 Recommendations for cancer research impact assessment 
Recommendation for cancer 
research impact assessment 
Lesson from this the empirical examples of cancer research impact 
assessment identified in this study 
Relevance to SCOT case study 
Identify the unit of analysis 
relevant to the assessment, for 
example a cancer centre, cancer 
research programme, one clinical 
trial, one study 
Many of these empirical examples chose to assess the impact of 
several studies. Montague and Valentim chose one clinical trial, 
showing it is possible to assess impact at the single study level. 
Focusing on one researcher alone is not encouraged.  
The SCOT case study will focus on one phase III RCT 
but it will be important to consider other trials/studies 
that may influence the impact of SCOT, for example, 
the IDEA collaboration, and other clinical trials 
currently in set-up. 
Identify the users of the cancer 
research, for example, 
patients/clinicians/funders. 
The users of cancer research can be the target of 
surveys/interviews/focus groups to collect information on impact. 
Alternatively, the researchers themselves can be the focus of surveys 
or interviews to collect information on how they perceive their 
research is being used. 
Relevant to the SCOT trial, the main users of the trial 
will be clinicians who prescribe adjuvant 
chemotherapy, patients who receive the 
chemotherapy and the healthcare systems that pay 
for the treatment and care for those patients.  
Identify the rationale for the 
impact assessment 
This rationale can be based around the 4 "As" and more than one may 
be relevant. The rationale for any assessment will help to inform the 
methods of assessment used. For example, if the rationale is to 
understand why and how impact occurs (analysis), the optimal 
methods may be interviews or case studies. If the rationale is mainly 
accountability, the main methods may be surveys and economic 
approaches.  
The SCOT case study is being used to test different 
approaches to impact assessment. The most obvious 
rationale for this study, which has already completed, 
would be to analyse if/how/why impact has occurred 
and to demonstrate accountability for the resources 
invested to perform SCOT. The rationale of allocation 
of future funds and advocacy are less relevant for this 
case study.  
Identify the main categories of 
impact relevant to the research in 
question. 
Within the cancer research examples identified in this study, there 
was a strong focus on health, policy and economic impacts.  
The categories of health, policy and economic impact 
are all relevant to the SCOT trial. Clinical practice 
impact is also highly relevant. 
Decide on which methods are most 
suited to the assessment. Be 
mindful of the strengths and 
limitations of each method. 
Surveys, interviews, documentary analysis, case studies and economic 
approaches were most commonly used in the empirical examples. 
Some methods and indicators of impact will be more suited to certain 
types of cancer research/clinical trials and it is necessary to be mindful 
of this if assessing more than one study. Care must be taken when 
making comparisons between the impact of studies. For example, 
The methods used in the SCOT case study will be 
chosen from these commonly used approaches listed. 
Thought will be given to the likelihood that SCOT 
impacted on practice and the fact that it was a non-
inferiority trial testing a reduction in treatment to 
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cancer research funded by pharmaceutical companies or testing new 
treatments in a topical area are more likely to be cited in the lay 
media, with increased awareness amongst the public. Also, cancer 
trials that test a reduction in treatment or those investigating 
treatments that are off-patent are more likely to be directly cost 
saving if using economic approaches whereas trials testing expensive 
treatments for health gain will be more impactful if assessing e.g. 
survival improvement, the value of any health gain. 
reduce toxicity, rather than an intensification of 
treatment with the aim of improving survival. 
Consider if a framework would 
help to collect data and 
communicate the results of the 
assessment 
There are six frameworks that have been identified from the overview 
of reviews that may be relevant to cancer research. Two that were 
used in the empirical examples were the Payback Framework and the 
modified CAHS by Montague and Valentim. A framework can also be 
used to structure surveys or interviews and this was done successfully 
in the study by Donovan and colleagues (2014). 
The six frameworks described above will be tested for 
their relevance to SCOT specifically.  
Consider the time and resources 
available to do any assessment and 
plan accordingly 
Documentary analysis using a framework to guide data collection is a 
good initial approach if time and resources are limited. More in depth 
analyses can be performed within several categories of a framework 
and using more than one method if time and resources allow. 
The time available to perform the SCOT case study 
analyses will be in line with the timeline for the overall 
doctoral study (approximately 3 years). The main 
resource will be researcher time. The researcher has 
expert clinical trials, statistical and health economic 
support for advice and access to SPSS and STATA 
software. Additional resources may require extra 
funding. Given these time and resources, it will be 
possible to do a number of in depth analyses, rather 





There are limitations of this study that must be acknowledged. Although the 
platform PROSPERO (205) was checked in advance to ensure a similar literature 
review was not being undertaken, the review protocol for this study was not 
registered in advance on the platform. This was an oversight and for any future 
studies this registration would ideally be performed. In addition, one researcher 
only (CH) screened the full articles for review, introducing potential selection 
bias into the review. Ideally there would have been two researchers available to 
screen the articles to improve reliability and validity of the final selection. This 
limitation was related to resource capacity and it was partly mitigated in this 
instance by using pre-defined inclusion and exclusion criteria in the screening 
process. The approaches to research impact identified from the previous 
literature were grouped under three main themes. Although there was space on 
the review proforma to collect other information deemed relevant to the 
research objective, if any other major themes regarding the topic exist, 
information on these themes was not systematically collected. Lastly, the 
literature search for review articles assessed the literature until April 2019. This 
meant that the empirical examples of cancer research impact assessment, by 
definition of their inclusion in those reviews, dated from before this time-point. 
There will undoubtedly be more recent examples of cancer research impact 
assessment that have been published which will not have been captured by this 
study. 
The two-part approach to this study was taken because of the anticipated 
challenge of conducting a primary review of empirical examples of cancer 
research impact evaluation, and to allow a critique of empirical studies in the 
context of lessons learnt from the wider literature. Justification for the approach 
taken is provided by looking at the titles of the articles identified. In only 14% 
(2/14) was the word ‘impact’ included, suggesting that performing a search for 
empirical examples of cancer research impact evaluation using traditional 
publication databases would have been challenging. Furthermore, all the studies 
identified were included within reviews of approaches to research impact 
evaluation, which negated the subjective decision of whether the studies 




Impact assessment is a way of communicating to stakeholders such as research 
funders and patients, the merits of undertaking cancer research and learning 
from previous research to develop better studies that will have positive impacts 
on society in the future.  This study is the first review to consider how to 
approach evaluation of the impact of cancer research specifically. The following 
chapter will look at publicly available research impact narratives to find 
examples of case studies describing the impact of cancer clinical trials.
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4 Chapter 4: Lessons on cancer trial impact 
assessment from the REF 2014 case studies 
4.1 Introduction 
Cancer trials are an essential component of cancer research and a key step in 
translating basic research findings to the clinic. In contrast to ‘blue skies’ 
research, clinical trials are usually focused on answering a specific research 
question, often asking if a novel approach to treatment is superior, equivalent, 
or not significantly worse compared to the current standard of care. As a type of 
applied research, performed at large expense and involving human participants, 
it could be argued that, out of the many types of cancer research that exist, 
clinical trials in particular should have real world impacts for patients and 
society.   
In Chapter 3, journal publications and the grey literature were both searched to 
identify key examples of when the impact of cancer research in general has been 
assessed. In order to understand how research impact assessment is relevant to 
cancer trials and how this assessment can be performed, it is useful to review 
previous examples of cancer trial impact evaluation specifically. As described in 
Chapter 1, the UK government allocates core research funding to higher 
education institutions based on an exercise known as the REF, and in 2014, 154 
UK universities were assessed in this way (206). For the first time in the history 
of this national funding allocation exercise, the impact of research performed by 
each university was evaluated by using expert review of narrative case studies. 
In this chapter, the REF 2014 case study repository was used to identify and 
analyse examples of cancer trial impact evaluation.  
Several authors have previously reflected on how universities evidenced the 
impact of their research in the REF 2014. Chowdhury, Koya and Philipson (17) 
reviewed 363 case studies in six disciplines from top or bottom ranking 
institutions and identified variables that predicted the average REF scores 
received by the institutions. For 92 case studies submitted under the discipline 
of Clinical Medicine, the number of publications in highly cited journals was the 
variable most consistently associated with higher REF scores. These authors also 
used automated word frequency analysis to identify themes of research 
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submitted under different disciplines. For Clinical Medicine, these included 
oncology, paediatrics, genetics, diabetes and heart disease research.  
Terämä et al (207) used computational text mining of the REF 2014 case studies 
to understand how higher education institutions interpreted impact. By analysing 
6,637 case studies, six classes of impact were identified (1 – Education; 2 – 
Public engagement; 3 – Environment & energy solutions; 4 – Enterprise; 5 - 
Policy; 6 – Clinical uses) and the class of impact described differed according to 
discipline. Similarly, a review of the REF 2014, commissioned by the Higher 
Education Funding Council for England, discovered that frameworks and 
taxonomies of impact were often context specific (208). Greenhalgh and Fahy 
(209) outlined 14 types of impact evidenced by higher education institutions in 
162 REF impact case studies describing the impact of primary healthcare 
research. They found that an influence on guidelines was most commonly 
described, followed by impact on informing policy change and changes in clinical 
or public health practice. 
The work reported in this chapter applies content analysis (see Chapter 2) to the 
REF 2014 case studies to understand how higher education institutions evidenced 
the impact of their cancer trials. The aim was to use this analysis in order to 
reflect on if, and how, impact assessment for cancer trials can be performed, 
and how impact evaluation can be improved, both for the REF 2021, and beyond. 
To meet these aims, the objectives of this study were:  
 to identify cancer trials included by higher education institutions in the 
REF 2014 case studies,  
 to quantify and explore the characteristics of these trials and the types of 
impacts they were claimed to have had,  
 to describe the types of evidence used by higher education institutions to 
substantiate those claims of impact, 
 to identify any examples of researchers or research users making active 




4.2.1 Overview of approach  
Content analysis was used for the purposes of this study and this choice of 
approach was based on the work by Greenhalgh et al (209). In the initial phases 
of this study, Professor Greenhalgh provided an example of the coding manual 
used for a previous analysis (209). That coding manual was not used for the basis 
of the manual in this study, but it still provided a useful example for the primary 
researcher (CH) of how coding manual is organised. The development of the coding 
manual for this content analysis is outlined in Chapter 2.  
4.2.2 Identification of a relevant sample for the purposes of analysis  
The REF 2014 impact case studies were publicly available via the REF 2014 website 
(31). Case studies were deemed relevant if they described the impact of one or 
more clinical cancer trials, with the cancer trial(s) being the main focus of the 
research described. In order to identify this sample, initially a search of the case 
studies was performed by combining the terms ‘cancer’ and ‘trial’ in the website 
search function (31). Several combinations of search terms were tried with the 
aim of producing the most sensitive search. The REF 2014 website has a simple 
search function and it was therefore not possible to search the title only or to use 
truncated words to capture a number of key search terms.  
This search identified case studies that included these words in any part of the 
submission (title, main text, or references). The case studies identified were read 
in full and the application of inclusion and exclusion criteria at this stage allowed 
the selection for final analysis.  Inclusion criteria required that the case study 
focused on the impact of clinical trials that prospectively recruited adult patients 
with a diagnosis of malignancy, or individuals without a known diagnosis but where 
the aim of the trial was to investigate the prevalence of cancer in future years, 
diagnosis, or screening of cancer. All stages of cancer and clinical trials of all 
phases were included.  Impact case studies were excluded if they described 
paediatric cancer trials. Case studies were also excluded if clinical trials were 
mentioned but were not the focus of the case study, for example if the case study 
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described basic science research and mentioned the development of a clinical trial 
as an example of the impact of that research.  
4.2.3 Content analysis 
The final version of the coding manual was used by the primary researcher (CH) 
to code all of the case studies and by LG to code five, randomly selected case 
studies. In Part 1 of the final coding manual used, the following information was 
recorded: (1) the institution responsible for the submission; (2) the Unit of 
Assessment and (3) the Summary Impact Type. For the clinical trials identified, 
the following key characteristics were extracted: (1) name; (2) phase of the trial; 
(3) type of cancer investigated; (4) focus of the trial (screening, diagnosis and 
treatment, other); (5) journal of publication cited in the case study; (6) category 
of funder; (7) primary endpoint; (8) if the primary endpoint was met. For the 
purposes of the final characteristic, trials were marked as positive if they met 
their pre-specified primary endpoint with statistical significance. For non-
inferiority trials, if the experimental arm of the trial was deemed to be 
statistically non-inferior than the control arm at the level of significance pre-
defined by the trialists, this was considered a positive result. For earlier phase 
trials such as phase I trials focusing on safety, if, for example, the authors set out 
to find a recommended phase II dose of a novel drug, and this was achieved and 
reporting in the trial findings, this was considered as having a positive result  
Part 2 of the coding manual captured the following information for each impact 
case study: (1) all categories of impact described; (2) examples of dissemination 
of trial information and results; (3) methods used by institutions to evidence 
impact; (4) clinical guidelines cited; (5) examples of when researchers or research 
users acted to enhance trial impact (32). This information was collected by 
reading and manually coding the ‘Details of Impact’ section of each case study. 
Final testing of this coding manual provided an inter-rater reliability score of 81%. 




4.3.1 Identification of impact case studies 
Out of 6,637 publicly available REF 2014 impact case studies, using the search 
word ‘cancer’ alone retrieved 494 case studies, the word ‘trial’ alone, 1120 and 
both together returned 234 case studies (Figure 4-1). Given that this search 
function returned all case studies that had the search terms anywhere within the 
case study, using both together improved the relevance of the search. The terms 
oncology (n=167), neoplasm (n=1) and malignant (n=63) were also used alone, and 
in combination with ‘trial’, but these searches did not identify any additional, 
relevant case studies compared to using the search strategy described above. 
 
Figure 4-1 Different search strategies applied to REF2014 case studies 
 
On reading the full submissions of these 234 case studies, 46 met the pre-
defined inclusion criteria. Figure 4-2 presents the search results and details the 












Figure 4-2 REF 2014 case studies search results 
 
4.3.2 Description of case studies  
The REF Unit of Assessment, Summary Impact Type, and name of institutions 
responsible for the submission for each of the final 46 case studies that met the 
study inclusion criteria are in Table 4-1. Nineteen (12%) out of 154 institutions 
participating in the REF 2014 submitted 46 case studies that specifically focused 
on cancer trials. Most of the higher education institutions were Russell Group 
Universities (89%; 16/19) (210), a members only association of 24 leading public 
research universities in the UK, whose member institutions submitted 68% of the 
highest ranked (4* outstanding) case studies in the REF 2014 (211). The majority 
(80%) of case studies describing cancer trials were defined as describing health 
impacts and most (83%) were in the field of Clinical medicine.  
 
 
REF 2014 Case 
studies available 
in database 
n = 6 637 
Included 
n = 46 
Returned results 




Full text review 
Excluded 
Not cancer research = 102 
Not trial research = 73 
Paediatric cancer = 6 
Cancer trials not main 
focus = 7  
Total n = 188 
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Table 4-1 Case study description (n=46 case studies) 
Code Number Percentage* 




    37 
8 
1 
      80% 
17% 
2% 
REF unit of assessment   
Clinical Medicine 
Public Health, Health Services and Primary Care 
Allied Health Professions, Dentistry, Nursing and 
Pharmacy 
Psychology, Psychiatry and Neuroscience 
Biological Sciences 





      83% 
   9% 
   4% 
   2% 
   2% 
Higher education institution (n=19)   
University College London 
Institute of Cancer Research 
University of Leeds 
University of Manchester 
Queen Mary University of London 
Imperial College London 
University of Cardiff 
University of Edinburgh 
University of Glasgow 
University of Nottingham 
University of Oxford 
University of Birmingham 
University of Bradford 
University of Bristol 
Cardiff University 
University of Cambridge 
King’s College London 
Newcastle University 






































  2% 
*May not add to 100% due to rounding.  
 
4.3.3 Description of cancer trials 
The number of trials specifically cited in each case study ranged from 1-7. 
Overall, 106 individual trials were referenced 110 times. The majority of trials 
identified (68%) were phase III randomised clinical trials and most trials focused 
on the treatment of cancer (88%); trials investigating screening and diagnosis 
were much less common at 5% and 4% respectively. A large proportion of these 






Table 4-2 Cancer clinical trial description 
Code Number Percentage 
Trials (n=110)*   
Trial focus 
Treatment of cancer or its side effects 
Screening 
Diagnosis 
Other (e.g. large observational trial to 


























Diagnoses of patients recruited to the included 








Central nervous system 
Head and neck (including thyroid) 






















Main source of clinical trial funding (n=110)**   
Industry only 
Charity and Research 
Council/Government/University 
Research Council/Government/University only 
Unknown 
Charity and Industry 

















*Each clinical trial (n=106) was counted for each individual case study in which it was mentioned 
(a total of 106 trials mentioned in separate case studies 110 times).  
 
The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial (212) was 
discussed in five separate case studies by four universities (213-217). The ATAC 
trial investigated the efficacy of an oral aromatase inhibitor compared to an oral 
anti-oestrogen, for the adjuvant endocrine treatment for postmenopausal 
women with hormone receptor positive, localised breast cancer.  When the same 
university submitted more than one case study describing the same clinical trial, 
the first case study focused on the impact on clinical practice change worldwide 
156 
 
and the sales for the drug company responsible for the production of the 
aromatase inhibitor (215). In the second case study, the focus was on subsequent 
research which was possible because of knowledge generated by the clinical trial 
(216). Impacts described in the other three ATAC trial case studies included the 
provision of tumour specimens for translational research and investigation of 
novel biomarkers (217), citation of the trial results in guidelines, and subsequent 
impact on clinical practice and breast cancer relapse (214, 217).  
The Prostate Testing for Cancer and Treatment (ProtecT) trial, (218) which was 
still recruiting at the time of the REF 2014 submissions, was described by two 
universities as an example of their work (219, 220). Both institutions outlined 
the collaborative approach to designing and performing this trial and the impact 
that the background work for the trial contributed to the concept of active 
monitoring for men with prostate cancer and on providing evidence to support a 
government decision not to introduce prostate cancer screening. 
As shown in Table 4-2, there were often collaborative funding streams for these 
clinical trials from industry, the charity sector and government led research 
councils. Figure 4-3 shows that the journals of publication included both cancer 
specific journals and those aimed at a more generic clinical readership. The 
most common primary outcomes evaluated were overall or cancer specific 
survival (18%; 20/110) or a measure of disease recurrence or progression (18%; 
20/110). Several trials used a co-primary endpoint (16%; 18/110). Although most 
trials (78%; 86/110) met their primary endpoint, one fifth of trials (20%; 22/110) 




Figure 4-3 Most frequent journal of publication for cancer trials identified from REF 2014 
case studies 
 
4.3.4 Categories of cancer trial impact 
The frequency with which different categories of impact were identified in the 























1. New knowledge and immediate research outputs 39  85% 
1.1 New knowledge generated directly from clinical trial. 38  83% 
1.2 New knowledge from clinical trial has contributed to a secondary 
analysis e.g. systematic review or meta-analysis. 
3  7% 
2. Capacity building for future research 24  52% 
2.1 Clinical trial has contributed to the development (or intentional 
ceasing of the development) of further research, clinical trials and 
researchers. 
19  41% 
2.2 Clinical trial has led to collaboration and/or data sharing. 3 7% 
2.3 Clinical trial has led to training of future clinicians and 
researchers. 
5  11% 
2.4 Clinical trial has led to innovation and novel infrastructure (other 
than health service related) e.g. the development of a novel 
technique or tool by a commercial company. 
4  9% 
3. Policy and guidelines 43  93% 
3.1 Clinical trial has influence policy agenda setting. 7  15% 
3.2 Clinical trial has led to a treatment approval (e.g. drug, device, 
procedure licensing, or marketing approval). 
15  33% 
3.3 Clinical trial contributed to clinical guidelines. 39  85% 
3.4 Clinical trial contributed to other public policy e.g. government 
policy. 
6  13% 
3.5 Clinical trial has provided justification of the implementation of 
existing policy. 
4  9% 
4. Health sector (Health service) 16  35% 
4.1 Clinical trial has influenced/benefited health service 
delivery. 
16  35% 
                        Health sector (Clinical practice) 37  80% 
4.2 Clinical trial has changed clinical practice and actual clinical 
practice has been evaluated. 
19  41% 
4.3 Clinical trial has changed clinical practice and potential or 
estimated clinical practice has been evaluated. 
30  65% 
5. Improved Health for patients and public 32  70% 
5.1 Clinical trial has contributed to improved health for patients 
(other than those in the trial) and actual health changes have been 
evaluated. 
7  15% 
5.2 Clinical trial has contributed to improved health for patients 
(other than those in the trial) and health changes have been 
estimated. 
29  63% 
6. Economic impact 25  54% 
6.1 Clinical trial has led to direct cost savings for the health 
service. 
12  26% 
6.2 Clinical trial has shown benefit of a diagnostic or management 
strategy that is cost effective. 
8  17% 
6.3 Clinical trial has led to measured or estimated benefits for the 
macro economy e.g. sales of drug for a pharmaceutical company, 
setting up a new spin off company. 
10  22% 
6.4 Clinical trial has led to measured or estimated benefits to the 
macro economy from a healthy workforce e.g. patient returning to 
work earlier. 
1  2% 
*Sub-categories not mutually exclusive 
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Most case studies (93%) described the impact of cancer trials on policy, and in 
particular, the citation of trial results in clinical guidelines. A list of the ten 
clinical guidelines in which these trials were most cited is in Figure 4-4. None of 
the case studies referred to social or cultural impacts of clinical trials. One case 
study did explain that a clinical trial had changed ’culture and behaviour’, but 
on reading the narrative this was coded as a change in the prescribing practice 
of clinicians (221). Another case study (222) discussed differences in cancer 
screening uptake between different socioeconomic groups which was partly 
identified by a clinical trial and has led to funding for a future trial to 
investigate and tackle this problem. There is potential for this subsequent trial 
to have substantial social impact if it successfully identifies ways to address this 
screening uptake imbalance.  
 
Figure 4-4 Guidelines most frequently reference in REF 2014 case studies 
 
4.3.5 Dissemination and knowledge transfer 
Overall, half (50%, 23/46) of case studies mentioned at least one type of 
dissemination. These examples were divided into a description of the publication 
of trial results in an academic journal (20% of case studies; 9/46), citation of the 
results publication in other academic articles (7%; 3/46) or other methods of 
communication (35%; 16/46) such as reports in the lay or social media, patient-
facing websites and conference presentations. 
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4.3.6 Methods of evidencing cancer trial impact 
Common methods used by higher education institutions to evidence the cancer 
trial impacts that were identified included: (1) identification of citations of trial 
publications in policy documents (78%; 36/46); (2) interrogation of real-life 
patient or population level data on clinical practice or health service use (52%; 
24/46); (3) the use of expert or user testimony (30%; 13/46); and (4) surveys 
(both quantitative and qualitative) (15%; 7/46). Testimonies were only from 
researchers and funders, with none from policymakers or patients. Although 
many (70%; 32/46) case studies described the impact that cancer trials had on 
changing health outcomes, only seven (15%) described an actual, rather than 
predicted or estimated, change in health of patients (Table 4-3). Several (39%; 
18/46) universities specifically quoted the monetary value of the funding linked 
to the research described in their case studies, totalling approximately £90 
million. None incorporated this monetary value in an estimation of the economic 
return on research investment.  
4.3.7 Researchers and research users enhancing cancer trial 
impact 
A minority (15%; 7/46) of case studies mentioned that researchers actively 
enhanced the impact of a clinical trial. Examples included researchers 
interacting with policymakers to give advice on how to pilot implementation of 
clinical trial findings (223) and researchers making efforts to ensure trial findings 
are presented in the lay media, health blogs, and charity websites (221). There 
was also an example of researchers training clinicians in the selection of patients 
that would benefit from radiotherapy treatment that had been developed in the 
context of a clinical trial (224). There was one example of when a research user 
enhanced the impact of a cancer trial. This occurred when a patient used the 
results from a cancer trial to  lobby the UK government to fund a novel drug to 
treat breast cancer for treatment of patients within the UK (225).  
4.4 Discussion 
There have been prior reviews of the REF 2014 case studies (17, 207, 209, 226, 
227), but this is the first analysis that focuses specifically on cancer research or 
clinical trials. This study shows that UK universities recognise cancer trials as 
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impactful research undertaken at their institutions. The relatively small number 
of universities submitting cancer trial case studies implies that this type of 
research is concentrated at specific locations. Over half of the case studies 
described the impact of more than one trial, raising the question of whether it is 
feasible to expect a single, rather than a combination of trials or a programme 
of trials research, to lead to tangible impacts on patients and society.  
Conversely, a number of different universities described the impact of the same 
trial, illustrating the collaborative approach adopted at those institutions.  
Trials recruiting patients with breast cancer constituted over a third of the 
cancer trials described as impactful by universities in the REF 2014; a much 
greater proportion than those recruiting patients, for example, with lung cancer 
(7%). This is not reflective of the actual, real world disease burden (228). For 
example, although breast cancer is the most common cancer (15% incidence) in 
men and women combined in the UK (229), lung cancer has the highest mortality 
rate and accounts for over one fifth of all cancer deaths (230). This over-
representation of breast cancer research aligns with the findings from the 
literature review in Chapter 3, which showed that that many published examples 
of cancer impact assessment also focused on breast cancer. Rather than implying 
that breast cancer trials are intrinsically more impactful, the focus on breast 
cancer in these case studies is more likely to align with the landmark trials that 
reported results within the assessment REF 2014 eligible period (1993-2014). 
There were no cancer clinical trials identified in the REF 2014 that reported the 
benefits of modern immunotherapies, widely regarded as a major recent 
advance in cancer treatment. Again, it is likely that this reflects the publication 
dates of key trials investigating immunotherapy, which commenced around 2010 
(231) and it will be interesting to explore if case studies describing 
immunotherapy trials are submitted to the REF 2021.  
This study has demonstrated that, in the REF 2014, higher education institutions 
did not exclusively use clinical cancer trials that met their pre-specified primary 
endpoints as examples of impactful research. (This is distinct from trials which 
do not meet their primary objective, which may be, for example, to recruit 
sufficient patients to answer a specific research question). Those trials described 
in the REF 2014 which did not statistically meet their primary endpoint included 
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the LIBERATE trial (232) and the FOCUS2 trial (233). The LIBERATE trial closed 
early because it had recruited enough patients to demonstrate an increase in 
breast cancer recurrence occurred in patients being managed with hormone 
replacement therapy to treat symptoms following cancer treatment. The 
submitting university argued that the impact of this trial was a change in 
guidelines to prevent subsequent use of hormone replacement therapy for this 
group of patients. Another example was the FOCUS2 trial, (233) which tested the 
optimal treatment for elderly and frail patients with metastatic CRC. Although 
the trial did not meet its primary endpoint, it demonstrated the feasibility of 
recruiting patients from an often under researched patient cohort. It also 
provided important information around toxicity and quality of life that has 
subsequently been cited in clinical guidelines and changed clinical practice. This 
demonstrates that the pathway to impact is not solely dictated by practice-
changing trials that demonstrate a novel treatment is beneficial compared to the 
standard of care, but that practice-affirming trials may be impactful by 
preventing harmful variation in practice (234, 235). 
The fact that some higher education institutions used early phase trials as 
standalone examples of impactful research in the REF 2014 shows that robust 
examples of real-life impact do not only emerge from large, later phase trials. 
As an example, a portfolio of trials which demonstrated the safety, optimal 
dosing and blood brain barrier penetration of a drug to treat brain tumours, led 
to both direct (licensing of the drug) and indirect impacts (a phase III trial 
performed at another institution, subsequent introduction of the drug into 
routine practice and increased revenue for the pharmaceutical company) (236). 
Another case study described the impact of early phase trials investigating the 
use a targeted treatment for patients with BRCA associated breast and ovarian 
cancer. The significant improvement in outcomes for this sub-group of patients 
meant these trials directly influenced international guidelines for genetic testing 
and led to further research investment and collaboration with industry for that 
institution. Submission guidelines indicate that examples of indirect impact will 
be welcomed in the REF 2021 (237, 238). 
The ten journals in which the clinical trials described in these case studies were 
most frequently published all had a journal impact factor over 5 and the top 
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three had a Journal Impact Factor above 25 (239). Also, one fifth of the case 
studies mentioned academic journal publication or citation of clinical cancer 
trials in other academic literature. This supports the findings from Chowdhury, 
Koya and Phillipson (17) that, although not an article level metric, and not a 
measure of impact, the research outputs underlying REF 2014 impact case 
studies were often published in journals with a high average citation count. This 
is likely to be driven in part by the REF requirement that the research described 
in the impact case studies is of high quality. Whether all high quality cancer 
research will necessarily be published in a high impact factor journal is 
debateable. For example, basic science projects, or studies in more niche areas 
of cancer research, such as radiation physics or investigation into rarer cancers, 
may be of high quality but will not be of sufficient interest to a wide readership 
to be included in major journals. Impact factor is not a useful term and should 
be considered a misnomer given that the term impact is now being used more 
frequently to refer to wider downstream effects from research rather than 
journal citation counts.  
Clinical practice impact was commonly discussed in these case studies. This 
study showed that clinical practice impact in the REF 2014 was often estimated 
by stating the results of clinical trials and predicting the real world changes that 
would occur if the findings were implemented. This was the same approach to 
impact assessment used in Chapter 3 in the study by Montague and Valentim 
(193). In contrast, only a small number of case studies evidenced actual impact 
that had occurred using methods such as the analysis of national audit data 
(224), quantification of drug sales to indicate practice change, (217, 240) or 
referencing epidemiological studies to show improved health outcomes (221). 
Describing actual impact presents significant challenges in terms of timelines 
and planning but gives a much stronger indication of the real-life benefits from 
cancer trials compared to estimations of potential impacts. Although there is no 
specific guidance for the REF 2021 that indicates demonstrable impacts will be 
scored more highly than predicted impacts, informal conversations with 
individuals involved in REF 2021 case study development have highlighted that 
universities are looking for stronger examples of actual impact for their case 
studies for the upcoming assessment. In addition, there was not much focus 
within these case studies on how much investment, financial or otherwise, was 
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required to perform the research described, nor was there reflection on the 
return on any investment. For the REF 2021 and beyond, this approach may be a 
useful way for universities to evaluate the impact of their cancer trials and to 
attribute impact to specific trials and investments into those trials. 
This study has shown that around half of case studies describing cancer clinical 
trials in the REF 2014 included a description of dissemination of research 
findings, and only a limited number of case studies described the process by 
which researchers or research users acted to maximise research impact. These 
findings do not imply that researchers or research users did not play an 
important role in the promotion, implementation, and the wider impact of 
cancer trial findings, but if this did occur, it was not identified by universities as 
important part of their impact narrative within these case studies. In addition, 
many examples of cancer trial impact from the REF 2014 case studies were 
predictions of impact. If these types of descriptions of impact are encouraged 
and rewarded by the government, there is no incentive for researchers and 
institutions to actually maximise the impact from cancer trials in real life.  
The independent review of REF 2014 led by Lord Stern (241) suggested a bigger 
emphasis should be placed on public engagement for the next REF period, 
however, this guidance has not changed for the REF 2021 (242). This contrasts 
with Australia’s new research assessment exercise (see Chapter 1), which 
includes engagement of the public by researchers as a key component that will 
be rewarded in their funding allocation framework. The REF also contrasts with 
an approach developed by several European nations and led by the Netherlands, 
which focuses on the productive interactions between science and society. 
Specifically, this consortium of nations has developed the SIAMPI framework (see 
Chapter 3 Table 3-3) which focuses on learning from impact assessment to 
develop and improve research institutions, and does not include a scorecard 
component. Government policy makers in the UK have a responsibility to drive 
an impact agenda that will improve future research and encourage institutions 
and individuals to increase trial impact. It would be beneficial if efforts to 
promote and maximise research impact this was explicitly incorporated into 
future REF guidance and rewarded in future REF assessments. 
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Lord Stern also suggested in his report that higher education institutions should 
be allowed to re-submit the same case study in 2021, recognising that the time 
lag (see Chapters 1 and 3) to impact that may occur. There is now guidance for 
the REF 2021 that resubmission of case studies will be allowed as long as new 
impacts from the same research have occurred. We know from this study that 
several institutions described the impact of the same clinical trial; this will be 
allowed in the REF 2021, but the REF guidance specifies that the contribution of 
the specific institution to the research in question is made clear. Finally, 
another difference that has been observed in the REF 2021 submission guidance 
compared to 2014 that is specific to Panel A (which includes Clinical Medicine), 
is that the experts reviewing submissions to this Panel will no longer prioritise 
the use of quantitative methods to assess and communicate impact when they 
are scoring the impact case studies. This may lead an increase in the use of 
more qualitative methods, such as qualitative surveys, testimonies, interviews, 
and focus groups, for submissions in 2021 compared to 2014.  
This study has shown that the lack of publicly available scores for REF impact 
case studies means that it is impossible to tell what type of clinical cancer trial, 
and which type of impacts, were scored favourably by the REF expert reviewers. 
The lack of insight into these scores could be viewed as beneficial, in that the 
influence of the subjective view of REF expert reviewers and the government on 
setting the impact agenda is reduced. Alternatively, publishing the impact case 
study scores would increase transparency around the REF evaluation process and 
would stimulate conversations around what does constitute an impactful cancer 
trial. Currently, it is difficult to have this conversation as there is a gap in 
understanding around which case studies in 2014 scored most highly.  
Lastly, policy impact has been identified in this study as an example of cancer 
trial impact that is important and relatively easy to measure. If policy impact is 
viewed as important and rewarded by the government via the REF, a 
straightforward way to maximise this impact is to recognise its perceived 
importance and for policy makers to mandate that major professional bodies 
update their guidance in a timelier manner. Trialists and patients could help the 
process of policy impact by lobbying policy makers and institutions to prioritise 
guideline updates.  
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Overall, the REF has several strengths. First, the inclusion of impact assessment 
within the REF exercise has brought impact assessment into the spotlight, and 
forced higher education institutions across the UK to consider the wider impact 
of the research they perform. It has helped to change the focus of research away 
from academic publications, and asked researchers to adopt a broader, societal 
view of research quality. Encouragingly, REF does not evaluate impact using a 
single metric, but rather asks for impact narratives which allows the impact of 
any research to be contextualised and discussed. The drawbacks of the REF in its 
current form include the lack of transparency around scoring and the inevitable 
bias and subjectivity that will accompany any expert review, especially as many 
of the individuals scoring the case studies will be experts in their fields, rather 
than experts in impact assessment. The aim of the REF is for allocation of 
resources, and there is little focus currently on learning from the impact case 
studies written for the exercise. In addition, creating the case studies comes at 
a huge cost for universities, in the hope that the direct return on investment in 
terms of funding awarding for a highly scoring case study will be worthwhile 
financially. The cost-effectiveness of performing the REF exercise itself would 
be improved with more focus on reflecting on the pathways to impact and 
maximising societal impact of future research. 
The lessons learned from this study that are relevant to assessing the impact of 
cancer trials are outlined in Table 4-4, alongside a description of how these 
lessons will be considered when planning and performing the SCOT trial impact 
case study in part II of this doctoral study.  
167 
 
Table 4-4 Lessons learned from this study regarding cancer trial impact evaluation and how these apply to the SCOT trial case study 
Lessons learned regarding cancer trial impact assessment Considerations for the SCOT trial impact case study 
"Negative" trials that do not meet their primary endpoint 
can be impactful (E.g. LIBERATE and FOCUS2). 
SCOT did meet its primary endpoint and demonstrated non-inferiority of 3 versus 6 months 
of treatment. However, the IDEA collaboration did not show non-inferiority in the overall 
population. Consideration may be given to if different types of impact are relevant for 
“negative” versus “positive” trials. 
Policy impact was commonly assessed in REF 2014 using 
clinical guideline citation.  
Guideline citation for one trial such as SCOT is a relatively straightforward assessment 
exercise and therefore will not be the focus of an in-depth analysis. If policy impact was 
being assessed for more than one trial, this would require more time and resource. This type 
of analysis for a number of trials simultaneously may be helped by using software, such as 
that used in the study by Lewison et al (Chapter 3).  
Clinical practice and health impact were often mentioned in 
these case studies by discussing trial results and predicting 
their effect on practice/health, but this was rarely 
evidenced using real world data. 
This is a gap that could be addressed in the SCOT case study by investigating how feasible it is 
to demonstrate actual clinical practice/health impact attributable to cancer trials. Relevant 
to the SCOT trial, these impacts would be a change in prescribing adjuvant chemotherapy for 
CRC and a reduction in subsequent toxicity from treatment, especially peripheral 
neuropathy.  
Many REF case studies described the impact of more than 
one trial and several clinical trials were described as 
research performed by several universities. 
When assessing SCOT, one must be mindful of any/all CTUs that contributed to design and 
set-up, as well as all of the centres and countries that recruited patients. In addition, SCOT 
was part of a pre-planned pooling of data with that from other trials/countries in IDEA and 
the impact of SCOT will be influenced by the reservoir of knowledge that exists from previous 
and other current trials. 
Those REF 2014 case studies which used headings and 
categories of impact within their narrative were easier to 
understand. 
As decided in Chapter 3, the categories of impact that will be considered for the SCOT case 
study will be policy, clinical practice, health and economic impact.  
None of the REF case studies mentioned the use of a 
framework to collect or communicate impact data. 
Several frameworks have already been identified (Chapter 3), which will be tested for their 
relevance to the SCOT trial.  
A list of indicators of impact relevant to cancer trials has 
been compiled as part of the coding manual used to 
perform content analysis for this study.  
This list was partly based on the list of indicators included in the Research Impact Framework 
(RIF) described in Chapter 3, but it was altered to better reflect indicators relevant to cancer 
trials. This list included in the coding manual has been reviewed to identify which indicators 
are likely to be most relevant to the SCOT trial. This list can be found at this link: 
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http://researchdata.gla.ac.uk/1135/ . These indicators will be used to guide data collection 
to build the SCOT clinical trial impact narrative. 
Higher education institutions are likely to have picked their 
most impactful trials for this REF 2014 exercise. This means 
it is not clear how their approaches to impact assessment 
would compare if they were asked to describe the impact 
of all cancer trials performed at their institution, some of 
which are likely to be less impactful. 
The SCOT trial was selected for this case study because it was a large study performed by 
Glasgow CTU. Consideration can be given to how these approaches may apply to trials that 
do not meet their primary endpoint or to smaller, earlier phase trials. 
Impact assessment in these case studies was strongly 
influenced by when the trials recruited and published their 
results (with the dates stipulated in the REF guidelines) and 
the time-lag to impact occurring. 
The SCOT case study for this research project will be done in the early years following the 
SCOT trial publication. It is important to recognise that the same case study performed in 10 
years would look different because impact will change and mature over time and as new trial 










There are several limitations to this analysis. Firstly, as with any review of the 
REF 2014 impact case studies, these case studies were not specifically intended 
for this type of secondary analysis. Consequently, the data used was not 
collected to align with the research question, which was to explore existing 
methods of approaches to evaluate the impact of cancer trials. Secondly, 
although having content validity for this study, the list of indicators of impact 
used to code these case studies will not be an exhaustive list of cancer trial 
impacts. In addition to the timeline restrictions regarding which cancer trials 
could be presented within the REF 2014 case studies, it is also important to 
recognise that universities will have picked the small number of cancer trials 
they perceived were the best representation of their work in terms of 
demonstrating impact. This means that the majority of the cancer trials 
performed by these universities are not being presented or assessed within this 
impact analysis, therefore it is not clear if the same approach to assessment 
used in the REF 2014 can be used across a whole programme of trials, which will 
include trials deemed less impactful by universities.  
The method of assessing inter-rater reliability that was used during development 
of the coding manual was a comparison of the number of identical responses 
between individuals, expressed as the percentage agreement between individuals. 
This is a recognised way to assess reliability and has the advantages of being 
simple to calculate and directly interpretable. The disadvantage of this measure 
is that it does not take into account the agreement that may occur due to chance 
and as such, may overestimate true agreement. This is more problematic with an 
increasing number of raters testing the assessment instrument. An alternative 
approach to estimate inter-rater reliability of the dichotomous, categorical data 
presented in this study would have been the  Cohen’s kappa (108). This is 
calculated by comparing the observed proportion of agreement between 
individuals to the predicted agreement based on chance. Both Cohen’s kappa and 
the predicted chance agreement are calculated using specific formulae (243, 244). 
The disadvantage of this approach is the lack of agreement on what level of kappa 
is acceptable, especially with regards to healthcare research (244). If the content 
analysis for this study had used continuous codes, inter-rater reliability would 
have been best evaluated using intra-class correlation (ICC) (245).  
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The result of this content analysis was a quantification of patterns identified in 
the impact case studies. An alternative approach would have been to adopt the 
similarly named but distinct approach of ethnographic content analysis or a 
qualitative analytical approach such as the application of grounded theory or 
thematic analysis. These methodologies emphasise both the role of the researcher 
and the context within which the documents are generated when constructing the 
meaning of the message in the documents being analysed. Usually, categories and 
themes emerge from the primary data (95). Quantitative content analysis was felt 
to be most appropriate for this study because the key objectives were to identify, 
describe, and quantify the characteristics of the cancer trials used by higher 
education institutions, and to what extent different categories of cancer trial 
impact were described in a systematic and structured way. The documents being 
analysed were secondary data sources and some aspects of the data were single 
words or phrases, rather than text, which would not have been amenable to purely 
qualitative analysis. In addition, the aim was to collect this information in a 
systematic and structured way rather than to explore any deeper meaning or 
themes around these trial characteristics. Finally, the categories of impact and 
methods for impact analysis of interest had already been generated from a review 
of the previous literature (Chapter 3), therefore the aim was not to explore new 
categories or methods emerging from the case studies. 
For the purposes of this study, the focus was on evaluating research impact. 
Going forward, it would also be useful to make an assessment of the investment, 
both economic and non-monetary, into cancer trials. This would allow the 
impact of trials to be contextualised in terms of the investment provided from 
funders, and burden for patients from participating in these trials (246). In 
addition, a binary assessment to indicate if the primary endpoint was met for 
each trial was used in this analysis. In future, this could be evaluated in greater 
detail by also looking at secondary endpoints or widening the evaluation to 
explore if a trial met its objective to recruit sufficient patients to answer a 
clinical question.  
It will be useful to repeat this exercise using the REF 2021 case studies to 
identify which cancer trials conducted during the REF 2021 time period 
(underpinning research in the period 1st January 2000 to 31st December 2020) are 
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regarded as most impactful by higher education institutions, and to understand 
how the methods of impact assessment have changed. Although not coded for 
the purposes of this study, a comparison of the dates of both the initial 
publication of clinical trial findings and the impact evidenced would be useful. 
This would improve understanding of the time taken to achieve impact from UK 
cancer trials. In one of the empirical studies identified in Chapter 3, the time lag 
from funding to clinical practice was estimated to be in the order of 15 years for 
cancer research (39). A better understanding of time lags specifically for cancer 
trials would provide insight into when an analysis of the return in cancer trial 
investment should ideally be performed and may identify opportunities to speed 
up impact in some scenarios (196).  
If an analysis is repeated using the 2021 submissions, it will be important to 
realise that any changes in approach to impact assessment and the impacts from 
cancer trials described in the case studies may relate to multiple factors. These 
include the clinical trials themselves, changes in submission requirements for 
the REF 2021 and lessons learnt from 2014 by expert reviewers regarding how 
they value impact and how they carry out this assessment.  
4.5 Conclusion 
This study has identified previous examples of cancer trial impact evaluation and 
described the strengths and weaknesses of different approaches to the 
evaluation of those trials. This study will be helpful to institutions in any country 
that conducts cancer trials, in particular in the UK as higher education 
institutions prepare their REF 2021 submissions. This study will also allow cancer 
trial funders to contextualise responses received when trialists describe the 
actual or potential impact of their work. Reflecting on the lessons learned 
regarding research impact assessment, how it has been performed previously for 
cancer research (Table 3-5 Chapters 3), and specifically for clinical cancer trials 
(Table 4-4 Chapter 4), the next section of this study will apply some of these 
lessons to assess the impact of the SCOT trial (Chapters 5-8).
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Linking Part I and Part II 
Part I of this thesis includes Chapters 3 and 4. The results from these Chapters 
were used to inform the analyses undertaken in Part II (results Chapters 5-8), 
which describe in-depth analyses of the impact of the SCOT trial. In Chapter 5 
surveys were used to explore clinical practice impact, Chapter 6 focused on 
economic impact and the analyses presented in Chapters 7 and 8 look at if, and 
how, the clinical practice and health impact of the SCOT trial can be assessed. 
Below is a description of how the results from Chapter 3, the overview of 
reviews and identification of examples of cancer research impact assessment, 
and Chapter 4, a review of REF case studies of cancer trial impact, informed the 
direction taken for the analyses reported in the subsequent Chapters.  
The findings of Chapter 3 demonstrated that policy, clinical practice, health, 
and economic impacts have been frequently assessed in previous evaluations of 
cancer research impact. These were also the categories of impact commonly 
described in the REF 2014 cancer trials case studies (Chapter 4). Given that 
SCOT was a phase III RCT that demonstrated non-inferiority between a new 
approach to treatment compared to the standard of care, these categories were 
all deemed relevant to SCOT and candidates for further investigation in this 
study.  
Policy impact of cancer research was often evaluated the REF case studies 
(Chapter 4) by assessing citation of research results within clinical guidelines 
written by medical professional bodies. This approach was also used in one of 
the study be Lewison et al (188) identified in Chapter 3. Although very relevant 
to the SCOT trial, this approach to impact assessment was not chosen to test in 
further detail in this study because it was considered that manually identifying 
the SCOT trial publication citation within guidelines could be performed in a 
relatively straightforward manner. If assessing the policy impact of a programme 
of trials, rather than a single trial, this endeavour would be more suitable for an 
in depth analysis and the work by Lewison and colleagues demonstrates one way 
this could be done using specific bibliometric software.  
The next category, clinical practice impact, was considered very relevant to the 
SCOT trial. Both surveys and interviews were identified as potential methods to 
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test clinical practice impact and relevant groups to survey/interview were users 
of the SCOT results, such as clinicians and patients, or alternatively, the SCOT 
trialists themselves. The previous work by Donovan et al (195) provided a good 
example of how to use a survey to ask cancer researchers how their work has 
impacted across a number of impact categories. Guthrie et al (196) showed that 
using informal interviews of researchers could provide information to build 
narrative case studies describing the impact of cancer research. In contrast, 
there were few examples identified in Chapter 3 and 4 of using surveys or 
interviews of research users, such as patients or clinicians, and this may have 
been linked to the time and resources available to perform these previous 
analyses.  
For the purpose of this study, a survey of clinicians was chosen as the preferred 
method to take forward for testing, with the aim that this approach could 
quantify the extent of implementation of the SCOT trial results. 
Surveys(195)Surveys rather than interviews were used initially to assess a high 
number and broad range of clinicians from a number of different locations. It 
was acknowledged that interviews of a small number of clinicians could be used 
in an additional analysis, if barriers to practice change were identified within 
the survey. The results of the survey are presented in Chapter 5. 
The results of the first survey presented in Chapter 5 led to consideration of how 
to evaluate the economic impact of the practice change identified. The work by 
Brown et al (184), Glover et al (39) and Lakdawalla et al (192) stood out in 
Chapter 3 as previous approaches to the assess the value of cancer research 
which could be tested specifically for the SCOT trial. Brown et al (184) 
estimated the social return on the research investment by the National Institute 
of Health (USA) to perform clinical trials investigating adjuvant treatment for 
colon cancer. The authors made assumptions to predict adoption of the clinical 
trial results into practice and calculated the number of deaths averted due to 
adoption of this new research evidence. In order to calculate the return on 
research investment ($1.66 billion USD), the cost of treatment (($10.8 million 
USD between 1978-1990), including an estimate of lost earnings during 
treatment, was subtracted from the value of deaths averted (valued by 
calculating the net value of average remaining lifetime earnings ($2.01 billion 
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USD)). The strengths of this analysis were the use of within trial and real world 
cost information, whereas the limitation of this evaluation was the uncertainty 
surrounding adoption of trial findings.   
Lakdawalla et al (192) analysed the value of gains in cancer survival attributable 
to cancer research funded by the US public and private sectors. These authors 
used a top down approach to estimate by how much life expectancy for cancer 
survival gains, the authors calculated that the life-year gains due to cancer 
research during this period amounted to $1.9 trillion USD of additional social 
value. The limitation of this approach was the lack of transparency around which 
individual research projects are being considered in this calculation.  
Glover et al (2015) (39) estimated the internal rate of return on cancer research 
conducted in the UK between the years 1991 and 2010 by identifying the most 
impactful research findings and calculating the investment required to produce 
these findings. The benefit of this approach over that by Ladawalla was that it 
was clearer which studies were included in their calculation. The authors 
monetised research benefits by identifying the QALY gain achieved 
(£25,000/QALY) within the UK from implementation of the research findings and 
included an estimation for the return on investment from this research to the UK 
GDP. The health service cost of implementing research findings and the original 
cost of conducting the research were subtracted from the predicted monetised 
health gains to calculate a net monetary benefit attributable to UK cancer 
research. The limitation of Glover’s approach was that only healthcare service 
costs of implementation were considered, whereas Lakdawalla et al (192) and 
Brown et al (184) considered broader societal costs and benefits. Also, the 
spillover benefit to the UK GDP used in Glover’s study was taken directly from 
the previous literature, with no attempt to calculate this for cancer research 
specifically. Lastly, the measure of benefit (QALY) was potentially biased 
towards research that, when implemented, resulted in survival gains, rather 
than disinvestment in a futile treatment, affirmation that current practice is 
optimal, or treatments that improve quality of life but not survival. Neither of 




Acknowledging the strengths and limitations of these analyses, an adaptation 
and combination of the approaches by Glover et al  and Brown et al (184) were 
selected to test the impact of the SCOT trial. Specifically, the healthcare service 
budget impact of implementation of the SCOT trial findings was tested. In 
addition, impact from a societal perspective and the additional value of 
potential QALY gain from implementation were investigated. This approach was 
performed from the perspective of all six countries that recruited to SCOT. The 
results of this analysis are presented in Chapter 6.  
The results of the REF 2014 case studies analysis reported in Chapter 4 
highlighted an apparent gap in using real world data to assess clinical practice 
and health impact from cancer trials. There were a small number of examples in 
the REF case studies of using hospital level data to explore the impact of clinical 
trials, but more commonly, the impact on practice and health was predicted by 
describing how many patients may affected if the trial results were used. The 
method of assessing cancer trial impact using administrative data was tested in 
this study by using chemotherapy prescribing records. This was first carried out 
using local data to explore how this could be approached statistically. The 
feasibility of accessing appropriate data and carrying out an analysis was then 
tested at the national, Scotland-wide level. The results of these studies are 
presented in Chapters 7 and 8.  
Lastly, the findings of Chapter 3 highlighted that using a framework to carry out 
and/or present the results of an impact analysis could be beneficial. Six 
different frameworks identified from the overview of reviews in Chapter 3 were 
tested for their relevance to the SCOT trial by incorporating results from 
Chapters 5-8 (Appendix 6). Documentary analysis was also used to populate the 






5 Chapter 5: Impact on clinician attitudes and self-
reported practice 
5.1 Introduction 
The dissemination of cancer trial findings to clinicians, patients, and policy 
makers influences the downstream impact that may be achieved from that trial. 
The subsequent implementation of trial findings by those stakeholders into real 
life practice is a necessary step if trial results are going to translate into health 
gains at a population level; clinicians play an instrumental role in this process. 
Although clinicians involve patients in the decision making process surrounding 
their management options, ultimately the doctor has responsibility for choosing 
and prescribing the patient’s treatment. For these reasons, clinicians were 
identified as key users of the SCOT trial findings and the downstream effect of 
the SCOT trial findings on their clinical practice was considered a key impact 
worth exploring.  
As outlined in Chapter 1, SCOT was a randomised phase III RCT which 
demonstrated that using 3 months of doublet chemotherapy (CAPOX or FOLFOX 
according to clinician choice) was non-inferior to 6 months for patients with 
stage II (with high risk features) and stage III CRC in the adjuvant setting. 
Important sub-group analyses showed that non-inferiority was met for patients 
receiving CAPOX, but not for those receiving FOLFOX, and for those with low-risk 
stage III disease but not for those with high-risk stage III disease. A separately 
presented analysis at ESMO 2019 demonstrated that non-inferiority was not met 
statistically for patients with stage II CRC with high-risk features.  
The SCOT trial was the biggest contributor to the IDEA collaboration (81), which 
was a study that pooled the results of six international randomised phase trials 
(ACHIEVE, HORG, IDEA-France, SCOT, SWOG/CALGB 70802, TOSCA). All of these 
trials assessed the comparison of 3 versus 6 months of doublet chemotherapy for 
stage III colon cancer. This collaboration did not meet the pre-specified non-
inferiority endpoint to show 3 months was not unacceptably worse than 6 months 
of treatment, although the clinical difference between the two approaches was 
small (3-year DFS difference of 0.9%, 5 year OS different of 0.4%). The subgroup 
findings from the SCOT trial were mirrored in this larger analysis.  
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Four of the trials in the IDEA collaboration, ACHIEVE2, HORG, TOSCA and SCOT, 
also recruited patients with stage II colon cancer and one (SCOT) recruited 
patients with rectal cancer. A separate IDEA collaboration analysis of patients 
with stage II disease was undertaken using the results from these four trials only 
(247). This analysis also did not meet the pre-defined non-inferiority endpoint 
but again the clinical difference between 3 versus 6 months of treatment was 
relatively small (5 year DFS difference 3.2%). Non-inferiority was met for 
patients with stage II disease receiving CAPOX (0.3% absolute difference) but not 
for FOLFOX (7.3% absolute difference).  
Previous surveys have been performed to investigate practice change following 
publication of the findings from the IDEA collaboration (81) and/or contributory 
trials. One of these surveys (248) was performed by Iveson et al in September 
2017, 4 months after the SCOT and IDEA findings were publicised at ASCO 2017, 
but before the full publications in peer-reviewed journals in March/April 2018. 
This survey was answered by 458 clinicians, a large percentage of whom were 
from Japan (51%), followed by the USA (17%) and the UK (10%). The responses to 
this survey indicated that even in the short time since dissemination of results as 
an abstract, most (90%) clinicians felt that 3 months of treatment was could be 
used for ‘some’ patients with stage III colon cancer. Overall, clinicians preferred 
to use 3 months (56%) versus 6 months (44%) of treatment for patients with low-
risk stage III colon cancer (in keeping with subgroup analysis showing non-
inferiority), and most used CAPOX (70%) in this context. In contrast, the majority 
(88%) still used 6 months to treat high-risk stage III disease (again in keeping 
with subgroup analysis) and there was a split between using CAPOX (59%) versus 
FOLFOX (41%) in this context. There were important between country 
differences in the choice of regimen. Across all scenarios, individuals from the 
USA preferred FOLFOX (73%), whereas those from Japan and Europe preferred 
CAPOX (77% and 65% respectively).  
A later study led by a Canadian group of researchers (249), surveyed 145 
clinicians regarding their perspectives towards the IDEA collaboration findings 
and how these results impacted on their prescribing patterns. Over half of their 
respondents were from South America, with only a small proportion (<12%) from 
Europe. Almost all of their respondents (98%) were aware of the IDEA 
178 
 
collaboration findings although over one fifth indicated that they found it 
challenging to communicate the results of IDEA, and specifically the concept of a 
non-inferiority trial to their patients. Interestingly, slightly less (75% versus 90%) 
respondents to this survey, compared to the earlier survey by Iveson et al, 
indicated that the IDEA collaboration findings supported the use of 3 months of 
adjuvant treatment in ‘some’ patients. In total, 71% specified that they had 
changed their clinical practice in response to the IDEA findings. A high 
proportion (81%) of the respondents to the survey preferred to use FOLFOX pre-
IDEA but this changed, with a majority (55%) preferring CAPOX in the post-IDEA 
period. Approximately 68% of respondents tailored the duration of adjuvant 
treatment delivered in line with stage III risk stratification, giving 3 months to 
patients with T1-3N1 disease, and 6 months to those with T4 and/or N2 disease. 
Nearly a third of respondents indicated that they still gave 6 months of 
treatment to all patients, whereas a very small minority (<1%) indicated that 
they had changed practice to give 3 months of treatment to all patients post-
IDEA. 
Finally, practice change in France in response to results from the IDEA-France 
trial (one of the contributors to the IDEA collaboration) was investigated in an 
online survey by Ouali et al (n=213) (250). These authors disseminated a survey 
to clinicians from January to March 2019 using mailing lists for three medical 
professional organisations in France. The results of this survey indicated a strong 
distinction in approach to treatment based on stage III risk stratification. For 
patients with low-risk stage III disease, 81% of respondents preferred to use 3 
months of treatment and 74% indicated they used CAPOX. For high-risk disease, 
almost all (99.5%) respondents agreed with the statement that adjuvant 
treatment should be given for 6 months and 94% preferred FOLFOX in this 
context. The preference for CAPOX for low-risk disease was particularly 
interesting in this clinician cohort because there was a strong preference within 
the IDEA-France trial for using FOLFOX (90%) rather than CAPOX (10%). The 
results of the all three of these surveys had not been published when the survey 
used for the purposes of this thesis was developed and disseminated.  
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The aim of the work in this chapter was to explore if clinicians were aware of 
the SCOT trial findings, if those findings made an impact on real life practice 
and if that impact changed over time.  
To meet this aim, the objectives were: 
(i) To explore clinicians’ awareness of recent clinical trial publications 
and their attitudes to using 3 months of adjuvant chemotherapy for 
CRC 
(ii) To document trial impact on clinical practice and if there were any 
barriers to change 
(iii) To explore the timing of any practice change  
(iv) To assess if clinicians’ attitudes and self-reported practice changed 
over time. 
5.2 Methods 
A survey was selected for the purposes of this study to allow elicitation of 
responses from a large number of participants from dispersed geographical 
locations. An online platform was chosen to allow rapid and widespread 
distribution and to reduce research costs associated with postage within the UK 
and internationally. Online Surveys® was used for development and piloting of the 
survey (outlined in Chapter 2). The final survey included four sections: i) Clinical 
studies and guidelines ii) Current practice iii) Attitudes towards using 3 months of 
adjuvant doublet chemotherapy for CRC (the experimental arm for SCOT/IDEA), 
and  iv) personal clinical practice details. 
Current practice at the time of survey completion was investigated using twelve 
hypothetical patient scenarios, six in which patients were aged under 70 years 
old and six in which patients were aged 70 years or older. This age cut off was 
used because of the increased uncertainty around using doublet chemotherapy 
for elderly patients due to a lack of randomised evidence specifically in this age 
group (see Chapter 1). This differentiation based on age was also suggested in 
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feedback from clinicians who piloted the survey, that patient age was likely to 
affect clinical practice. A list of the patient scenarios used in the survey is 
provided in Appendix 3.  
Scenarios relevant to stage II disease were separated by molecular disease 
characteristics. Specifically, scenarios describing stage II patients with tumours 
deficient in mismatch repair (MMR) proteins (dMMR) which are characterised by 
high levels of micro-satellite instability (MSI-H), were distinguished from patients 
with tumours proficient in MMR proteins, also known as micro-satellite stable 
(MSS) tumours (251). Patients with stage II dMMR CRC tumours have better 
survival (252) but appear to respond less well to fluoropyrimidine chemotherapy 
compared to patients with pMMR tumours. MMR status does not appear to 
predict response to oxaliplatin-based treatment (252). 
All survey respondents who answered the first survey were asked if they would 
be willing to be contacted again and those who agreed were sent a follow up 
survey in August 2020. The same questions from the first survey regarding the 
acceptability of 3 months of doublet chemotherapy were included. The same 
patient scenarios were used except it was specified that patients had colon 
cancer rather than CRC. This was based on feedback from respondents 
completing the first survey that it would be more straightforward to answer 
questions based on patients with colon cancer alone, given then higher 
uncertainty regarding the use of adjuvant chemotherapy for patients with rectal 
cancer (see Chapter 1). In addition, stage II scenarios were separated into T3N0 
and T4N0 (Figure 5-1). These changes were made in response to feedback from 
clinicians completing the first survey that T stage (T3 versus T4) was an 
important determinant of treatment choices for patients with stage II disease.  
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Figure 5-1 Disease characteristics for stage II patient scenarios  
 
In the second survey, clinicians were asked to respond to patient scenarios 
initially disregarding the impact of COVID-19, and then asked to repeat the 
questions indicating changes in their practice due to the pandemic. In these 
answers, respondents were asked to indicate enduring changes that were likely 
to be maintained in their future practice, rather than temporary changes they 
made during the first peak of the pandemic. Responses to the second survey 
were linked to responses to the first survey from the same participants.  
In the UK, a list of colorectal oncologists who prescribe adjuvant chemotherapy 
(n=247) was compiled for the purposes of this study by asking National Cancer 
Research Institute (NCRI) network leads in England and one oncology consultant 
in each of Scotland, Wales and Northern Ireland for a current list of their 
colorectal oncologists. The intention was that this list would be representative 
of the whole population of consultant CRC oncologists in the UK and therefore 
be a generalisable sample of all individuals who were responsible for 
chemotherapy prescribing in the adjuvant setting in the UK (107). It was 
recognised that this wider population would include other professional groups, 
such as oncology registrars, nurse specialists, or pharmacists, who may also 
prescribe chemotherapy in this context. There was no obvious means to 













Each person on the list of UK oncologists was sent an invitation email with a 
personal password protected link. The initial email was sent on 8th April 2019 and 
reminder emails were sent in an attempt to improve the response rate (253). The 
first reminder was sent on 29th April 2019 and a final reminder was sent on 21st 
May 2019. The survey closed on the 30th May 2019. 
To disseminate the survey outside the UK, and to those within the UK who were 
not consultant oncologists, a generic survey link was generated for this group of 
respondents that could be forwarded via email. This link was sent to personal 
contacts, colleagues, oncology organisations who agreed to forward the link to 
their membership (ESMO and the Clinical Oncology Society of Australia) and the 
link was posted on Twitter® and on the message board of a UK medical 
professional organisation (Royal College of Radiologists). Some UK oncologists used 
the generic link to complete the survey but informed the primary researcher they 
had used this link rather than their personalised survey invitation. When this was 
the case, this was accounted for in the response rate for UK CRC oncologists. This 
generic link was generated and disseminated on 10th April 2019 and was closed on 
the 30th May 2019.  
The plan was to disseminate the second survey one year after the first survey, in 
April 2020. Due to the COVID-19 pandemic, this was postponed to August 2020. 
This follow-up survey was distributed solely by email correspondence using the list 
of email addresses provided by those respondents who agreed to be contacted 
again. If respondents replied to indicate they no longer treated CRC or had taken 
an extended break from clinical practice, these individuals were removed from 
the distribution list and not used for the purposes of calculated a response rate. 
This survey was kept open for approximately seven weeks (31st August- 28th 
October 2020) and two reminder emails were sent to potential participants during 
that time (24th September and 12th October). Figure 5-2 outlines the timeline for 
survey development, piloting, and dissemination.  
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Figure 5-2 Survey development and dissemination Abbreviations: NEJM, New England 
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The SCOT trial demonstrated 3 months of treatment was non-inferior to 6 
months in the overall trial population, therefore any shortening of treatment 
from 6 to 3 months could be considered to align with SCOT results. However, to 
make it clear which changes in practice were in keeping with the subgroup 
results reported in the SCOT trial publication from 2018 (41), ‘SCOT non-
inferiority met’ versus ‘SCOT non-inferiority met’ will be used when describing 
survey results based on disease risk or regimen used. Updated SCOT trial results 
describing 5 year OS have not yet been published, therefore these subgroup 
labels of ‘non-inferiority met’ and ‘non-inferiority not met’ relating to 5 year 
OS, rather than 3 year DFS, may change once those results are known. 
5.3 Results 
5.3.1 Survey response rate and respondent characteristics 
In total, 265 clinicians participated in the first survey. Respondents were from 
Europe (180/265, 68%), USA/Canada (36/265, 14%), Asia (26/265, 10%), 
Australia/New Zealand (20/265, 8%), South America (2/265, 1%) and Africa 
(1/265, 0.4%) (Figure 5-3).  
 
 
Figure 5-3 Location of survey respondents 
 
Table 5-1 shows the location of respondents alongside an indication of which, if 
any, of the IDEA collaboration trials recruited in each country.  
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Table 5-1 Location of survey respondents according to country of recruitment to IDEA 







recruited to an 
IDEA 
collaboration 
trial in this 
country? 
If yes, which trial Number of patients 
recruited from this 
location to the 
named trial 
England 89 (34) Yes SCOT 5,244 (UK) 
Scotland 16 (6) Yes SCOT 5,244 (UK) 
Northern Ireland 6 (2) Yes SCOT 5,244 (UK) 
Wales 4 (2) Yes SCOT 5,244 (UK) 
UK (Unknown 
nation) 
26 (10) Yes SCOT 5,244 (UK) 
United States 35 (13) Yes CALGB/SWOG 80702 2,536 (USA and 
Canada) 
Japan 25 (9) Yes ACHIEVE/ACHIEVE 2 1,313 (ACHIEVE) 
525 (AHIEVE 2) 
Australia 19 (7) Yes SCOT 197 
Italy 11 (4) Yes TOSCA 3,759 
Spain 6 (2) Yes SCOT 237 
France 6 (2) Yes IDEA-France 2,010 
Denmark 6 (2) Yes SCOT 311 
Sweden 3 (1) Yes SCOT 83 
Netherlands 3 (1) No NA NA 
Germany 3 (1) No NA NA 
Morocco 1 (<1) No NA NA 
Singapore 1 (<1) No NA NA 
New Zealand 1 (<1) Yes SCOT 16 
Greece 1 (<1) Yes HORG 1,115 
Canada 1 (<1) Yes CALGB/SWOG 80702 2,536 (USA and 
Canada) 
 Brazil 1 (<1) No NA NA 
Argentina 1 (<1) No NA NA 
 
The majority of respondents were oncologists (258/265, 97%); most had been 
practicing in the field of oncology for at least 10 years (196/265, 74%) and 
treated only or predominantly patients with CRC (215/265, 81%). The response 
rate from the pre-specified list of UK oncologists was 51% (126/247). In total, 
106/197 (54%) of clinicians who agreed to be contacted and confirmed they still 
treated patients with CRC in August 2020, completed the follow up survey. They 
were from the UK/Europe (83/106, 78%), USA/Canada (12/106, 11%), Australia 
(6/106, 6%), Asia (4/106, 4%) and South America (1/106, 1%). The exact location 
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and characteristics of the clinicians who answered both surveys are shown in 
Appendix 3.   
5.3.2 Clinician awareness of clinical studies 
The majority of respondents (95%) were aware of clinical studies that reported 
results in the two years prior to April 2019, which assessed the optimal duration 
of doublet adjuvant chemotherapy for patients with CRC. This level of awareness 
was higher for UK (99%) versus international clinicians (90%) (Fisher’s exact 
p=0.001). Almost exclusively, the studies named by respondents were the IDEA 
collaboration or those trials that contributed data to the IDEA collaboration. 
Clinicians from the UK were significantly more likely to mention the SCOT trial 
(51% of UK respondents versus 19% of international respondents, p<0.000 ꭓ2) and 
international respondents were more likely to name the IDEA collaboration (50% 
of international respondents versus 38% of UK clinicians, p=0.181 ꭓ2). Figure 5-4 
shows the studies named by all respondents by location.  
 
Figure 5-4 Studies identified by UK and international survey respondentsN=141 for the 
number of clinicians from the UK and n=124 for the number of international clinicians. Each 
respondent could name more than one trial. SCOT: Short Course Oncology Trial 
(NCT00749450); IDEA: Duration of Adjuvant Chemotherapy for Stage III Colon Cancer; TOSCA: 
Three or Six Adjuvant Colon (OsSC number 2007-000354-31); HORG: Hellenic Oncology 
Research Group (NCT01308086); CALGB/SWOG: Cancer and Leukemia Group B/South-West 
Oncology Group 80702 (NCT01150045); ACHIEVE: Adjuvant Chemotherapy for Colon Cancer 
with High Evidence (UMIN Clinical Trials Registry number UMIN 000008543). “Other” free 
text answers: “ACTS CC 02 trial”, “SAFFA” and “Japanese trial testing 1 year of treatment 























5.3.3 Trial impact on current clinical practice  
Overall, 243 (92%) of survey respondents indicated that they had changed their 
practice in response to the clinical studies they had named, 3 (1%) were unsure 
and 19 (7%) indicated that they had not changed their practice. UK clinicians 
(99%) were significantly more likely to report a change in practice compared to 
international clinicians (83%, p<0.001 Fisher’s exact). Out of the respondents 
who specifically named the SCOT trial (n=164), 98% (n=160) reported that they 
had changed their practice.  
5.3.3.1 Scenarios describing patients aged under 70 
For the six individual patient scenarios describing patients aged under 70, 
clinicians were most likely (93%) to change their practice in response to recent 
trials for patients with T3N1 disease (Figure 5-5a) (SCOT non-inferiority met). 
For the three scenarios describing patients with high-risk stage III disease (SCOT 
non-inferiority not met), the proportion of clinicians changing their practice was 
less. This proportion was similar if patients had one high-risk feature (T1-3N2, 
46%; T4N1, 45%) but lower if two high-risk features were present (T4N2, 38%). 
For patients with stage II disease (SCOT non-inferiority not met), overall 33% of 
respondents indicated a practice change; this was more common for patients 
with MSS disease (36%) compared to MSI-H disease (30%). 
Specifically looking at treatment duration chosen for each scenario, for low-risk 
stage III disease (SCOT non-inferiority met), using 3 months treatment (85%) was 
the most common choice. For patients with high-risk stage III disease (SCOT non-
inferiority not met), most clinicians indicated they would chose to use over 3-6 
or 6 months of treatment (84% average for three high-risk scenarios). For 
scenarios describing stage II disease with high-risk features (SCOT non-inferiority 
not met), either over 3 months (MSS disease) or active monitoring (MSI-H 





Figure 5-5 Self-reported practice change for scenarios describing patients aged under 70 
years old  a) Practice change b) Duration of treatment chosen. 
5.3.3.2 Scenarios describing patients aged 70 years old and over 
The same trends were identified for older patients but there was more 
heterogeneity in practice within the responses for each scenario compared to 
practice for younger patients. Figure 5-6a shows the percentage practice change 
and Figure 5-6b shows duration of treatment chosen for each scenario. Three 
months of treatment was the most popular duration for patients with low-risk 
stage III disease (SCOT non-inferiority met) and over 3 months was most popular 
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Figure 5-6 Self-reported practice change for scenarios describing patients aged 70 years old 
and over.  a) Extent of practice change b) Duration of treatment choices 
The choice of both regimen and duration of practice for all twelve scenarios are 
shown in Appendix 3. Summarising these results, and highlighting which 
practices aligned with the experimental trial arms in the IDEA study and SCOT 
trial, Table 5-2 shows the proportion of clinicians who specifically chose 3 
months of doublet chemotherapy. For individuals who changed their approach to 
treatment dependent on age, the patterns of change for each scenario are 
shown in Appendix 3. In the second survey, the majority (92%, 98/106) of 
respondents reported they use biological rather than chronological age when 
treating patients aged 70 years and over. The definition of biological age was 
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b) Duration of treatment (70 years and over)
3 months Over 3 months Active monitoring
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Table 5-2 Proportion of clinicians choosing 3 months of doublet chemotherapy
  Three months of doublet chemotherapy 
  <70 years ≥70 years 
Low-risk stage III disease¶ 86% 54% 
High-risk stage III disease overall 16% 15% 
High-risk stage III (T4N1) 18% 17% 
High-risk stage III (T3N1) 19% 17% 
High-risk stage III (T4N2) 11% 13% 
Stage II* overall 16% 9% 
Stage II* MSS 20% 8% 
Stage II* MSI-H 12% 10% 
*With high-risk features ¶ SCOT non-inferiority met for this subgroup 
Lastly, clinicians were asked if they treated patients with rectal cancer in the 
adjuvant setting and if so, if they treated these patients using similar 
management strategies as they had outlined for the twelve hypothetical patient 
scenarios. Amongst UK respondents, 126/141 (89%) indicated they treat patients 
with rectal cancer in the adjuvant setting and 91/126 (72%) of these use the 
same treatment strategy as they outlined in the patient scenarios. For 
international clinicians, 117/124 (94%) indicated they treat patients with rectal 
cancer in the adjuvant setting and 49/117 (42%) treat those patients in a similar 
manner to as they outlined in the survey treatment scenarios.  
5.3.4 Influences and barriers to practice change 
Overall, clinicians most commonly indicated that listening to conference 
presentations was the mechanism of dissemination of trial results that had 
influenced their subsequent practice change (30%) (Figure 5-7). This was closely 
followed by reading a journal or specifically a high impact journal (26%), and 
discussion with colleagues (24%). Reading articles in the lay or social media (1%) 
or looking at a poster at a conference (1%) were the mechanism of trial result 




Figure 5-7 Mechanisms of dissemination of trial results that most influenced clinician 
practice change Overall, 243 respondents out of 265 answered this question. Respondents 
could chose more than one mechanism of dissemination (n=528 individual answers 
selected by 243 respondents indicating that on average (mean), respondents selected 2 
mechanisms each).  
 
The one UK clinician who did not change their practice explained that they were 
already prescribing 3 months of CAPOX chemotherapy for patients with “low-risk 
Duke’s C disease”, and 6 months of CAPOX for patients with “high-risk Duke’s C 
disease”. For them, the trial results were “confirmatory”. The barriers to 
practice change chosen by the 18 international clinicians who reported no 
practice change were: a) the strength of evidence provided by recent clinical 
trials (72%; 13/18), b) the fact that no clinical guideline existed to support a 
practice change (11%; 2/18), c) their colleagues had not changed their practice 
(11%; 2/18) and d) they had not treated any patients yet who specifically fitted 
the trial criteria (6%; 1/18).   
 
5.3.5 Timing of practice change 
In the second survey, participants were asked at which time point they made 
their main practice change for patients with stage III colon cancer. The options 
were: June 2017 (IDEA and SCOT initial results disseminated), March 2018 (IDEA 
full publications), June 2020 (updated IDEA results). The same question was 
asked for patients with stage II disease but an additional time point was added: 


























Mechanisms of dissemination of trials results that most 
influenced clinician practice change
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June 2019 (IDEA stage II results presented in abstract form at ASCO conference). 
Overall, 82% reported their practice change for patients with stage III disease 
occurred either after the initial ASCO 2017 presentation or in response to the 
full journal publication nine months later (Figure 5-8).  
 
Figure 5-8 Timing of practice change (stage III disease)  One clinician who chose a time-
point that was not pre-specified stated that the timing of the SCOT trial results (exact time-
point not indicated) had the most influence on their practice. 
When describing practice change for patients with stage II disease, 57% of the 
second survey respondents indicated that they had changed their practice, with 
the largest proportion (20%) of practice change being attributed to the 
dissemination of stage II IDEA results at ASCO 2019 (Figure 5-9).  
 
Figure 5-9 Timing of practice change (stage II)  Of the three respondents who did not 
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their practice, one stated the ACHIEVE2 trial results and one stated: “Previous retrospective 
analysis of use of oxaliplatin.” 
5.3.6 Change in practice over time 
5.3.6.1 Change in self-reported practice: Stage III  
Disregarding any changes in practice driven solely by the COVID-19 pandemic in 
their responses, the biggest change in practice between April 2019 and August 
2020 was that approximately one fifth of clinicians shortened the duration of 
treatment used for patients with stage III disease and one high-risk feature (T4 
or N2). The change in regimen and duration of treatment chosen for patients 
aged under 70 by individual clinicians who answered both surveys are shown in 
Figure 5-10.  There were no other changes affecting over 10% of clinicians in 
either the choice of regimen or duration of treatment. Clinicians used a similar 
treatment approach for low-risk stage III (SCOT non-inferiority met) and high-risk 
stage III disease (SCOT non-inferiority not met) with two high-risk features 
(T4N2) at both time-points. The results for stage III scenarios describing patients 


















Figure 5-10 Change in practice between April 2019 - August 2020 for patients aged under 70 years old  N=106 The first survey was carried out in April 2019 
and the second survey in August 2020. Duration of treatment is on the left side of the diagram and regimens chosen is on the right side. Panel A (reading 
across) shows results for the scenario describing low risk stage III disease (T1-3N1) (SCOT non-inferiority met) and how choices for duration and regimen 
of treatment changed for the same clinicians between the first and second survey. Panel B shows the same results for two scenarios combined describing 
high risk stage III disease (SCOT non-inferiority not met) with one high risk feature (T4 or N2). Panel C shows the same results for the scenario describing 
high risk stage III disease (SCOT non-inferiority not met) with both high risk features (T4N2). The only change in opinion affecting over 20% of respondents 






5.3.6.2 Change in self-reported practice: Stage II 
Longitudinal practice change for stage II patients was also assessed in both age 
groups. The scenarios were changed from describing a patient with T3/4 disease 
to T3 disease and T4 disease separately, meaning that a direct comparison of 
answers was not possible. For scenarios describing younger patients (Figure 5-11 
below), 3 months of doublet chemotherapy (SCOT experimental arm treatment) 
was used by a minority of respondents across all scenarios at both time-points 
(April 2019 and August 2020). In 2020, it was clear that, in general, doublet 
chemotherapy was more popular for patients with T4 compared to T3 tumours. 
For T3 tumours, active monitoring (MSI-H) or 6 months of capecitabine (MSS) 
were used most frequently. A very similar pattern was seen for older patients, 
(Figure 12-10 in Appendix 3), although the use of doublet chemotherapy was less 
for patients aged 70 and over across all scenarios compared to treatment choices 
for younger patients. Also, active monitoring was the most popular treatment for 
T3 MSS tumours, compared to 6 months of capecitabine for patients aged under 
70 years old.  
In the second survey, clinicians were asked if they ever intentionally prescribe 3 
months of fluoropyrimidine monotherapy and 22% (23/106) indicated it was a 
treatment strategy that they use. This question was tested indirectly in the 
scenario questions within both surveys, and Figure 5-11 below (‘CAP3 and FU3’), 
and Figures 12-1 to 12-8 in Appendix 3, show that 3 months of capecitabine or 3 
months of 5-fluorouracil were responses for stage II disease that were chosen by 
a minority of clinicians at both time-points. The directed question in the follow-
up survey was complementary to this scenario information and helped to 
quantify the proportion of clinicians who would ever use this approach, 






Figure 5-11 Treatment choices for patients aged under 70 with stage II disease Includes 
comparison of clinician choices between April 2019 and August 2020 (n=106). For 2019, this 
diagram includes responses only from individuals who answered both surveys. The red 
boxes indicate when responses align with the treatment delivered in the experimental arm 
of the SCOT trial/IDEA collaboration.  




Specifically focusing on stage II patients, clinicians in August 2020 indicated they 
were more likely to use doublet chemotherapy for treating stage II disease 
irrespective of age after the results of the IDEA collaboration were known 
compared to prior to the dissemination of the IDEA findings (Figure 5-12). 
Despite this, there was still a minority of respondents who indicated they never 
used doublet chemotherapy for patients with stage II disease (16% (17/106) for 




Figure 5-12 Use of doublet chemotherapy for patients with stage II disease a) aged under 70 
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5.3.6.3 Change in attitudes 
In keeping with their scenario related practice choices, in the first survey (Figure 
5-13) clinicians most strongly agreed that CAPOX for 3 months could be 
considered a standard of care to treat patients with low-risk stage III disease 
(91%) (SCOT non-inferiority met). They most strongly disagreed that 3 months of 
FOLFOX could be a standard of care for high-risk stage III disease (81%) (SCOT 
non-inferiority not met) and there was most uncertainty (corresponding to 
clinicians indicating they neither agreed nor disagreed) when offering 3 months 
of CAPOX or FOLFOX for stage II disease (SCOT non-inferiority not met). Clinician 
opinions (n=106) generally remained consistent between April 2019 and August 
2020 (see Figure 12-1Appendix 3). The largest changes were an increase in 
agreement that 3 months of FOLFOX could be an acceptable standard of care for 
patients with low-risk stage III disease and an increase in agreement that 3 
months of CAPOX is an acceptable standard of care for stage II disease with high-
risk features. There was a corresponding rise in disagreement with 3 months of 
FOLFOX as a standard treatment for stage II disease.  
 
Figure 5-13 Clinician attitudes to using 3 months of treatment as standard of care for the 
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5.3.6.4 Enduring adjuvant practice changes due to COVID-19 
There were no significant differences (Fisher’s exact test p<0.05) between 
management choices disregarding the influence of the COVID-19 pandemic and 
those made reflecting enduring changes to practice because of the COVID-19 
pandemic from the August 2020 survey. This demonstrates that, even if a 
temporary alteration to clinician practices did occur early in the pandemic, 
respondents do not feel that the pandemic will have enduring changes to their 
practice for patients with colon cancer in the adjuvant setting. The difference in 
practice reported in August 2020, taking into account enduring changes from the 
COVID-19, are shown in Appendix 3 Table 12-5.  
5.4 Discussion 
This study surveyed of a large number of clinicians, all of whom confirmed they 
prescribed adjuvant chemotherapy to patients with CRC. The results of the IDEA 
collaboration were clearly well known within this group of respondents, and in 
particular, the SCOT trial results were well known in the UK. The increased 
awareness of SCOT for UK versus international clinicians may be linked to the 
fact that many of the UK respondents will have recruited patients to the SCOT 
trial (>4,000 SCOT patients from the UK). This provides a clear message to 
trialists that active efforts to disseminate their trial findings may be needed in 
countries where their trial did not recruit. It also supports the findings from 
Lewison et al (188) (Chapter 3) that UK guidelines, which are in part written by 
UK clinicians, more frequently cite UK research than would be expected based 
on the world literature. 
The mechanisms of dissemination in the first year since the IDEA and SCOT 
publication that most influenced practice indicates to trialists that channels of 
communication and dissemination of results other than the peer-reviewed 
publication are important and worth focusing on in order to maximise trial impact. 
Guidelines were less important in this survey. Rather than indicating that 
guidelines do not influence practice per se, this response may reflect the time lag 
to widespread change in the relevant guidelines in this instance. For example, the 
NICE guidelines in the UK had not been updated when the first survey was 
distributed (254). This result prompts reflection on the high priority placed on 
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policy change, in particular in the REF 2014 case studies of cancer clinical trials 
(see Chapter 4), in particular the importance placed on policy change as a pre-
requisite for practice change. Few respondents indicated that social/lay media 
articles or conference posters were important mechanisms of dissemination of 
trial results. This may reflect either that the results of these particular trials were 
not disseminated via those mechanisms or that these are ways of communicating 
the results of clinical trials that have less influence on practising clinicians.  
Regardless of the location of respondents, the main message from this study was 
that a large proportion of clinicians have altered their practice in response to 
IDEA and SCOT, and that these trials can be considered practice changing. The 
impact of these trials on attitudes and practice occurred to a major extent by 
April 2019, with minimal change in the following 18 months. This demonstrates 
there was a very short time lag between dissemination of initial results and 
implementation into practice to some extent.  
There was a stronger indication from UK clinicians that they regarded their 
practice as having changed in response to the trials they had named. This may 
be linked to the fact that more UK clinicians were aware of the SCOT results in 
April 2019 and that SCOT met its non-inferiority margin statistically, whereas 
this was not the case for the IDEA collaboration. In addition, it is know from IDEA 
(81) that UK clinicians prefer to use CAPOX whereas clinicians in locations such 
as France and the USA preferred FOLFOX. Given the stronger evidence for using 
shorter duration for CAPOX compared to the evidence for FOLFOX, this may also 
have influenced this difference between UK and international responses. 
This study has shown that practice change has mainly occurred in line with the 
stratification of stage III disease into low and high-risk. This stratification was 
coined based on results from the IDEA collaboration, and is itself an unexpected 
impact from these trials. It is especially surprising that this division in treatment 
approach was maintained in August 2020 given that updated IDEA collaboration 
results showed very little clinical difference in 5-year OS between using 3 versus 
6 months of CAPOX in the high-risk stage III setting. This perhaps indicates the 
power of the initial trial results in drawing a line along which clinicians are and 
are not happy to reduce treatment duration (83). An opportunity for an 
implementation study would be to investigate in more detail the barriers that 
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may exist that are preventing clinicians from changing practice for this group. 
These barriers may include patient actual preference or preference as perceived 
by clinicians, the strength of evidence, clinicians’ own perception of risk and 
non-inferiority of shorter treatment in a higher risk setting, or prescribing 
practices suggested by colleagues and guidelines.  
Results from a recently reported within-trial survey (255) of SCOT trial 
participants from Australia and New Zealand has shown that, on average, 
patients indicated the benefits of treatment that would warrant taking 6 months 
rather than 3 months of adjuvant treatment were 2-3 years extra survival 
beyond 5 or 15 years life expectancy, or 5-15% extra survival beyond a 5 year 
survival rate of 65-85%. These benefits are larger than then benefits of an extra 
3 months of chemotherapy calculated in SCOT/IDEA. These results differ from a 
previous survey by the same group which assessed preferences for receiving 6 
months of adjuvant chemotherapy for CRC versus observation, when the benefit 
required to accept chemotherapy was only 1 month extra survival or 1% survival 
gain on 5 year survival (256). These results show the importance of duration of 
treatment, and reflects that patients put high importance on receiving some 
active treatment in the adjuvant setting, but they consider carefully the balance 
of toxicity versus benefit of this treatment.  
Clinicians also indicated they were less likely to have changed practice for 
patients with stage II disease. Indeed, in the August 2020 survey, some clinicians 
indicated they never use doublet treatment for patients with stage II disease. 
The stage II IDEA findings aligned closely with results for the stage III population 
(87), therefore the reduced uptake of study results into practice may reflect a 
lower use of doublet chemotherapy in this setting rather than the strength of 
trial evidence.  
The avoidance of doublet chemotherapy in this context is highly likely to be 
influenced by the results of previous trials discussed in Chapter 1. For example, 
the subgroup analysis from the MOSAIC trial which failed to confirm an overall 
survival advantage from adding oxaliplatin to fluorouracil specifically for stage II 
patients (257). This highlights an opportunity for clinicians to improve certainty 
in this area by increasing dialogue around the approach to treatment of this 
group. It also may encourage clinician trialists responsible for the stage II IDEA 
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collaboration to focus on dissemination of these results specifically and to help 
interpretation of those results for clinicians in the context of previous trials 
assessing the merits of using doublet treatment specifically in this patient 
cohort.   
This study has shown that patients with stage II MSI-H disease, regardless of age, 
are more likely to be offered doublet treatment or avoid adjuvant therapy 
altogether, compared to those with MSS stage II disease. This aligns with the 
results of previous clinician surveys performed before IDEA, (258) and although a 
minority of CRC patients have MSI-H disease (259), reinforces the case for 
ensuring this information is available to clinicians at the time of decision 
making. It also indicates that recent trial results investigating shorter duration 
of doublet treatment specifically are more likely to influence prescribing for 
MSI-H rather than MSS stage II disease for which proportionally, doublet 
chemotherapy is used less. Results according to MSI status are not available for 
the SCOT trial, however further information on molecular influences on disease 
outcomes dependent on treatment duration may become available with the 
analysis of tissue samples from SCOT trial patients in the TransSCOT programme 
(260).  
The extent of self-reported practice change in response to recent trials was also 
less for older versus younger patients, concurring with results from the recently 
published survey of French clinicians (250). Reduced impact on practice for older 
patients is likely to again reflect the less frequent use of doublet chemotherapy 
for older versus younger patients generally. This may be due in part to previous 
individual and pooled trial subgroup analyses showing a lack of benefit from 
adding oxaliplatin to fluoropyrimidine for older patients (56, 65, 257) (see 
Chapter 1), although there are reports that some benefit of oxaliplatin may be 
maintained in older patients (261, 262), especially based on more recent trial 
findings (68). It also raises the bigger question of the gap in evidence for this age 
group and the need for randomised clinical trials specifically in this area.  
 
Although an age cut-off was chosen for the practicalities of survey development, 
the vast majority of clinicians indicated they use biological rather than 
chronological age when making treatment decisions. It is therefore 
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acknowledged that clinicians are unlikely to alter their practice across such a 
strict age cut off in real life. This reflects the difficulty with making any 
treatment decisions based on age alone and explains why most national 
guidelines from professional bodies (NCCN, ESMO, ASCO) do not mention age. 
Recently updated NICE CRC guidelines do mention that age is taken into 
consideration but do not give direction on how this may specifically affect 
treatment choices (254).  
 
As described in Chapter 1, the SAFFA trial (51) compared 3 months of protracted 
venous infusion 5-fluorouracil against 6 months of bolus 5-FU/leucovorin in 
patients with stage II/III CRC (n=801) and showed there was no OS difference 
between the treatment arms. This strategy has not yet been tested using 
modern infusional regimens, such as modified deGramont, in both arms. In the 
second survey, clinicians were asked if they ever intentionally used 3 months of 
adjuvant fluoropyrimidine monotherapy for patients with stage II disease and a 
minority of respondents indicated this was a treatment approach that they 
adopted. Ideally, it would be useful to ask this question directly regarding 
patients with stage III disease also, although the scenario analyses give us insight 
as to the likely answer. In both surveys, no clinicians chose 3 months of 
fluoropyrimidine monotherapy for scenarios described patients with stage III 
disease aged under 70. For patients with stage III disease aged 70 and over, 3 
months of fluoropyrimidine was occasionally chosen by a small number of 
clinicians. Further investigation into clinician opinion would be helpful to 
understand if those who routinely use 3 months of monotherapy for stage II or 
stage III disease are applying the results of the SAFFA trial, or if they are 
extrapolating the results of the IDEA collaboration when they make this 
treatment choice. These results also raise another gap in existing trial evidence 
for clinicians making decisions in this field. 
 
The results from this study show that, if dependent on clinician preference alone 
and not constrained by institutional policies, there are unlikely to be significant 
enduring changes due to COVID-19 going forward that differ from practice 
decisions based on clinical trial evidence alone. There is still a lack of published 
data on actual chemotherapy prescribing during the peaks of the pandemic and 
practice currently. More information is needed to map the effect of the 
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pandemic on adjuvant prescribing for CRC, especially on the choice of duration 
of treatment and regimens used.  
 
The findings from these surveys support the results from previous studies 
performed by Iveson et al (248) and Yu et al (249, 250) in that most clinicians 
agreed that 3 months of adjuvant doublet chemotherapy can now be used for 
‘some’ patients with CRC. The findings also strongly supported results from 
those previous surveys (248-250) and a survey of French clinicians (250) which all 
demonstrated the strong influence of stage III risk classification on duration of 
treatment prescribed. Specifically, 3 months of doublet chemotherapy was used 
often for low-risk stage III disease (SCOT non-inferiority met), whereas 6 months 
was still used for high-risk disease (SCOT non-inferiority not met). There does 
seem to have been a shift over time across these surveys, with more respondents 
indicating they would reduce treatment duration, to align with the experimental 
arm of the SCOT trial and IDEA collaboration, in both the low-risk and high-risk 
setting in this study compared to the one performed in September 2017 by 
Iveson et al (248). For example, in September 2017, 56% of clinicians used 3 
months of treatment for low-risk disease compared to 85% for younger patients 
and 60% for older patients in this survey. For patients with high-risk stage III 
disease, in the September 2017 survey, 12% of clinicians used 3 months of 
treatment; this compared to 16% in younger patients and 17% in older patients in 
this survey. There was no distinction made between age groups in the 2017 
survey for direct comparisons of these responses.  
 
There was a strong preference for using CAPOX in the low-risk stage III setting 
was identified across previous surveys and those reported in this study. Iveson et 
al (248) demonstrated a split in using CAPOX versus FOLFOX for high-risk stage III 
disease, similar to the findings of this study, whereas in the survey of French 
clinicians (250), most used FOLFOX. These differences are likely to represent the 
locations of respondents within the surveys and the regimen preferences that 
existed pre-SCOT and IDEA. For example, most patients in IDEA-France (263) 
received FOLFOX, all patients in CALGB-SWOG 80702 (USA/Canada) (264)were 
given FOLFOX, all patients in ACHIEVE (Japan) (265) received CAPOX and the 
majority of patients treated in the UK within the SCOT trial (41) had CAPOX. This 
study was the first to report survey results for patients with stage II CRC and the 
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only study to include two surveys at distinct time-points, indicating a change in 
the approach to treating high-risk stage III patients over time, in particular the 
increased use of 3 months of treatment for patients with one high-risk factor (T4 
or N2).  
 
The strengths of this study include the relatively good response rate in the UK 
and a good spread of locations from outside the UK. Rather than providing 
clinicians with a list of trials and asking them if they were aware of specific 
trials, this survey required that clinicians wrote the name or primary author of 
the trial. This is a less biased test of awareness of the clinical trials of interest 
compared to the approach used in previous surveys (249, 250). This study offers 
a snapshot of clinician practice one year following the results. The surveys 
conducted only in France (266) and the one that mainly had respondents from 
Canada, USA and South America (249) can be seen as complementary, given the 
low numbers of respondents from France and Canada in this study. This is the 
also only study to look at clinician views over two time points. 
This study also has limitations. A sample of clinicians were surveyed and there 
will be inherent response bias in any sample. Specifically, those who responded 
may have been more enthusiastic, more likely to be aware of trial findings and 
more motivated to change practice compared to survey non-responders. 
Response rate was captured for UK CRC oncologists but it was not possible to 
estimate a response rate for those clinicians located outside the UK, or who 
were not on the pre-specified list of UK CRC oncologists. There was also no 
information regarding the non-respondents amongst the UK CRC oncologists and 
how they differed from the respondents.  
In the development of the surveys used in this study, consideration was given to 
the optimal way of asking clinicians about practice change in response to the 
results of the SCOT trial findings. Initially, the plan was to ask clinicians to recall 
their practice pre-SCOT trial publication and to compare this to current practice 
post-trial.  Advice from an expert in impact evaluation (104) indicated that this 
approach would be open to recall bias which would undermine the validity of the 
responses, especially given the time period (years) from which respondents 
would be asked to recall their previous practice. It was identified that the 
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optimal way to analyse how practice has changed would have been to perform a 
repeated measures study with a separate survey before and after the trial 
publication. This was not possible due to the timeline of this study, which 
commenced after the SCOT trial had ended and was published. Therefore, the 
option of a survey shortly after the initial publication, with a follow up survey 
one year later, was the appropriate option to gauge initial short term and longer 
term changes in practice.    
The impact of these trial findings specifically for patients with rectal cancer, 
and how this may have varied compared to colon cancer, was not explored and 
warrants further investigation. In addition, the impact of deficiency in MMR 
proteins on prescribing for stage III disease was not analysed. This may become 
more relevant as novel agents such as immune-checkpoint inhibitors are tested 
in the adjuvant setting. Also, the results of the FOXTROT trial, (267) presented 
at ASCO 2019, showed that six weeks of neoadjuvant chemotherapy for patients 
with colon cancer was well tolerated and can improve surgical morbidity. The 
work in this chapter did not explore how the FOXTROT results may have 
influenced the impact of the IDEA trials, although even if chemotherapy is 
moved to earlier in the disease trajectory, it is likely that the importance the 
IDEA results on duration of practice will still be relevant. Lastly, the patient 
scenarios in the surveys used in this study asked clinicians to assume patients 
were fit (performance status 0-1) and to indicate their choices for the majority 
of patients they treat. In a real world stetting these choices may be diluted 
based on patient, disease and other external variables. For this reason, an 
analysis of actual prescribing records would be a stronger indicator of current 
practice, although would not capture clinician perspectives and attitudes as has 
been achieved in this study.  
 
5.5 Conclusion 
In conclusion, the IDEA collaboration and contributory trials have impacted on 
clinician attitudes and self-reported practice. This study suggests that across 
several countries, patients with CRC are now being offered shorter adjuvant 
treatment. These changes will hopefully lead to the health benefits of less 
toxicity whilst maintaining survival gains. This study has shown that surveying 
research users, in this case clinicians, is a useful tool to analyse the health 
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sector impact of a clinical cancer trial. The results from this study will be 
utilised in Chapter 6 to inform estimation of the potential downstream health 
and economic effects from the implementation of trial findings.
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6 Chapter 6: Assessing the economic value of 
implementation of the SCOT trial findings 
6.1 Introduction 
A number of the REF case studies analysed in Chapter 4 described the economic 
impact of clinical cancer trials; these impacts usually related to sales of drugs or 
describing the results of cost-effectiveness analyses conducted alongside trials, 
rather than predicting or evidencing economic gains from the trial findings.In 
this chapter, an adaptation of the methods used by Glover and colleagues (39) 
and Brown et al (184) were tested as an approach to evaluate the impact of the 
SCOT trial. Specifically, the aim of this study was to estimate the economic 
value of implementing the SCOT trial findings in the six countries that recruited 
to SCOT.  
To meet this aim, the following objectives were identified: 
i) Calculate the cost-effectiveness of the treatments tested within the SCOT trial 
from the perspective of the six countries that recruited to SCOT: Australia, 
Denmark, New Zealand, Spain, Sweden, and the UK. 
ii) Estimate the budget impact of implementing the SCOT trial findings in these 
six countries using the costs calculated in part (i) of the study. 
iii) Estimate the quality adjusted life year (QALY) gain from implementation of 
the SCOT trial findings across the six countries and calculate the monetised 
value of that QALY gain across a range of willingness to pay (WTP) thresholds.  
iv) Use the results from parts (i)-(iii) of this study to estimate the return on 
investment in the SCOT trial.  
6.2 Methods 
The methods for this analysis align with the study objectives, and are divided into 
four parts: i) a cost-utility analysis ii) budget impact analysis iii) estimation of 
QALY gains at a population level and iv) using the results from the previous three 
steps to estimate the return on investment in the SCOT trial.  
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6.2.1 Cost-utility analysis 
The main purpose of undertaking any economic evaluation is to evaluate all the 
changes in costs and benefits associated with a new treatment approach in 
comparison to the current standard of care. By allowing a comparison to 
alternative treatment options that are currently used in practice, it is possible to 
make informed decisions about what is the most cost-effective course of action.  
Cost-utility analysis is a commonly used type of economic evaluation which 
compares the costs and outcomes of alternative interventions, where the 
outcomes are measured in terms of utility, which is then combined with data on 
survival to calculate adjusted life expectancy. The common outcome is QALYs 
(268), which incorporate both length of life (an assessment of the time affected 
by a health outcome) by the quality of that time period (the preference for being 
in that health state on a scale of 0 to 1) (268). Cost-utility analysis is the 
recommended method by many reimbursement bodies globally because survival 
and quality of life are important clinical trial outcomes and the generic QALY 
outcome from cost-utility analysis allows for comparisons across unrelated 
interventions and disease areas, which is particularly helpful for decision makers 
(112).  
For the purposes of this analysis, a within trial cost-utility analysis was 
performed using the data from the SCOT trial. This was an update of a previously 
performed cost-utility analysis of the SCOT trial from a UK perspective (75). The 
objectives of undertaking this additional analysis were to (a) integrate updated 
OS and DFS data from the SCOT trial, which became available in 2019, and (b) to 
perform the analysis from the perspectives of each of the countries that 
participated in SCOT. Both of these objectives add novelty to the study and 
differ from the original SCOT economic analysis. 
6.2.1.1 Outcomes 
Survival was calculated using partitioned survival analysis and a within trial time 
horizon (75). As is recommended good practice in conducting a within trial cost-
utility analysis for survival and costs extending beyond one year (112), discounting 
(269) of survival times was performed to adjust future health effects so that gains 
in survival occurring after year 1 were valued less than those occurring in the first 
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year of treatment (positive rate of time preference). Survival outcomes were 
available for up to 10 years for 4,592 patients, which represented longer follow 
up compared to the previous UK analysis that utilised survival data up to 8 years 
(75). Partitioned survival analysis was used to estimate the mean survival in three 
health states (time on treatment (ToT), DFS and recurrence).  
Quality of life was estimated using patient-level responses to the EuroQol-5 
dimension-3 level (EQ-5D-3L) questionnaire, (270) which were converted into 
utilities using preference weights. Value sets for preference weights specific to 
each country (271-274) were applied sequentially to the EQ-5D profiles for all 
patients in the SCOT trial for whom EQ-5D responses were available. EQ-5D results 
were only available for a sub-group of patients (n= 1 832) because collection of 
this data ceased after a pre-planned testing period to ensure sufficient 
information to inform analysis had been collected (275).  In order to apply EQ-5D 
to the whole population, linear regression was performed to adjust for health 
state, regimen received, disease risk stage, age, gender, and ethnicity. This model 
differs from the one used in the previous UK perspective analysis by the addition 
of an extra co-variate representing disease stage. Specifically, rather than 
dividing patients into those with stage III high-risk disease (T4 or N2) and “other”, 
in this analysis, patients were divided as either having stage II, low-risk stage III 
or high-risk stage III disease. In this model, ‘i’ refers to each patient and ‘t’ to 
time from randomization: 
𝑈𝑡𝑖𝑙𝑖𝑡𝑦𝑖𝑡 = 𝛽0 + 𝛽1𝑂𝑛𝑇𝑟𝑒𝑎𝑡𝑖𝑡 + 𝛽2𝑅𝑒𝑐𝑢𝑟𝑖𝑡 + 𝛽3𝐴𝑟𝑚: 6𝑀𝑖 + 𝛽4𝐶𝐴𝑃𝑂𝑋𝑖
+ 𝛽5𝐿𝑅𝑆𝐼𝐼𝐼𝑖 + 𝛽6𝐻𝑅𝑆𝐼𝐼𝐼𝑖 + 𝛽7𝑀𝐴𝐿𝐸𝑖 + 𝛽8𝐴𝐺𝐸𝑖 + 𝛽9𝐴𝑓𝑟𝐴𝑖
+ 𝛽10𝑆𝑜𝑢𝐴𝑖 + 𝛽11𝐶ℎ𝑖𝑛𝑒𝑠𝑒𝑖 + 𝛽12𝑂𝑡ℎ𝑒𝑟𝐸𝑡𝑖 + 𝑒𝑖𝑡
 
 
Where patient health state (on treatment and recurrence) could change over time. Standard errors were clustered at the 
patient level. 
To obtain the final outcome measure for the cost-utility analysis (197), average 
QALY outcomes for each health state from the regression model and each arm 
were estimated by adjusting the mean utility for each health state by the survival 
for the same health state using an integrated quality-survival product (276). The 
life years for the QALY calculation were discounted (to reflect the present value 
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of QALYs incurred in the future (269)) at a rate of 3.5% as per recommended good 
practice. 
6.2.1.2 Costs 
The costing process in any economic evaluation involves three stages:  
identification of appropriate cost items, measurement of the resource use, and 
valuation – applying monetary unit costs related to the measured resources and 
multiplying them (277). In this analysis, for years 0-6, individual per patient costs 
were calculated by multiplying the amount of resource used (mg of drug or number 
of nights/days attending hospital) by the appropriate unit cost (see Chapter 2). 
For inpatient and day cases occurring when patients received adjuvant 
chemotherapy, pharmacy costs were subtracted from these unit costs to avoid 
counting drug costs twice. On treatment and follow up time was divided into pre-
specified time points and mean costs accrued for each arm of the trial over pre-
specified time intervals was estimated. Specifically, the pre-specified time-points 
used in this analysis aligned with the time-points at which follow up information 
was collected within the SCOT trial (see Table 13-5 Appendix 4). These average 
costs were adjusted for censoring using the Kaplan-Meier Sample Average (KMSA) 
method (75). Specifically, mean costs were adjusted for the probability that a 
patient in that arm of the trial survived to the start of the time-point. The 
probability of being alive was interpolated from the Kaplan-Meier survival curves 
(Kaplan-Meier estimator) (278, 279). The following formula outlines how the KMSA 
calculation was performed: 
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑐𝑜𝑠𝑡 =  ∑ 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑎𝑙𝑖𝑣𝑒 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑗 𝑥 𝑚𝑒𝑎𝑛 𝑐𝑜𝑠𝑡 𝑎𝑡 𝑗 
 
As extended follow-up was undertaken beyond the initial trial time horizon, 
survival data was available for a longer duration compared to the within trial cost 
data, therefore a model was used to estimate annual costs for the years when 
actual costs data was not available (7-10 years). The same model of linear 
regression for estimating utilities was used, but incorporating an adjustment for 
year 1 costs that included chemotherapy medication and a higher use of 
hospitalization resources compared to all other years.  
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𝑌𝑒𝑎𝑟𝑙𝑦 𝑐𝑜𝑠𝑡𝑠 =  𝛽0 + 𝛽1𝑂𝑛𝑇𝑟𝑒𝑎𝑡𝑖𝑡 + 𝛽2𝑅𝑒𝑐𝑢𝑟𝑖𝑡 + 𝛽3𝐴𝑟𝑚: 6𝑀𝑖 + 𝛽4𝐶𝐴𝑃𝑂𝑋𝑖
+ 𝛽5𝐿𝑅𝑆𝐼𝐼𝐼𝑖 + 𝛽6𝐻𝑅𝑆𝐼𝐼𝐼𝑖 + 𝛽7𝑀𝐴𝐿𝐸𝑖 + 𝛽8𝐴𝐺𝐸𝑖 + 𝛽9𝐴𝑓𝑟𝐴𝑖
+ 𝛽10𝑆𝑜𝑢𝐴𝑖 + 𝛽11𝐶ℎ𝑖𝑛𝑒𝑠𝑒𝑖 + 𝛽12𝑂𝑡ℎ𝑒𝑟𝐸𝑡𝑖  +  𝛽13𝑌𝑒𝑎𝑟1𝑡   
+ 𝛽14𝑌𝑒𝑎𝑟1 ∗ 𝐴𝑟𝑚: 6𝑀𝑖 + 𝑒𝑖𝑡 
 
 
The average annual costs estimated using the model were also adjusted for the 
probability of a patient surviving to the start of that year using the KMSA method. 
Discounting was applied to all costs incurred after the first year of treatment.  
6.2.1.3 Cost-utility 
In order to compare the costs and effects to determine cost-utility, the 
incremental net monetary benefit (INMB) approach was used (280). More 
commonly an incremental cost-effectiveness ratio (ICER) is reported for cost-
utility analyses and requires a WTP threshold (representing 
society’s/reimbursement agencies’ willingness to pay per QALY) to determine if 
the QALY gain from a novel treatment is cost-effective compared to the standard 
of care (268). For example, in England, the National Institute for Health and Care 
Excellence (NICE) use a WTP threshold of £20,000-£30,000 per QALY for making 
their recommendations (197). In an ICER calculation, a novel treatment is assessed 
as cost-effective compared to the comparator treatment if the difference in costs 
divided by the difference in QALYs between the treatments is less than or equal 
to the WTP threshold. The INMB incorporates the WTP threshold into the 
calculation: 
𝐼𝑁𝑀𝐵 =  (𝑊𝑇𝑃 𝑥 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑄𝐴𝐿𝑌) − 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑐𝑜𝑠𝑡    
 
An INMB over zero indicates that an intervention is cost-effective compared to 
usual care at the specified WTP threshold.  In some countries, a WTP may not be 
used, or it may not be explicitly stated in public documents even if one is used 
(281). 
For this analysis, the monetary value of one annual gross domestic product (GDP) 
per capita for each country was used as a WTP threshold. This was based on the 
WHO guidelines for appropriate cost-effectiveness thresholds, which suggest using 
a value of 1-3 times the GDP per capita (282) and was used as the best available 
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benchmark that would be consistent across countries. Using country specific WTP 
thresholds would have been inconsistent and often they are not explicitly 
expressed by agencies for many countries. The lower end of the WHO range was 
used because it is recognised that the WTP per QALY of individuals or populations 
are often below this GDP per capita. Also, although proponents of using the QALY 
as an outcome measure in economic evaluations suggest that the value of a QALY 
is the same under all conditions, there is some evidence that the WTP of 
individuals for a QALY may vary based on if a treatment is life extending or life 
improving.  Lower value may be placed on life improving treatments, such as the 
shorter duration of chemotherapy under evaluation in this study (283).  
Six separate fully pooled, one country costing cost-utility analyses were 
conducted, one for each country, followed by a fully pooled, multi-country costing 
approach for the purposes of subgroup analysis. For the one country costing 
approach, resource use and outcome results for all patients in the trial were used, 
and single country specific unit costs and utility values were applied to all 
patients. For the fully pooled, multi-country approach, unit costs specific to the 
country patients were recruited from were used.  A healthcare system perspective 
was adopted and calculations were performed in USD unless otherwise specified. 
6.2.1.4 Sensitivity analysis 
Probabilistic sensitivity analysis (284) was undertaken to address and quantify 
potential sampling uncertainty within the cost-utility analysis (285).  
Bootstrapping (110, 286) with 1000 iterations was the method utilised to perform 
this sensitivity analysis. Bootstrapping is the method of re-sampling with random 
replacement of variables from the original sample to create an empirical 
distribution to act as an estimate of the true population distribution from which 
the sample was drawn. This bootstrapped distribution was used to calculate 95% 
confidence intervals (CIs) around the primary results. Deterministic sensitivity 
analysis (284), used to account for variations in a specific input parameter or set 
of parameters, was used in this study to calculate the incremental NMB over a 
range of WTP thresholds. Finally, cost-effective acceptability curves (CEACs) (287) 
and cost-effectiveness planes were used to illustrate the probability of cost-
effectiveness of the two treatment durations over a range of WTP thresholds 
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(288). A main CEAC for the overall trial results was produced, as well as CEACs for 
important patient, disease and treatment related subgroups.  
6.2.1.5 Subgroup analysis 
Subgroup analysis was performed using a fully pooled analysis in terms of 
outcomes but by using a multi-country costing approach. This meant that unit 
costs specific to each country were applied to patients in the SCOT trial that 
were recruited from that country. Given that most patients were recruited from 
the UK, unit costs from this location were given the most weight in the analysis. 
The subgroups chosen for further investigation aligned with the important pre-
planned and post-hoc subgroup analyses from the SCOT trial (41) and IDEA 
collaboration (81): extended risk stage and treatment regimen. Differences in 
cost-effectiveness between trial arms by gender and age group were also 
investigated. Age was categorised into under 70 versus 70 and over, as this was a 
clinically meaningful split.  
6.2.2 Budget impact analysis 
A budget impact analysis was the method used for the second part of this study. 
The purpose of a budget impact is the ‘forecast of rates of use (or changes in 
rates of use) with their consequent short and medium-term effects on budgets 
and other resources to help health service managers plan changes that result 
from the introduction of a new technology.’ (Dictionary of Health Economics 
from (289)) Budget impact differs from the types of economic analyses described 
above in that the effectiveness of treatments is generally not considered and 
costs are considered over a short-term time horizon that would be relevant to 
budget planning (1-5 years, rather than potential lifetime costs for an economic 
evaluation). Budget impact analyses are most often used by reimbursement 
bodies after an initial economic evaluation, to help estimate the likely financial 
consequences for a healthcare system of a decision to fund a novel therapy. 
6.2.2.1 Budget impact framework  
Figure 6-1 outlines the analytical framework used for the budget impact 
analysis. The eligible population for this budget impact analysis consisted of 
patients diagnosed with stage II or III CRC who receive adjuvant oxaliplatin-
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based doublet chemotherapy. The budget impact of SCOT trial implementation 
was calculated by estimating the change in healthcare costs if a specified 
proportion of patients were treated with an intended 3 months, rather than 6 
months of chemotherapy after the publication of the SCOT trial results. An 
assumption was made that any patient receiving doublet chemotherapy in the 
adjuvant setting pre-SCOT would receive 6 months of treatment. A summary of 
the values used in the budget impact analysis and a list of the sources is 





Figure 6-1 Budget impact analysis analytical framework 
 
Country specific population  
Incident cases of newly diagnosed CRC in the country of interest per annum 1. Eligible 
population  
Patients diagnosed with stage III CRC or stage II CRC per annum 
Patients with stage II and stage III disease who have radical primary surgery 
and receive adjuvant oxaliplatin-doublet chemotherapy 
2. Time Horizon  Annual budgets over 5 years 
3. Current and future 
treatment mix  
SCOT trial findings not introduced SCOT trial findings introduced 
4. Healthcare system 
treatment related 
costs 
5.  Healthcare system 
condition related 
costs 
7. Budget impacts 
Chemotherapy medication costs 
Hospitalisation resource costs 
(Year 1 of management for each 
patient**)  
Chemotherapy medication costs 
Hospitalisation resource costs 
(Year 1 of management for 
each patient**)  
Hospitalisation resource costs 
(Year 2-5 of management for 
each patient**)  
Hospitalisation resource costs 
(Year 2-5 of management for 
each patient**)  
Treatment costs: Chemotherapy drug costs and hospitalisation resource use 
costs (Year 1 of management for each patient**) 
Condition costs: Hospitalisation resource use costs (Years 2-5 of 
management for each patient**) 
















 **All patients enter the model at year 1 of their treatment. For those entering in year 1 of the model, costs for 
years 1-5 will be included. For those entering in year 2 of the model, costs for years 1-4 will be included. For 
those entering in year 3 of the model, costs for year 1-3 will be included etc.  
* This framework specifically focuses on the use of 6 versus 3 months of doublet chemotherapy. Other treatments 
that may be used, e.g. 6 months of fluoropyrimidine monotherapy. The doublet regimen assessed in this study is 
CAPOX or FOLFOX. In real life, occasionally patients have a contra-indication to fluoropyrimidine-based chemotherapy 
and may receive an alternative, such as raltitrexed, S1, UFT/LV or TAS-102 (depending on the country of treatment).   
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6.2.2.2 Data sources for budget impact framework 
The population of interest included in the budget impact analysis was estimated 
for each country using an epidemiological approach, based on the incidence of 
disease (118), identified from published literature and country specific reports.  
Incident rather than prevalent cases were utilised because the treatment of 
interest is only prescribed once for newly diagnosed stage II or III CRC. Data on 
undiscounted chemotherapy costs were taken from the cost-utility analysis (part 
(i)) of this study). Non-drug costs of resource utilisation for both the standard 
treatment and the intervention from the trial were also utilised. Those 
hospitalisation costs incurred in the first year were assumed to be treatment 
related and those in the following years (1-4) were assumed to be condition 
related. Including non-drug costs was in keeping with the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) guidelines but it recognised 
that this is not advocated by some country-specific budget impact analysis 
guidelines (Australia)(117).  
Rather than making the assumption that all patients would receive shorter 
treatment after the SCOT trial findings were disseminated, the results from the 
clinician survey (Chapter 5) were used to estimate the proportion of patients who 
would receive shorter treatment post-SCOT. The survey estimates accounted for 
differences in practice change for patients aged under 70 versus 70 and over. The 
details of how the survey results were applied are included in the footnotes of 
Table 13-6 in Appendix 4.  
Figure 6-2 demonstrates how the eligible population was calculated and the extent 
of practice change applied. The time horizon chosen for the budget impact 






Figure 6-2 Eligible population and extent of practice change 
 
6.2.2.3 Sensitivity analysis 
Uncertainty around key parameters in the budget impact analysis was addressed 
in a one-way sensitivity analysis. A set of base case parameter values were chosen 
to act as the main comparator around which sensitivity analyses for each country 
were performed by changing the values of these main cost drivers. The parameters 
that were altered were: i) the proportion of patients diagnosed with CRC that 
received adjuvant chemotherapy, ii) the proportion of those patients who 
received the intervention of a shorter duration of chemotherapy, and iii) the time 
horizon of the analysis. As is recognised good practice, inputs for the sensitivity 
analyses were taken from published literature and reports where possible rather 






















































* Based on real world data including 
patients of all ages ≥ 18 years. 
¶ These estimates account for 
differential rates of practice change 
for patients aged under 70 versus 




Three scenario analyses were also performed. First, patients with a diagnosis of 
colon cancer only were considered by excluding patients with rectal cancer. Next, 
the budget impact of patients with stage III disease only was estimated. These 
scenario analyses were conducted due to the increased uncertainty regarding the 
use of doublet chemotherapy and practice change in response to SCOT for patients 
with rectal cancer and stage II disease (see Chapters 1 and 5).  
A third scenario analysis was undertaken to calculate the budget impact from a 
societal, rather than a healthcare system perspective. Specifically, the loss of 
productivity from absenteeism at work during chemotherapy treatment, and the 
costs to patients to travel to hospital in the first year of treatment were included. 
There are three main approaches used in the literature to value productivity loss. 
These are shown in Table 13-4 Appendix 4 (based on (290, 291)). The human 
capital approach and the time patients were absent from employment during 
chemotherapy treatment were the focus of this evaluation. To calculate 
productivity loss, average country specific annual wages were used to calculate 
the earnings lost if 50% of patients aged 65 or under did not work during their time 
on treatment. The value of 50% was chosen based on the range of values provided 
by clinicians in response to a survey question about the proportion of patients that 
continue full time employment during adjuvant chemotherapy treatment 
(Appendix 3 Figure 12-12). The average time on treatment aligned with the time 
on treatment for each trial arm within the SCOT trial, calculated in the cost-utility 
analysis. The proportion of individuals who work part time in each country was 
also taken into account. Given the median age of patients receiving chemotherapy 
in the SCOT trial was 65 years, to calculate the proportion of patients aged 65 and 
under, the number receiving chemotherapy was divided in half. The productivity 
loss per patient using this approach was calculated using the following equation: 
𝑃𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑙𝑜𝑠𝑠 =  0.5𝑥(𝑛𝐶) ∗ ((𝑇 ∗ 𝑌) ∗ (𝑅 ∗ 𝑝𝑡))  
 
nC: Number of patients with CRC treated with adjuvant chemotherapy annually. T: Time on treatment. Y: Average yearly 




The unit costs to calculate productivity loss are detailed in Table 6-1. One source 
was used for the average annual wage for each country (OECD Economic Outlook, 
Volume 2019, Issue 2) (292). 
Table 6-1 Average yearly wage 
Cost category Unit cost (USD) Source 
Productivity loss 
estimates: average yearly 
wage (USD) 
  
Australia 54 501 OECD Economic Outlook Volume 2019, 
Issue 2 Denmark 57 150 
New Zealand 44 031 
Spain 38 758 
Sweden 46 695 
United Kingdom 47 226 
 
To calculate travel costs, an assumption that patients had a 30 mile round trip to 
attend hospital for chemotherapy or outpatient appointments was taken from the 
previous CRC literature (293). Travel for inpatient admissions was not included 
because although the number of nights spent in hospital for each patient was 
collected, it was unclear how many separate inpatient admissions this 
represented. It was also unclear what proportion of patients would have paid for 
their own travel to hospital for the purposes of these admissions rather been 
admitted to hospital from an outpatient clinic or being brought by ambulance.  A 
mileage cost of 0.66 USD/mile was used to calculate travel costs (294). Travel 
costs were calculated using individual patient level data from the SCOT trial and 
were adjusted for the probability of survival (as per costs for main budget impact 
analysis). Patients of all ages were included for calculation of travel costs. The 
average travel cost incurred per patient in year 1 of treatment was calculated as 
follows:  
𝑇𝑟𝑎𝑣𝑒𝑙 𝑐𝑜𝑠𝑡𝑠 = (𝑛𝐶) ∗ (𝐷𝑐 ∗ 30(𝑚))  
 
nC: Number of patients with CRC treated with adjuvant chemotherapy annually. Dc: Average total number of daycase or 
outpatient attendances. m: Average cost of mileage per mile. 
For the purposes of calculating both productivity loss and travel costs from the 
perspective of each country, purchasing power parity for private consumption 
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(295), rather than health specific purchasing power parity (used for chemotherapy 
and hospitalisation costs), was used to convert country specific currencies to USD. 
6.2.3 Calculation of QALYs gained from implementation 
Part iii) of the analysis was a calculation of the average QALY gain if the SCOT 
trial was implemented in these six countries over a 5-year time horizon. The 
average per patient QALY outcomes for the first 5 years for 3 versus 6 months of 
treatment were used from the within trial cost-utility analysis and applied to the 
eligible population of patients affected by SCOT trial implementation using the 
same BIA framework described above.  
6.2.4 The value of implementation of the SCOT trial 
An estimation of the cost of running the SCOT trial was obtained from a 
representative from Glasgow CRUK Clinical Trials Unit that ran the SCOT trial in 
collaboration with the Oncology Clinical Trials Unit in Oxford. The economic 
returns on the investment in the SCOT trial were calculated by subtracting the 
sum of the budget impact and monetised QALYs from the total cost of 
performing the SCOT trial. 
6.3 Results 
6.3.1 Cost-effectiveness of 3 months versus 6 months of 
treatment 
6.3.1.1 Description of SCOT trial patients 
Key patient, disease and treatment related factors for patients recruited from 
each country in the SCOT trial (n=6,065) are outlined in Table 6-2. Across all 
locations, average age was similar, there were more males than females, and 
most patients were fit, with a WHO performance status of zero. Notable 
differences included that Australian clinicians preferred to use FOLFOX (78%), 
whereas those from other locations used more CAPOX. There were no patients 
with stage II disease recruited from New Zealand, although the overall number 
from this country was small. There were more patients with low versus high-risk 
stage III disease in all countries, except New Zealand and Sweden. Disease 
compliance was higher for the 3-month versus the 6-month arm and higher for 
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fluoropyrimidine compared to oxaliplatin, regardless of treatment arm. 
Oxaliplatin compliance was lowest in Denmark and Sweden and in particular 
oxaliplatin compliance dipped to under 50% for patients in the 6-month arm from 
Denmark.  
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Figure 6-3 shows separate Kaplan-Meier curves for each partitioned survival 
outcome across the whole study period (maximum survival in either arm was 






Figure 6-3 Kaplan-Meier curves a: Overall survival b: Disease free survival c: Time on 
treatment.  
Figure 6-4 shows the Kaplan-Meier curves (max duration 10 years) showing the 
differences in the area under the curves for recurrence, DFS, and time on 







Figure 6-4 Survival curves partitioned by health state  a: 3 month arm b: 6 month arm.  
The average time spent in these three health states for patients in each trial 
arm is shown in Table 6-3. DFS was longer but recurrence was also higher for the 
3-month arm (neither statistically significant). Longer average time in the DFS 
state was partly influenced by the shorter time on treatment. Time on 
treatment was significantly longer in the 6-month versus 3-month treatment 
arm, however, it was not double, reflecting the poorer treatment compliance 
with longer treatment (see Table 6-2). Mean life expectancy was higher for 
patients in the 3 versus 6-month arm (not statistically significant).  
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Table 6-3 Survival times for each trial arm 
Health state 3 month arm 
N=3035 (50.04%) 
6 month arm 
N=3030 (49.96%) 
Incremental (CI) p-value 
ToT 0.21 (0.21, 0.22) 0.39 (0.39, 0.40) -0.18 (-0.19, -0.17) <0.001 
DFS 7.35 (7.21, 7.49) 7.17 (7.02, 7.31) 0.19 (-0.01, 0.38) 0.063 
Recurrence 0.82 (0.74, 0.90) 0.78 (0.69, 0.85) 0.05 (-0.06, 0.17) 0.351 
Total (OS) 8.39 (8.27, 8.50) 8.33 (8.21, 8.44)  0.06 (-0.10, 0.22) 0.443 
Kaplan-Meier estimate used for computation of expected time in each health state. 
Survival time estimated up to 10 years post randomisation for n=4,592 and up to 8 
years for 1,473 patients.  
Missing values for ToT means that the number of patients used for this calculation was 
lower (n=3018 for 3 month arm and n=3013 for 6 month arm). 
Undiscounted times used. 
 
Quality of life 
The linear regression output for UK utilities is provided below and in included in 
Appendix 4 for other countries. As expected, utilities were reduced when 
patients were receiving chemotherapy treatment, patients who had longer 
treatment (6-month arm) and when they experienced disease recurrence 
compared to a disease free state. Patients who received CAPOX had a minimally 
higher average utility compared to patients prescribed FOLFOX.  
Table 6-4 Regression output for UK utilities 
UK utilities 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment -0.0396* 0.004 
    Recurrence -0.0694* 0.015 
Arm: 6 months (ref: 3 
months) 
-0.0154* 0.007 
Characteristics   
    CAPOX 0.0042 0.008 
    Low-risk stage III 0.0002 0.012 
    High-risk stage III -0.0062 0.011 
    Male 0.0163* 0.007 
    Age 0.0016* 0.001 
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    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -0.0817* 0.039 
       South Asian -0.1453* 0.536 
      Chinese -0.0477 0.076 
      Other 0.0186* 0.022 
Constant   
Comparison is a 65 year old, Caucasian female patient on 3-month trial arm in 
a DFS health state and stage II disease treated with FOLFOX. *p<0.05 
 
Figure 6-5 demonstrates the average utility values at baseline and up to eight 
years for patients in each arm of the SCOT trial for each country. Once country 
specific utility weights were applied, health-related quality of life estimates 
were lowest for New Zealand and highest for Sweden. Given that fully-pooled 
outcome data was used for this calculation, any differences solely reflect 
differences in the estimates of how individuals from those specific countries 
value quality of life, rather than any observed difference between patients from 





Figure 6-5 Fully pooled results for quality of life calculated by applying country specific 
utilities to EQ-5D responses Relevant 95% confidence intervals are represented by error 
bars either side of each point estimate. “M”: month, “Y”, year. 
 
The final outcome of interest was QALY gain. The QALY gain from using 3 versus 
6 months of treatment is shown in Table 6-6.  
6.3.1.3 Costs 
The output from the linear regression model used to extrapolate costs for years 
7, 8 and 9 from a UK perspective are shown below (Table 6-5) and in Appendix 4 
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Table 6-5 Regression output for yearly costs from UK perspective 
UK costs (Regression used to model costs for years 7-10) 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment 13,974* 314 
    Recurrence 10,706* 800 
Arm: 6 months (ref: 3 
months) 
282 153 
Arm (6 months)*Year 1 672 382 
Year 1 6114* 349 
Characteristics   
    CAPOX -4915* 291 
    Low-risk III 49 328 
    High-risk III 217 304 
    Male -394 269 
    Age 23 13 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -1550 844 
       South Asian 127 1048 
      Chinese 453 1679 
      Other -231 428 
Constant 4508* 939 
Comparison is a Caucasian female patient on 3-month trial arm aged 65 years 
with stage II disease, treated with FOLFOX after year 1 in a disease free state. 
 
The average undiscounted chemotherapy and hospitalisation cost per patient for 
each country of using 3 versus 6 months of treatment and the difference 
between treatment durations are shown in Figure 6-6 and mean discounted costs 
for each country are outlined in Table 6-6. These costs represent the combined 
costs over a period of up to 10 years. Spain and the UK had the lowest 
chemotherapy unit costs, whereas chemotherapy unit costs were very similar for 
Australia, New Zealand, Sweden, and Denmark. The differences in 
hospitalisation costs aligned with the ratios between UK and other country costs 
used in the calculation (see Chapter 2). Costs calculated using a multi-country 
approach aligned closely with those from the UK because most patients in the 





Figure 6-6 Mean undiscounted costs per patient Costs given per arm and difference 
between trial arms for each country a) chemotherapy medication costs b) hospitalisation 
costs. 
 
6.3.1.4 Cost utility, sensitivity and sub-group analyses 
The cost-effectiveness of 3 versus 6 months of treatment was estimated by 
comparing the costs and outcomes for each trial arm. Overall, 3 months of 
treatment was a dominant strategy, being more effective and cost-saving 
compared to 6 months across all locations (Table 6-6). The differences between 
EQ-5D responses (Figure 6-3) are also reflected in the difference in QALY gains 
between countries, which ranged from 0.11 for Sweden to 0.17 for New Zealand 
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The INMB was greater than $8,000 across all locations, with over 99% probability 
that the 3-month arm was cost-effective for all countries at a WTP threshold of 
one GDP/capita.  
Table 6-6 Country specific cost-utility analysis results 




NMB using 1 x GDP 
per capita (95% CI) 
Probability 
of being CE 
at WTP of 1 
x GDP per 
capita (%) 
Australia   GDP: 53, 000 USD   
3 months 37,289 (35,520; 39,226) 6.28 (6.17; 
6.40) 
295, 494 (288,886; 
302,170) 
99.6% 
6 months 42,830 (40,691; 44,999) 6.13 (6.00; 
6.26) 
282, 158 (275, 
037; 239,783) 
0.4% 






Denmark   GDP: 62,000 USD   
















New Zealand   GDP: 42,000   
















Spain   GDP: 31,000   
















Sweden   GDP: 52,000   
















UK   GDP: 40,000 USD   







































Figure 6-7 demonstrates the INMB across a range of WTP thresholds. Sweden had 
one of the highest cost-savings, therefore at lower WTP provided the highest 
INMB. As the WTP for a QALY gain increases, the INMB was highest from a New 
Zealand perspective because of the highest QALY gain when New Zealand 
specific EQ-5D weights were applied in the calculation of utilities.  
 
Figure 6-7 INMB over a range of WTP thresholds for each country INMB: Incremental net 





The CEACs for each location demonstrated that 3 months of treatment is cost-
effective compared to 6 months over a large range of thresholds up to 
$200,000/QALY. Focusing on the cost-effectiveness planes, for all countries the 
point estimates for cost-effectiveness of 3 versus 6 months of adjuvant 
treatment for CRC were all within the South East quadrant, that is, the shorter 
treatment was the dominant strategy. Also, the majority of the bootstrapped 
estimations were also in the lower right hand quadrant of the cost-effectiveness 
plane, indicating that three months of treatment produced both a cost saving 
and a quality of life gain. A minority of data points sat in the lower left 
quadrant, indicating that shorter treatment is still cost saving but leads to 
reduced QALYs. The country specific WTP thresholds of one GDP per capita are 
displayed on each cost-effectiveness plane as a dashed line. Point estimates and 
bootstrapped results lying below the line show that 3 months of treatment is 
cost-effective compared to 6 months using the specific threshold indicated. It is 







Figure 6-8 Country specific CEACs and cost-effectiveness planes Displaying 1000 
bootstrapped iterations of the incremental cost/QALY for 3 months versus 6 months of 
treatment from the perspective of all six healthcare. The blue circle on the cost-
effectiveness planes indicates the relevant incremental cost/QALY point estimate and the 
green dashed line indicates a WTP threshold (1 GDP/capita) for each country.  
The results of subgroup analyses are provided in Figure 13-2 Appendix 4. There 
was most uncertainty for patients receiving FOLFOX. At a WTP threshold of 
$42,000 USD, the probability of 3 months of FOLFOX being cost-effective was 
77%, compared to 99% for CAPOX. Comparing patients aged under 70 versus 70 
and over, the cost-effectiveness planes show us that, for the older group, a 
number of bootstrapped estimations lie in the upper right quadrant, indicating 
that 3 months of treatment is more costly than 6 months of treatment, although 
at the same time providing a QALY gain. Interestingly, for male patients, the 
CEAC shows cost-effectiveness of 3 months compared to 6 months of treatment 
dips at higher WTP thresholds and the corresponding cost-effectiveness plane 
shows that this is driven by a reduction in QALY gain, rather than an increase in 
costs for the 3-month arm. Focusing on extended stage of disease, there was the 
greatest spread of bootstrapped results for patients with stage II disease which 
was also the smallest of these subgroups (n=1,114). At a WTP threshold of 
$42,000, the probability of 3 months of treatment being cost-effective compared 
to 6 months was 90.3%, 96.3%, and 87.5% for patients with stage II, low-risk 
stage III and high-risk stage III respectively.  
6.3.2 Analysis of budget impact 
Table 6-7 shows the number of patients for each country estimated to receive 3 
months rather than 6 months of adjuvant doublet chemotherapy after 
implementation of the SCOT trial results. This estimate was highest for the UK 
and lowest for New Zealand. Chemotherapy medication costs, treatment related 
and condition related hospitalisation costs for each country over 5 years show 
that most cost savings from SCOT trial implementation were mainly driven by a 
reduction in the treatment related hospitalisations (year 1) for the shorter 
treatment approach of 3 months versus 6 months.  
Combining all relevant healthcare costs, the estimated healthcare system 
savings of implementation of SCOT trial findings over 5 years ranged from $3.6 
million USD (New Zealand) to over $61.4 million USD (UK). The combined base 
236 
 
case budget impact was $152 million USD. The values are provided in country 
specific currencies in Appendix 4 Table 13-17. The impact for New Zealand was 
lowest due to the smallest eligible population and cost difference per patient. 
Although the cost-utility analysis showed that the cost savings per patient from 
using shorter treatment were highest from the perspective of Australia, the UK 
had the largest budget impact due to the biggest eligible population.  
Table 6-7 Budget impact analysis base case and scenario analysis in country specific 
currency All values for budget impact included in this table indicate cost savings USD 
(millions).   
Australia Denmark New 
Zealand 
Spain Sweden United 
Kingdom 
Annual number of 
patients receiving 
3 months of 
treatment who 
would have 
received 6 months 
pre-SCOT 
957 495 187 2,304 406 2,906 
Chemotherapy 
medication costs 
over 5 years 
2.0 0.5 0.3 1.8 0.8 1.9 
Treatment related 
hospitalisations in 
(year 1 for each 
individual patient) 
over 5 years 
21.4 6.5 3.1 40.2 8.8 56.1 
Condition related 
hospitalisations  
(years 2-5 for each 
individual patient) 
over 5 years 
1.3 0.4 0.2 2.4 0.6 3.4 
Total budget 
impact = 
Medication cost + 




24.7 7.4 3.6 44.4 10.2 61.4 
 
6.3.2.1 Budget impact sensitivity analysis 
A one-way sensitivity analysis was performed in which key parameters used in 
the budget impact calculation were increased or decreased in turn to investigate 
the effect on the extent of budget impact. These parameters and the values 
used in the sensitivity analysis are outlined in Figure 6-9, alongside a Tornado 
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diagram for each country showing the corresponding variation in 5-year cost 
savings. For example, if it was assumed that all patients with stage III CRC 
receive 3 rather than 6 months of adjuvant doublet chemotherapy, the overall 




Figure 6-9 Budget impact analysis one-way sensitivity analysis Parameters used to perform the sensitivity analysis are shown in the table 
embedded within this figure. There are six tornado diagrams, one for each country displaying 6 one-way sensitivity analyses. The letter on the 
right hand side of each diagram indicates the parameters changed, according to the values displayed in the table. For example, for “A”, the 
proportion of patients with stage II CRC receiving adjuvant chemotherapy has been altered from 10% (low estimate) to 50% (high estimate) around 
the baseline case of 20%. The line in the middle of each tornado diagram indicates the baseline budget impact estimated for that country (see 
Table 6-7 for those results listed under “Total budget impact”.
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Removing patients with stage II disease from the analysis (Table 6-8) had little 
effect (total savings $145 million USD) because of the small population deemed 
eligible to be affected by a practice change in the base scenario for this study. 
Excluding patients with rectal cancer in a scenario analysis led to a decrease in 
the budget impact by less than half (total $102 million USD) because incidence 
of rectal cancer is generally less than colon cancer for stage II/III disease.  
Productivity loss had a significant monetary impact over five years, in excess of 
the healthcare budget impact for the same time-period. The combined travel 
cost impact over 5 years across all countries amounted to $4.5 million USD. The 
total estimated budget impact across all countries over 5 years from a societal 
perspective (adding base case budget impact, productivity loss and travel costs) 
amounted to $340 million across all six countries.  
Table 6-8 Budget impact scenario analysis results  
Australia Denmark New 
Zealand 
Spain Sweden United 
Kingdom 
Base case total 
budget impact = 
Medication cost + 




24.7 7.4 3.6 44.4 10.2 61.4 
Scenario analysis (otherwise as per base scenario) 
Rectal Cancer 
Excluded 
17.1 5.0 2.4 29.2 6.9 41.3 
Stage II excluded 23.5 7.1 3.4 42.4 9.8 58.7 
Productivity loss 
(50% aged 65 years 
and under stop 
work) 
29.2 10.1 5.1 48.8 11.8 78.8 
Travel costs 0.6 0.2 0.1 1.5 0.3 1.8 
 
6.3.3 QALY gain from SCOT trial implementation 
In order to undertake an assessment of economic impact in the SCOT trial 
following the approach used by Glover et al (39), it was necessary to calculate 
the country specific QALY gain from implementation. This was calculated using 
the same incident population over 5 years as in the budget impact model. 
Average QALY outcomes from the 3 and 6-month arms of the trial were applied 
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to the estimated proportion of patients receiving an intended 6 versus 3 months 
of treatment pre and post-SCOT. Table 6-9 shows the average QALY gain and the 
monetised values of these gains.  
Table 6-9 QALY gain over 5 years from a country specific perspective and the monetised 
value of that QALY gain *WTP threshold: $42,000 USD   
Australia Denmark New 
Zealand 









16.1 4.4 3.5 38.7 4.3 48.8 
 
Figure 6-10 demonstrates the change in monetised QALY gains for each country 
at different WTP thresholds using the main point estimate for QALY outcome 
from the two arms of the SCOT trial calculated in the cost-utility analysis (part i) 
of this study).  
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6.3.4 Estimating the return on the investment in the SCOT trial 
The overall value of conducting and implementing the SCOT trial was calculated 
by comparing the amount spent on developing and running the trial across six 
countries (see Appendix 4), to the cost savings and monetised health benefits 
from implementation. Table 6-10 shows the components of this calculation. 
Overall, subtracting the costs to run the trial, the economic value of conducting 
and implementing the SCOT trial was $259 million USD. Adopting a societal 
perspective, by adding productivity loss and travel calculations (188.3), brought 
this figure to $447 million USD.  
Table 6-10 Calculation of economic value of investment in the SCOT trial Return on 
investment (USD): (-8.8) – (151.7 + 115.8) =  258.7 million USD gain.     
Australia Denmark New 
Zealand 
Spain Sweden United 
Kingdom 
Total 







8.8 million USD (deficit) -8.8 
Output        










16.1 4.4 3.5 38.7 4.3 48.8 +115.8 




Three months of adjuvant, oxaliplatin-based chemotherapy is cost-effective and 
cost saving compared to 6 months from the perspective of all countries that 
recruited to the SCOT trial. Using updated survival data, mean life expectancy 
was better in the 3 month arm (not statistically significant), whereas in the 
previous cost-utility analysis, life expectancy was non-significantly higher in the 
6 month arm. In addition, although there was a QALY gain from shorter 
treatment in the previous cost-utility analysis, it was higher in this study (only 
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statistically significant for New Zealand), driven both by increased life 
expectancy and quality of life improvement. Any cost-effectiveness differences 
between countries was driven by the unit costs for hospitalisations and 
chemotherapy medication, as well as the country specific weights attached to 
quality of life measures.  
Regarding unit costs, publicly available list prices were used for every country. 
Although it is unlikely any within-country variation in these list prices would 
change the cost-effectiveness outcomes, it is important for decision makers from 
each country to read these results in the context of country specific cost used. 
For example, the UK costs calculated from this analysis are lower than estimated 
in a previous UK perspective cost-utility analysis (75). This is because a 
difference source of unit costs was used in this analysis (eMIT) compared to the 
previous analysis (BNF). eMIT costs were felt to be more appropriate for this 
analysis for two reasons. Firstly, eMIT is the source of unit costs for generic 
drugs recommended by NICE guidance (197). Secondly, when BNF unit costs were 
investigated for use in this analysis, these costs were in some instances ten 
times higher compared to both eMIT costs and medication unit costs for the 
other countries in this analysis. This supports the concept that even within 
country sources can vary and interpretation of any results should be mindful of 
this variation. If BNF costs had been used in this analysis, the cost savings from 
SCOT trial implementation may have been several times the current estimate. 
In this study, the cost-effectiveness of shorter treatment was most certain for 
patients with low-risk stage III disease. The previous cost-utility analysis from a 
UK perspective (75) split patients into high-risk stage III and “other” and 
therefore it was not possible to explore the difference for patients between 
stage II and low-risk stage III. The cost-effectiveness for patients with low-risk 
stage III disease was driven by non-significant improvements in life expectancy, 
QALY gain, and cost saving associated with shorter treatment.  
Subgroup analysis also revealed that the cost-effectiveness of using 3 versus 6 
months of treatment was less certain for patients receiving FOLFOX, especially 
at higher WTP thresholds. This was because of the small mean benefit in life 
expectancy from using longer treatment with this regimen (not statistically 
significant). However, FOLFOX for 3 months was still seen to be a cost-effective 
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treatment compared to 6 months because of the costs savings and improved 
quality of life associated with shorter treatment. This contrasts with a recent 
model based cost-utility analysis specifically relevant to patients with high-risk 
stage II disease (296), which used information from the SCOT trial (utilities), the 
TOSCA trial (adverse events) and the pooled high-risk stage II IDEA analysis 
(survival outcomes). The authors of that model-based study concluded that, 
although the cost-effectiveness of 3 months of CAPOX was demonstrated, 3 
months of FOLFOX was not cost-effective compared to 6 months of FOLFOX. This 
result was driven by the fact that, as in this study, FOLFOX was a more 
expensive treatment compared to CAPOX and 3 months of FOLFOX was less 
effective than 6 months.  
Approximately 1.8 million people (297) are diagnosed with CRC per annum 
globally, with the annual cost of managing this disease projected at over $39 
billion USD (298). Around half of these patients (299) present with stage II-III 
disease, therefore making savings relevant to this patient cohort has the 
significant cost consequences. This study shows that implementing SCOT trial 
findings in six high-income countries translates to savings of hundreds of millions 
of dollars, in the order of  a 17-fold increase on the original SCOT investment, 
and the total global impact is likely to be several times this estimation. Adding 
in the QALY gain related to this implementation, for the base-case analysis from 
a healthcare perspective meant the return on the initial investment was  30-
fold; if societal perspective gains were included, this increased to over 50-fold. 
This is in line with previous estimates of the return on medical research in the 
USA (twenty fold return) (300) and compares favourably to a previous analysis of 
non-cancer clinical trial impact performed by US authors who identified a four-
fold return on investment (301). That US study analysed the impact of a 
programme of trials but was limited by the fact that if cost-utility and 
implementation information was not available for certain trials, only the costs of 
conducting the trial, and none of the benefits, were included in the estimation. 
Also, the implementation of new treatment strategies tested within many of the 
individual trials assessed in that study occurred at a cost to the health-service 
rather than being cost-saving. 
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The main part of this budget impact analysis considered direct healthcare 
service costs only. A previous estimate of the burden of all cancers on the 
European Union economy was calculated at $126.3 billion for the year 2009 
(302), with 40% related to direct healthcare costs and 40% related to 
productivity costs. The analysis from the report Medical Research: What’s it 
Worth (149) (Table 3-1 Chapter 3), suggested that valuing either health gain or 
work costs will often outweigh direct health care savings. The findings from this 
study supports the results from both of those studies, and taking a societal 
perspective significantly increased the cost savings related to SCOT trial finding 
implementation. The incidence of CRC is increasing in younger patients (303), 
therefore it could be argued that this provides even greater rationale to include 
the impact of treatment, morbidity and mortality from CRC on patient 
employment when evaluating the downstream effects of research findings.  
The strengths of this study are the use of within trial data to calculate costs, 
utilities, and survival gains associated with the treatments being assessed. The 
analysis was also strengthened by using the implementation estimate from a 
survey of clinicians. This method applied evidenced practice change rather than 
making assumptions on potential practice change, which have inherent 
limitations. Using clinician self-reported change was a more realistic approach to 
evidencing impact than previous cancer trial impact studies have utilised. Using 
these assessments of implementation add weight to this type of analysis, 
because without these results it would be impossible to know the extent of 
practice change or if change in practice would have occurred anyway, without 
the clinical trial and its associated cost. 
This study has some important limitations. Firstly, using a fully pooled approach, 
varying unit costs alone are likely to underestimate between-country differences 
compared to fully splitting the analysis (112). A partially split approach was 
avoided because two of the countries that recruited to SCOT (Sweden and 
Denmark) did not collect hospitalisation resource use information. A fully split 
approach was not used for the same reason. Also small numbers of patients from 
some locations and varying follow up times for patients from different countries 
would have led to increased uncertainty about the validity of outcome measures 
based on patients from each country alone. 
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For the purposes of the budget impact analysis, an assumption was made that 
the clinicians who reported they prescribed 3 months of doublet chemotherapy 
post-SCOT, used 6 months of doublet chemotherapy pre-SCOT. It would have 
been optimal to have an estimation of actual prescribing practices pre-SCOT. 
There is most uncertainty surrounding how this assumption applies to patients 
with stage II disease because improvement in OS from adding oxaliplatin to 
fluoropyrimidine has not been demonstrated and, (63) (304) for this reason, 
clinicians may give fluoropyrimidine monotherapy. This uncertainty was 
addressed by only including the small proportion of stage II patients that are 
likely to receive doublet chemotherapy, by varying this parameter in the budget 
impact sensitivity analysis, and by excluding patients with stage II disease as one 
of the budget impact scenario analyses. Similarly, despite being included in 
several international guidelines, the use of doublet chemotherapy in the 
adjuvant setting for rectal cancer is more controversial compared to colon 
cancer, with fewer randomised trials to support its use. The budget changes 
relevant to rectal cancer treatment were therefore more uncertain compared to 
those for colon cancer and this is the reason why patients with rectal cancer 
were also excluded within a scenario analysis. Lastly, the budget impact analysis 
assumed that the proportion of patients receiving FOLFOX (32%) versus CAPOX 
(68%) pre- and post-SCOT was the same as in the SCOT trial (41). Given the 
higher uncertainty regarding the non-inferiority of using 3 months of FOLFOX, 
clinicians may switch to CAPOX. This is most relevant to clinicians from 
Australia, who showed a preference for FOLFOX within SCOT.  
A societal perspective was included in a sensitivity analysis, recognising the 
merits of taking a broader approach to evaluating the impact from medical 
research. Specifically, the value of lost earnings was calculated, in line with the 
previous analysis by Brown et al (184). However, the approach to assessing 
societal gains in this way are not without controversy. In particular, using the 
human capital approach has been criticised because it only recognises the 
productivity loss associated with those of working age, and does not incorporate 
the value of the loss of leisure time or informal care giving for those of any age 
in the population. The approach is also limited in that it may overestimate the 
loss accrued when patients do not attend work due to treatment or illness, 
because in a real-world setting, their workload may be picked up by a colleague 
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or their post may be filled with another worker during that time. Although there 
is disagreement in the literature regarding whether productivity costs relating to 
treatment should be considered (versus those relating to morbidity and/or 
mortality only), previous analyses relevant to adjuvant CRC treatment have 
included the cost to society of patients not being able to attend working during 
the period they are receiving chemotherapy (296). 
In the study by Glover and colleagues (39), the authors calculated an internal 
rate of return on investment into cancer research as a percentage return on the 
investment every year for perpetuity. This was not calculated in this study 
because the QALY gain assessed in the cost-utility analysis was not for the 
lifetime of patients enrolled in the trial. Not using the internal rate of return 
approach means that the results from this study cannot be compared with others 
in the literature that are reported in that manner. 
For the SCOT trial, where the QALY gain was minimal and did not meet 
statistical significance for 3 months versus 6 months of treatment, it is not clear 
that adding this extra step of valuing QALYs, beyond on the budget impact 
analysis alone, was necessarily worthwhile. Clearly, the main value from 
implementing SCOT findings will be on cost savings (the first of Buxton’s 
categories (100) as described in Chapter 3) and in reducing toxicity from 
treatment, rather than on extra years of life gained. Nevertheless, it was useful 
to explore how this calculation of QALY gain from implementation is performed 
because it will be important if applying this approach to other clinical trials, in 
particular to trials with a superiority end-point. The economic value of 
implementing superiority trials will be a balance between the QALY gains from 
using a new treatment (the fourth of Buxton’s categories), minus the extra cost 
of using that treatment in a real world healthcare setting. 
6.5 Conclusion 
This study has widened the transferability of cost-utility analysis results from the 
SCOT trial. This type of analysis alongside multi-national clinical trials ensures 
all countries that recruited to the trial have results relevant to their decision 
makers. This study has also estimated positive impact on 5-year healthcare 
budgets from implementing SCOT trial findings of over $150 million USD across 
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six countries, with potential additional value being added from QALY gain from 
shorter treatment. These vast savings could fully justify the investment in 
conducting the SCOT trial. 
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7 Chapter 7: Impact of the SCOT trial on local 
practice 
7.1 Introduction 
Assessing practice change is one important indicator of how clinicians and patients 
are interpreting and discussing cancer trial results. Evaluating clinical practice 
will indicate if clinicians consider that a novel treatment that has been tested 
within a clinical trial is suitable for use within a real world patient population and 
if the institutional environment is favourable for practice change in line with trial 
findings.  
As shown in Chapter 5, a survey of research users such as clinicians is one tool that 
can be used to explore the impact of cancer trials on practice. One of the 
shortcomings of using a survey includes the inherent selection bias, specifically, 
only a sample of the population of practising clinicians will respond to a survey 
and it is not always clear how representative the sample is of the population of 
interest. Another limitation of the survey in Chapter 5 is that clinicians’ self-
reported practice in the years following publication of SCOT and the IDEA 
collaboration have been investigated, however there is no documentation of 
prescribing practices from before the results of these trials were known. Lastly, 
it was not clear from the survey alone if what clinicians have reported they do 
aligns with their actions.  
To address these issues, and to assess the impact of the SCOT trial on clinical 
practice in a different way, the aim of the work in this chapter was to evaluate 
clinical practice change in response to the SCOT trial using administrative 
healthcare data. Specifically, the chemotherapy prescribing records for patients 
with a diagnosis of CRC within one health board in Scotland (Greater Glasgow and 
Clyde (GG&C)) before and after publication of the SCOT trial findings were used. 
GG&C is the largest health board in Scotland and covers a population of 1.2 million 
individuals. Within this study, five different approaches to evaluating the impact 
of the SCOT trial on prescribing practices were tested to explore the optimal way 
of assessing trial impact.  
The objectives of this chapter were to: 
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i) Describe patient, disease, treatment information and outcomes 
relevant to the cohort of patients receiving adjuvant chemotherapy for 
CRC in GGC 
ii) Analyse the impact of the SCOT trial findings on clinical practice 
within this health board   
iii) Test a number of quantitative methods to undertake this analysis  
 
7.2 Methods 
The process of data acquisition and linkage of datasets is outlined in Chapter 2. 
The variables used for this analysis and the datasets from which they were derived 
are outlined in Table 14-2 Appendix 5.  
7.2.1 Cohort derivation 
The inclusion criteria used to define the relevant cohort of patients for the 
purpose of this analysis were: 
 Patients of any age diagnosed with stage II or stage III colon or rectal cancer 
who had received adjuvant chemotherapy for CRC with 5-fluorouracil or 
capecitabine alone or in combination with oxaliplatin. These patients were 
identified using a regimen descriptor variable in ChemoCare. 
 Patients who received adjuvant chemotherapy between January 2010 and 
March 2018. 
The incident, rather than prevalent, population was used. This meant that only 
those patients who started adjuvant chemotherapy within these dates were 
included. Follow up was until the end of January 2019.  
Exclusion criteria were: 
 Patients receiving chemotherapy regimens other than those described 
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 Patients who received adjuvant chemotherapy as part of a clinical trial 
 Patients with known metastatic disease (even if this metastatic disease was 
resected) 
 Patients who received only capecitabine monotherapy in combination with 
radiotherapy. (Patients were included if they received capecitabine 
monotherapy concurrently with radiotherapy but also received adjuvant 
chemotherapy. The concomitant capecitabine prescription was not 
included for the purposes of this analysis.) Patients who received short 
course radiotherapy at any stage were included as long as all other criteria 
were met. 
 Patients who received neo adjuvant chemotherapy (other than 
capecitabine in combination with radiotherapy). 
No national data dictionary existed for ChemoCare datasets across Scotland, 
therefore it was not known if the ChemoCare systems in other locations would 
have regimen names that could be used for cohort derivation as was the case for 
ChemoCare WoSCAN. Identifiable clinical portal records were also not available at 
a national level. Acknowledging these issues, to provide information on how best 
to define the cohort when using an anonymised national dataset, the study cohort 
for GG&C was also defined using i) Cancer Audit/QPI and ii) ACaDMe SMR06 
datasets, and the three methods of cohort definition were compared.  
The method of derivation for the final cohort of patients used for analysis was 
based on the ChemoCare system. An updated search for the GGC cohort was 
performed in January 2020 to identify patients who commenced adjuvant 
chemotherapy between April 2018 and March 2019.  
Patients were divided into two groups based on the regimen of adjuvant 
chemotherapy they received at cycle one of treatment. Although it was recognised 
that clinicians may switch chemotherapy regimens during treatment due to 
tolerability, for the purposes of this study, the choice of therapy at cycle one was 
assumed to indicate a clinician’s preferred therapy for each individual patient. 
The two patients groups were: a) those who received oxaliplatin-fluoropyrimidine 
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doublet chemotherapy at cycle one and b) those who received fluoropyrimidine 
monotherapy at cycle one. This split was based on the hypothesis that SCOT trial 
findings were most likely to impact patients who received the treatment that was 
tested within the SCOT trial (doublet chemotherapy). The cohort of patients 
receiving monotherapy at initiation of adjuvant therapy were used as a 
control/comparison group.   
In order to analyse the impact of the SCOT trial findings on practice, a measure 
of the duration of treatment received by each patient was required. This was 
calculated by using the number of cycles of chemotherapy delivered, taking 
account of the regimen of chemotherapy delivered at each cycle, for example, 
FOLFOX or CAPOX, which are delivered fortnightly or three weekly respectively. 
This assessment did not utilise the calendar time and therefore between-cycle 
delays to treatment were intentionally not accounted for within this calculation. 
A binary indicator to demonstrate if the duration of chemotherapy received was 
over 3 months or less than or equal to 3 months was also used. Three months was 
chosen in line with the experimental arm of the SCOT trial (41). The assumption 
was made that if a patient received over 3 months of treatment, it was unlikely 
that the clinician and patient intended to align practice to the experimental arm 
of the SCOT trial. It was recognised in advance that a proportion of patients would 
not reach 3 months of treatment due to tolerability, toxicity, or patient choice to 
stop treatment, rather than a conscious decision from the clinician at the time of 
treatment initiation to give this duration. However, it was also assumed that the 
proportion of patients not reaching 3 months of treatment due to tolerability, 
toxicity or patient choice, would be stable pre and post-SCOT.  
The influence of the SCOT trial findings on clinical practice were represented using 
a dichotomous, time dependent independent variable with 0 representing the 
time-period prior to 1st June 2017, when the SCOT trial results were first 
publicised at ASCO, and 1 representing the time-period after June 2017.  
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7.2.2 Statistical methods used to analyse chemotherapy datasets  
7.2.2.1 Descriptive analysis and comparison of proportions 
Descriptive statistics (percentages/counts) were used as the first method to 
analyse the chemotherapy prescribing data. Average duration of chemotherapy 
delivered was compared at different time-points using the median duration of 
treatment and the non-parametric Mann-Whitney U test (110). A binary outcome 
variable representing the duration of treatment received was also used and the 
proportion of patients receiving longer treatment across two time-points was 
compared using the Chi-squared test (110).   
7.2.2.2 Regression analysis 
Univariate linear regression (110) was used to investigate the change in average 
duration of chemotherapy received (continuous variable), dependent on the 
timing of the dissemination of the SCOT trial results. Univariate analysis was also 
performed to explore the effect of patient, disease, and treatment related 
variables on the duration of chemotherapy prescribed. Multi-variate analysis was 
used to explore the impact of the SCOT trial on chemotherapy duration whilst 
accounting for these other co-variates. Co-variates were added to the multivariate 
model in a step-wise manner (110).  
For the purposes of the regression analyses using individual patient level data, the 
following patient, disease, and treatment related factors were identified in 
advance as important co-variates to be used within any regression analysis: 
gender, age (≤ 70 years old and >70 years old), social deprivation category, stage 
of disease (stage II, low-risk stage III and high-risk stage III) and the chemotherapy 
regimen used at the first cycle of treatment. This age cut-off was chosen as a 
clinically relevant, as identified in the piloting stage for the survey (Chapter 5 
Results). 




= 𝛽0 + 𝛽1𝑆𝐶𝑂𝑇 + 𝛽2𝐺𝑒𝑛𝑑𝑒𝑟 + 𝛽3𝐴𝑔𝑒𝑔𝑟𝑜𝑢𝑝 + 𝛽4𝑆𝐼𝑀𝐷 + 𝛽5𝑟𝑖𝑠𝑘𝑠𝑡𝑎𝑔𝑒
+ 𝛽6𝑅𝑒𝑔𝑖𝑚𝑒𝑛 + 𝑒
 
 
This process was repeated but using logistic regression (110) with a binary 
outcome (dependent) variable, signifying if a patient received over three months 
of treatment. The following equation was used for the multivariate logistic 
regression: 
𝐿𝑜𝑔 𝑜𝑑𝑑𝑠 𝑜𝑓 𝑟𝑒𝑐𝑒𝑖𝑣𝑖𝑛𝑔 𝑜𝑣𝑒𝑟 3 𝑚𝑜𝑛𝑡ℎ𝑠 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
= 𝛽0 + 𝛽1𝑆𝐶𝑂𝑇 + 𝛽2𝐺𝑒𝑛𝑑𝑒𝑟 + 𝛽3𝐴𝑔𝑒𝑔𝑟𝑜𝑢𝑝 + 𝛽4𝑆𝐼𝑀𝐷 + 𝛽5𝑟𝑖𝑠𝑘𝑠𝑡𝑎𝑔𝑒
+ 𝛽6𝑅𝑒𝑔𝑖𝑚𝑒𝑛 + 𝑒
 
 
7.2.2.3 Segmented regression with individual patient level data 
Segmented regression, also known as piecewise regression (305), was the third 
approach tested. This method was used to account for whether a gradual change 
in practice may have occurred over the whole time-period being studied, which 
could have explained any change around the time of dissemination of SCOT trial 
results. Time (in years) was included as a continuous variable from the time the 
first patient commenced treatment. Two additional variables were also created 
for each patient to allow calculation of the change in intercept of the fitted 
regression slopes pre versus post-June 2017. The first variable (“time1”) 
represented time prior to June 2017 and the second represented time after June 
2017 (“time 2”). These were created as mutually exclusive variables with time1 
taking a value of zero if time2 took any value over zero and time2 taking a value 
of zero if time1 took any value over zero. Both of these variables were then 
included in a linear regression model to understand the trend in outcome 
(treatment duration in weeks) over time in two distinct periods, pre-June and 
post-June 2017. Two further variables were created to represent the intercepts 
of the predicted trend lines pre-June 2-17 and post-June 2017. This allowed 
visualisation of the fitted regression line pre-SCOT and post-SCOT and calculation 
of the difference in the slopes and intercepts of both lines as an indication of the 
impact of the SCOT trial findings on clinical practice.  
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The equations used to apply piecewise regression using linear and logistic 
regression methods are shown below: 




𝐿𝑜𝑔 𝑜𝑑𝑑𝑠 𝑜𝑓 𝑟𝑒𝑐𝑒𝑖𝑣𝑖𝑛𝑔 𝑜𝑣𝑒𝑟 3 𝑚𝑜𝑛𝑡ℎ𝑠 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
= 𝛽0 + 𝛽1𝑡𝑖𝑚𝑒1 + 𝛽2𝑡𝑖𝑚𝑒2 + 𝛽3𝑖𝑛𝑡1 + 𝛽4𝑖𝑛𝑡2 + 𝑒
  
An important assumption for the purposes of these analyses was that variables 
other than time were unlikely to be confounding the effect of the SCOT trial 
findings given that there were minimal changes in demographics, disease or 
treatment characteristics in the cohort before and after the time of 
dissemination.  
7.2.2.4 Interrupted time series analysis  
The dataset was converted into a time series by calculating the mean duration of 
treatment received by patients within consecutive, monthly time-periods. These 
monthly mean durations were plotted graphically to illustrate the change in 
practice across the whole study period. The time series was interrupted at the 
time of the initial dissemination of the SCOT trial findings and separate linear 
regression lines were fitted for the pre versus post-SCOT period. This analysis was 
repeated by creating a time series of the proportion of patients receiving over 3 
months of treatment per month and using logistic regression to test the difference 
between pre and post-SCOT prescribing.  
The three main variables used for the purposes of this analysis were:  
T: the time elapsed since the start of the study. This was measured in months.  
Xt: a dummy variable indicating the pre-intervention period (coded 0) and post-
intervention period (coded 1). 
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Yt: the outcome (duration of treatment in weeks when using linear regression or 
log odds of the proportion of patients receiving over 3 months of treatment when 
using logistic regression) at time t.  
The following regression model was used: 
 𝑌𝑡 = 𝐵0 + 𝐵1𝑇 + 𝐵2𝑋𝑡 + 𝐵3𝑇𝑋𝑡   
 
This model intentionally accounted for the effect of an underlying time trend on 
the intervention of interest within the time series dataset. β0 represented the 
intercept of the regression curve and the baseline level of the outcome 
(proportion of patients receiving over 3 months of treatment or treatment 
duration in weeks) at time zero. Β1 indicated the underlying time trend across the 
whole period. β2 represented any level change following the intervention and β3 
indicated the slope change by using the interaction between the underlying time 
and intervention (TXt). B coefficients were derived from the regression output to 
understand if there was a significant underlying time trend, if there was a 
significant level change and or if there was a slope change. The counterfactual 
situation in which the pre-SCOT patterns of prescribing continued unchanged was 
modelled using linear regression. This allowed the predicted mean treatment 
duration based on actual data versus the counterfactual situation to be compared. 
For logistic regression, exp(β) represented the corresponding log odds.  
This model was checked for seasonality by using a visual inspection of the time 
series plot (306). To check for autocorrelation, visual inspection of residuals and 
partial residuals from the model were used (306). This was supplemented by using 
a Durbin-Watson test (307), with a d-statistic of 2.0 indicating no serial 
correlation, a result closer to 0 indicating evidence of positive correlation and a 
result closer to 4 indicating negative correlation. 
7.2.2.5 Median percentage dose delivered 
The median percentage dose of chemotherapy mediations received by individual 
patients was calculated as an alternative way to investigate practice change. 
The median percentage dose received was compared pre versus post-SCOT using 




7.3.1 Cohort derivation  
Figure 7-1 shows how the final study cohort using GG&C data was identified using 
ChemoCare data. Appendix 5 Figure 14-1 shows the results for the comparison of 









N= 163 removed 
 SCOT trial participants 
 Capecitabine in combination with 
radiotherapy only 
 Raltitrexed chemotherapy only  
N=957 
Step 3 
N= 44 removed 
 Time of treatment delivery > 8 
months  
 ChemoCare record reviewed and 
patient excluded if did not meet 




N= 57 removed (Clinical Portal 
information used) 
 Metastatic disease (n=51) 
 Small bowel tumour (n=2) 
 Neo-adjuvant chemotherapy (n=2) 
 No clinical information to confirm 




Initial cohort identified by analyst (CC) from 
ChemoCare by searching for all individuals 
who commenced a chemotherapy regimen 
named “Adjuvant Colorectal”, “Adjuvant 




7.3.2 Descriptive analysis of cohort 
The final cohort of patients totalled 998 individuals; 856 from the first data 
acquisition in March 2019 and 142 from the update in January 2020. Table 7-1 
outlines demographic, disease and treatment related variables for the cohort of 
patients treated with adjuvant chemotherapy in GGC between 2010-2019 and 
any differences in the cohorts of patients starting chemotherapy pre versus post 
June 2017.  
Table 7-1 Description of whole cohort receiving adjuvant chemotherapy in GGC  “Pre-
SCOT”: before June 2017. “Post-SCOT”: After June 2017.  
Demographic, disease 











Sex    
Male        394 (52%) 128 (53%) 522 (52%) 
Female  361 (48%)  115 (47%)  476 (48%) 
Age    
Median age (IQR) 64 (56-71) 65 (56-71) 64 (56-71) 
Age group      
≤70 years 555 (74%) 183 (75%) 738 (74%) 
>70 years 199 (26%) 61 (25%) 260 (26%) 
Deprivation category    
1 257 (34%) 72 (30%) 329 (33%) 
2  118 (16%)  48 (20%) 166 (17%) 
3  88 (12%) 36 (15%) 124 (12%) 
4  111 (15%) 29 (12%) 140 (1%4) 
5  176 (23%) 56 (23%) 232 (23%) 
Unknown  5 (1%) 2 (1%)  7 (1%) 
Location of disease    
Colon 551 (73%) 194 (80%) 745 (75%) 
Rectosigmoid or 
Rectum 
204 (27%) 49 (20%) 253 (25%) 
Duke’s stage    
B 230 (30%) 77 (32%) 307 (31%) 
C 521 (69%) 166 (68%) 687 (69%) 
Unknown  4 (1%) 0 (0%) 4 (0%) 
T stage    
X 1 (0%) 0 (0%) 1 (0%) 
0 0 (0%) 1 (0%) 1 (0%) 
1 19 (3%) 8 (3%) 27 (3%) 
2 46 (6%) 13 (5%)  59 (6%) 
3 410 (54%) 144 (59%)  554 (56%) 
4 273 (36%) 77 (32%) 350 (35%) 
Unknown 6 (1%) 0 (0%) 6 (1%) 
N stage    
0 229 (30%) 78 (32%) 307 (31%) 
1 339 (45%) 117 (48%) 456 (46%) 
2 181 (24%) 48 (20%) 229 (23%) 
Unknown 6 (1%) 0 (0%) 6 (1%) 
Stage III risk groups    
Low-risk 240 (46%) 83 (50%) 323 (47%) 
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High-risk 280 (54%) 82 (50%) 362 (53%)  
Treatment regimen    
CAPOX 385 (51%) 114 (47%) 499 (50%) 
FOLFOX 99 (13%) 40 (16%) 139 (14%) 
Capecitabine 255 (34%) 87 (36%) 342 (34%) 
IV 5-fluorouracil 15 (2%) 3 (1%) 18 (2%) 
 
The average age of patients receiving adjuvant treatment was 64 years (IQR 56-
71), with a higher proportion of men (52%) compared to women (48%). A large 
proportion (33%) of patients in this group were in the most deprived deprivation 
category (SIMD 1). This corresponds to the areas of red shading in Figure 7-2 
which outlines the distribution of SIMD deciles in the City of Glasgow and 
surrounding areas. The majority of patients GGC who received adjuvant 
chemotherapy had a diagnosis of colon cancer (75%) and there was a higher 
proportion of patients with stage III (69%) compared to stage II (31%) disease.  
 
Figure 7-2 Scottish Index of Multiple Deprivation categories (deciles) for Glasgow City and 
surrounding areas  Dark red indicates the most deprived decile. Adapted from source: 
https://simd.scot/#/simd2020/BTTTFTT/11/-4.2530/55.8579/. Accessed 16th June 2020. 
The only significant difference between patients treated prior to June 2017 
compared to post June 2017 was a higher proportion of patients with rectal 
cancer (25% post versus 20% pre) with a corresponding lower proportion of 
patients with colon cancer treated after June 2017 (75% versus 80%) (ꭓ2 
p=0.034). 
In total, (n=638, 64%) of patients initiated treatment with oxaliplatin doublet 
chemotherapy, whereas (n=360, 36%) of patients received fluoropyrimidine 
monotherapy at cycle one of treatment. Across both groups, there was a clear 
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preference (84% of patients) in prescription of capecitabine based regimens 
(CAPOX or capecitabine alone) compared to regimens using intravenous 
fluoropyrimidine (FOLFOX or 5-fluorouracil alone, 16% of patients). Table 14-3 
and Table 14-4 in Appendix 5 outline the patient, disease, and treatment 
characteristics for the cohort of patients commencing treatment with doublet 
chemotherapy versus those receiving fluoropyrimidine monotherapy separately. 
Figure 14-2 in Appendix 5 shows the treatment received for the 35% (n=349) of 
patients who switched regimens during their treatment.  
7.3.3 Description of practice change 
7.3.3.1 Overall cohort 
The distribution of treatment duration based on the number of cycles of 
chemotherapy delivered for the overall cohort is shown below.  
 
Figure 7-3 Histogram demonstrating the distribution of treatment duration (weeks) for GG&C 
cohort. 
 
The average duration of treatment delivered based on number of cycles was 24 
weeks (median, IQR 12-24 weeks) and overall the majority (73%; 732/998) of 
patients received over 3 months of treatment. Figure 7-4 shows the proportion of 

















treatment by year of treatment. The yearly median duration of treatment, 
calculated using number of cycles is also displayed. Overall, the median duration 
of treatment prior to June 2017 was 24 weeks (IQR 18-24 weeks). This decreased 
to 12 weeks (IQR 12-24 weeks) for patients commencing chemotherapy after this 
time point until the end of the study (Mann-Whitney U test p<0.001).  
 
Figure 7-4 Average treatment duration by year  Proportion of patients receiving over three 
months of adjuvant chemotherapy (primary y axis (left)) and median duration of treatment in 
weeks (secondary axis (right) from 2010-2019.  
Figure 7-5 shows there was a decrease from 82% to 47% in the proportion of 
























































Average treatment duration and proportion of 
patients receiving over 3 months of treatment




Figure 7-5 Change in proportion of patients receiving over 3 months of treatment. 
 
7.3.3.2 Practice change according to type of regimen 
The median duration of treatment for patients specifically receiving doublet 
chemotherapy at their first cycle of treatment (n=638) was also 24 weeks (IQR 
12-24) across the whole time-period. Figure 7-6a shows the proportion of 
patients who started treatment with oxaliplatin-fluoropyrimidine chemotherapy 
that received over 3 months of treatment by year, and the median duration of 
treatment across the whole period (2010-2019). The proportion of patients 
getting over 3 months of treatment was approximately the same or higher in the 
years 2010-2016 compared to in the overall cohort. However, the opposite was 
true for years 2017-2019, with this proportion dropping compared to the overall 
cohort. The median duration of treatment pre-June 2017 was 24 weeks (IQR 18-
24) and after June 2017 was 12 weeks (IQR 12-20 weeks), (Mann-Whitney U test 
p<0.001). 
Figure 7-6b displays the same information for patients commencing treatment 
with single agent fluoropyrimidine chemotherapy. There was minimal difference 
in the proportion receiving over 3 months of chemotherapy or the median 
duration of treatment in 2017-2019 compared to the previous years. The median 
duration of treatment pre-June 2017 was 24 weeks (IQR 15-24) and after June 













Overall cohort: Change in proportion of patients 




Figure 7-6 Duration of treatment by year dependent on regimen prescribed  Proportion of 
patients treated receiving over 3 months of adjuvant chemotherapy (primary y-axis (left)) 
and median duration of treatment in weeks (secondary y-axis (right) from 2010-2019. a: 
Patients receiving doublet chemotherapy at first treatment cycle. b: Patients receiving 
monotherapy at first treatment cycle.  
Dividing time into a dichotomous variable to investigate the impact of the SCOT 
trial findings, prior to June 2017, 85% of patients who were given oxaliplatin-
fluoropyrimidine doublet chemotherapy received over 3 months of treatment. 
This significantly declined to 31% of patients in the post-SCOT period (ꭓ2 
p<0.001) (Figure 7-7). There was no significant change in the proportion of 
patients receiving over 3 months of treatment after June 2017 (76%) compared 
to before June 2017 (77%, ꭓ2 p=0.774) for those patients treated with 


















































Doublet chemotherapy: Treatment duration and proportion of 
patients receiving over 3 months of treatment 



















































Monotherapy: Treatment duration and proportion of patients 
receiving over 3 months of treatment





Figure 7-7 Change in proportion of patients who received over 3 months of treatment pre 
June 2017 versus post June 2017 A: Patients receiving doublet chemotherapy at cycle one. 
B: Patients receiving fluoropyrimidine monotherapy at cycle one.  
7.3.4 Regression analysis  
7.3.4.1 Linear regression analysis 
There was a significant decrease (6.30 weeks reduction, p<0.001) in the average 
duration of treatment received after June 2017 compared to before this time-
point for patients receiving doublet chemotherapy at their initial treatment 
cycle (Table 7-2). For patients who received monotherapy at their initial 
treatment cycle, there was no significant change in treatment duration after, 
compared to prior to June 2017 (0.32 week decrease, p=0.718), even adjusting 
for other patient and disease related factors (0.24 week decrease, p=0.794).  
For patients treated with doublet chemotherapy, looking at other patient and 
disease characteristics across the whole study period, those with high-risk stage 
III disease received 2.7 weeks longer treatment compared to those with stage II 
disease (p=<0.001) (Table 7-2). Adjusting for patient and disease characteristics, 
there was still a significant decrease in average treatment duration after June 
2017 (“post SCOT”) compared to before this time-point (6.34 weeks reduction, 
p<0.001). For patients receiving monotherapy, there were no co-variates that 
significantly affected the average treatment duration on univariate analysis or 






































Table 7-2 Results of univariate and multivariate linear regression  
Doublet Monotherapy  
Unadjusted co-
efficient (95% CI) 
Adjusted co-
efficient (95% CI) 
Unadjusted co-
efficient (95% CI) 
Adjusted co-
efficient (95% CI) 
SCOT 
    
Post-SCOT -6.30 (-7.4, -5.21) -6.34 (-7.45, -5.23) -0.32 (-2.08, 1.43) -0.24 (-2.06, 1.58) 
Age group 
    
≥ 70 -1.55 (-2.98,  0.16) -1.51 (-2.83, -0.19) -0.76 (-2.29, 0.76) -0.47 (-2.18, 1.24) 
Sex 
    
Female -0.37 (-1.40, 0.66) -0.18 (-1.13, 0.76) -0.46 (-1.98, 1.06) -0.53 (-2.08, 1.01) 
Risk stage 
    
Low-risk 
III 
0.99 (-0.55, 2.53) 1.91 (0.47, 3.34) -1.65 (-3.62, 0.33) -1.75 (-3.90, 0.40) 
High-risk 
III 
2.71 (1.20, 4.23) 3.07 (1.66, 4.48) -0.29 (-2.21, 1.63) -0.16 (-2.26, 1.93) 
Regimen 
    
FOLFOX 0.03 (-1.22, 1.28) 0.19 (-0.98, 1.36) 0.92 (-2.57, 4.40) 0.75 (-2.86, 4.37) 
Disease site 
   
Rectal -0.41 (-1.56-0.75) -0.92 (-1.99, 0.15) 0.53 (-1.31, 2.36) 0.57 (-1.34, 2.49) 
SIMD 
    
2 -0.44 (-2.00, 1.12) -0.22 (-1.64, 1.19) -2.17 (-4.43, 0.01) -2.28 (-4.59, 0.03) 
3 -0.24 (-2.00, 1.53) 0.34 (-1.27, 1.95) -1.92 (-4.44, 0.51) -2.06 (-4.52, 0.40) 
4 0.63 (-1.00, 2.26) 0.54 (-0.94, 2.03) 0.17 (-2.27, 2.62) 0.12 (-2.35, 2.59) 
5 -0.10 (-1.48, 1.28) 0.15 (-1.12, 1.41) -0.99 (-3.08, 1.10) -1.11 (-3.25, 1.03) 
 
Focusing on patients who received doublet chemotherapy, on multivariate 
analysis there was a significant interaction between the dichotomous time 
variable (pre versus post June 2017) and regimen delivered at cycle one 
(p<0.001), and between the same time variable and disease risk stage 
(p=0.0059). Patients receiving CAPOX were more likely have shorter treatment 
after June 2017 compared to before this time-point whereas the same change 
was not seen for patients receiving FOLFOX (Table 7-3). Regarding disease risk 
stage, there was a significant decrease in treatment duration after June 2017 
across all risk stages but the change was most marked for patients with low-risk 






Table 7-3 Change in treatment duration post-SCOT for patients prescribed doublet treatment 
dependent on regimen and risk stage  
Average change in 
treatment duration post-




CAPOX -8.05 (-9.25, -6.84) <0.001 
FOLFOX -1.02 (-3.44, 1.39) 0.404 
Risk stage 
Stage II -5.64 (-9.65, -1.62) 0.006 
Low-risk III -8.60 (-9.97, -7.23) <0.001 
High-risk III -4.04 (-5.75, -2.34) <0.001 
 
Regarding patients who received fluoropyrimidine monotherapy, there was a 
significant interaction with time as a dichotomous variable and disease risk stage 
(p=0.0206) and age group (p=0.0067). Looking at these subgroups in more detail 
demonstrated that there was no significant change in treatment duration 
regardless of age or disease risk stage (Table 7-4).  
Table 7-4 Change in treatment duration post-SCOT for patients prescribed monotherapy 
dependent on age and risk stage  
Average change in 
treatment duration 
post-SCOT in weeks 
p value 
Age 
<70  0.80 (-4.86, 3.27) 0.696 
>70 -0.34 (-2.42, 1.73) 0.744 
Risk stage 
Stage II 0.89 (-1.32, 3.10) 0.429 
Low-risk III -2.15 (-8.24, 3.95) 0.484 
High-risk III -3.29 (-6.85, 0.27) 0.069 
 
7.3.4.2 Logistic regression analysis 
Focusing on patients who received doublet chemotherapy, the odds of a patient 
receiving over 3 months of treatment decreased by 92% after June 2017 
compared to before this time-point (OR 0.08, 95%CI 0.05-0.12, p<0.001). There 
was minimal change in these odds (OR 0.07, 95% CI 0.04-0.11, p<0.001) in a 
multivariate analysis adjusting for patient and disease related characteristics 
(Table 7-5).  
For patients who received monotherapy, there was no significant change in the 
proportion of patients receiving over 3 months treatment (OR 0.92, 95%CI 0.53-
1.61, p=0.774) post-SCOT. Patients in SIMD category 2 were less likely (OR 0.47, 
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95%CI 0.23-0.96, p=0.038) than those in category 1 (most deprived) to receive 
over 3 months of treatment but the overall effect of SIMD on treatment duration 
was not significant (p=0.1367). There were no other patient or disease 
characteristics that significantly affected the proportion of patients receiving 
over 3 months of treatment. 
Table 7-5 Results of univariate and multivariate logistic regression.  
Doublet Monotherapy  
Unadjusted odds 
ratio (95% CI) 
Adjusted odds 
ratio (95% CI) 
Unadjusted odds 
ratio (95% CI) 
Adjusted odds ratio 
(95% CI) 
SCOT 
    
Post-SCOT 0.08 (0.05-0.12) 0.07 (0.04-0.11) 0.92 (0.53-1.61) 0.92 (0.51-1.66) 
Age group 
    
≥ 70 0.63 (0.40-0.99) 0.54 (0.31-0.94) 0.65 (0.40-1.06) 0.64 (0.37-1.13) 
Sex 
    
Female 0.90 (0.64-1.27) 0.95 (0.63-1.44) 0.78 (0.48-1.28) 0.74 (0.45-1.23) 
Risk stage 
    
Low-risk III 0.93 (0.57-1.52) 1.47 (0.82-2.62) 0.60 (0.33-1.10) 0.66 (0.34-1.30) 
High-risk III 2.05 (1.23-3.42) 3.23 (1.75-6.00) 0.96 (0.51-1.80) 1.14 (0.56-2.29) 
Regimen 
    
FOLFOX 1.08 (0.71-1.64) 1.20 (0.71-2.02) 1.07 (0.34-3.34) 0.94 (0.28-3.16) 
Disease 
site 
    
Rectal 1.03 (0.70-1.51) 0.84 (0.53-1.34) 1.04 (0.57-1.88) 1.02 (0.54-1.92) 
SIMD 
    
2 0.76 (0.45-1.26) 0.74 (0.40-1.37) 0.47 (0.23-0.96) 0.43 (0.21-0.91) 
3 0.88 (0.49-1.59) 1.15 (0.56-2.37) 0.52 (0.24-1.13) 0.47 (0.22-1.04) 
4 0.88 (0.51-1.52) 0.78 (0.41-1.50) 1.14 (0.47-2.80) 1.14 (0.46-2.83) 
5 0.86 (0.54-1.36) 0.90 (0.52-1.57) 0.63 (0.32-1.26) 0.61 (0.30-1.25) 
 
As found on linear regression, using logistic regression, there was a significant 
interaction for patients receiving doublet chemotherapy between both the 
regimen received (p<0.001) and disease risk stage (p=0.031) with the timing of 
the SCOT trial results. Subgroup analysis showed that for patients prescribed 
CAPOX treatment at cycle one, the odds of receiving over 3 months of treatment 
decreased by 97% post-SCOT (p<0.001) whereas for those prescribed FOLFOX the 
odds decreased by 51% and this drop was non-significant (p=0.1130). There was a 
significant decrease in the odds of receiving over 3 months of treatment across 
all disease stages, but the change was most marked for patients with low-risk 
stage III disease (OR 0.03, 95%CI 0.01-0.06, p<0.001). Table 7-6 shows the odds 
ratio for receiving over 3 months of treatment post-SCOT compared to pre-SCOT 





Table 7-6 Change in odds of receiving over 3 months of treatment post-SCOT for patients 
prescribed doublet treatment dependent on regimen and risk stage  
Odds ratio for receiving over 3 
months of treatment post-SCOT 
compared to before this time-point 
p value 
First regimen 
CAPOX 0.03 (0.02, 0.06) <0.001 
FOLFOX 0.49 (0.21, 1.18) 0.113 
Risk stage 
Stage II 0.06 (0.01, 0.29) <0.001 
Low-risk III 0.03 (0.01, 0.06) <0.001 
High-risk III 0.16 (0.08, 0.30) <0.001 
  
For patients receiving monotherapy, disease risk stage (p=0.0040) and age group 
(p=0.0080) interacted significantly with the timing of publication of SCOT trial 
results. There was no significant change in the proportion of patients receiving 
over 3 months of treatment post-SCOT for either age group. Regarding patients 
with different disease stages, there was no significant change in prescribing for 
patients with stage II or low-risk stage III disease but there was a significant 
decrease in the proportion of patients receiving over 3 months for individuals 
who had high-risk stage III disease (OR 0.27, 95%CI 0.07, 0.98, p=0.047). Table 
7-7 shows the odds ratio for receiving over 3 months of treatment post-SCOT 
compared to pre-SCOT by age group and risk stage.   
Table 7-7 Change in odds of receiving over 3 months of treatment post-SCOT for patients 
prescribed monotherapy dependent on regimen and risk stage  
Change in odds of receiving over 3 
months of treatment post-SCOT 
p value 
Age 
<70  0.62 (0.28, 1.35) 0.227 
>70 1.33 (0.51, 3.45) 0.563 
Risk stage 
Stage II 1.69 (0.74, 3.88) 0.213 
Low-risk III 0.33 (0.66, 1.92) 0.217 




7.3.5 Segmented regression  
7.3.5.1 Segmented linear regression 
The third approach used to investigate clinical practice change was segmented 
logistic and linear regression. Assessing the impact of the SCOT trial findings by 
using the date when the trial results were disseminated, whilst also accounting 
for any time related trend, there was a significant change in the number of 
weeks of doublet treatment received after versus before June 2017. The average 
duration of doublet chemotherapy delivered just before June 2017 was 22.0 
weeks of chemotherapy (95% CI 21.0-23.0) and just after June 2017 was 16.0 
weeks (95% CI 14.0-18.0), which was a significant decrease (Figure 7-8, -6.5 
weeks, 95% CI-8.3 to -3.8, p<0.001). In addition to this level change, there was 
also significant change in treatment duration over time in the post SCOT period 
(graph slope post June 2017 in Figure 7-8) compared to the pre-SCOT period 
(slope change -2.2 weeks/year, 95%CI -3.8 to -0.57, p=0.008).  
 
Figure 7-8 Segmented linear regression (doublet) 
 
Patients receiving monotherapy in the adjuvant setting were used as a 
comparator group. There was no significant change in prescribing identified pre 
versus post June 2017 in either the treatment duration just before versus just 
after June 2017 (0.56 week decrease, 95%CI -4.06, 2.94, p=0.753) or in the time 
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2.56, 2.66, p=0.971). There was one obvious outlier in this plot (2014 receiving 
over 30 weeks of treatment). The individual patient level data was reviewed for 
this patient and there was no reason to indicate that this was not adjuvant 
therapy being delivered. For this reason, this individual was kept within the 
analysis.   
 
Figure 7-9 Segmented linear regression (monotherapy) 
 
7.3.5.2 Segmented logistic regression 
Segmented logistic regression (Figure 7-10) showed a significant change in the 
proportion of patients receiving over 3 months of treatment post June 2017 
compared to pre June 2017 when accounting for this underlying time trend for 
individuals who received doublet chemotherapy at cycle one of treatment. 
There was a significant change in the level of the regression lines (OR 0.07 (0.03-
0.16 p<0.001) corresponding with a 93% decrease in the odds of a patients 
receiving over 3 months of treatment post versus pre-SCOT. Despite this acute 
jump in prescribing, there was no significant difference in the slope (trend) of 
the fitted regression lines in the pre versus post June 2017 trend (OR 0.60 (0.34-
1.08, p=0.091). This indicates that there was no difference in the trend over 
time pre-SCOT versus post-SCOT in the proportion of patients receiving over 3 
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Figure 7-10 Segmented logistic regression (doublet) 
 
In comparison, the same analysis applied to patients initiating treatment with 
monotherapy demonstrated minimal change in the fitted trend (Figure 7-11) post 
versus pre June 2017.  Specifically, there was no significant change in the 
level/intercept (OR 1.14 (95% CI 0.36-3.55) p=0.827) or slope (OR 0.77 (95% CI 
0.35-1.69) p=0.512) of the pre versus post SCOT prescribing practices.  
 



























7.3.6 Interrupted time series analysis  
7.3.6.1 ITSA using a continuous outcome variable 
The fourth approach used to analyse the impact of the SCOT trial findings on 
practice was interrupted time series analysis. First, a scatter plot of the time 
series data was constructed to identify any underlying trends in the time series 
data. On visual inspection of the time series plot (Figure 7-12) there were no 
obvious seasonal trends in chemotherapy prescribing and there was no obvious 
autocorrelation in the time series (see Appendix 5 for results of these tests).  
 
Figure 7-12 Time series plot for patients receiving doublet chemotherapy (average monthly 
duration of treatment) 
 
This time series was intentionally interrupted at the date 1st June 2017, and 
trends pre and post June 2017 were assessed and compared. There was an 
upward trend in the average duration of treatment  prior to this time point 
(slope: increase in 0.04 weeks/month (95%CI 0.01, 0.06) p<0.001) (Figure 7-13) 
and a downward trend in treatment duration post-SCOT (slope: decrease by 
0.18weeks/month (95%CI -0.32, -0.04) p=0.012). There was a significant change 
in average treatment duration post versus pre June 2017 (decrease by 5.72 
weeks (95% CI -8.20,-3.24) p<0.001) with a statistically significant change in the 
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situation was modelled in which the SCOT trial results were not disseminated, 
and the pre-June 2017 trend continued unchanged. This counterfactual situation 
is represented by the blue dashed line in Figure 7-13.  
 
Figure 7-13 ITSA doublet (linear regression) 
 
Patients receiving monotherapy at cycle 1 were used a comparator group. This 
cohort achieved the pre-specified criteria for a suitable control group using ITSA 
because there was no difference in the average proportion of patients receiving 
over 3 months of treatment prior to June 2017 (p=0.241) or any difference in the 
trend over time (line slope) pre-SCOT (p=0.818) compared to patients receiving 
doublet chemotherapy. The time series for this patient cohort showed no 
obvious seasonal trends in prescribing (Figure 7-14) and there was no 
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Figure 7-14 Time series plot for patients receiving monotherapy (average monthly duration 
of treatment) 
 
Interrupting the time series at June 2017 showed there was no significant 
difference in post SCOT versus pre-SCOT prescribing practices for this patient 
cohort (Figure 7-15). There was a non-significant trend over time in average 
treatment duration pre-SCOT (0.03 weeks/month (95%CI -0.01, 0.07) p=0.162) 
which was unchanged post-SCOT (0.03 weeks/month (95%CI -0.20, 0.25) 
p=0.826), difference -0.01 (95%CI -0.29, 0.28) p=0.970). There was no change in 
the average duration of treatment received around the June 2017 time-point 
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Figure 7-15 ITSA monotherapy (linear regression) 
 
7.3.6.2 ITSA using a binary outcome variable 
This analysis was repeated by plotting the proportion of patients who received 
over 3 months of treatment per month in GG&C from 2010-2019 and 
investigating the difference in prescribing pre versus post June 2017. There was 
no obvious seasonality and no autocorrelation detected for either of these time-
series (see Appendix 5).  
For patients receiving doublet treatment, interrupting the time series at June 
2017 showed a significant change in the odds of receiving over 3 months of 
treatment post-SCOT (decrease in odds by 94% (OR 0.06, 95%CI 0.02, 0.17), 
p<0.001). There was no significant change in the slope of the pre versus post 
SCOT for the trend in patients receiving over 3 months of treatment over time 
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Figure 7-16 ITSA doublet (logistic regression) 
 
For patients receiving monotherapy, there was no significant change in 
prescribing identified (Figure 7-17). The level change in the odds of a patient 
receiving over 3 months of treatment was 1.12 ((95%CI 0.32, 3.82) p=0.863) and 
the slope change was 0.96 ((95%CI 0.90, 1.02) p=0.174) (Figure 7-17).  
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Table 7-8 summarises results from the four ITSAs, showing the average duration 
of chemotherapy delivered and the estimated proportion of patients receiving 
over 3 months of treatment at the last time series interval (June 2019), both for 
patients receiving doublet chemotherapy at and those receiving monotherapy at 
cycle one of treatment. The same outcomes estimated from the counterfactual 
plots are included for comparison. These give an estimation of the prescribing 
practices if no change at occurred in June 2017 and the trend line from pre-June 
2017 had continued unchanged. 
For patients initiating treatment with doublet chemotherapy, the proportion of 
patients getting over 3 months of treatment decreased from 93% (95% CI 84-97) 
in the modelled counterfactual situation to 20% (95% CI 10-37) using the real 
world data. Similarly, the average treatment duration of treatment fell from 23 
weeks (95% CI 22-23) to 12 weeks (95% CI 11-13) for this patient cohort. For 
those receiving monotherapy at cycle one, the decrease was less marked and 
non-significant with 73% (95% CI 60-84) of patients receiving over 3 months of 
treatment in June 2019 versus 87% (95% CI 74-94) in the counterfactual situation. 
The change in average treatment duration from 21 weeks in real life to 20 weeks 
in the predicted model.  
 
Table 7-8 Comparison of outcomes from time series versus counterfactual models 
 Prescribing practice post-SCOT 
(June 2019) 




Proportion of patients receiving >3 
months of treatment (%) 
20 (10-37) 73 (58-84) 
Mean duration of treatment 
(weeks) 
12 (11-13) 20 (18-22) 
Counterfactual Proportion of patients receiving >3 
months of treatment (%) 
93 (84-97) 87 (74-94) 
Mean duration of treatment 
(weeks) 
23 (22-23) 21 (19-23) 
 
Taking the cohort of patients and the outcome that showed the biggest change 
across June 2017, an exploratory analysis was done for patients receiving 
doublet chemotherapy. ITSA was repeated using the binary outcome of the 
proportion of patients receiving over three months of treatment, but 
interrupting the time series at two arbitrary time-points: June 2014 and January 
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2016. The results are shown in Appendix 5. There was no significant change in 
the trend or level of practice change at these time points.  
7.3.7 Median dose delivered 
The last approach used to investigate practice change post-SCOT trial was 
calculation of the average dose of treatment delivered before and after trial 
dissemination. The median dose of fluoropyrimidine and oxaliplatin delivered to 
patients in GG&C before versus after June 2017 is shown in Table 7-9 according 
to the regimen that patients were prescribed at cycle one of their treatment. 
There was a clear decrease in the median dose delivered for patients receiving 
CAPOX, but this was not replicated for other regimens.  
Table 7-9 Median chemotherapy doses received 
First Regimen 
Fluoropyrimidine  
Median dose delivered (IQR) 
  Pre-SCOT Post-SCOT 
Difference  
(Mann-Whitney U) 
CAPOX 86% (72-96%) 49% (41-51%) p<0.001 
FOLFOX 81% (50-93%) 82% (49-98%) p=0.6028 
Capecitabine 77% (51-92%) 81% (48-91%) p=0.7799 
5-fluorouracil 89% (63-97%) 90% (8-99%) p=0.8590 
First Regimen 
Oxaliplatin 
Median dose delivered (IQR) 
  Pre-SCOT Post-SCOT 
 Difference  
(Mann-Whitney U) 
CAPOX 63% (42-79%) 46% (37-50%) p<0.001 
FOLFOX 61% (44-72%) 53% (45-75%) p=0.7097 
Capecitabine 0% (0-0%) 0% (0-0%) p=0.3103 
5-fluorouracil 0% (0-0%) 0% (0-65%) p=0.3159 
 
7.4 Discussion 
A significant change in the average duration of adjuvant chemotherapy received 
and in the proportion of patients receiving over 3 months of chemotherapy 
occurred after the dissemination of the SCOT trial findings in June 2017 for 
patients treated in GG&C. This impact was driven by a change in adjuvant 
treatment with a doublet regimen.  
Comparing patients who were initiated on doublet treatment in GG&C health 
board between 2010-2019 (see Table 14-3 Appendix 5) compared to patients 
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enrolled in the SCOT trial, GG&C patients were, on average, younger (median 
age GGC 62 years versus 65 years in SCOT trial). Also, there were more patients 
with rectal cancer in the GGC cohort (22% vs 18%) however, this may have been 
related to the fact that rectosigmoid tumours were included in this 
categorisation in the GGC cohort whereas they may have been included with 
colon cancers in the SCOT trial. In the SCOT trial, 33% of patients received 
FOLFOX chemotherapy, and in particular 31% of UK patients in SCOT received 
FOLFOX (see results in Chapter 6). This compared to 22% in the GG&C cohort of 
patients. There was a similar proportion of patients with stage II cancer in both 
the SCOT trial (18%) and this real world cohort (15%).  
Using five different approaches, alternative ways of quantitatively assessing the 
extent of the SCOT trial impact were explored. The first approach was a 
descriptive analysis and comparison of proportions. These were a powerful way 
of identifying the main message from the data, this is, that practice did change 
across the time-point of interest, and this approach provided in basic terms, the 
extent of that change. 
An advantage of the second approach used was that several factors other than 
the SCOT trial which could potentially impact treatment duration, or affect the 
likelihood of a patient receiving over 3 months of treatment, were assessed and 
accounted for in the analysis of practice change. On reflection, the main 
research question was to investigate the timing of the SCOT trial on treatment 
duration. Unless there was a strong pre-existing reason to expect that patient, 
disease, or regimen related factors were significantly different in the pre-versus 
post-SCOT period, it is unlikely these variables would be confounding the effect 
of the SCOT trial on the outcome of interest. This was supported by the results 
of this analysis, which showed there was minimal difference in the change in 
prescribing post June 2017 when accounting for these factors; indeed the extent 
of practice change was larger when these factors were incorporated into a 
multivariate analysis. Although an important analysis to have performed, this 
gave confidence to the decision not to include these factors within the next two 
analysis approaches.  
The third approach used was segmented regression and the main advantage over 
the regression already performed was that the underlying effect of time trends 
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were accounted for whilst also using individual patient level data. This approach 
addressed the question of whether any changes in prescribing identified were a 
reflection of an underlying trend over time that would have occurred regardless 
of the SCOT trial, rather than the trial itself. Although using individual patient 
level data was an advantage as it used every data point available, plotting every 
individual’s duration of treatment or binary outcome as to whether they 
received over 3 months of treatment meant the plots were crowded and 
susceptible to the influence of outlier values.  
Using ITSA provided a better way compared to segmented regression with 
individual patient data to visualise changes in prescribing over time. This was 
because each estimate on the scatterplot represented the mean duration or 
proportion of patients receiving over 3 months of treatment for that month. As 
for segmented regression, using ITSA it was possible to adjust for time specific 
trends that may have overestimated the effect of time on practice. Additional 
advantages to ITSA were the ability to plot the counterfactual situation in which 
the prescribing trends were unaffected by any change occurring around June 
2017, which again provided a powerful visual presentation of the impact on 
prescribing that had occurred. The main disadvantage of using ITSA was that the 
data was aggregated into monthly groups, meaning that the granularity from the 
raw data was lost.   
For the first four approaches, the use of two outcomes in the analysis were 
compared: treatment duration in weeks and the proportion of patients receiving 
over 3 months of treatment. On reflection, using a binary indicator gave a 
stronger indication of potential impact of the SCOT trial, given that if patients 
received over 3 months of chemotherapy, it was unlikely they were being 
prescribed therapy with the experimental arm of the SCOT trial in mind. Using a 
continuous variable of treatment duration was less relevant to the research 
objective, which was to assess SCOT impact.  
The final approach to evaluate practice change was to calculate average doses 
of chemotherapy delivered. An advantage of this approach was that it allowed 
comparison with the results of the SCOT trial. The median dose of 
fluoropyrimidine chemotherapy delivered in the six-month arm of the SCOT trial 
was 83.2% (56.7-95.7%), and this was comparable to the pre-SCOT dose received 
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across all four regimens in this cohort. The median dose of oxaliplatin 
chemotherapy delivered in the six-month arm of the SCOT trial was 70.2% (44.3-
87.1%), with the average dose of oxaliplatin delivered for patients commencing 
treatment with CAPOX or FOLFOX in GG&C being slightly less than this trial 
estimate. The results using median dose delivered pre versus post-SCOT 
supported the findings from the earlier approaches that there was the clearest 
change in practice for patients prescribed CAPOX chemotherapy at cycle one of 
treatment.  
An important finding from the literature review in Chapter 3 was that attributing 
impact to a specific research study might be challenging. In an attempt to 
address this issue, the counterfactual situation, in which the SCOT trial did not 
occur, was assessed in this study in two ways. Firstly, a comparator group of 
patients who received monotherapy at cycle one were analysed to test if the 
timing of the dissemination of the SCOT trial findings had the same effect on 
practice compared to the cohort receiving doublet chemotherapy. There was no 
significant change in practice using any of the methodologies in this study for 
patients receiving monotherapy at cycle one of treatment. Secondly, within the 
ITSAs which modelled prescribing trends for patients, the pre-SCOT regression 
lines were extended to predict the average treatment duration or proportion of 
patients receiving over 3 months of treatment for each month post-SCOT if the 
pre-SCOT regression line had continued unchanged.  
There are limitations to this study. Chemotherapy prescribing practice was only 
assessed in one health board. It is likely that clinicians will be influenced by the 
prescribing practices of their colleagues (see Chapter 5 survey results) and that 
different locations may have separate local prescribing guidelines. GG&C is also 
the health board where the original chief investigator of the SCOT trial was 
based and where the CTU that developed the trial is housed. It is possible that 
for these reasons, clinicians in GG&C were more likely than other locations to 
adopt the SCOT trial findings; the adoption of evidence and guidelines has been 
shown in previous studies to occur to a greater extent in the location where the 
research or guidelines were developed (308). It would therefore be useful to 
understand if the same prescribing practices changes identified in this study 
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occurred on a wider scale, for example at a regional, national (Scotland and/or 
UK) or international level.  
Performing the ITSA analysis in particular would benefit from having a larger 
group of patients. When using ITSA, the number of data points available either 
side of the intervention and the number of observations at each time interval 
are both factors which affect the power of the analysis (306). Ideally, a 
minimum of nine data points pre and post intervention would be available and at 
least 100 observations per time interval is encouraged (309). Although this study 
met the first criteria, the second was not reached. Having a larger cohort to 
perform ITSA would also mean that separate ITSA for patient cohorts grouped by 
important co-variates could be explored.  
The attribution of the practice change observed in this study to the SCOT trial 
was assessed using the timing of the SCOT trial abstract publication and an 
investigation of the counterfactual as described above. Despite the merits of this 
approach, it must be acknowledged that other events may have occurred at the 
time point chosen that are not described or that are unknown (for example a 
change in clinician staffing at GGC, individual clinician experience, change in 
management) which may be contributing to practice change. The IDEA 
collaboration, to which SCOT contributed, published their results at the same 
ASCO conference in June 2017. It is therefore impossible to distinguish the 
effect of these abstracts individually using quantitative methods, and a more 
qualitative approach would be required. Considering the results from the survey 
(Chapter 5) in which many UK clinicians indicated they were aware of both the 
SCOT trial and the IDEA collaboration, it is highly likely that clinicians were 
applying the findings from both of these studies when making clinical decisions 
after June 2017.  
Finally, this cohort was defined by those receiving chemotherapy. There was 
therefore no information provided on patients who did not received adjuvant 
chemotherapy and no estimation of the proportion of patients diagnosed or 
undergoing major surgery that receive adjuvant treatment. This information 
would be useful to understand the reach of any practice change and if the 
impact of the SCOT trial could be increased by ensuring all patients who are 





This chapter has analysed the impact of the SCOT trial findings on clinical 
practice and explored a variety of different methodologies for assessing this 
impact. A selection of these approaches will be used and developed in Chapter 8 
for analysis of national level chemotherapy prescribing data. The lessons learned 
from this analysis would be equally applicable to assessing the impact of other 
clinical trials in future. Even if the outcome variable of interest (treatment 
duration or proportion of patients receiving over 3 months of treatment in this 
study) is not the same, the approach of using the time the results were 
published as a dichotomous variable, will be relevant. 
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8 Chapter 8: Impact on national practice 
8.1 Introduction 
The analysis in Chapter 7 gave important insights into the extent of 
chemotherapy prescribing practices in GG&C both before and after the SCOT 
trial results were initially disseminated. As described in the discussion section of 
Chapter 7, these results are not necessarily generalisable to a wider patient 
group of patients. In order to address this limitation, an analysis of prescribing 
practices at a national level was performed. This required a completely different 
approach to data acquisition due to the governance issues and logistics involved 
in accessing chemotherapy prescribing data on a national scale.  
Out of the approaches to analysis tested in Chapter 7, three were used in this 
study: descriptive statistics, regression analysis, and ITSA. The regression 
analysis and ITSA were performed using a binary outcome variable only, rather 
than comparing the use of a binary and continuous outcome variable as was done 
in Chapter 7. The national dataset was also analysed without dividing patients 
into those who initially received doublet versus single agent chemotherapy. 
Instead, the regimen prescribed at cycle one was used as a co-variate in the 
regression analysis. 
The aim of this study was to evaluate the implementation of SCOT trial results 
nationally in Scotland to provide a better idea of the scale and reach of trial 
impact. The objectives of this chapter were to: 
i) Explore the feasibility of using administrative healthcare data to identify a 
cohort of patients who received adjuvant chemotherapy in Scotland and 
reflect on how this compares to using locally acquired data 
ii) Describe the cohort of patients who receive adjuvant treatment, including 
their survival outcomes 
iii) Utilise a selection of methods tested in Chapter 7 to analyse the impact 
of the SCOT trial findings on adjuvant clinical practice at a national level. 
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For the purposes of reporting the results of this analysis, the time-period prior to 
June 2017 is termed ‘pre-SCOT’ and after June 2017 is ‘post-SCOT’.  
8.2 Methods 
The process of gaining access to national level datasets is described in Chapter 2 
and variables used in the final analysis on a national level are outlined in 
Appendix 5 Table 14-6. Additional information on patient co-morbidity (Charlson 
index) and the location where treatment was delivered (one of three cancer 
networks in Scotland) was available in the national compared to the local GG&C 
dataset, and these were added as co-variates in the regression analysis.  
The descriptive analysis performed in this study was extended (compared to 
Chapter 7) to include an assessment of survival. This was to allow a more in 
depth comparison of this cohort compared to patients enrolled in the SCOT and 
IDEA trials. Three and 5-year overall and CRC cause specific survival was 
calculated using the Kaplan-Meier method and plotted graphically using a 
Kaplan-Meier curve. Survival was defined from the date of first chemotherapy 
cycle delivered and cause specific survival was defined by using death from CRC. 
The non-parametric log-rank test was used to test the difference in survival 
between different patient cohorts that had been divided into groups using 
categorical variables. A more in depth description of the regimens and duration 
of treatment delivered for this cohort was also performed. Patients were divided 
into groups dependent on age and disease stage to mimic the patient scenarios 
used in the first survey described in Chapter 5.  
In this national study, logistic regression analysis was extended to include a 
subgroup analysis to understand the change in treatment duration after June 
2017 for groups of patients with specific characteristics. In addition, patients 
who started chemotherapy after June 2017 only were analysed to identify if any 
patient characteristics were associated with a higher likelihood of a patient still 
receiving over 3 months of treatment after the results of the SCOT trial were 
disseminated.  
Finally, ITSA was performed for the overall patient cohort and separately for the 
cohort of patients considered SCOT eligible versus ineligible. Patients were 
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deemed “SCOT eligible” if they had stage II disease with high-risk features or 
stage III CRC and commenced treatment with fluoropyrimidine-oxaliplatin 
doublet chemotherapy within 11 weeks of major CRC surgery. High-risk features 
for stage II disease were defined as: T4 disease, extramural venous invasion, 
poor differentiation, less than 10 lymph nodes retrieved at operation, 
obstruction or perforation. There was no information available on perineural or 
lymphatic vascular invasion in this dataset, therefore these were not used for 
patient selection. In this national analysis, due to the increased number of 
patients for inclusion in the analysis compared to the local data, any months 
within the time series that contained data for less than five patients were 
excluded.  
8.3 Results 
8.3.1 Feasibility of using administrative healthcare data to define 
a national cohort 
Figure 8-1 outlines the steps taken to create the final patient cohort for this 
analysis. The aim was to identify patients with CRC who received adjuvant 





Continued on next page 
All patients with QPI 
entry and their records 
N = 16,309, n =16,273 
All patients with CRC 
diagnosis (including historic) 
and their SMR06 records 
N = 59,569, n = 46,743 
- Drop if historic (pre 2006) CRC 
diagnosis (N=782 excluded, 58,787 
kept; n=538 excluded, 46,205 kept) 
- Drop incidences of non-CRCs 
(N=11,520 excluded, 47,267 kept; 
n=331 excluded, n=45,874 kept) 
- Drop all incidences at autopsy only 
(N=813 excluded, 46,454 kept; n=807 
excluded, 45,067 kept) 
- Drop all incidences of secondary CRC 
incidences, different dates (N=607 
excluded, 45,847 kept; 0 excluded, 
45,067 kept) 
- Drop all records if two different types 
of CRC with same incidence date 
(N=400 excluded, 45,447 kept; n=192 
excluded, 44,875 kept) 
- Drop least severe stage/grade if two 
CRC (same type) on same incidence 
date. (N=336 excluded, 45,111 kept; 0 
excluded, 44,875 kept) 
- If stage/grade is the same, drop by 
record completeness and random 
selection (N=236 excluded, 44,875 
kept; n=0 excluded, 44,875 kept) 
- Drop second incidence of CRC 
within cohort. (N=36 excluded, 
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16,273 kept) 
- Drop all patient records if two 
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same incidence date (N=0 
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excluded, 16,273 kept) 
- Drop least severe stage/grade if 
two CRC (same type) on same 
incidence date. (N=1 excluded, 
16,273 kept; n=0 excluded, 
16,273 kept) 
- If stage/grade is the same, drop 
by record completeness and 
random selection (N=0 
excluded, 16,273 kept; n=0 
excluded, 16,273 kept) 
SMR06  
N = n = 44,875 
QPI  
N = n = 16,273 
Patient has both SMR06 and QPI record  
N = 15,918 
Same cancer diagnosis SMR06 and QPI 
N = 15,645 
Same diagnosis SMR06 and QPI 
N =14,860 
All diagnoses of Stage II/III CRC 
N = 7,958 Stage II: 3,975 Stage III: 3,983 
All patients have had adjuvant 
chemotherapy (QPI record)  
N = 2,611 Stage II: 768 Stage III: 1,843 
All patients have had major surgery 
related to their CRC diagnosis 
N = 7,189 Stage II: 3,666, Stage III: 3,523 
Drop if diagnosis date differs in 
QPI versus SMR06 by more 
than 6 months. n=273 
excluded. 
Drop if diagnosis date <01 Jan 
2013 or >01 Jan 2018. n= 785 
excluded. 
Drop if not stage II or stage III 
CRC (QPI staging used. If QPI 
stage missing, SMR06 staging 
used). n=6902 excluded.  
Drop if did not have major 
surgery or if major surgery 
occurred more than one 
month before or one year 
after diagnosis n=777 
excluded  
Drop if patient did not have 
adjuvant chemotherapy as 
first adjuvant treatment 






Figure 8-1 National cohort derivation using national, linked datasets 
 
8.3.2 Description of overall cohort  
Using this method of cohort derivation, between January 2013 and January 2018, 
7,958 patients in Scotland were diagnosed with stage II/III CRC (stage II 3,975 
(50%) stage III 3,983 (50%)). In total, 7,189 (90%) of these patients underwent 
major CRC surgery within a year of their diagnosis (stage II 3,666 (51%), stage III 
3,523 (49%)). Of those patients diagnosed with CRC, 2,611 (33%) received 
adjuvant chemotherapy (19% (n=768) of stage II patients and 46% (n=1,843) of 
patients diagnosed with stage III). This represented 36% of those who had 
All patients have a ChemoCare record 
N = 2,508 
All patients have had chemotherapy 
regimen starting within 6 months of 
major surgery N = 2,494 
No neoadjuvant chemotherapy  
N =  2,476 
Only specified adjuvant regimens 
 N = 2,431 
Sufficient follow up data to investigate 
duration  
N = 2,312 
FINAL COHORT  
N = n = 2,310 
Drop if no ChemoCare 
record.  n=103 excluded. 
Drop if any adjuvant 
chemotherapy does not start 
within 6 months of major 
surgery date. n=15 excluded. 
Drop if received Neoadjuvant 
chemotherapy (not including 
capecitabine given as part of 
Neoadjuvant LCRT). n= 18 
excluded. 
First regimen (within 6 
months of surgery date) not 
an adjuvant regimen i.e. 
advanced regimen (n=10) or 
SCOT trial (n=35).  
Adjuvant LCRT within first 6 
months following surgery. 
n=12 excluded. 
No LCRT within 6 months of surgery  
n = 2,419 
Less than 8 months follow up 
from data of first cycle of 
adjuvant chemotherapy n= 
107 excluded. 
Full TNM staging not 





N = 719,598 
n = 46,894 
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undergone major surgery (stage II: 21%, stage III: 52%). In total, 2,101 (57%) of 
patients with stage II disease who had major surgery within a year of diagnosis 
were identified as fitting into the high-risk category and 667 (87%) of stage II 
patients who received adjuvant chemotherapy fitted into the high-risk category. 
Table 8-1 shows the proportion of patients with stage II disease that had high-
risk features for each of these cohorts. As described above, this table does not 
include information on lymphovascular invasion or obstruction/perforation 
because this information was not available within this dataset.  
Table 8-1 High-risk disease features for patients with stage II disease  
Number Percentage 
Patients with stage II CRC who had major surgery  3,666 100% 
Any high-risk feature 2101 57% 
Of patients with any high-risk feature (n=2101):   
Extramural venous invasion 1355 64% 
Lymph node yield <10 176 8% 
Poor differentiation 507 24% 
T4 disease 882 42% 
Patients with stage II CRC who had major surgery 
and chemotherapy 
768 100% 
Any high-risk feature 667 87% 
Of patients with any high-risk feature (n=667)   
Extramural venous invasion 474 71% 
Lymph node yield <10 29 4% 
Poor differentiation 135 20% 
T4 disease 637 96% 
 
8.3.3 Practice change cohort 
The final cohort for the purposes of analysing the impact of the SCOT trial on 
prescribing consisted of 2,310 patients (Figure 8-1). Table 8-2 describes the 
characteristics of this cohort and compares patients treated with adjuvant 
chemotherapy pre-June 2017 and post-June 2017.  
Three quarters of patients were aged 70 and under and there was a slight male 
preponderance. A majority of patients had stage III CRC and patients were more 
likely to have colon rather than rectal cancer. As was the case for local/GG&C 
prescribing (Chapter 7), there was a clear preference for using capecitabine-
based regimens compared to those based on using intravenous 5-fluorouracil.  
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Almost half of patients were from the West of Scotland (WoSCAN), with the 
remainder split almost evenly between the South-East (SCAN) and North 
(NoSCAN). Of note, the proportion of patients included from SCAN after June 
2017 was less compared to pre-June 2017 because granular chemotherapy 
prescribing records post-SCOT were available for a shorter time-period compared 
to in NoSCAN and WoSCAN. There were 452 patients treated in the GG&C health 
board during this period (first chemotherapy dose from June 2013 to May 2018). 
The cohort of patients list in the local analysis identified from ChemoCare 
(Chapter 7) as having treatment during the same period was 528.  











Number  1957 (85%) 353 (15%) 2310 (100%) 
Age    
Median age 
(IQR) 65 (57-71) 65 (57-71) 64 (55-71) 
Age groups    
70 and under 1466 (75%) 261 (74%) 1727 (75%) 
Over 70 491 (25%) 92 (26%) 583 (25%) 
Gender       
Male 1034 (53%) 203 (58%) 1237 (54%) 
Female 923 (47%) 150 (42%) 1073 (46%) 
Location       
SCAN 489 (25%) 37 (10%) 526 (23%) 
WoSCAN 966 (49%) 197 (56%) 1163 (50%) 
NoSCAN 502 (26%) 119 (34%) 621 (27%) 
Stage       
II 593 (30%) 88 (25%) 681 (29%) 
III 1364 (70%) 265 (75%) 1629 (71%) 
Risk stage       
II 593 (30%) 88 (25%) 681 (29%) 
Low-risk III 626 (32%) 122 (35%) 748 (32%) 
High-risk III 738 (38%) 143 (41%) 881 (38%) 
Regimen       
CAPOX/RALOX 1023 (52%) 177 (50%) 1200 (52%) 
FOLFOX 164 (8%) 54 (15%) 218 (9%) 
Cap alone 709 (36%) 110 (31%) 819 (35%) 
FU alone 61 (3%) 12 (3%) 73 (3%) 
Site       
Colon 1530 (78%) 276 (78%) 1806 (78%) 
Rectum 427 (22%) 77 (22%) 504 (22%) 
SIMD       
1 343 (18%) 59 (17%) 402 (17%) 
2 368 (19%) 70 (20%) 438 (29%) 
3 388 (20%) 90 (25%) 478 (21%) 
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4 399 (20%) 64 (18%) 463 (20%) 
5 459 (23%) 70 (20%) 529 (23%) 
Charlson score       
Mean 
0.54 (SD 
0.92) 0.38 (0.77) 0.1 (0.9) 
 
Figure 8-2 shows the Kaplan-Meier curve for OS from date of first chemotherapy 
for the whole cohort. There were 370 deaths from any cause with a median 
follow up for 3.68 years (95%CI 3.59-3.77 years). Separate Kaplan-Meier curves 
showing the difference in OS for subgroups are included in Appendix 5.  
 
Figure 8-2 Kaplan-Meier curve showing OS from date of first chemotherapy cycle 
 
Figure 8-3 shows the Kaplan-Meier curve for CRC survival. There were 307 deaths 
from CRC in this cohort with a median follow up time of 3.62 years (95%CI 3.50-
3.70 years). Separate Kaplan-Meier curves showing the difference in CRC specific 
survival for subgroups are included in Appendix 5. Median survival was not 
reached for either OS or CRC outcomes. Table 14-7 in Appendix 5 lists 3 and 5-
year OS and CRC survival for the whole cohort and for patient subgroups divided 




Figure 8-3 Kaplan-Meier curve showing cancer specific survival (CRC) from date of first 
chemotherapy 
 
8.3.4 A description of practice change  
There was a significant decrease in the proportion of patients receiving over 3 
months of treatment post-SCOT (75%) versus pre-SCOT (42%, ꭓ2 p<0.001) (Figure 
8-4). 
 





































The median duration of treatment for the whole cohort was 18 weeks (IQR 12-
24). Prior to June 2017 median treatment duration was 21 weeks (IQR 14-24 
weeks) and this decreased to 12 weeks (IQR 12-21weeks) for patients starting 
adjuvant chemotherapy after June 2017 (Mann-Whitney U test p<0.001). Figure 
8-5 demonstrates the median duration of treatment received per year.  
 
Figure 8-5 Median duration of treatment per year from 2013-2018 Treatment duration 
calculated in weeks using cycles of treatment. Y-axis label (weeks).  
For patients aged under 70 years old, prior to June 2017, over 3 months of 
CAPOX was a clear preference for patients with stage III disease, and using 
capecitabine for over 3 months was utilised most often for patients with stage II 
disease (Figure 8-6). After June 2017, the use of 3 months or less of CAPOX 
increased across all scenarios, in particular for patients with low-risk stage III 
disease. Patients with high-risk stage III disease and with N2 disease as the only 
high-risk factor were more likely to receive the shorter duration of CAPOX (25%) 
compared to those with T4 disease as the only high-risk factor (T4N1 14%).  
Regarding patients aged 70 and over, there was a higher use of capecitabine 
monotherapy across all scenarios compared to treatment of patients in the 
younger age group (Figure 8-6). Post-SCOT, again, as for younger patients, a rise 
in the use of CAPOX for 3 months or less was observed, in particular for those 
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with stage III disease, although numbers in this sub-group were small (<20) so 
these results should be interpreted with caution.  
Table 8-3 shows how these results compare with the findings from the first 
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Figure 8-6 Treatment regimen and duration of chemotherapy delivered pre- versus post-SCOT  
 
Table 8-3 Proportion of patients receiving 3 months or less of doublet chemotherapy post-SCOT Results from national administrative dataset compared to 








  Three months of doublet chemotherapy 
  <70 years ≥70 years 
  Survey National data Survey  National data 
Low-risk stage III 
disease 
86% 73% 54% 48% 
High-risk stage III 
disease 
16% 48% 15% 42% 
T4N1 18% 45% 17% 29% 
T1-3N2 19% 56% 17% 47% 
T4N2 11% 45% 13% 50% 
Stage II* overall 16% 22% 9% 11% 
Stage II* MSS 20%   8%   
Stage II* MSI-H 12%   10%   
T4N0   19%   8% 
T3N0   25%   14% 
297 
 
8.3.5 Logistic regression: overall cohort 
On univariate analysis, there was a decrease of 76% in the odds of receiving over 
3 months of treatment in the post-SCOT period compared to before the results 
of this trial were known (unadjusted OR 0.24, 95% CI 0.19-0.30, p<0.001). 
Looking across the whole study period, the chemotherapy regimen used at cycle 
one, socio-economic status, location of treatment and risk stage significantly 
affected the likelihood of a patients receiving more than 3 months of treatment, 
regardless of when the SCOT trial results were disseminated (Table 8-4). 
Specifically, patients with low-risk stage III disease were less likely overall to 
receive over 3 months of treatment compared to those with stage II disease (OR 
0.70 (0.56-0.88)). Individuals receiving FOLFOX (OR 0.52, 95%CI 0.39-0.70) and 
those receiving 5-fluorouarcil (OR 0.12 (0.07-0.21)) were less likely to receive 
over 3 months of treatment compared to patients treated with CAPOX, whereas 
patients treated with capecitabine monotherapy were more likely to receive 
over 3 months (OR 1.27, 95% CI 1.03-1.56). Patients treated in the North of 
Scotland were less likely to receive over 3 months of treatment compared to the 
South East (OR 0.45, 95% CI 0.35-0.58). Lastly, patients in some of the less socio-
economically deprived areas (SIMD 3 (OR 0.64, 95%CI 0.48-0.86) and 4 (OR 0.73, 
95% CI 0.54-0.98) were less likely to receive over 3 months of treatment 
compared to SIMD group 1 (most deprived).  
As was observed in the local analysis in Chapter 7, adjustment for all of the 
included variables on multivariate logistic regression did not markedly affect the 
odds of a patient receiving longer treatment post-SCOT, which was significant 
(Table 8-4). Assessment for interactions between co-variates and the timing of 
the SCOT trial showed there was a significant interaction with the SCOT trial 
variable and regimen, risk stage and co-morbidity. These were investigated 







Table 8-4 Univariate and multivariate analysis of factors affecting the likelihood of patients 
receiving over 3 months of treatment Abbreviations: OR, odds ratio; Ref, reference 
category; SCOT, Short Course Oncology Treatment; WoS, West of Scotland; NoS, North of 
Scotland; SCAN, South East Scotland; CAPOX, capecitabine and oxaliplatin chemotherapy; 
FOLFOX, 5-fluorouracil and oxaliplatin chemotherapy; SIMD, Scottish Index of Multiple 













SCOT Pre-SCOT Ref 
     
 
Post-SCOT 0.240135 0.189879 0.303692 0.22594 0.175847 0.290304 
Age group <70 Ref 
     
 
70+ 0.871744 0.711503 1.068073 0.815386 0.645342 1.030236 
Sex Male Ref 
     
 
Female 0.884206 0.739303 1.057511 0.8007 0.65867 0.973357 
Risk stage Stage II Ref 
     
 
LRIII 0.698989 0.557327 0.876659 0.800292 0.61309 1.044656  
HRIII 0.988799 0.789606 1.238243 1.289375 0.98007 1.696295 
Location SCAN Ref 
     
 
WoS 1.120699 0.883893 1.420947 1.46312 1.126871 1.899704  
NoS 0.450374 0.35023 0.579153 0.635802 0.481086 0.840274 
Regimen CAPOX 
      
 
FOLFOX 0.519386 0.386298 0.698327 0.557514 0.400948 0.775218  
Capecitabine 1.268454 1.03406 1.55598 1.371677 1.068775 1.760424  
5-
Fluorouracil 
0.119525 0.068472 0.208642 0.143764 0.079551 0.259807 
Disease site Colon 
      
 
Rectum 0.77052 0.624019 0.951414 0.795 0.629358 1.004237 
SIMD 1 
      
 
2 0.840213 0.618554 1.141302 1.026409 0.734774 1.433796  
3 0.642452 0.47879 0.862058 0.930591 0.668743 1.294965  
4 0.728553 0.540424 0.982174 1.033795 0.738428 1.447308  




      
 
1 1.051083 0.845609 1.306486 0.97436 0.768825 1.23484  
>1 1.04336 0.779296 1.3969 0.896923 0.649357 1.238871 
 
8.3.5.1 Subgroup analysis 
The percentage of patients receiving over 3 months of treatment prior to and 







Table 8-5 The proportion of patients receiving over 3 months of treatment pre versus post-
SCOT dependent on patient, disease, and treatment related factors Abbreviations: LR, low-
risk; HR, high-risk; SCAN, South East Scotland; WoS, West of Scotland; NoS, North of 
Scotland; CAPOX, capecitabine and oxaliplatin; FOLFOX, 5-fluorouracil and oxaliplatin; 
CAP, capecitabine; FU, 5-fluorouracil; SIMD, Scottish Index of Multiple Deprivation. 
  Pre-SCOT Post-SCOT 
  
>3 months of 
chemotherapy 
>3 months of 
chemotherapy 
Age group     
Under 70 77% 40% 
70 and over 72% 49% 
Gender     
Male 77% 43% 
Female 73% 42% 
Risk stage     
II 75% 61% 
LR3 73% 24% 
HR3 78% 47% 
Location     
SCAN 78% 27% 
WoS 82% 47% 
Nos 60% 39% 
Regimen     
CAPOX 80% 23% 
FOLFOX 57% 56% 
CAP  77% 72% 
FU 28% 0% 
Disease Site     
Colon 76% 46% 
Rectum 73% 30% 
SIMD     
1 80% 44% 
2 77% 44% 
3 71% 41% 
4 74% 36% 
5 76% 47% 
Charlson index 
groups     
0 77% 38% 
1 73% 56% 
>1 73% 50% 
 
Multi-variate logistic regression analysis was performed for each sub-group 
separately to understand the effect of the SCOT trial whilst accounting for other 
variables.  Table 8-6 demonstrates the adjusted odds of getting over 3 months of 





Table 8-6 Subgroup analysis Abbreviations: LR, low-risk; HR, high-risk; SCAN, South East 
Scotland; WoS, West of Scotland; NoS, North of Scotland; CAPOX, capecitabine and 
oxaliplatin; FOLFOX, 5-fluorouracil and oxaliplatin; SIMD, Scottish Index of Multiple 













Risk stage Stage II 0.5378 0.3370 0.8582 0.5405 0.3262 0.8956 
 
LR III 0.1125 0.0715 0.1770 0.0883 0.0540 0.1444  
HR III 0.2519 0.1737 0.3652 0.2540 0.1703 0.3788         
Age group Under 70 0.2048 0.1555 0.2697 0.1853 0.1377 0.2494  
70+ 0.3743 0.2378 0.5892 0.3542 0.2173 0.5772         
Sex Male 0.2206 0.1612 0.3019 0.2022 0.1437 0.2845  
Female 0.2617 0.1834 0.3734 0.2541 0.1745 0.3701         
Regimen CAPOX 0.0746 0.0510 0.1093 0.0656 0.0438 0.0984  
FOLFOX 0.9309 0.5010 1.7296 0.9435 0.4186 2.1269  





     
        
Location SCAN 0.1062 0.0499 0.2263 0.0822 0.0365 0.1851  
WoS 0.1937 0.1400 0.2680 0.1903 0.1362 0.2660  
NoS 0.4287 0.2849 0.6452 0.3531 0.2174 0.5734         
Disease 
site 
Colon 0.2651 0.2035 0.3454 0.2554 0.1932 0.3376 
 
Rectum 0.1608 0.0944 0.2737 0.1060 0.0568 0.1981 
        
SIMD 1.0000 0.1948 0.1092 0.3474 0.2097 0.1131 0.3888  
2.0000 0.2424 0.1427 0.4118 0.2093 0.1177 0.3721  
3.0000 0.2797 0.1741 0.4494 0.2702 0.1608 0.4540  
4.0000 0.2003 0.1148 0.3497 0.1586 0.0863 0.2914  
5.0000 0.2811 0.1678 0.4709 0.2808 0.1587 0.4969 
        
Co-
morbidity 
Charlson 0 0.1891 0.1427 0.2506 0.1768 0.1308 0.2390 
 
Charlson 1 0.4653 0.2745 0.7888 0.4416 0.2501 0.7796  
Charlson >1 0.3631 0.1595 0.8266 0.2696 0.1048 0.6934 
 
 
For those patients who received CAPOX, on unadjusted and adjusted regression 
analysis there was a large and significant change in the proportion of patients 
receiving over 3 months of treatment post-SCOT versus pre-SCOT whereas no 
significant change was seen for patients receiving FOLFOX or capecitabine 




met significance at the 0.05 level. No patients received over 3 months of 5-
fluorouarcil in the post-SCOT period.  
Practice change post-SCOT was significant regardless of disease type (colon 
versus rectum), sex, socio-economic status and co-morbidity. It was also 
significant for all locations and both age groups, although it was less marked for 
patients living in the North of Scotland and for patients aged over 70 years. In 
both instances, this was because pre-SCOT, there was already a large proportion 
of patients treated with 3 months or less of adjuvant chemotherapy (North of 
Scotland (40%), aged over 70 (28%)). Regarding risk stage, on adjusted analysis, 
there was a significant change for patients with low-risk stage III and high-risk 
stage III. 
8.3.5.2 Adjuvant treatment post-SCOT only 
Focusing only on patients starting chemotherapy after June 2017 (n=353), results 
from a multivariate model demonstrated that patients receiving FOLFOX (OR 
3.82 95% CI 1.90-7.70) or capecitabine (OR 8.33 95% CI 4.31-16.09) were more 
likely to still receive over 3 months of treatment compared to those receiving 
CAPOX post-SCOT. This aligns with the post-SCOT treatment choices shown in 
Figure 8-6. Patients with low-risk stage III disease treated after June 2017 were 
significantly less likely to receive the longer duration of treatment compared to 
those with stage II disease (OR 0.37 95% CI 0.18-0.78). Patients with a Charlson 
Index of 1 (higher level of comorbidity) were more likely to have over 3 months 







Figure 8-7 Adjusted odds of receiving over 3 months of treatment for patients starting 
adjuvant treatment after June 2017  Abbreviations: LR, low-risk; HR, high-risk; WoS, West of 
Scotland; NoS, North of Scotland; SCAN, South-East Scotland; FOLFOX, 5-fluorouracil and 
oxaliplatin; CAPOX, capecitabine and oxaliplatin; CAP, capecitabine; SIMD, Scottish Index 
of Multiple Deprivation; vs, versus. 
8.3.6 Interrupted time-series analysis 
There was a clear decrease in the monthly proportion of patients receiving over 
3 months of treatment after June 2017 compared to prior to this time-point 
(Figure 8-8). The estimated proportion of patients receiving over 3 months of 
treatment at the end of the study period (chemotherapy start date in April 2018) 
was 34% (95% CI 28-40%) based on actual prescribing data, compared to 67% (95% 
CI 57-76%) based on extrapolation of the trend in the treatment duration pre-
SCOT (absolute reduction in percentage by  33%).  
There was a significant decrease in the proportion of patients receiving over 3 
months of treatment immediately after June 2017, compared to immediately 
before this time point (a level difference of 0.41 (0.27-0.61, p<0.001)). There 




post-SCOT (difference in slopes of graphs pre versus post-SCOT: 0.95 (0.91-0.99, 
p=0.024). 
 
Figure 8-8 Change in monthly proportion of patients receiving over 3 months of treatment 
(overall cohort)  The blue dots in the diagram indicate the monthly proportion of patients 
receiving over 3 months of chemotherapy. The red lines show the predicted trend in the 
proportion of patients receiving over 3 months of chemotherapy based on actual 
prescribing data. The dashed blue line indicates the predicted proportion of patients 
receiving over 3 months of chemotherapy if the pre-SCOT trend line (red) is continued 
uninterrupted (counterfactual situation). The month signifies the date which a patient 
started chemotherapy. Overall, there was an absolute decrease in percentage of 33% for the  
proportion of patients receiving over 3 months of treatment at the end of the study period 
from the actual versus counterfactual trend line. 
Practice change was driven by changes in treatment for patients who met the 
SCOT trial criteria. For these SCOT eligible patients (Figure 8-9), the difference 
between the proportion of patients receiving over 3 months of treatment using 
actual data (24%, 95%CI 17-31%) versus the counterfactual situation (75%, 95% CI 
63-84%) was 51%. There was a large and significant difference in the proportion 
of patients receiving over 3 months of treatment immediately after SCOT 
compared to before June 2017 (OR 0.20 (0.12-0.35, p<0.001)). There was also a 
significant change in the trend in prescribing over time post-SCOT versus pre-






Figure 8-9 Change in monthly proportion of patients receiving over 3 months of treatment 
(SCOT eligible)  The blue dots in the diagram indicate the monthly proportion of patients 
receiving over 3 months of chemotherapy. The red lines show the predicted trend in the 
proportion of patients receiving over 3 months of chemotherapy based on actual 
prescribing data. The dashed blue line indicates the predicted proportion of patients 
receiving over 3 months of chemotherapy if the pre-SCOT trend line (red) is continued 
uninterrupted (counterfactual situation). The month signifies the date which a patient 
started chemotherapy. Overall, absolute decrease in percentage of 51%for the proportion of 
patients receiving over 3 months of treatment at the end of the study period for the trend 
line based on actual data versus the counterfactual. The pre-SCOT time trend was 1.00 
(0.98-1.01, p=0.615), post SCOT was 0.93 (.87-0.99, p=0.615). 
 
For SCOT ineligible patients (Figure 8-10), the predicted proportion of patients 
receiving over 3 months of treatment at the end of the study period (June 2018) 
using actual prescribing data was 58% (95% CI 50-65%) compared to a 
counterfactual estimate of 61% (95% CI 49-71%) (3% difference). There was no 
significant difference in the slope or level change of the prescribing trends 
across the June 2017 time point (difference in slope 0.99 (0.91-1.08, p=0.871); 






Figure 8-10 Change in monthly proportion of patients receiving over 3 months of treatment 
(SCOT ineligible) The blue dots in the diagram indicate the monthly proportion of patients 
receiving over 3 months of chemotherapy. The red lines show the predicted trend in the 
proportion of patients receiving over 3 months of chemotherapy based on actual 
prescribing data. The dashed blue line indicates the predicted proportion of patients 
receiving over 3 months of chemotherapy if the pre-SCOT trend line (red) is continued 
uninterrupted (counterfactual situation). The month signifies the date which a patient 
started chemotherapy. 3% change (increase) in proportion of patients receiving over 3 
months of treatment at the end of the study period for the actual versus counterfactual 




This study shows that it was feasible to identify a cohort of patients with CRC 
who were treated with adjuvant chemotherapy in Scotland using administrative 
healthcare data. The demographics, disease, and treatment related factors were 
broadly similar to the characteristics of the GG&C cohort (2010-2019). CAPOX 
was the preferred doublet regimen used by clinician for this Scottish population, 
as was the case in the GG&C study and in the SCOT trial. The main difference 
between the patients in the GG&C (Chapter 7) versus this national level study 
was that there was a higher percentage (33%) of patients living in the most 
deprived locations (SIMD group 1) in GG&C compared to the national level (17%).  
In this study 17% of patients had a diagnosis of rectal cancer; this compared to 
18% in the SCOT trial (41) and 25% of patients in the GG&C analysis. The 
discrepancy in GG&C results is likely to be in a large part due to the fact that 
rectosigmoid tumours were classified as rectal rather than colon tumours in the 




cancer in that location. SCOT was the only trial that contributed to the IDEA 
collaboration that recruited patients with rectal cancer and there is less 
consensus regarding the use of adjuvant chemotherapy for rectal cancer 
generally (Chapter 1). Therefore, although this study has demonstrated a 
significant reduction in the proportion of patients receiving over 3 months of 
chemotherapy post-SCOT, the underlying assumption that 6 months is an 
accepted standard of care in this setting is less robust and any interpretation of 
practice or practice change associated with implementation of trial findings 
must be interpreted in this context. 
The 5-year OS for this cohort (Appendix 5) compared favourably to the survival 
reported in the IDEA collaboration (82.4% for 3 month arm and 82.8% for 6 month 
arm). The limitation of this comparison is that a minority of patients in this 
study had sufficient follow up to provide a reliable estimate of 5-year OS. 
Unfortunately, the result from this study could not be compared to 5-year OS 
specifically from the SCOT trial because the longer-term results from SCOT alone 
have not yet been published.   
This analysis demonstrated that the duration of adjuvant chemotherapy 
delivered in Scotland changed significantly and rapidly within months of the 
dissemination of the SCOT trial findings. The extent of change was similar to 
results for patients from GG&C, although in GG&C the proportion of patients 
receiving over 3 months of chemotherapy in the pre-SCOT period was higher 
(82% versus 75%). This study has shown that population level data can provide 
important insights into real world treatment choices and allow analysis of how, 
and when, clinical trial evidence is implemented into practice. The population 
level analysis widens the generalisability of these results compared to the local 
study of prescribing practices that was performed (Chapter 7). This was 
especially important to explore given that the trial in question was developed by 
clinicians working in the local GG&C location. 
When practice change did occur, the biggest change in practice was relevant to 
patients who met the SCOT trial inclusion criteria. This implies that for the SCOT 
trial (and IDEA collaboration), the findings of these trials were probably not 
being applied too far beyond patients resembling the original trial populations, 




considered practice change for patients receiving doublet chemotherapy. The 
change in practice was seen most clearly for patients receiving CAPOX, whereas 
in contrast, patients receiving FOLFOX were more likely to still receive over 3 
months of treatment post-SCOT. A change in practice particularly affecting 
patients prescribed CAPOX aligns with the results from the pre-planned subgroup 
analyses from SCOT and IDEA, which both showed that non-inferiority was met 
when CAPOX was used but not for FOLFOX. Practice change was also highest for 
patients with low-risk stage III disease compared to those with stage II or high-
risk stage III CRC, again in line with the strength of evidence from SCOT and IDEA 
subgroup analyses. It is interesting to note that this distinction in application of 
trial results by subgroup occurred in Scotland even before the full publication of 
SCOT trial results was disseminated (April 2018). 
It was clear (Figure 8-9) that the monthly proportion of SCOT eligible patients 
receiving over 3 months of chemotherapy started to decline in February 2017, 
approximately four months prior to the dissemination of SCOT results. If patients 
started adjuvant treatment at the end of February, they would be reaching 3 
months of treatment at the end of May/start of June. This phenomenon could 
therefore be explained if clinicians not only changed their practice for patients 
commencing treatment in June 2017, but if they used the results to terminate at 
3 months the treatment that was ongoing at that date.  
Looking at duration of treatment and the regimens used in more detail pre- 
versus post-SCOT allowed direct comparison with the survey results from 
Chapter 5.  The results of the survey reported in Chapter 5 highlighted that age 
may affect the extent of practice change, with older patients being less affected 
by the SCOT trial findings due to the lower use of doublet chemotherapy in this 
cohort. Although there was a bigger change observed for patients aged under 70 
in this study, there was still a significant change in practice for those aged 70 
and over, and adjusting for age did not significantly alter the change the 
reduction in odds of patients receiving over 3 months of treatment post-SCOT. In 
keeping with the survey results (Chapter 5), there was a lower use of doublet 
chemotherapy for patients in the older age group in general.  
For patients aged under 70, there was a higher use of 3 months of doublet 




the survey results. This may be explained by the influence of international 
clinicians, who were less likely to change practice and more likely to use 
FOLFOX, compared to UK oncologists. It also suggests that clinicians are not over 
reporting their practice change in the survey, and if anything, the survey 
estimates may have under-estimated SCOT and IDEA impact. For both age groups 
in the national cohort, patients with high-risk stage III disease were less likely to 
receive the shorter duration of doublet chemotherapy if they had T4 as their 
only high-risk feature compared to N2. This does not fit with the survey results 
that showed minimal difference in practice between patients with either one of 
the high-risk stage III features, but does fit with the practice change that was 
predicted by an independent clinician reviewing the IDEA results at the ESMO 
plenary session described in Chapter 1 (78). 
Overall, the proportion of patients receiving 3 months or less of doublet 
chemotherapy in this real world dataset, and the proportion of clinicians 
choosing this treatment option in the survey, were very similar for stage II and 
low-risk stage III disease, for both age groups (<10% difference between survey 
and national data). The main difference between these studies related to 
treatment decisions for high-risk stage III CRC. In the survey, less than 20% of 
clinicians chose 3 months of treatment for each of the high-risk scenarios, 
whereas in the national dataset, around 40-50% of patients on average were 
receiving 3 months or less of this treatment option. One explanation for this 
could be that in the real world setting, patients were receiving shorter 
treatment because of toxicity, rather than an intentional choice on the part of 
their treating physician. However, if this was true, the same logic would apply to 
low-risk stage III disease, where the same magnitude of difference was not 
observed. The national dataset looked at prescribing up to mid-2018, whereas 
the survey was performed in 2019, therefore an argument regarding increased 
adoption of trial results nationally would also not stand. The explanation for this 
difference may lie in clinicians underreporting a change in practice if they 
perceive the change to be controversial, or it may reflect differences in practice 
change between Scottish versus other UK or international clinicians, especially 




Only half of patients diagnosed with stage III disease during this period in 
Scotland received adjuvant chemotherapy. This is in line with recent estimates 
from England (258) and raises the question of why so few patients are receiving 
this treatment. The QPI target for adjuvant chemotherapy delivery for patients 
aged 50-74 with stage III CRC in Scotland is 70%; those who refuse treatment or 
receive neoadjuvant chemotherapy are excluded from the calculation (310). The 
proportion of patients with stage II disease receiving adjuvant chemotherapy was 
even less, but this was expected, and is partly dictated by the proportion of 
patients with stage II disease with high-risk features. This finding shows the 
utility of using real world data to estimate trial impact. Specifically, these 
results demonstrate that predicting practice change associated with the SCOT 
trial based on incidence of stage II/III CRC alone would have over-estimated the 
health service impact. 
One limitation of this study (and the GG&C study in Chapter 7) is that it is not 
possible to claim causality of the SCOT trial on the practice change identified, 
only to suggest that the SCOT trial contributed to or was associated with the 
difference in prescribing practices seen after June 2017, compared to before 
June 2017. Despite this limitation, in combination with the survey results 
(Chapter 5), these two methods present a strong picture of practice change in 
response to SCOT, showing, as suggested in the literature review in Chapter 3, a 
mixed methods approach to evaluation can be worthwhile.  
This study used four years of data from before the SCOT trial findings were 
disseminated but only one year of data after June 2017. It is therefore not clear 
from this study if this change in practice was maintained over a longer period or 
if any changes to the treatment of the SCOT ineligible cohort would have 
emerged with longer follow up. It would be interesting to have data for 
additional years to know if the effects of disease stage and regimen remain, now 
that stage II results (87) and updated OS (83) results have been published. The 
results from the GG&C (Chapter 7) give reassurance that the trends seen in this 
study in 2018 are likely to be maintained in 2019. In future work it would also be 
interesting to see the effect of the COVID-19 pandemic on prescribing in this 
patient cohort. It would not be unreasonable to expect that clinicians may have 




order to reduce healthcare service use. It would be interesting to explore if any 
change in prescribing practices during the pandemic revert to pre-COVID trends 
after the main viral peaks have subsided, as predicted by the results in Chapter 
5. 
There was also insufficient follow up post-SCOT to compare health outcomes 
such as survival pre versus post June 2017. Even if longer follow up had been 
available, no routine collection of patient reported outcomes currently exist 
nationally for CRC patients to evaluate the potential decrease in toxicity (for 
example peripheral neuropathy and diarrhoea) that may accompany the practice 
change observed. The likely impact of SCOT on these health outcomes can only 
be estimated at this stage, using the numbers of patients in this cohort. The 
SCOT trial findings demonstrated that the percentage of patients experiencing at 
least grade 2 neuropathy was 58% in the 6-month trial arm and 25% with an 
intended 3-months of treatment. Applying this to the number of patients 
receiving oxaliplatin-fluoropyrimidine doublet treatment post-SCOT in this 
cohort (n=231), if no practice change had occurred and 75% of patients had still 
received over 3 months of chemotherapy in June 2018, approximately 100 
patients would be expected to suffer from neuropathy that was severe enough to 
affect their activities of daily living. In contrast, the prediction of the proportion 
of patients having over 3 months of chemotherapy using actual data (24%) means 
that this number will drop to 32. In addition, Chapter 6 indicated that the 
discounted cost savings per patient over 10 years from using 3 rather than 6 
months of chemotherapy are approximately $4,553 USD. Applying these savings 
to patients receiving doublet chemotherapy in this real world cohort translates 
to a healthcare system saving in Scotland of $523,595 (approximately £382,224) 
for patients commencing chemotherapy within the one-year period post-SCOT. 
Also, if it is assumed that patients who receive an intended 6 months rather than 
3 months of treatment have at least 6 additional consultant outpatient visits and 
chemotherapy day bed visits, for patients in the SCOT eligible cohort, this would 
translate to a reduction in requirement of almost 700 outpatient and 700 day 
case trips per year in Scotland.  
In addition to the results from the individual patient analysis, there are other 




data. If datasets such as this one used in this study are to be available to 
investigate cancer trial impact in future, it is important to be transparent about 
the process of data acquisition. Table 8-7 explains the main challenges 
encountered to achieve data access, and outlines recommendations for 
conducting the same process in future.  
Many of these recommendations in Table 8-7 are aimed at policy makers and 
specifically the Scottish government. One of the major suggestions is to invest in 
staff and infrastructure to support data acquisition and linkage in particular to 
employ more people to support data extraction from ChemoCare sites in the 
North and East of Scotland. Looking to the future, a more permanent solution to 
the difficulty around accessing data from the five different ChemoCare locations 
in Scotland would be to hold this data centrally, as is currently done in England 
(311). 
Another major recommendation is to replace the current model for access to 
administrative health care data in Scotland of ‘link and destroy’ for individual 
research projects (312). Currently, multiple researchers might apply for the 
same or similar data to be linked, but this is all done in silos. Although it does 
help to address many of the privacy concerns from data controllers, it is not an 
efficient use of data providers’ resources. The current model, in which this 
dataset will be destroyed in 5-10 years, poses a threat to research integrity and 
transparency, in the sense that it will difficult to reproduce results that have 












Table 8-7 Challenges of building a linked, administrative healthcare dataset for CRC on a 
national scale and recommendations for repeating this process for other tumour types in 
future. 
Issue Barrier Recommendation* 
Data 
specification 
No national data dictionary existed to 
describe information held in each 
ChemoCare system. This made 
dialogue with ChemoCare analysts to 
plan the project specification more 
difficult, ultimately leading to the 
requirement for a substantial PBPP 
amendment to reflect the actual data 
received versus the variables originally 
approved.  
Data dictionaries for datasets being 
linked are a requirement to know in 
advance which data variables will 
be accessed and linked.  
Capacity The length of time required to obtain 
ChemoCare datasets was partly 
attributable to a lack of capacity for 
staff within regional cancer networks 
to engage with the process. The 
responsibility for physically 
downloading reports from the 
ChemoCare system was often 
performed by an individual whose 
major responsibility was service 
provision. In addition, one ChemoCare 
site had specific difficulties with the 
software required to store large 
datasets. 
Investment is required to ensure 
sufficient staff capacity at regional 
sites so that resource is not being 
diverted from service provision 
without proper recognition of this 
effort.  
 
Staff capacity at central sites needs 
to be sufficiently robust so that 
there is no slowing of data transfer 
and linkage set-up due to external 
pressures such as annual 
leave/sickness/other projects. 
There should be continuity in the 
staff managing data transfer and 
linkage. 
Data transfer Each transfer of data from data 
providers external to PHS required 
careful communication between the 
sender and recipient because data 
deposited in the secure transfer 
environments was automatically 
deleted if not picked up within 72 
hours. Launch of a new secure file 
transfer system coincided with the 
data transfer and indexing process and 
at times, it was necessary to utilise a 
separate platform because of problems 
with the new system. 
All parties involved in a data 
transfer need to prioritise 
communicating effectively within 
the same time window regarding a 
data transfer if the data transfer is 
to be successful. 
 
A secure data transfer platform is 
required. It should be 
straightforward to use by central 
and regional data analysts, with 
ready access to information 
technology support if any technical 
issues arise. 
Data linkage Data linkage took longer than 
anticipated because the first attempt 
experienced technical problems. This 
unexpected difficulty was partly due to 
the number of datasets being linked, 
as well as the impact of the Covid-19 
pandemic when resource 
reprioritisation was required within 
PHS.   
Easier data linkage would be 
possible if the data  was held by a 
central data controller, such is the 
case for SMR datasets in Scotland 
and as occurs with the Systemic 
Anti-Cancer Therapy database in 




Data Access The datasets outlined in Chapter 2 
Figure 2-4 represent most of the full 
dataset that was approved, however, 
unscheduled care data is still not 
available.  
 
A secure research environment to 
store and analyse data is required 
to meet data governance and 
privacy requirements. The NSH is 
one example of this type of 
research environment. Others exist 
and some are industry-led, for 
example, AIMES Management 
Services Ltd. 
 
Preserving linked data, such as the 
datasets described in this project, 
as a repository should be a priority. 
This will facilitate data access for 
future researchers and reduce 
wastage of resources. 
Resources A substantial portion of the time-line 
stipulated by the funder for this 
project was dedicated to data access.  
The timeliness of data access has 
previously been documented as a 
barrier in several other UK projects 
(313, 314) and raises a broader issue 
around the ability of early career 
researchers to use nationally linked 
cancer datasets that include 
chemotherapy data in Scotland within 
the current landscape. The cost for 
data access correlates with the 
number of datasets external to PHS 
being linked, which also makes it 
infeasible for an early career 
researcher without links to another 
group or significant funding. 
Training of staff at regional sites is 
required to ensure they have the 
skills required for efficient 
extraction, analysis, and transfer of 
large datasets. These staff also 
need access to proper information 
technology infrastructure that can 
deal with large datasets.  
 
 
* Regional datasets = the same information for different locations within the same country are 
held by individual data controllers at a regional level, for example ChemoCare datasets. Regional 
sites = the organisations holding regional datasets. Central datasets = datasets which are stored 
and maintained at a national level, for example SMR datasets in Scotland. Central sites = the 
organisations holding central datasets.   
 
Accessing administrative data is a hot topic in the light of the COVID-19 
pandemic, when the importance of having access to real world data in a timely 
manner to know how patients are being treated and the corresponding outcomes 
became clear. A group led by Dr Ben Goldacre has been commissioned by the UK 
government to investigate how healthcare data can be used both efficiently and 
safely for research purposes in light of the COVID-19 pandemic. This review, the 
results of which are expected in mid-2021, is being performed in parallel with 
the Data Strategy for Health and Social care which aims to improve data use 




There are efforts in Scotland to streamline and improve the use of cancer 
specific administrative datasets. For example, the Cancer Medicines Outcomes 
Project (CMOP) was commissioned by the Scottish government in response to the 
2016 Beating Cancer: Ambition and Action report (316). The overarching aim of 
the CMOP programme is to maximise the use of electronic records to understand 
outcomes for patients treated with cancer medicines in Scotland, and one of the 
key objectives is to test the scalability of linking cancer medicines datasets at a 
national level (317). A separate programme of work, the Scottish Cancer Registry 
and Intelligence Service (SCRIS) (318), was established in 2017 with the aim of 
creating a national Cancer Intelligence Platform, with national reporting of 
cancer outcomes and treatments available to approved users via a dashboard. In 
late 2020, chemotherapy prescribing data (ChemoCare) covering 100% of the 
population was added to this platform. Due to data privacy concerns, this system 
is not intended to grant access to researchers to analyse individual patient level 
data, rather its primary function is for use by service providers in their delivery 
of cancer services in Scotland.  
More recently, stakeholders within the Scottish Government have recognised the 
potential benefits of preserving the linkage between datasets and storing data 
indefinitely for use by multiple research projects, whilst maintaining appropriate 
information governance protocols. Specifically, Research Data Scotland (RDS) 
was launched in 2019 as part of the Programme for Government (21). This is a 
not for profit organisation which aims to improve the economic, social and 
environmental wellbeing of Scottish residents by enabling access to linked data, 
not limited to healthcare datasets, for research in the public good.  
Allowing researchers to use this type of administrative data to assess the impact 
of clinical trials  in a real world population could be beneficial for government 
organisations, such as the Scottish Medicine Consortium in Scotland or NICE in 
England to inform future decision making on drug approvals. These regulatory 
bodies often have to rely on trial data to extrapolate the effectiveness and cost 
of treatments in a real world setting. In addition, knowing how trial evidence 
impacts on practice within a population will allow the government to understand 
practice across different locations and build national treatment guidelines that 




this way will also show policy makers if there are any issues with equity of 
provision of care across communities, for example, based on socio-demographic 
characteristics of the population. In this way, trial impact assessment could be 
used to co-ordinate access to medicines and other new treatments in a way that 
improves the health of the population as a whole.  
8.5 Conclusion 
The duration of adjuvant CRC treatment changed at a population level in 
Scotland after June 2017. This suggests a rapid translation of clinical trial 
evidence into practice and it is predicted this will lead to important health and 
health service impact at a national level. This study has shown that it is feasible 
to use patient level prescribing data at a national level in Scotland to investigate 
clinical trial impact, although significant investment of time and resources was 




9 Chapter 9: Discussion 
This thesis has argued that cancer trial impact is important and that 
understanding how to approach its evaluation is worthwhile. This refutes a more 
traditional dogma that the act of performing research itself and the pursuit of 
knowledge alone are intrinsically valuable. In 2021, we live in a society of rising 
pressures on government, charity, and industry budgets. Increasingly, these 
organisations want to know if the cancer research they chose to financially 
support, and the cancer trials they decide to develop, are actually making a 
difference. This study has investigated how these impacts can be evaluated. 
9.1 Summary of this research 
The work in Chapter 3 identified that there is not one accepted approach to 
evaluate research impact and that literature discussing the assessment of cancer 
research impact is scarce. This gap was addressed by identifying key examples of 
cancer research impact evaluation, thereby allowing the categories, methods 
and frameworks used for impact evaluation within these cancer studies to be 
highlighted and discussed.  
An analysis of the REF 2014 case studies in Chapter 4 demonstrated that higher 
education institutions mainly relied on documentary analysis, expert testimony, 
economic evaluations and occasionally, pre-existing audits of practice, to 
describe cancer trial impact. There were no approaches to impact assessment 
used within these case studies that had not already been identified in the 
overview of the literature (Chapter 3), nor were there any examples of in-depth 
impact analyses undertaken specifically for the purpose of the REF 2014. 
Nevertheless, these case studies did show the types of impacts most relevant 
and most often assessed for clinical cancer trials specifically. These categories 
were policy impact, impact on new knowledge, and benefits to health or the 
health sector. 
The case study in this thesis showed that clinicians were using evidence from a 
large, phase III clinical trial (SCOT) in practice. This impact was successfully 
demonstrated using surveys and analysis of prescribing data. As highlighted in 




was useful. The limitation of the survey was that it was not clear if self-reported 
practice reflected real world prescribing, and the drawback of administrative 
data analysis was the ability to assess the attribution of any changes specifically 
to clinicians’ application of trial results; these approaches were therefore 
complementary.  
The dataset used for the national analysis represented the first time that 
systemic anti-cancer data has been collated on a Scotland-wide basis, and linked 
with other administrative datasets for the purposes of research. This allowed 
exploration of practice change on a national scale and overcame many of the 
issues with generalisability from analysis of local data only. This dataset also 
provided better transparency around how the patient cohort was derived, and 
gave information on patients that received chemotherapy, as well as those not 
treated with adjuvant chemotherapy across all locations. Although the barriers 
to accessing data were ultimately overcome, the process of data acquisition has 
provided lessons for how this issue could be tackled in future. 
Lastly, this thesis has shown that health economic approaches can be applied to 
assess the impact of a clinical cancer trial, and that survey data can be used to 
strengthen this approach by providing an indication of implementation of trial 
results. In this instance, the value of the health sector and health impacts from 
trial implementation far outweighed the initial research investment to conduct 
the SCOT trial.  
9.2 Finding a framework for SCOT trial impact evaluation 
Six frameworks for impact evaluation were identified and discussed in Chapter 3 
as being potentially relevant to cancer research. Appendix 6 includes a 
description of how these frameworks can be applied to the SCOT trial, using the 
results from the analyses conducted in Chapters 5-8, as well as additional 
documentary analysis. A modified version of the Payback framework has been 
included below (Figure 9-1) to summarise the impacts of the SCOT trial. An 
accompanying list of indicators of impact that are relevant to SCOT can be found 
at the following link: http://researchdata.gla.ac.uk/1135/, based on the list of 
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The modified Payback framework is drawn above as a linear pathway but it is 
unlikely that pathways to impact will be unidirectional, predictable or consistent 
between different cancer trials. Figure 9-2 below shows a more realistic 
depiction of the pathways to impact applied to the SCOT trial. If using the 
modified Payback framework, or any of the other frameworks outlined in 
Appendix 6, it is important to be flexible in considering the processes through 





Figure 9-2 Potential pathways to impact for the SCOT trial Impacts in grey are those not identified for SCOT but examples of other types of impacts that 
could be investigated for other clinical cancer trials.
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9.3 Lessons learned for future trial design from the SCOT 
impact case study 
Using the survey results from Chapter 5, it is clear that the post-hoc subgroup 
analysis, which stratified stage III patients into low and high-risk, had an important 
influence on the implementation of SCOT trial results. This raises the question of 
whether the difference in outcome according to tumour and nodal stage could 
have been predicted, and if the analysis could have been planned rather than post-
hoc. If designing a similar non-inferiority trial in the future, it would be important 
to consider that clinicians treating any type of cancer may be reluctant to reduce 
standard treatment for higher risk patients and it would be useful to try to define 
high-risk patients a priori. Reflecting on the previous surveys performed by 
Blinman and colleagues (255, 256), it would also be useful to ask patients in 
advance of developing a trial, what decrease in benefit they consider to be not 
unacceptably worse than the standard of care, and to plan the statistical trial 
analysis accounting for these preferences.  
The analysis of administrative healthcare data reported in Chapters 7 and 8 
demonstrated that the treatment regimen used (CAPOX versus FOLFOX) also 
impacted on implementation of trial findings. The subgroup analysis based on 
regimen type was pre-planned, but the findings from the impact evaluation raise 
the question as to whether more could have been done to account for potential 
differences in outcome based on regimen, for example using random allocation of 
patients between FOLFOX and CAPOX treatment. Prior to SCOT, the X-ACT trial 
had shown that capecitabine monotherapy was not only non-inferior to 
fluorouracil, but there was a trend to better survival (293) and the SAFFA trial 
indicated that the method of administration of intravenous 5-fluorouracil may have 
had an effect on efficacy of treatment (51). In defence of the SCOT trialists, not 
randomising by the regimen prescribed allowed for a pragmatic trial design and 
reflected the freedom of choice oncologists would have had in the clinic. It 
appears however, in this instance, by not using randomisation, it is now impossible 
to know from the SCOT trial results if there is a true difference in efficacy 
between the regimens and this has made the trial findings more difficult to 




The results of the survey in Chapter 5 indicate there was more uncertainty around 
the use of shorter treatment for patients with stage II disease and that clinicians 
were less comfortable commenting on their practice for rectal cancer in the 
adjuvant setting. Patients with stage II disease and/or rectal cancer were included 
in the SCOT trial but not across the whole IDEA collaboration. If planning the IDEA 
collaboration today, a better approach would be to agree in advance the 
population of patients to be recruited across IDEA trials. The survey results in 
Chapter 5 also showed that clinicians approached the treatment of patients aged 
over 70 differently to younger patients, with the results from Chapters 7 and 8 
indicating that patients receiving doublet chemotherapy in a real world setting 
are, on average, younger that those recruited to SCOT. Overall, these findings 
highlight to trialists to be mindful of patient age and to think of how clinicians can 
be reassured in future regarding how to apply trial results to older patients. This 
may involve doing a separate trial for older patients, which has been done in the 
FOCUS2 trial (233) (discussed in Chapter 4), or ensuring sufficient numbers of 
patients are recruited to older cohorts to allow robust conclusions to be drawn 
from subgroup analyses.  
Regardless of these drawbacks, what is clear from the impact assessment is the 
huge benefit from planned international collaboration at the outset of performing 
a trial. In addition, SCOT was the only IDEA collaboration trial that collected 
health economic data, which allowed thorough comparison of the cost-
effectiveness of 3 versus 6 months of treatment; this should be encouraged for 
other phase III RCTs going forward. SCOT also collected pathological specimens for 
patients recruited to the trial (260) which has allowed a programme of 
translational work to be subsequently developed (TransSCOT). Impact evaluation 
(Appendix 6) has highlighted that analysis of these specimens has already led to 
new research and the generation of new knowledge. In this way, impact 
assessment demonstrates the wider impact that the SCOT trial is already having on 
future research, which would have been the case regardless of whether non-





9.4 Do the methods used in this thesis work for assessing 
clinical cancer trial impact? 
9.4.1 Surveys 
The advantages of using surveys for cancer trial impact assessment (Chapter 5) 
were that a large number of clinicians from several locations could be reached, 
this approach allowed an element of quantification of impact on practice, and 
compared to administrative data, had the benefit that clinician awareness of trials 
and attitudes towards trial results could be assessed.  
One of the major drawbacks, which will apply to any survey being conducted in 
this context, was that there was no recognised list of CRC oncologists that existed 
and was easily accessible, for the UK or internationally. Time and effort was 
required to build a UK list for the purposes of this project, but despite this effort, 
there was no way of checking the final list was correct, and the list will now be out 
of date. There was also no information available on non-responders, making it 
impossible to explore potential response bias. These issues could be potentially be 
addressed by the creation of a live list of all such oncologists, maintained by 
research institutions or funders, such as the NCRI, CRUK or Royal Colleges in the 
UK, or may be something that the clinical trials community may want to build in 
future, as a collaborative, nationally held resource. The use of any list would still 
require buy-in from clinicians to garner survey responses, and the potential for 
response bias, whereby more motivated researchers are more likely to reply, 
would still exist. A further issue with surveys is the burden on respondents, who 
are often busy clinicians. The fact that the surveys used in this study provided 
mainly quantitative results can also be seen as a limitation as well as a strength.  
In future, surveys could be used to question researchers and trialists themselves 
regarding all impacts from their trials. This would be a useful approach to cancer 
trial impact evaluation in particular if the person undertaking the assessment was 
not familiar with the trial or topic area, or if a large number of trials were being 




surveys, and one of the empirical examples of cancer research impact identified in 
Chapter 3 (Donovan et al) shows how this can be done (195). 
9.4.2 Health economic approaches 
The method used in this study to assess the economic value of cancer research, 
adapted from Glover et al (39) and Brown et al (184), was successfully applied to 
one cancer clinical trial. This analysis relied heavily on health economic data 
collected as part of the SCOT trial. This type of analysis would still have been 
possible if health economic trial data did not exist but would have relied on cost, 
resource, and utility data either collected as part of previous trials or linked with 
administrative datasets.  
An interesting piece of work would be to apply this type of assessment for a 
number of trials, for example, all trials conducted by one CTU or supported by a 
specific funder. This approach to assessing a programme of trials has been 
performed previously (2006) in a non-cancer setting by Johnston and colleagues, 
who assessed the return on the investment into phase III RCTs (n=28) funded by the 
US National Institute of Neurological disorders (301). These types of evaluations at 
the programme level can be limited by selective advocacy of the most impressive 
outputs, and any evaluation of a programme of cancer trial work would need to 
include the investment into all trials, not only those that met their primary 
objective. If assessing the impact of other trials in future, in particular trials with 
a superiority end-point, it would be useful  to understand if, when new 
interventions are applied to routine clinical practice, they are achieving the same 
level of benefit in a real world setting compared to the select groups of patients 
recruited to phase III clinical trials (319). 
The analysis in Chapter 6 used implementation of SCOT trial results at the core of 
the assessment. Earlier phase trials are less likely to impact on practice and will 
have other important consequences for drug sales and future research, 
collaborations, or stopping a futile treatment from being developed further. If 
assessing a programme of trials that includes a mixture of early and late phase 




assessment of these different types of impacts. Alternatively, it could be 
recognised in advance that investment into early phase trials are critical to the 
pathway of developing and running larger trials that will ultimately change 
practice and health, and this investment is simply added to the cost-deficit side of 
the equation.  
9.4.3 Administrative data analysis 
The approach of using prescribing data for the analyses conducted in Chapters 7 
and 8 provided robust evidence of the impact of the SCOT trial. The strength of 
using administrative data was that it provided a clear message that practice 
change actually occurred, and that this change could be measured. Different 
methods to analyse prescribing data were tested. In this instance, the change in 
practice was obvious even using simple descriptive statistics. Out of the other 
methods tested, ITSA was the additional method that added the most value; the 
strengths of the ITSA were the ability to visualise the trends in prescribing pre and 
post-SCOT, as well as the counterfactual situation. ITSA may be even more useful 
as a method to apply to the assessment of other clinical cancer trials where 
practice change is less obvious using descriptive analysis alone.  
9.4.4 Documentary analysis 
Although not the focus of any of the results chapters, documentary analysis was 
utilised when applying impact frameworks to describe the impact of the SCOT trial 
(Appendix 6). Analysis of secondary sources of information in this way is likely to 
be a core part of any research impact assessment and in this instance 
complemented the results of specific assessments (Chapters 5-8) by allowing a 
narrative of clinical trial impacts to be generated.  
9.4.5 Case studies 
Within this study, the methods outlined above were used to populate an impact 
case study for the SCOT trial. Case studies are a standalone method for impact 
evaluation, and put simply, involve the process of taking a specific research 




research. Case studies are a good approach to evaluate the impact of clinical trials 
because each trial is a research entity that can be the focus of a separate case 
study. Impact case studies are now a well-known approach to impact assessment in 
the UK because of the REF 2014, but their utility should be viewed as extending 
beyond the REF.  
9.4.6 Methods not used in this thesis 
There were several methods for research impact assessment identified in Chapter 
3 that were not employed in this study, but that could be relevant to cancer trial 
assessment in future. The most obvious is an in-depth assessment of policy impact. 
Although this was done to a limited extent using documentary analysis in Appendix 
6, Lewison et al (188, 189, 191) (Chapter 3) have shown that this could be 
performed on a larger scale using bibliometric software. This may be an approach 
to cancer trial impact that could be used by funders or research organisations to 
understand how a collection of cancer trials influences policy, and how soon after 
trial investment this impact occurs.  
All of the approaches described above may be broadly applicable to clinical trials 
covering disease entities other than cancer. The differences for trials assessing 
other diseases may include the time lines expected for changes in health from trial 
implementation. For example, cancer trials often assess improvements in survival 
over many years, whereas other disease sites such as cardiology or infectious 
diseases, may focus on much shorter time lines such as an improvement in blood 
pressure, or, as we have seen in recent COVID-19 trials, 28-day mortality (320). 
Also, the treatments tested in trials may differ for other fields, for example, there 
may be a stronger focus on surgical techniques or device interventions, rather than 
on investigational medicinal products. This study has focused on a trial assessing 
drug treatments, but even within cancer trials, different approaches to impact 
evaluation may be required for trials focusing on a different part of the cancer 




9.5 Reflection on cancer trial impact evaluation from the 
perspective of different cancer trial stakeholders 
In an ideal world, the impact of every cancer trial that is performed would be 
assessed. In addition, this assessment would be considered and planned, both 
before a trial is carried out and after the results have been disseminated. This is 
an aspirational statement but it is a useful exercise to consider how this could be 
done. Specific suggestions for how cancer trial stakeholders can engage with and 
support the process of cancer trial impact evaluation going forward are discussed 
below.  
9.5.1 Funders 
Cancer research funders have indicated that achieving wider impacts are a key 
driver for their work. For example, CRUK state the aim of their research is ‘to beat 
cancer sooner’, with the objective to see three-quarters of patients diagnosed 
with cancer surviving the disease within the next twenty years (321). The NCI, the 
largest cancer research organisation in the world, have a mission to help ‘all 
people live longer, healthier lives’ (322). Finally, the Institute of Cancer Research 
in the UK has a vision of ‘a world where people can live their lives free of cancer 
as a life-threatening disease’ (323). It is not clear how funders will be able to show 
their donors they are achieving the aims set out in their mission statements, unless 
they actively evaluate and reflect on the impact of research performed as a results 
of their funding decisions. 
Cancer charities such as CRUK have faced major pressures on their budgets due to 
the COVID-19 pandemic and they face tough decisions surrounding funding 
allocation going forward. Using a framework, such as the one outlined in Section 
9.2.7, to create impact narratives, could help funders decide how to allocate their 
increasingly limited funds. An example of good practice was identified in Chapter 3 
in the article from Donovan et al (195) which described an evaluation of the 
impact of investments by the National Breast Cancer Charity in Australia. Cancer 




whilst keeping their mission statement at the core of any reflection on the impacts 
identified.  
Whereas using impact narratives can help funders with allocation of resources, 
using economic approaches to impact assessment could be used to advocate for 
increased funding from donors. In particular, adopting an economic approach to 
assessment can show members of the public that their investment in charity 
funded research will have health and societal gains which far outweigh the initial 
charity contribution, and at times may even be cost-saving, especially in countries 
where the healthcare systems are run using public money.  
Lastly, despite the rapid uptake of SCOT trial results into practice, this study has 
shown that it still took over ten years from the SCOT study being granted research 
funding to practice impact. Using impact evaluation to document trial timelines 
and to reflect on if current trial timelines are appropriate will be a useful exercise 
for funders. Events during the COVID-19 pandemic have shown the speed with 
which impactful trials can be performed when required. A better understanding of 
trial development and set-up timelines, through impact evaluation, could help 
funders outline timelines in which they expect their trials to be completed and 
potentially increase the impact from their investments. 
9.5.2 Research institutions 
We know that research institutions are being asked to evaluate the impact of their 
work, and that in the UK, core government research funding is dependent upon 
these evaluations. Chapter 4 showed that a major focus for cancer impact 
narratives from higher education institutions in the REF 2014 was on policy. There 
was an apparent gap in assessing less obvious impacts such as improvements in 
research capacity and innovation, and on longer-term impacts on health and the 
economy. Now this gap has been highlighted, research institutions can be aware of 
how their approaches to impact assessment can be improved going forward. The 
results from Chapter 6 show that the economic value of research can often far 




by research institutions to lobby the UK government to increase the overall pot of 
money being distributed in the REF. 
We know that in 2014, preparation of submissions to the REF cost UK higher 
education institutions £246 million, with £55million spent on impact evaluation. 
This was a 133% increase from the Research Assessment Exercise in 2008 which did 
not include evaluation of research impact (241). If the assessment of real-world 
cancer trial impact is to be sustainable, and if it is to happen for reasons other 
than the REF, provision of resources to perform such evaluations will need to be 
addressed either through core funding or specifically within project specific 
research grants.  
9.5.3 The pharmaceutical industry  
Pharmaceutical companies appear to be increasingly interested in sharing their 
clinical trial data and using real world data to explore the effectiveness and 
impact of their products on patient health outside of clinical trials. Pharmaceutical 
companies will often be considering the impact of their drug, rather than the 
impact of a specific clinical trial, but the principal is similar. This interest is 
reflected in the recent acquisition of Flatiron, an oncology specific electronic 
health records company, by a large, cancer-focused pharmaceutical business 
(Roche) for $1.9 billion USD (324). Flatiron have partnerships with a large network 
of cancer clinics and research facilities. In addition, companies such as Lily, GSK 
and Johnston and Johnston are also now routinely sharing their clinical trial data 
for the purposes of research, on platforms such as Vivli (325), the Yoda Project 
(326), and Clinical Study Data Request.com (327). This is a clear recognition that 
trial data can be used for more than the purpose of the original trial proposal. 
Also, as we have seen with the development of the Oxford-Astrazeneca COVID-19 
vaccine, there was a commitment by the pharmaceutical company to provide the 
vaccine at a not-for-profit cost for a specific time-period. Clearly, these 
companies are partly driven by financial gain, but there are indications that the 
industry as a whole recognises the importance of working closely with researchers 
and looking at real world data to make better investment decisions and achieve 




9.5.4 Cancer researchers 
Cancer researchers are increasingly being asked on research funding applications 
to think about the impact of their proposed trials, and this study will provide these 
researchers with a framework for how to approach these assessments. It is 
important for researchers to recognise the burden of doing impact assessment 
early and to ask for proper investment from their institutions and funders to 
support these activities. There are also implications from the SCOT impact case 
study for CRC clinicians and trialists designing their own trials. Firstly, this study 
has shown that real world impact can often be diluted if not as many patients as 
expected actually receive cancer treatment tested within the trial. It has also 
shown that it can be difficult to predict when subgroup analyses from clinical trials 
will be used in practice and how they will be applied.  
9.5.5 Clinical Trials Units and the wider trials community 
In the UK, CTUs and the broader trial community, including NCRI groups and trial 
networks, make decisions on which cancer trials are developed. In this way, just 
like government policy makers and funders, the trial community have control of 
allocating investment of research time and money. A clear way for the trials 
community to engage with the impact agenda could start with each CTU or trials 
group having a clear mission statement, co-developed with patients, around the 
types of impact they would like to see arising from their trials. It is likely that 
CTUs would benefit from coming together to discuss and share their thoughts and 
to build a culture of evaluation in which approaches to cancer trial impact 
assessment are routinely shared between CTUs, peers, and stakeholders. If not 
being done already, evaluation of trial impact at the stage of trial development 
could improve decision making around which trials to support, by looking further 
than the merits of the scientific question being asked. This could be done in a 
straightforward manner by using the modified Payback Framework described 
above, and producing a narrative for each potential trial around the expected 




Whereas ex-ante evaluation could help with funding allocation, assessing the 
impact of trials that have already been performed could help groups such as CTUs 
advocate for more investment overall from their funders, and allow analysis of 
what types of trials are aligning with their overall goals. These ex-post impact 
narratives should be stored in an accessible way to provide a rich resource for 
early career trialists, including statisticians, clinicians and others involved in trial 
development. Such a resource would allow trialists to learn from the experience of 
those individuals who have designed trials before them, and would also help to 
compare the wider impacts of newer trials with complex designs. If the act of 
reflecting on trial impact is not considered or prioritised, this opportunity for 
learning how to improve on trial design is lost. The trials community could also 
disseminate patient-facing cancer trial impact narratives, for example, via their 
CTU websites. The COVID-19 vaccine trials have provided an unprecedented 
example of trial impact occurring on an international scale with significant media 
coverage. In most other circumstances, patients who participate in clinical trials 
are not always aware of the trial results, or how their participation may have 
benefited other individuals. 
9.5.6 Patients 
Patients often help the trial community to decide which trial ideas to develop. The 
recent impact summit, described in Chapter 1 (35), identified that designing and 
building research programmes with central partnership between patients and 
researchers in mind helps to maximise the impact from those research projects. 
Specific to cancer trials, CTUs could ask their patient advocates which impacts the 
CTU should focus on, the optimal trade-off between the burden of the trial 
schedule for patients recruited to the trial versus the potential impact of that 
trial, and which research questions are most important when considering the 
downstream impacts they would like to see come to fruition. They could also ask 
patient representatives to help disseminate their trial results on patient-facing 





A patient representative was involved in publishing a description of the process to 
access health care data described in Chapter 2. They were surprised at the length 
of time required to achieve data access. In their own words (included with 
permission), “From a patient perspective it’s hard to comprehend that the data 
isn’t linked and that this type of work is done time and time again on the same 
data – seems wasteful and blinkered.” Hopefully the account included in this study 
will demonstrate the need for both researchers and patients to lobby policy 
makers for better infrastructure to be in place to streamline this process in future 
and to avoid wastage of public investment.  
9.5.7 Unanswered questions across stakeholder groups 
There are unanswered questions and criticisms of impact evaluation that need to 
be addressed. First, it is not yet clear whose responsibility it will be to perform 
these evaluations. If impact evaluation is to be taken seriously, it requires 
infrastructure and investment in people who have the skill set to plan and conduct 
impact assessments. Given the investment, critics will ask if research impact 
assessment is actually a cost-effective exercise in its own right. Unless the results 
of impact assessments are communicated, and provide lessons that are used, the 
value of performing impact evaluation and the enthusiasm to invest resources to 
do so will wane.  
Assessments also need to be performed in a timely manner so that the results can 
actually be fed back to develop more impactful cancer trials. The reality is that 
trialists are often busy clinicians and CTU directors and project managers are often 
stretched in their capacity. In order to incorporate reflection on impact and its 
evaluation into their current responsibilities, these individuals will need to have 
the time and resources available in order to plan an impact strategy. In addition, 
there will need to be funds to pay for these activities, either from core funding or 
incorporated into trial specific grants. 
It is important to safeguard individual researchers when it comes to cancer trial 
impact evaluation. As described in Chapter 2, when bibliometrics were first 




and promotion. The mistake was being made of counting what could be counted 
rather than what was a meaningful reflection of research performance and quality. 
There is a similar risk when it comes to broader impact evaluation. It will be 
important not to place undue pressure on an individual researcher to produce 
impactful research. As highlighted in one of the reviews in Chapter 3 (169), 
research by definition is an investigation of the unknown, which is dictated by 
uncertainty. Research success can be due to luck and serendipity and can 
sometimes take years to achieve. Pressuring individuals to ensure their research 
produces wider impacts may be counterintuitive because it may limit risk taking 
and the expansive, creative thinking that is an intrinsic part of the research 
process. Even when applied at the programme or institute level, care needs to be 
taken regarding how impact evaluation is used by institutions to make short-term 
investment decisions and promotions. This differs from encouraging researchers to 
maximise the impact of nay work they do, which can be achievable. Table 9-1 
offers suggestions of how better to evaluate, communicate and maximise cancer 
trial impact in the future.   
Table 9-1   Recommendations for cancer trial impact assessment  Abbreviations: HEI, higher 
education institution; CTU, Clinical Trials Unit.  
 Recommendations: Target group 
Evaluating the 
impact of cancer 
trials 
 
- Educate trialists to anticipate the types of data required to 
evaluate impact and the collection methods to acquire this data. 
HEIs 
Funders  
- Use indicators of cancer trial impact (for example, those in the 
content analysis coding manual) to identify the wider impacts of 




- Assess how cancer trial results are used by decision makers. This 
will create a narrative of the pathways through which impact 
occurs (direct and indirect). This process may uncover unexpected 





- Identify examples of researchers or patients actively contributing 
to maximising trial impact. 
Trialists  
CTUs 
- Evaluate the impact of negative trials. Demonstrating impacts 
that do not rely on positive trial results will encourage funders 
and researchers to adopt a broader approach to trial assessment. 
Trialists 
CTUs 




- Give researchers access to real world data, in particular 
healthcare administrative datasets and real world cost data.  
Policy makers 
Communicating 
the impact of 
cancer trials 
- Publicise cancer trial impact evaluations. Platforms for publicising 
evaluations could include patient facing charity websites, CTU 
websites and clinical trial registries as well as more formal 






impact of cancer 
trials 
- Incorporate impact assessment into the trial design process. This 
will generate ideas for researchers and CTUs of how they can take 









- Continue to provide opportunities for trialists to engage with 
stakeholders, including patients, in the planning stages of clinical 
trial design to specifically explore the types of wider trial impacts 
that are important to stakeholders.  
Funders 
CTUs 
- Ask patients what type of impacts are important from their 





9.6 Strengths and limitations 
A substantial strength of this study is the novelty of the question addressed. This 
study has brought clarity to a broad topic and distilled this into a more tangible 
discussion specific to cancer trials. Specifically, identification and critique of key 
examples of cancer research impact assessment and analysis of the REF case 
studies with a focus on cancer trials, are both novel additions to the impact 
evaluation literature.  
An easier option for the focus of this study would have been to look solely at the 
implementation of trial results. However, after becoming familiar with the topic of 
research impact evaluation, it was evident that focusing on implementation alone 
would have ignored other types of impact relevant to cancer trials. The decision to 
adopt a broader approach to looking at trial impact was supported by the results 
from the REF case study analysis, which showed that cancer trials that do not meet 
their primary endpoint can still be impactful. Another strength of this work was 
the achievement of analysing SCOT trial impact at a national level. Prior to this 
study, no resource existed for this analysis to be carried out, and it was also not 
clear how the data could be used to investigate trial impact.  
There are also several limitations to consider. First, a decision was made to 
perform an in-depth evaluation of one trial rather than to perform superficial 
assessments across several trials. The disadvantage of this approach is that it did 
not demonstrate the generalisability of the methods chosen and raises the question 
as to whether the methods used to evaluate SCOT could be applied to other trials. 
Secondly, the methodology used to assess SCOT trial impact was mainly 
quantitative, with no in-depth exploration of why impact occurred or if barriers to 




analysis (IDEA) from the impact of a single trial (SCOT) and this would have needed 
to be asked specifically within the surveys used or through using interviews with 
clinicians. Taking a qualitative approach to understand the process of trial impact 
would have been more relevant if there was a strong signal from a quantitative 
analysis that the impact expected had not occurred.   
Real world change in health outcomes are often cited by researchers and funders 
as the ultimate mission from cancer research. An important expected impact from 
SCOT was a reduction in treatment toxicity in a real world setting, in particular, a 
decrease in peripheral neuropathy from using shorter treatment. Nevertheless, in 
this study, a detailed analysis of health outcomes attributable to SCOT was not 
undertaken. This type of analysis would have required access to administrative 
health records that included a measurement of treatment toxicity. The ChemoCare 
system in the South-East of Scotland does record this type of toxicity information 
but these variables did not form part of the national data set used in this project.  
Associated with the work in Chapter 6, is the limitation of the concept of payback 
on the initial investment in the SCOT trial. Specifically, the financial investment 
and the subsequent cost savings in this assessment come from different sources; 
the financial investment is mostly provided by charities and research institutions, 
whereas the cost savings are enjoyed by the public health service, or if taking a 
wider perspective, by employers and patients. An implicit assumption in this study, 
and in many previous studies on this topic (39, 187), was that the cost of running a 
cancer trial can be subtracted from the cost savings to a healthcare system or 
patients. However, these costs come from separate budgets and the opportunity 
cost of investing in a cancer trial is not the same as the opportunity cost of 
investing in a new medicine or health technology. The only way this can be 
considered payback, is if a broad, societal view is taken of research investment. 
Specifically, one must assume that charities and research institutions are investing 
with the aim of societal benefit and their investment source has been provided by 
the same society it is looking to improve. This assumption may not hold when 




There is overlap with some of the economic approaches to impact assessment with 
more traditional health economic ‘return on investment’ (328) calculations. One of 
the well-publicised criticisms of return of investment assessments is that, in the 
majority of cases, there is a positive return. Thinking about the similarities with 
impact assessment poses the question of whether it is useful to perform an 
evaluation that is ultimately always going to indicate that doing research has had 
some form of return compared to the input to the research process itself.  
Lastly, an important limitation of this work was the minimal patient involvement. 
Initial conversations with a patient advocate were carried out in the first year of 
this study but it was difficult to have fruitful conversations because the concept of 
research impact and its assessment was still being understood and explored by the 
primary researcher (CH).  
9.7 Future directions: Research questions arising and 
gaps identified from this work 
In future it would be interesting to interview stakeholders such as patients, 
funders, researchers, research institutions and CTUs to investigate which 
categories of impact they value. In one of the articles identified in Chapter 3, the 
authors used the results of their literature review to ask patients which types of 
impacts from health research were most important (163). The development of 
patient-centred metrics of impact would also be worthwhile. As we move to 
embed patient reported outcomes into routine datasets, this will present a new 
opportunity to analyse trial impact from this more patient centred perspective. If 
what is important to patients is established at the outset, the impact assessment 
could be focused to explore to what extent this outcome was impacted by clinical 
trial implementation in a real world setting.  
In Chapter 4, there was reflection on the burden for patients in participating in 
cancer trials, for example, the extra clinic visits, tests, and side effects from 
potentially futile treatment. In SCOT, patients recruited to the experimental arm 
of the trial experienced less toxicity from treatment and received less treatment, 




considering the overall ‘investment’, financial or otherwise, into cancer trials in 
general, this concept of the burden on patients as part of the investment into a 
trial, could be explored further.  
As described in Chapter 3, the concept of evaluating the returns from research 
initiated in the USA and Australia in the early 2000s. At that time, this approach 
was not identified as assessing the ‘impact’ of research, rather it was known as the 
concept of showing ‘exceptional returns’ (300) from research by looking at its 
downstream socioeconomic effects. An editorial ‘Putting a value on medical 
research’, published in the Lancet in 2006 (319), after Buxton’s WHO review in 
2004 (100), argued the importance of developing this under researched area of 
evaluating returns from research. It began with a quotation from the renowned 
American health activist and philanthropist, Mary Lasker, “If you think research is 
expensive, try disease.” Despite this call to action, two decades on, and this field 
of research is still relatively under developed. 
The approach to assess the economic value of conducting the SCOT trial used in 
this study focused on the cost-savings and health gains attributable to SCOT 
implementation. As outlined above, no assessment was made of the spillover 
effect of performing SCOT to the private sector or UK GDP. Examples of spillover 
may include private companies using 3 months of doublet chemotherapy in the 
standard of care arm in their next clinical trials. Researchers who received training 
as part of the SCOT trial effort may work on industry-funded trials in future, thus 
contributing the expertise learnt through their time working on a publicly funded 
trial, to future research efforts funded by the private sector. Also, the knowledge 
learnt through studies performed as part of the translational programme of work 
associated with the SCOT trial is likely to produce knowledge that can be used by 
pharmaceutical companies in their efforts to find new treatments for CRC. 
Although there have been previous attempts by US (329, 330) and UK (179) authors 
to estimate the extent to which publicly funded research can affect privately 
funded research and development, and the processes through which this may 
occur, the literature on how to approach this issue specifically is not well 
developed and is generally not disease specific. There is a need for a better 




the assessment of the economic value of investment in one or a number of clinical 
cancer trials. 
Chapter 8 demonstrated the extent of practice change after June 2017 relating to 
adjuvant chemotherapy prescribing in Scotland, but it would be interesting to 
calculate the real world cost savings related to this change. This would be possible 
because an update to the national dataset (December 2020) now contains detailed 
information on the doses of hospital and community medication prescriptions, as 
well as patient level information costing linked to inpatient and outpatient 
hospital attendances. More work is required to assess the best way to use this cost 
information within an analysis of the cost implications from trial implementation. 
Other research questions that have arisen from the work specifically described in 
Chapter 8 include why the proportion of patients receiving adjuvant chemotherapy 
was lower than expected, in particular for patients with stage III disease. Also, it is 
unknown why regional variation in the duration of adjuvant treatment delivered 
existed within Scotland prior to the dissemination of the SCOT trial findings, even 
accounting for co-morbidity and the regimen used.  
This study has considered the impact of the SCOT trial in detail. This raises the 
question regarding the next trial that is needed for patients in this area. The next 
trial in this space is likely to include patients with colon cancer only. This is 
because in the decade since the SCOT trial was developed and performed, there 
has been a divergence in approach to managing colon versus rectal cancer and in 
particular, there has been a shift in relation to rectal cancer to giving more 
treatments in the neoadjuvant setting (331-333). The results from Chapters 5-8 
showed that many patients with stage II disease or those aged over 70 receive 
single agent chemotherapy in the adjuvant setting. Although SCOT provided 
evidence for using a shorter duration of doublet treatment, these results do not 
provide evidence to support using a shorter duration of monotherapy. If a trial 
comparing treatment duration for monotherapy was being designed, it would be 
another opportunity (as was performed for SCOT), to collect patient tumour 
samples and to perform detailed molecular profiling of tumours. It may also be an 
opportunity to use a cross-sectional trial design, as was performed for one of the 




context. Lastly, Chapter 5 indicated that the molecular characteristics of CRC 
tumours, in particular mismatch repair protein deficiency, are important 
determinants of treatment decisions. Recent evidence has shown that MSI-high 
tumours of all types respond well to immune checkpoint blockade (334) (335). 
There is a current UK trial that is assessing the addition of a checkpoint inhibitor 
immunotherapy to adjuvant chemotherapy for patients with MSI-high stage III 
disease (336). This trial is already using 3 months duration of treatment in the 
standard of care treatment schedule. 
9.8 Final reflections 
Performing cancer trials is a major industry that requires huge financial 
investment, as well as input from cancer patients. Going forward, research funders 
are going to be even more judicious in their investment decisions. There cannot be 
a randomised clinical trial to answer every uncertainty in clinical practice, 
therefore if cancer trials are being performed, it is imperative that we learn as 
much as possible from the process of conducting each trial, as well as from the 
trial results. Ultimately, a major reason for doing research impact evaluation is to 
make better decisions in future; decisions around what research to do, how it 
should be performed and prioritised, how the results can be interpreted and used, 
and what we can learn from completed trials that will improve decisions for trials 
in development.  
In order for the findings of this study to be impactful, the messages outlined in this 
discussion need to reach policy makers, researchers, patients, and the cancer trial 
community. These stakeholders need to agree that impact assessment is 
worthwhile and invest resources at an institutional level to adopt cancer trial 
impact evaluation. This study demonstrated there was a lack of impact assessment 
tools relevant to cancer clinical trials. Instrumental impacts from this study will 
arise through the utilisation by stakeholders of the framework relevant to cancer 
clinical trials provided above (modified Payback Framework) and/or the list of 
indicators of cancer trial impact provided in the content analysis coding manual. 
Further value will be realised if impact evaluation undertaken using these 




completed trials are not as impactful as expected, and subsequent actions are 
taken to maximise impact. Another important direct impact from this study is the 
access to a novel administrative dataset in Scotland that can now be used to 
answer other important research questions on a national scale.  
Conceptual impacts from the findings of this study may include opening the 
dialogue around how impact evaluation is relevant to cancer clinical trials and 
laying the foundation to develop this concept specific to cancer research. This 
study will demonstrate to UK researchers that impact evaluation does not need to 
be only relevant to the REF, and there is the potential to take greater control of 
the impact agenda going forward. Bringing wider impact further up the agenda for 
CTUs, researchers and funders may ultimately refocus the lens through which trial 
success is viewed and the Payback Framework modified to increase relevance to 







10 Appendix 1 CRC chemotherapy regimens 
Table 10-1 Chemotherapy regimens used to treat CRC in the adjuvant setting Abbreviations: 
FU, fluoropyrimidine; LV, leucovorin; OX, oxaliplatin; m, modified; mg, milligram; m2 meter 
squared; BD, twice a day; PO, per oral; CRC, colorectal cancer. 
Name Type FU LV Ox Timing 




PO 14 days 
every 21 days 
NA 130mg/m2 3 weekly 
Mayo Clinic  
or Bossett 




Nil Monthly (5 
days every 
month) 
Roswell Park Bolus FU 500mg/m2 bolus 500mg/m2 
(High dose) 
Nil Weekly (For 
6 out of 8 
weeks) 




85mg/m2 Weekly (For 
6 out of 8 
weeks) 
FU infusion INFUSIONAL FU 








Infusional FU 400mg/m2 bolus 





Nil 2 weekly 
FOLFOX4 Infusional FU 400mg/m2 bolus 






































11 Appendix 2 Review Search Terms 
11.1 Search Terms for systematic review 
Keywords: 
Impact (title) 
AND (framework* OR pathway* OR tool* OR measur* OR categor* OR demonstr* 
OR evaluat* OR method* OR model* OR metric* OR assess*) 
Research (title) 
 
MeSH terms:  
Research, Biomedical Research, Health Services Research. 
 
 
11.2 Search strategy Ovid Medline 
 
Table 11-1 Search terms Ovid Medline 
1 impact.ti. 
2 (framework* or pathway* or tool* or measur* or categor* or 
demonstr* or evaluat* or model* or method* or metric* or 
assess*).ti. 
3 1 and 2 
4 exp Research/ 
5 exp Biomedical Research/ 
6 exp Health Services Research/ 
7 research.ti. 
8 4 or 5 or 6 or 7 
9 3 and 8 





12 Appendix 3 Supplementary survey material 
Table 12-1 Clinical scenarios included in both surveys 
 Survey 1 April 
2019 
Survey 2 August 
2020 
Patients aged under 
70 
Colorectal cancer Colon Cancer 
1 T3N1 T3N1 
2 T4N1 T4N1 
3 T3N2 T3N2 
4 T4N2 T4N2 
5 T3/4 MSS T3MSS 
6 T3/4 MSI-H T4MSS 
7 - T3 MSI-H 
8 - T4 MSI-H 
Patients aged 70 
years and over 
Colorectal cancer Colon Cancer 




scenarios as above 
Post COVID enduring 
changes 
Colorectal cancer Colon Cancer 
 - Same 16 scenarios 
as above (8 patients 
aged under 70, 8 
patients aged 70 
and over). 
Table 12-2 Locations of respondents to first survey 

















































Table 12-3 Practice details for respondents to first survey 



























Type of practice    
Clinical academic (public and 
private) 
Clinical academic (public only) 
Clinical academic (private only) 
Health service (public and 
private) 
Health service (public only) 







































Time spent treating patients 
with CRC 














Table 12-4 Location and practice details for respondents of the follow- up survey 










































              1 (1%)  
Type of practice  
Clinical academic (public and private) 
Clinical academic (public only) 
Clinical academic (private only) 
Health service (public and private) 
Health service (public only) 


























































































































































































Figure 12-1 Regimen and duration of treatment chosen for six scenarios describing patients 
aged under 70 years old  The colour of the bars indicates the proportion of respondents 
who indicated their treatment choice represented a change in practice in response to 






































































































































































































































Scenario 5 T3-4N0 (MSS)











































































Scenario 6 T3-4N0 (MSI-H)
















































































Scenario 1 T3N1 












































































Scenario 2 T4N1 

























































































































































Scenario 4 T4N2 





Figure 12-2 Regimen and duration of treatment chosen for six scenarios describing patients 
aged 70 and over The colour of the bars indicates the proportion of respondents who 
indicated their treatment choice represented a change in practice in response to clinical 






Figure 12-3 Scenario 1: T3N1 disease. Details of regimens used by the clinicians (43% of 
total) who selected different treatment regimens for patients dependent on age Responses 
for those clinicians who did not change their mind are not shown. Patients under 70 years 
old (left) versus over 70 years old (right). The most common change in practice for low risk 
stage III patients was from doublet chemotherapy for 3 months in younger patients to 
capecitabine monotherapy for 6 months in older patients. The colours of the bars within this 













































































Scenario 5 Stage II MSI low 












































































Scenario 6 Stage II MSI high





Figure 12-4 Scenario 2: T4N1 disease. Details of regimens used by the clinicians (49% of 
total) who selected different treatment regimens for patients dependent on age. Responses 
for those clinicians who did not change their mind are not shown. Patients under 70 years 
old (left) versus over 70 years old (right). For high-risk stage III disease, the biggest change 
was from 6 months of doublet chemotherapy to 6 months of capecitabine. The colours of 
the bars within this diagram are not significant. 
 
 
Figure 12-5 Scenario 3: T4N1 disease. Details of regimens used by the clinicians (44% of 
total) who selected different treatment regimens for patients dependent on age. Responses 
for those clinicians who did not change their mind are not shown.  Patients under 70 years 
old (left) versus over 70 years old (right). For high-risk stage III disease, the biggest change 
was from 6 months of doublet chemotherapy to 6 months of capecitabine. The colours of 





Figure 12-6 Scenario 4: T4N2 disease. Details of regimens used by the clinicians (45% of 
total) who selected different treatment regimens for patients dependent on age. Responses 
for those clinicians who did not change their mind are not shown. Patients under 70 years 
old (left) versus over 70 years old (right). For high-risk stage III disease, the biggest change 
was from 6 months of doublet chemotherapy to 6 months of capecitabine. The colours of 





Figure 12-7 Scenario 5: T3-4N0 MSI Low disease. Details of regimens used by the clinicians 
(38% of total) who selected different treatment regimens for patients dependent on age. 
Responses for those clinicians who did not change their mind are not shown. Patients 
under 70 years old (left) versus over 70 years old (right). For stage II disease, the switch was 
most often from 6 months of capecitabine for younger patients to active monitoring for 








Figure 12-8 Scenario 6: T3-4N0 MSI high disease. Details of regimens used by the clinicians 
(28% of total) who selected different treatment regimens for patients dependent on age. 
Responses for those clinicians who did not change their mind are not shown. Patients 
under 70 years old (left) versus over 70 years old (right). For stage II disease, the switch was 
most often from 6 months of capecitabine for younger patients to active monitoring for 













High risk stage III T4 or N2 (≥ 70 years) 










































Figure 12-9 Switch in individual treatment choices for scenarios describing patients with stage III disease aged 70 and over The left side of each graph 
displays the treatment choices in April 2019. The right side of the graphs depict the treatment choices for the same group of clinicians (n=106) in August 
2020. If an individual has changed their choice this is shown by a diagonal, rather than straight connecting grey line. The colours of the bars within this 





Figure 12-10 Treatment choices for patients aged 70 and over with stage II disease with a 
comparison of clinician choices between April 2019 and August 2020 (n=106) For patients 
with MSS disease, in August 2020 most clinicians still chose 6 months of capecitabine 
(31%) or active monitoring (42%) for T3 disease. However, the use of active monitoring 
increased (42% versus 8%) and the use of capecitabine decreased (43% vs 31%) compared 
to responses from the same clinicians to the T3/4 MSS scenario in April 2019. Overall, 8% of 
clinicians chose 3 months of CAPOX and none chose over 3 months of CAPOX to treat T3 
MSS disease. Also no clinicians chose to use FOLFOX of any duration in August 2020. 




Regarding patients with T4 MSS disease, the commonest treatment choice in August 2020 
was 6 months of capecitabine (41%). There was a slight increase in the use of CAPOX (15% 
to 17%) and a slight increase in active monitoring (8% to 10%) compared to the responses 
for T3/4 MSS disease in April 2019. Only 7% of respondents indicated they use over 3 
months of doublet chemotherapy in this situation (3% CAPOX and 4% FOLFOX). Regarding 
MSI-H disease, the most common choice both in April 2019 (60%) and August 2020 (T3: 
(91%) T4 66%), was active monitoring. At both time-points, there was a higher use of 
doublet chemotherapy compared to fluoropyrimidine monotherapy for both T3 and T4 
disease. The red boxes indicate when responses align with the treatment delivered in the 
experimental arm of the SCOT trial/IDEA collaboration.  
 
Figure 12-11 Change in individual clinician opinions between April 2019-August 2020 for the 
group of clinicians who answered both surveys (n=106). If an individual has changed their 
choice this is shown by a diagonal, rather than straight connecting grey line. Any changes 
>10% are highlighted. Low-risk stage III (SCOT non-inferiority met), high-risk stage III (SCOT 
non-inferiority not met), stage II disease with high-risk features (SCOT non-inferiority not 




Low-risk stage III 
disease 
High-risk stage III 
disease 
Stage II disease with high-risk features 
FOLFOX 3 months as a standard of care CAPOX 3 months as a standard of care 
Low-risk stage III 
disease 
High-risk stage III 
disease 










Table 12-5 Change in clinician (n=106) preferences in August 2020.  Disregarding (pre) and 




70    
70 and 










T1-3N1       T1-3N1       
Capox 3m 96 96 1 Capox 3m 54 53 1 
Capox 3-6m 2 2 1 Capox 3-6m 0 0 NA 
Capox 6m 0 0 NA Capox 6m 0 0 NA 
Folfox 3m 5 4 1 Folfox 3m 9 8 1 
Folfox 3-6m 1 0 1 Folfox 3-6m 0 0 NA 
Folfox 6m 1 1 1 Folfox 6m 1 0 NA 
Capecitabine 
3m 0 1 1 
Capecitabine 
3m 2 2 1 
Capecitabine 
3-6m 0 1 1 
Capecitabine 
3-6m 1 6 0.119 
Capecitabine 
6m 1 1 1 
Capecitabine 
6m 26 23 1 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 0 0 NA FU 3-6m 0 0 NA 
FU 6m 0 0 NA FU 6m 2 2 1 
AM 0 0 NA AM 1 6 0.119 
T4N1       T4N1       
Capox 3m 51 55 0.583 Capox 3m 36 37 1 
Capox 3-6m 17 20 0.718 Capox 3-6m 9 11 0.815 
Capox 6m 14 13 1 Capox 6m 7 3 0.332 
Folfox 3m 3 2 1 Folfox 3m 3 2 1 
Folfox 3-6m 2 3 1 Folfox 3-6m 8 10 0.806 
Folfox 6m 19 13 0.338 Folfox 6m 11 8 0.632 
Capecitabine 
3m 0 0 NA 
Capecitabine 
3m 4 6 0.748 
Capecitabine 
3-6m 0 0 NA 
Capecitabine 
3-6m 6 9 0.594 
Capecitabine 
6m 0 0 NA 
Capecitabine 
6m 20 18 0.858 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 0 0 NA FU 3-6m 0 0 NA 
FU 6m 0 0 NA FU 6m 2 1 1 
AM 0 0 NA AM 0 1 1 
T3N2       T3N2       
Capox 3m 45 54 0.271 Capox 3m 39 37 0.886 
Capox 3-6m 18 18 1 Capox 3-6m 10 11 1 
Capox 6m 21 13 0.19 Capox 6m 8 5 0.569 
Folfox 3m 0 0 NA Folfox 3m 1 1 1 
Folfox 3-6m 2 3 1 Folfox 3-6m 7 6 1 





3m 0 0 NA 
Capecitabine 
3m 2 7 0.17 
Capecitabine 
3-6m 0 0 NA 
Capecitabine 
3-6m 4 7 0.538 
Capecitabine 
6m 0 0 NA 
Capecitabine 
6m 17 17 1 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 0 0 NA FU 3-6m 0 0 NA 
FU 6m 0 0 NA FU 6m 1 1 1 
AM 0 0 NA AM 0 0 NA 
T4N2       T4N2       
Capox 3m 25 35 0.129 Capox 3m 26 29 0.754 
Capox 3-6m 22 20 0.863 Capox 3-6m 5 11 0.192 
Capox 6m 31 23 0.27 Capox 6m 14 11 0.671 
Folfox 3m 0 0 NA Folfox 3m 1 1 1 
Folfox 3-6m 2 4 0.683 Folfox 3-6m 8 8 1 
Folfox 6m 26 24 0.749 Folfox 6m 19 18 1 
Capecitabine 
3m 0 0 NA 
Capecitabine 
3m 2 5 0.445 
Capecitabine 
3-6m 0 0 NA 
Capecitabine 
3-6m 4 5 1 
Capecitabine 
6m 0 0 NA 
Capecitabine 
6m 15 17 0.848 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 0 0 NA FU 3-6m 0 0 NA 
FU 6m 0 0 NA FU 6m 1 1 1 
AM 0 0 NA AM 0 0 NA 
T3N0 MSS       T3N0 MSS       
Capox 3m 17 18 1 Capox 3m 8 8 1 
Capox 3-6m 1 0 1 Capox 3-6m 0 0 NA 
Capox 6m 0 1 1 Capox 6m 0 0 NA 
Folfox 3m 0 0 NA Folfox 3m 0 0 NA 
Folfox 3-6m 0 0 NA Folfox 3-6m 0 0 NA 
Folfox 6m 0 0 NA Folfox 6m 0 0 NA 
Capecitabine 
3m 5 7 0.768 
Capecitabine 
3m 5 4 1 
Capecitabine 
3-6m 10 12 0.822 
Capecitabine 
3-6m 12 12 1 
Capecitabine 
6m 40 33 0.386 
Capecitabine 
6m 33 29 0.651 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 0 0 NA FU 3-6m 1 0 1 
FU 6m 3 1 0.621 FU 6m 3 2 0.683 
AM 30 34 0.654 AM 44 51 0.407 
T3N0 MSI-H       T3N0 MSI-H       
Capox 3m 8 8 1 Capox 3m 7 6 1 
Capox 3-6m 0 0 NA Capox 3-6m 0 0 NA 
Capox 6m 0 0 NA Capox 6m 0 0 NA 
Folfox 3m 0 0 NA Folfox 3m 0 0 NA 
Folfox 3-6m 0 0 NA Folfox 3-6m 0 0 NA 





3m 0 0 NA 
Capecitabine 
3m 0 0 NA 
Capecitabine 
3-6m 0 2 0.498 
Capecitabine 
3-6m 0 0 NA 
Capecitabine 
6m 2 1 1 
Capecitabine 
6m 3 1 0.621 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 0 0 NA FU 3-6m 0 0 NA 
FU 6m 0 0 NA FU 6m 0 0 NA 
AM 95 93 0.829 AM 96 98 0.806 
T4N0 MSS       T4N0 MSS       
Capox 3m 36 33 0.77 Capox 3m 18 20 0.724 
Capox 3-6m 8 2 0.101 Capox 3-6m 3 2 1 
Capox 6m 1 2 1 Capox 6m 0 0 NA 
Folfox 3m 0 0 NA Folfox 3m 0 0 NA 
Folfox 3-6m 2 2 1 Folfox 3-6m 0 1 1 
Folfox 6m 5 4 1 Folfox 6m 4 2 0.683 
Capecitabine 
3m 3 9 0.134 
Capecitabine 
3m 7 7 1 
Capecitabine 
3-6m 8 9 1 
Capecitabine 
3-6m 13 10 0.66 
Capecitabine 
6m 36 35 1 
Capecitabine 
6m 43 40 0.778 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 1 0 1 FU 3-6m 2 0 1 
FU 6m 2 2 1 FU 6m 5 4 1 
AM 4 7 0.538 AM 11 20 0.119 
T4N0 MSI-H       T4N0 MSI-H       
Capox 3m 29 22 0.353 Capox 3m 18 16 0.852 
Capox 3-6m 4 6 0.748 Capox 3-6m 1 1 1 
Capox 6m 0 0 NA Capox 6m 0 0 NA 
Folfox 3m 0 0 NA Folfox 3m 0 0 NA 
Folfox 3-6m 3 1 0.621 Folfox 3-6m 1 1 1 
Folfox 6m 3 4 1 Folfox 6m 4 2 0.683 
Capecitabine 
3m 1 1 1 
Capecitabine 
3m 1 0 1 
Capecitabine 
3-6m 1 2 1 
Capecitabine 
3-6m 2 2 1 
Capecitabine 
6m 6 8 0.783 
Capecitabine 
6m 8 6 0.783 
FU 3m 0 0 NA FU 3m 0 0 NA 
FU 3-6m 0 0 NA FU 3-6m 0 0 NA 
FU 6m 1 1 1 FU 6m 1 1 1 






Figure 12-12 Clinicians’ estimation of the proportion of patients of working age who 
continue to work full time during their adjuvant treatment for CRC 
 
13 Appendix 4 Supplementary material for 
economic evaluation 
Table 13-1 Types of economic evaluation. Information adapted from text in (15) 
Type of economic evaluation Description 
Cost-effectiveness analysis Costs are measured in monetary terms whereas consequences are 
measured in natural units of effectiveness, for example, units of 
blood pressure reduction, live-years gained. The effect of interest 
must be common to the alternative treatments being compared.  
Cost-utility analysis Costs are measured in monetary terms but outcomes are measured 
in utilities, and typically reported as quality-adjusted life years 
(QALYs). As QALYs are a generic measure of health gain, this allows 
the cost-effectiveness of treatments within different areas of health 
care to be compared to assess the opportunity cost of spending on 
those treatments within a fixed budget. Other generic measures of 
health gain that can be used include the disability adjusted life year 
(DALY) or health years equivalent (HYE).   
Cost-benefit analysis Both costs and effects are measured in monetary units. Outcome 
measures must be converted to monetary values and this may be 



























Estimated proportion of patients




example, health gain. CBA allows comparison of the cost-
effectiveness of interventions in different disciplines.  
Cost-minimisation analysis Comparison of the costs of alternative interventions. The 
consequences of the interventions are assumed to be equal.  
 
Table 13-2 Types of multi-country perspective economic evaluations (Adapted from ((112))) 





































Table 13-3 Pros and cons of different types of multi-county economic evaluations  (Adapted 
from ((112))) 















use and clinical 
benefits 




use and costs 
√  √ √ 
Maximises statistical 
power for treatment 
effect 
√ √ √  
Minimises collection 
of unit cost data 
 √ √ √ 
Allows consistent 
reporting of 
treatment effects in 
economic and clinical 
manuscripts 






Figure 13-1 An explanation of types of unit costs. This figure was made based on a discussion 
with a representative from the pharmaceutical industry. 
Table 13-4 Types of productivity loss calculation 
Productivity costs estimation Description 
Human capital approach The value of absenteeism at work for patients who are unwell is 
measured using gross (pre-tax) wage. This can include paid or unpaid 
work. It is contentious whether this estimation should include time away 
from work when receiving treatment. The criticism of the human capital 
approach is that it estimates potential lost production rather than the 
loss experience in real life which will be mitigated by compensating 
factors, such as an employee replacing that individual in the workplace 
(the basis of the friction cost approach).  
Friction cost approach Considers productivity costs from an employer’s perspective. The friction 
period is the time that employers take to recover from the productivity 
loss from an absent employee. For example, the time to fill this vacancy. 
Often short term vacancies produce similar estimate to using the human 
capital approach but for longer term absence, the productivity loss 
calculated using the friction cost approach will be less than the human 
capital approach.  
Incorporation of productivity costs into 
health effects 
Productivity costs are included in the measure of health effects when, for 
example, the QALY is used, because it is assumed that individuals will 
incorporate the impact of health conditions on their ability to work when 




1. Actual selling price: 
Price received by the drug 
manufacturer. May be the 
same as the in-market price 
 
Pharmacy/Hospital 
2. In-market price: 
Price paid by a hospital or pharmacy 
retailer to the drug manufacturer. 
This may include a mark-up 
compared to the actual selling price 
if there is a wholesaler who 
distributes/packages medication on 
behalf of the drug company. This 
price is tender driven and will be 
subject to negotiation. 
 
Wholesaler 
3. Drug tariff price: 
Price that the NHS will pay a 
hospital or community pharmacist 
for a medication. Often higher than 
the in-market price. These prices 
are available through the UK 
Chemist and Drug list.  
 
4. List price: 
The official drug price. 
Often the highest price out 





this approach, it would therefore be double counting if estimating health 




Table 13-5 Time-point of data collection  These time-points following the approach taken for 
the SCOT trial economic analysis (75).  
Time-point (Survival to start of the time 
period) 
Cost period (Costs incurred during 
this time period) 
1 (Survival at baseline/time zero) 1 (0-1.5 months) 
2 (Up to 1.5 months) 2 (1.5-3 months) 
3 (Up to 3 months) 3 (3-4.5 months) 
4 (Up to 4 months) 4 (4-5 months) 
5 (Up to 5 months) 5 (5-6 months) 
6 (Up to 6 months) 6 (6-9 months) 
7 (Up to 9 months) 7 (9-12 months) 
8 (Start of year 12) 8 (12-18 months) 
9 (Up to 18 months) 9 (18-24 months) 
10 (Start of year 2) 10 (2-3 years) 
11 (Start of year 3) 11 (3-4 years) 
12 (Start of year 4) 12 (4-5 years) 
13 (Start of year 5) 13 (5-6 years) 
14 (Start of year 6) 14 (6-7 years) 




16 (Start of year 8) 16 (8-9 years) No actual cost data 
17 (Start of year 9) 17 (9-10 years) No actual cost data 
 
Table 13-6 Variables and values used to populate the budget impact framework 
Parameter Value  Source of information 
Incident population diagnosed 
with stage III disease per year 
Colon; Rectum All incidence estimates from Globoan (2018) 
(337).  
Australia  2740; 1215 Stage proportion from Australian Institute of 
Health and Welfare 
(https://www.aihw.gov.au/reports/cancer/cance
r-data-in-australia/data).(338) 
Denmark 817; 407 Stage proportion from Danish report (339). 
New Zealand 523; 250 Total number from NZ Ministry of Health. Stage 
proportions based on Australian source. 
Spain 6271; 3268 Stage proportion based on UK source (340). 
Sweden 1145; 546 Stage proportion based on Swedish report 
provided via personal communication with  
UK 8100; 3934 Stage proportion from Cancer Research UK 
Bowel Statistics. (299) 
Incident population diagnosed 
with stage II disease per year 
Colon/Rectum  
Australia 2740; 1215 All incidence estimates from Globoan (2018). 
Stage proportions from same source used for 
stage III. 
Denmark 888; 292 
New Zealand 523; 250 
Spain 6030; 3143 
Sweden 976; 465 
UK 7788; 3784 
Proportion of patients with stage 
III CRC that receive adjuvant 
chemotherapy 
  
Base case  65%  Mean of low (56%) and high (75%) estimate. 
Also, aligns approximately with: 
Swedish report (341) 60% colon 2018 
Van Steenbergen et al (342) 2011 Netherlands 
68% for patients aged 65-74 years.  
Lima et al 2011 (343) Canada 61%.  
Upadhyag et al 2015 (344) USA 65%. 
Low estimate 55% Taylor et al 2020 (258) 56% England  
High estimate 75% Boland et al 2013 (345) 74% USA (excluded 
aged 80+) 
Ortiz et al 2019 (346) 75% Puerto Rico 
Proportion of patients with stage 
II CRC that receive adjuvant 
chemotherapy 
  
Base case  20% Yang et al 2018 (304, 347) USA 21%  
Taylor et al 2020  (258) England 16%  
Swedish report 2018 (341) 20% colon (10% 
rectum) 
Low estimate 10% Chosen by primary researcher as a reasonable 
low estimate for the purposes of this budget 
impact analysis. 
High estimate 50% Fotheringham et al 2019 (348) 50-60% UK 
Out of those patients with stage 
III CRC that receive adjuvant 
chemotherapy, the proportion 





Base case 71% Taylor et al (Table 1) (258).This estimate 
includes patients of all ages ≥18 years old. 
Low estimate 50% Chosen by primary researcher as a reasonable 
low estimate for the purposes of this budget 
impact analysis. 
High estimate 100% Chosen by primary researcher as a reasonable 
high estimate for the purposes of this budget 
impact analysis. 
Out of those patients with stage 
II CRC that receive adjuvant 
chemotherapy, the proportion 
who receive doublet treatment. 
  
Base case 31% Taylor et al (Table 1) (258).This estimate 
includes patients of all ages ≥18 years old. 
Low estimate 15% Chosen by primary researcher as a reasonable 
low estimate for the purposes of this budget 
impact analysis. 
High estimate 50% Chosen by primary researcher as a reasonable 
high estimate for the purposes of this budget 
impact analysis. 
Percentage of clinicians using 3 
months of doublet 
chemotherapy to treat patients 
under 70 with stage III CRC 
post-SCOT trial (i.e. practice 
change) 
  
Base case 54% International survey*  
Percentage of clinicians using 3 
months of doublet 
chemotherapy to treat patients 
aged 70+ with stage III CRC 
post-SCOT trial (i.e. practice 
change) 
  
Base case 37% International survey** 
Overall practice change 
estimate Stage III 
  
Base scenario 50% 
 
Data from a real world data set showed that of 
those patients receiving doublet chemotherapy, 
76% were aged under 70 years old and 24% 
were aged 70 years and over (258). Combining 
these real world estimates with practice change 
calculated using an international survey: 
0.76 x 54% = 41% 
0.24 x 37% = 9%  
Sum=50%  
Low estimate 25% Chosen by primary researcher as a reasonable 
low estimate for the purposes of this budget 
impact analysis. 
High estimate 100% Chosen by primary researcher as a reasonable 
low estimate for the purposes of this budget 
impact analysis. 
Percentage of clinicians using 3 
months of doublet 
chemotherapy to treat patients 
under 70 with stage II CRC post-
SCOT trial (i.e. practice change 
if assume that 100% of patients 
prescribed doublet 
chemotherapy pre-SCOT 
receive an intended 6 months of 
treatment) 
  




Percentage of clinicians using 3 
months of doublet 
chemotherapy to treat patients 
aged 70+ with stage II CRC 
post-SCOT trial. 
  
Base case  8% International survey. **** 
Overall practice change 
estimate Stage II 
  
Base scenario 18% Data from a real world data set showed that of 
those patients receiving doublet chemotherapy, 
76% were aged under 70 years old and 24% 
were aged 70 years and over (258). Combining 
these real world estimates with practice change 
calculated using an international survey: 
0.76 x 20% = 15% 
0.24 x 8% = 2%  
Sum=18%  
Low estimate 10% Chosen by primary researcher as a reasonable 
low estimate for the purposes of this budget 
impact analysis. 
High estimate 30% Chosen by primary researcher as a reasonable 
low estimate for the purposes of this budget 
impact analysis. 
 
*Based on hypothetical patient scenarios for patients aged <70 years old. This calculation accounts 
for differences in clinician practice for low risk stage III (T1-3N1) and high-risk stage III (T4 or N2) 
disease.  In the survey, 86% clinicians reported they use 3 months of doublet chemotherapy for 
low-risk stage III disease and 16% of clinicians reported they use 3 months of doublet chemotherapy 
for high-risk stage III disease. In the SCOT trial (Lancet Oncology publication April 2018 Figure 3), 
approximately 54% of stage III patients in the trial cohort had low risk disease and 46% had high-
risk disease. Therefore, the overall proportion of patients with stage III disease receiving doublet 
chemotherapy for 3 months post-SCOT = (86% 3 months doublet chemotherapy x 54% patients with 
low risk stage III CRC) + (16% 3 months doublet chemotherapy x 46% patients with high risk stage 
III CRC) = 54%. 
** Based on hypothetical patient scenarios for patients aged 70+ years old. In the survey, 53% of 
clinicians reported that they use doublet chemotherapy for 3 months for low-risk stage III disease 
and 15% of clinicians reported they use 3 months of doublet chemotherapy for high-risk stage III 
disease. Overall proportion of patients treated with stage III disease receiving doublet 
chemotherapy for 3 months therefore = (53% 3 months doublet chemotherapy x 56% patients with 
low risk stage III CRC) + (15% 3 months doublet chemotherapy x 46% patients with high risk stage 
III CRC) = 37%. 
***Based on hypothetical patient scenarios for patients aged <70 years old. Proportion of clinicians 
using 3 months of doublet chemotherapy post-SCOT was 20% for microsatellite stable disease and 
12% for MSI-H disease. Assuming approximately 20% of patients with stage II CRC will have MSI-H 
disease, overall proportion receiving 3 months of doublet chemotherapy post-SCOT: (0.8 x 20%) + 
(0.2x12%) = 18%.  
**** Based on hypothetical patient scenarios for patients aged <70 years old. Proportion of clinicians 
using 3 months of doublet chemotherapy post-SCOT was 8% for microsatellite stable disease and 
10% for MSI-H disease. Assuming approximately 20% of patients with stage II CRC will have MSI-H 
disease, overall proportion receiving 3 months of doublet chemotherapy post-SCOT: (0.8 x 8%) + 
(0.2 x 10%) = 8%. 
Table 13-7 Utility regression (Australia) 
Australia utilities 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment -0.0378* 0.004 
    Recurrence -0.0644* 0.014 






Characteristics   
    CAPOX 0.0040 0.007 
    Low risk stage III -0.0023 0.010 
    High risk stage III -0.0086 0.010 
    Male 0.0213* 0.007 
    Age 0.0014* 0.000 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -0.0719* 0.035 
       South Asian -0.1229* 0.047 
      Chinese -0.0302 0.064 
      Other 0.0166 0.0210 
Constant 0.7701 0.027 
Explanation: Comparison is a 65-year old, Caucasian female patient on the 3 




Table 13-8 Utility regression (Denmark) 
Denmark utilities 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment -0.0363* 0.003 
    Recurrence -0.0572* 0.013 
Arm: 6 months (ref: 3 
months) 
-0.0129* 0.006 
Characteristics   
    CAPOX 0.0037 0.006 
    Low risk stage III -0.0017 0.009 
    High risk stage III 0.0072 0.009 
    Male 0.0193* 0.006 
    Age 0.0013* 0.000 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -0.0630* 0.031 
       South Asian -0.1123* 0.043 
      Chinese -0.0235 0.052 
      Other 0.0150 0.019 
Constant 0.7909 0.024 
Explanation: Comparison is a 65-year old, Caucasian female patient on the 3 
month trial arm in a disease free health state and stage II disease treated with 
FOLFOX. *p<0.05 
Table 13-9 Utility regression (New Zealand) 
New Zealand utilities 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment -0.0526* (0.005) 




Arm: 6 months (ref: 3 
months) 
-0.0178* (0.009) 
Characteristics   
    CAPOX 0.0051 (0.009) 
    Low risk stage III -0.0060 (0.013) 
    High risk stage III -0.0129 (0.013) 
    Male 0.0288* (0.009) 
    Age 0.0016* (0.000) 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -0.0859* (0.039) 
       South Asian -0.1161* (0.048) 
      Chinese -0.0467 (0.072) 
      Other 0.0253 (0.026) 
Constant 0.6931 (0.034) 
Explanation: Comparison is a 65-year old, Caucasian female patient on the 3 
month trial arm in a disease free health state and stage II disease treated with 
FOLFOX. *p<0.05 
Table 13-10 Utility regression (Spain) 
Spain utilities 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
-0.0360* 0.004 
    On treatment -0.0632* 0.015 
    Recurrence -0.0157* 0.007 
Arm: 6 months (ref: 3 
months) 
0.0052 0.008 
Characteristics   
    CAPOX 0.0052 0.008 
    Low risk stage III 0.0002 0.010 
    High risk stage III -0.0074 0.010 
    Male 0.0129 0.007 
    Age 0.0014* 0.000 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -0.0725* 0.036 
       South Asian -0.1529* 0.056 
      Chinese -0.0473 0.091 
      Other 0.0243 0.020 
Constant 0.7957 0.029 
Explanation: Comparison is a 65-year old, Caucasian female patient on the 3 
month trial arm in a disease free health state and stage II disease treated with 
FOLFOX. *p<0.05 
 
Table 13-11 Utility regression (Sweden) 
Sweden utilities 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  




    Recurrence -0.0355* (0.008) 
Arm: 6 months (ref: 3 
months) 
-0.0091* (0.004) 
Characteristics   
    CAPOX 0.0026 (0.004) 
    Low risk stage III -0.0008 (0.006) 
    High risk stage III -0.0057 (0.006) 
    Male 0.0115* (0.004) 
    Age 0.0008* (0.000) 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -0.0317 (0.020) 
       South Asian -0.0668* (0.027) 
      Chinese -0.005 (0.038) 
      Other 0.0148 (0.012) 
Constant 0.8466 (0.016) 
Explanation: Comparison is a 65-year old, Caucasian female patient on the 3 
month trial arm in a disease free health state and stage II disease treated with 
FOLFOX. *p<0.05 
 
Table 13-12 Yearly cost regression (Australia) 
Australia costs (Regression used to model costs for years 7-10) 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment 16,127* 375 
    Recurrence 12,674* 961 
Arm: 6 months (ref: 3 
months) 
334 180 
Year 1 7,178* 420 
Year 1*Arm (6 months) 756 455 
Characteristics   
    CAPOX -5,683* 346 
    Low risk III 70 390 
    High risk III 260 360 
    Male -476 321 
    Age  16 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -1,866 978 
       South Asian 137 1,220 
      Chinese 486 1,964 
      Other -297 505 
Constant 5,104 1,119 
Explanation: Comparison is a Caucasian female patient on the 3 month trial 
arm aged 65 years with stage II disease, treated with FOLFOX after year 1 in a 
disease free state. 
 
Table 13-13 Yearly cost regression (Denmark) 
Denmark costs (Regression used to model costs for years 7-10) 




Health states (ref: 
disease free) 
  
    On treatment 15,795* 365 
    Recurrence 12,335* 934 
Arm: 6 months (ref: 3 
months) 
325 176 
Year 1 6,997* 408 
Year 1*Arm (6 months) 744 423 
Characteristics   
    CAPOX -5,559* 337 
    Low risk III 65 380 
    High risk III 251 351 
    Male -462 312 
    Age 78 15 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -1811 957 
       South Asian 156 1195 
      Chinese 471 1,915 
      Other -290 492 
Constant 5,007 1,089 
Explanation: Comparison is a Caucasian female patient on the 3 month trial 
arm aged 65 years with stage II disease, treated with FOLFOX after year 1 in a 
disease free state. 
 
Table 13-14 Yearly cost regression (New Zealand) 
New Zealand costs (Regression used to model costs for years 7-10) 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment 11,960* 261 
    Recurrence 8,948* 659 
Arm: 6 months (ref: 3 
months) 
237 129 
Year 1 5,153* 286 
Year 1*Arm (6 months) 589 317 
Characteristics   
    CAPOX -4204* 243 
    Low risk III 32 272 
    High risk III 180 255 
    Male -322 223 
    Age 18 11 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -1273 720 
       South Asian 98 887 
      Chinese 425 1422 
      Other -171 360 




Explanation: Comparison is a Caucasian female patient on the 3 month trial 
arm aged 65 years with stage II disease, treated with FOLFOX after year 1 in a 
disease free state. 
 
Table 13-15 Yearly cost regression (Spain) 
Spain costs (Regression used to model costs for years 7-10) 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment 12,636* (279) 
    Recurrence 9,533* (706) 
Arm: 6 months (ref: 3 
months) 
252 137 
Year 1 5,474* 307 
Year 1*Arm (6 months) 617 338 
Characteristics   
    CAPOX -4443* 259 
    Low risk III 38 290 
    High risk III 129 271 
    Male -346 239 
    Age 20 12 
    Ethnic (ref: 
Caucasian) 
  
       African/Caribbean -1365 761 
       South Asian 107 940 
      Chinese 435 1,508 
      Other -191 382 
Constant 4,132 832 
Explanation: Comparison is a Caucasian female patient on the 3 month trial 
arm aged 65 years with stage II disease, treated with FOLFOX after year 1 in a 
disease free state. 
 
Table 13-16 Yearly cost regression (Sweden) 
Sweden costs (Regression used to model costs for years 7-10) 
Variable Co-efficient S.E. 
Health states (ref: 
disease free) 
  
    On treatment 12,636* 1,034 
    Recurrence 15,548* 397 
Arm: 6 months (ref: 3 
months) 
342 183 
Year 1 7,225* 455 
Year 1*Arm (6 months) 673 482 
Characteristics   
    CAPOX -5,484* 361 
    Low risk III 103 412 
    High risk III 269 373 
    Male -522 340 
    Age 34 17 






       African/Caribbean -2,011 957 
       South Asian 201 1,223 
      Chinese 305 1,952 
      Other -400 517 
Constant 4,584 1,183 
Explanation: Comparison is a Caucasian female patient on the 3 month trial 
arm aged 65 years with stage II disease, treated with FOLFOX after year 1 in a 











Figure 13-2 Subgroup analyses CEACs and cost-effectiveness planes The WTP threshold 
plotted for the subgroup cost-effectiveness planes was $42,000, in line with the UK NICE 





Table 13-17 Budget impact analysis results in country-specific currency 
Country currency 
(rounded to nearest 
100,000) 
Australia Denmark New Zealand Spain Sweden United 
Kingdom 
Base scenario budget impact 
Chemotherapy 










hospitalisations in (year 1 
for each individual 









hospitalisations  (years 2-
5 for each individual 





$200,000 €1,800,000 6,400,000 
kr 
£2,500,000 
Total budget impact = 
Medication cost + Cost of 
treatment and condition 





$4,300,000 €33,600,000 116,000,000 
kr 
£45,800,000 
Scenario analysis (otherwise as per base scenario) 




$2,900,000 €22,100,000 78,600,000 
kr 
£30,800,000 












The SCOT study received the following project specific funding: 
UK 
SCOT Original Grant: 
MRC (subsequently transferred to NIHR NETSCC) 
Grant Ref: G0601706 
Duration: 96 months, 1st Dec 2006 – 30th November 2014 
Total awarded: MRC contribution £2,449,391 (FEC £3,061,732) 
 
CRUK CTU Core Funding (Estimated): 
Used in the 12 month gap between the MRC and HTA funding. 
2 X 1.0 Full Time Equivalent (FTE) Clinical Trial Coordinators 
0.25 FTE Project Manager 
0.5 FTE Clinical Trial Administrator 
0.3 FTE Statistician 
 
Total cost = £129,000 (Grant: C6716/A9894) 
 
Extension to Follow-up: 
NIHR HTA 
Grant Ref: 14/140/84 
Duration: 30 months, 1st Dec 2015 – 31st May 2018 
Total awarded: £274,695 
 
Within the UK, the study was also supported with NCRN/SCRN/NIHR 
infrastructure funding within the participating sites.  
 
(UK total £2,853,086, appox $3.8 million USD) 
 
Sweden 
Swedish Cancer Society (as part of a larger (2 million SEK; approx. $175,000 USD) 
annual grant for CRC research; proportion for SCOT trial not quantifiable.) 
 
Denmark 
Interreg grant. Approximately $700,000 USD (5 million Danish Kr). 
 
These funders had no role in the identification, design, conduct, and reporting 
of the analysis. 
 





14 Appendix 5 Supplementary material relevant to 
analysis of administrative healthcare data 
Table 14-1 Datasets request as part of PBPP application 1718-0026  
Dataset Data 
controller 
Description Years requested 
for the purposes 
of this project 
NRS Deaths NRS This dataset is collected by National Records Scotland (NRS), 
which is a Scottish government institution. It contains 
information on date, cause and place of death for all deaths 
registered in Scotland since 1974. PHS is granted access to 
extracts from this dataset for research/linkage purposes.  
2006-2018 
SMR00 PHS  This dataset contains patient level episode data on outpatient 
appointments across all specialities (except A & E and Genito-
urinary medicine). Data collection began in Scotland in the 
1990s. Data collection within 6 weeks of outpatient 
attendance.   
1997-2018 
SMR01 PHS  SMR01 comprises patient level episode data on hospital 
inpatient and day case discharges from acute specialities in 
Scotland. Data is available in computerised format from 1968. 
1997-2018 
SMR04 PHS  SMR04 contains data for patients receiving care in Mental 
Health facilities (inpatient and day cases). 
2006-2018 
SMR06 PHS  SMR06 is also known as the Scottish Cancer Registry and 
established 1954. Collects information relevant to the 
diagnosis and management of malignant neoplasms, as well 
as carcinoma in situ and some benign tumours. Data is 
collected annually. CORECT-R Scotland has requested 
















































National prospective audit dataset collected and stored 
regionally on an annual basis (April each year). NHS boards 
are required to report their activity against QPIs as part of a 
mandatory national cancer quality programme. Healthcare 
Improvement Scotland is responsible for the external quality 
assurance of cancer services against tumour specific QPIs. 
2013-2018 
QPI SCAN NHS 
Lothian 
National prospective audit dataset collected and stored 











National prospective audit dataset collected and stored 
regionally on an annual basis (April each year). 
2013-2018 
PLICS PHS PLICS is the patient level information costing system and 
contains cost variables derived from SMR00, SMR01 and 
SMR04. This top down costing system was developed to 
allow hospital costs to be attributed to patient activity in a 
detailed way to reflect key cost drivers such as length of stay 
and apportions hospital site and speciality specific direct 
costs to individual patient records on admission, per day, for 
theatre time and specific high cost items. PLICS is not yet 











SICSAG is the Scottish Intensive Care Society Audit Group 
dataset and contains both episode level and daily information 
provided for each patient.  
2006-2018  
Radiotherapy NA Detailed radiotherapy data is currently not available on a 
national basis in Scotland and held loco-regionally by 
radiotherapy centres. Key information on radiation treatment 
delivered (for example if radiotherapy was delivered and date 
of treatment) is currently available within the Scottish Cancer 
Registry (SMR06). However, granular radiotherapy data (for 
example dose, technique and modality) is currently held by 
individual hospital institutions which deliver radiotherapy.  A 
process is in development to make radiotherapy data 
available nationally – this involves Scottish radiotherapy 
centres sending data extract to Public Health England, who 
curate the data to a common standard prior to returning to 






PHS The Prescribing Information System (PIS) is a data source for 
all prescribing of medicines (and their costs) that are 
prescribed and dispensed in the community in Scotland. 
Includes medications prescribed in hospital but dispensed in 
the community but not those dispensed in hospital. 
Information for this dataset is supplied by the Practitioner 




PHS Originally established in 2007 to monitor compliance of each 
NHS board with the maximum four hour waiting time target. 
Departments may submit individual episode level data 
(detailed information on each patient attendance) or 
aggregate level data (often smaller minor injury units). Sites 
that submit episode level data account for 94% of national A 
and E attendances.  
2011-2018  
GP Out of 
Hours 
PHS A Scottish government commissioned (2014) dataset to 
improve understanding of activity, demand and capacity at a 





PHS The SAS dataset contains individual level records of all patient 
contact with the service.  
2011-2018 
NHS 24 PHS The NHS 24 dataset contains individual level records of all 






14.1 Comparison of methods of cohort derivation for the 
GG&C cohort 
The primary researcher (CH) did not have access to patient level information 
from QPI and ACaDMe raw datasets and therefore this step of cohort derivation 
was reliant on the ChemoCare (CC) and QPI (FC) data providers. Within the 
ACaDMe dataset, patients with a diagnosis CRC (ICD-10 codes 18-20) and with 
Duke’s B or Duke’s C disease in SMR06, who had undergone CRC surgery and who 
received chemotherapy within six months of this surgery were identified. Duke’s 
stage was used because it had a superior completion rate within SMR06 
compared to TNM staging. When using the QPI dataset, patients with either 
Duke’s B or C CRC who had received adjuvant chemotherapy were identified 
using a variable called “ADJONC” and criteria “2” which indicated that 
chemotherapy was given to that patient with adjuvant intent. This variable 
(ADJONC) was available from 2010 (pre-QPI) and continued to be collected as 
part of the QPI dataset.  
The accuracy of the SMR06 diagnostic ICD-10 codes and the staging and 
pathological data provided by the Cancer Audit data was assessed on a small 
subset of patients within the final ChemoCare cohort using patient identifiable 
data. For the purposes of this analysis, if there were disease staging or 
pathological details missing from these data sources, these were retrieved by 
looking at the individual patient electronic records. If this information was still 
not available, these fields were designated as missing. 
Figure 14-1 shows the cohorts defined using three different approaches. The 
largest cohort was obtained using Cancer Audit/QPI data (n=1096) and 334 
patients were identified in the Cancer Audit/QPI cohort that were not present in 
the final ChemoCare cohort.  The majority (88%, 164/186) of patients who met 
the inclusion criteria but who were not the ChemoCare dataset resided outside 
GG&C; they were included in the QPI GG&C data extraction because their CRC 
diagnosis occurred in the GG&C health board. Cancer Audit data identifies all 
patients diagnosed with CRC in GG&C whereas the ChemoCare dataset defines 
patient location using the health board of residence. Patients who reside outside 




tertiary treatment centre for imaging, diagnostic biopsies, or surgery and this 
explains why the Cancer Audit cohort is larger. The approximate specificity and 
sensitivity of using Cancer Audit data was estimated. Overall, using Cancer 
Audit/QPI data to identify patients with stage II/III disease who received 
adjuvant chemotherapy had a sensitivity of approximately 90% and a specificity 
of 95% compared to what was considered the gold standard for this cohort, 
which was ChemoCare data which was cleaned and prepared using identifiable 
electronic portal records.  
The ACaDMe (SMR06) cohort was the smallest of the three cohorts used and the 
majority of these patients were found in the Cancer Audit or ChemoCare 
databases. Thirty-nine patients were identified using ACaDME that were not in 
the other two databases but only two of these patients met the inclusion 
criteria. Because the primary researcher did not have direct access to the 
ACaDME datasets, it was not possible to interrogate this method of cohort 
derivation further. For example, it was unclear which codes had been used to 





Figure 14-1 Comparison of GG&C cohort definition using three approaches 
 
The cohort chosen for further analysis was the original in ChemoCare cohort. 
ICD-10 codes were available for 99% (n=851/856) patients and twenty patients 
were randomly picked to check the accuracy of the ICD-10 code against patient 
identifiable data and these were correct in 19/20 cases. One case had recorded 
the diagnosis as colon cancer, whereas a code of rectosigmoid cancer would 
have been more specific. Disease staging information and pathological details 
were provided by the QPI dataset. TNM staging was available for 849/858 (99%) 
records and Duke’s staging was available for 841/856 (98%) records. A different 
set of twenty electronic records were reviewed to check the accuracy of these 
entries. There was 100% concordance between the Tumour and Nodal staging 
(TNM codes), Duke’s staging and pathological details (for example, number of 
nodes sampled, margin positivity, degree of differentiation) for these patients 















95/333 SCOT trial participants. 
186/333 relevant to study cohort: 
- 164 identified in WOSCAN 
extract 
- 22 not identified using 
ChemoCare 
-  
52/333 not relevant to study cohort: 
- 27 metastatic disease 
- 3 alternative diagnosis 
- 10 no information or private 
treatment 
- 5 raltitrexed 
- 6 neoadjuvant chemotherapy 
- 1 adjuvant 
chemoradiotherapy 
  
5/39 relevant to 
study cohort.  
Not identified using 
ChemoCare or 




Table 14-2 Variables used for GG&C analysis 
Category of 
variable Variable name/description Name in dataset Variable type Dataset Formation of derived variables 
Disease 
characteristics Tumour stage tstage Raw AcaDME (SMR06) and Clinical Portal NA 
  Nodal stage nstage Raw AcaDME (SMR06) and Clinical Portal NA 
  Extended risk stage riskstage Derived NA Derived from T-stage and N-stage 
  Duke's stage dukes Raw AcaDME (SMR06) and Clinical Portal NA 
  Site of disease  Site Raw AcaDME (SMR06) and Clinical Portal NA 
Patient 
characteristics Gender Gender Raw AcaDME (SMR06) and Clinical Portal NA 
  Age age   Derived NA 
Derived by analyst (CC) from ChemoCare record using date of 
birth. Age at first chemotherapy treatment 
  Age grouping ageg2 Derived NA 
Derived from age by primary researcher (CH). Groupings 
were under 70 and 70 and over. 
  
Scottish Index of Multiple 
Deprivation category Depcat Derived NA 
Derived by analyst (CC) from ChemoCare record using post-
code and SIMD codes (quintiles).  
  Height HEIGHT Raw   NA 
  Weight WEIGHT Raw   NA 
  Body surface area BSA Derived NA 
Derived by primary researcher (CH) using HEIGHT and 
WEIGHT 
  Cohort identifier ID Derived NA Derived by primary researcher (CH) to anonymise data 
Treatment 
characteristics Drug regimen* REGIMEN Raw ChemoCare GG&C NA 
  Drug name DRUGNAME Raw ChemoCare GG&C NA 
  
Date of chemotherapy 
delivery APT_DATE Raw ChemoCare GG&C NA 
  Drug dose DRUGDOSE Raw ChemoCare GG&C NA 
  Drug dose per m2 DOSEM2 Derived NA 





prescribed first_regimen Derived NA 
Derived by primary researcher (CH) from ChemoCare record 






Duration of treatment 
(calculated using cycles) total_weeks Derived NA 
Derived by primary researcher (CH) from ChemoCare record 
using drug name, drug dose and date of chemotherapy 
delivery 
  
Date of first adjuvant 
chemotherapy treatment first_Apt Derived NA 
Derived by primary researcher (CH) from ChemoCare record 
using drug name, drug dose and date of chemotherapy 
delivery 
  
Year of first adjuvant 
chemotherapy treatment year Derived NA 
Derived by primary researcher (CH) from ChemoCare record 
using date of chemotherapy delivery 
  
Month of first adjuvant 
chemotherapy treatment month Derived NA 
Derived by primary researcher (CH) from ChemoCare record 
using date of chemotherapy delivery 
  
Indication of if patient 
received over 3 months of 
treatment over12w Derived NA 
Derived by primary researcher (CH) using derived variable 
"total_weeks" 
  
Time since first patient in 
cohort started adjuvant 
treatment time Derived NA 
Derived by primary researcher (CH) using date of first 
adjuvant chemotherapy delivered 
  
Indication if adjuvant 
chemotherapy delivered 
before or after ASCO 2017 ASCO Derived NA 
Derived by primary researcher (CH) using date of first 
adjuvant chemotherapy delivered 
  
Indication of if patient's 
first adjuvant 
chemotherapy regimen was 
monotherapy or doublet 
treatment doublet Derived NA 
Derived by primary researcher (CH) from ChemoCare record 





Table 14-3 Demographic, disease and treatment related variables for patients receiving 
doublet chemotherapy at cycle one (GG&C analysis) 
Demographic, 
disease or treatment 
related variable 
Pre-SCOT  Post-SCOT  Total Number  
(percentage) (percentage)  (percentage) 
n= 484 (76%) n= 154 (24%) n=638 
Sex       
Male 262 (54%) 76 (49%) 338 (53%) 
Female 222 (46%) 78 (51%) 300 (47%) 
Age       
Median age (IQR) 62 (54-67) 62 (53-68) 62 (54-68) 
Age group         
≤70 years 414 (86%) 127 (82%) 541 (85%) 
>70 years 70 (14%) 27 (18%) 97 (15%) 
Deprivation category       
1 167 (35%) 50 (32%) 217 (34%) 
2 79 (16%) 24 (16%) 103 (16%) 
3 50 (10%) 23 (15%) 73 (11%) 
4 70 (14%) 20 (13%) 90 (14%) 
5 115 (24%) 35 (23%) 150 (24%) 
Unknown 3 (1%) 2 (1%) 2 (0%) 
Location of disease       
Colon 346 (71%) 118 (77%) 464 (73%) 
Rectosigmoid or 
Rectum 
138 (29%) 36 (23%) 174 (27%) 
Duke’s stage       
B 81 (17%) 16 (10%) 97 (15%) 
C 400 (83%) 138 (90%) 538 (84%) 
Unknown 3 (1%) 0 (0%) 3 (0%) 
T stage       
X 1 (0%) 0 (0%) 1 (0%) 
0 0 (0%) 1 (1%) 1 (0%) 
1 15 (3%) 8 (5%) 23 (4%) 
2 35 (7%) 11 (7%) 46 (7%) 
3 240 (50%) 81 (53%) 321 (50%) 
4 188 (39%) 53 (34%) 241 (38%) 
Unknown 5 (1%) 0 (0%) 5 (1%) 
N stage       
0 80 (17%) 16 (10%) 96 (15%) 
1 252 (52%) 100 (65%) 352 (55%) 
2 147 (30%) 38 (25%) 185 (29%) 




Stage III risk groups       
Low risk 177 (44%) 75 (54%) 252 (47%) 
High risk 222 (56%) 63 (46%) 285 (53%) 
Treatment regimen       
CAPOX 383 (80%) 114 (74%) 499 (78%) 
FOLFOX 99 (20%) 40 (26%) 139 (22%) 
 
Table 14-4 Demographic, disease and treatment related variables for patients receiving 
single agent chemotherapy at cycle one (GG&C analysis) 
Demographic, disease 
or treatment related 
variable 
Pre-SCOT  Post-SCOT  Total Number  
(percentage) (percentage) (percentage) 
n= 270 (75%) n= 90 (25%) n= 360 
Sex       
Male 132 (49%) 52 (58%) 184 (51%) 
Female 138 (51%) 38 (42%) 176 (49%) 
Age       
Median age (IQR) 70 (61-74) 69 (61-73) 69 (61-74) 
Age group         
≤70 years 141 (52%) 56 (63%) 197 (55%) 
>70 years 129 (48%) 34 (38%) 163 (45%) 
Deprivation category       
1 90 (33%) 22 (24%) 112 (31%) 
2 39 (14%) 24 (27%) 63 (18%) 
3 37 (14%) 14 (16%) 51 (14%) 
4 41 (15%) 9 (10%) 50 (14%) 
5 61 (23%) 21 (23%) 82 (23%) 
Unknown 2 (1%) 0 (0%) 2 (1%) 
Location of disease       
Colon 204 (76%) 77 (86%) 281 (78%) 
Rectosigmoid or 
Rectum 
66 (24%) 13 (14%) 79 (22%) 
Duke’s stage       
B 149 (55%) 61 (68%) 210 (58%) 
C 120 (44%) 29 (32%) 149 (41%) 
Unknown 1 (0%) 0 (0%) 1 (0%) 
T stage       
X 0 (0%) 0 (0%) 0 (0%) 
0  0 (0%) 0 (0%) 0 (0%) 
1 4 (2%) 0 (0%) 4 (1%) 
2 11 (4%) 2 (2%) 13 (4%) 
3 170 (63%) 63 (70%) 233 (65%) 
4 84 (31%) 25 (28%) 109 (30%) 
Unknown 1 (0%) 0 (0%)  1 (0%) 




0 149 (55%) 62 (69%) 211 (59%) 
1 86 (32%) 18 (20%) 104 (29%) 
2 34 (13%) 10 (11%) 44 (12%) 
Unknown 1 (0%) 0 (0%) 1 (0%) 
Stage III risk groups       
Low risk 63 (53%) 8 (29%) 71 (48%) 
High risk 57 (48%) 20 (71%) 77 (52%) 
Treatment regimen       
Capecitabine 255 (94%) 87 (97%) 342 (95%) 
IV 5-fluorouracil 13 (6%) 3 (3%) 18 (5%) 
 
 
Figure 14-2 Treatment switch First regimen: CAPOX (n=265, 76%), FOLFOX (n=74, 21%), 
CAP alone (n=15, 4%), FU alone (n=1, (0.3%)). The largest proportion of treatment switching 
was a change from using CAPOX in cycle one to capecitabine monotherapy at the last cycle 












































































Figure 14-5 Plot of residuals (linear regression doublet chemotherapy) 
 
 

































0 10 20 30 40
Lag





































0 10 20 30 40
Lag





Figure 14-7 Plot of residuals (linear regression monotherapy) 
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Figure 14-9 Plot of residuals (logistic regression doublet chemotherapy) 
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Figure 14-11 Plot of residuals (logistic regression monotherapy) 
 
Figure 14-12 Plot of partial residuals (logistic regression monotherapy) 





Linear regression doublet 2.13 
Linear regression monotherapy 2.14 
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Logistic regression monotherapy 2.35 
 
Figure 14-13 ITSA with interruption at January 2013 
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Table 14-6 Variables used for national analysis 
Category of variable 
Variable 




analysis Codes to identify cohort 
Variable 
type Dataset Formation of derived variables 
Disease information ICD-10   
Cohort 
Definition C18, C19, C20 Raw SMR06 NA 
Diagnosis Previous CRC previous_crc_cancer 
Cohort 
Definition No previous diagnosis 
Derived 
by eDRIS SMR06 
Derived by eDRIS. Patient has diagnosis of ICD10 18-20 
cancer prior to 2006.  
Diagnosis Diagnosis incidence_date_fmt 
Cohort 
Definition 2013-2018 Raw SMR06 NA 
Diagnosis Diagnosis diagdate_fmt 
Cohort 
Definition 
Date of diagnosis 
between 1st January 
2013 and 1st January 
2018 Raw QPI NA 
Disease type Site   
Working 
variable C18, C19, C20 Derived SMR06 C18 and C19=colon (Code=1). C20=Rectum (Code=2).  
Disease information Site disease 
Working 
variable 1,2 Derived QPI 
site is a raw variable in QPI which is descriptive e.g. Caecum, 
ascending colon. There are 12 options. These were 
converted first to numbers. 1 and 3-10 are colon, 2 is 
"currently unknown await update", 11 is rectum and 12 is 
not recorded. These numbers are used to create a new, 
derived variable called "disease". 1 and 3-10 are "1" (Colon), 
11 is "2" (rectum) and 2 and 12 are "." (unknown). If the QPI 
raw variable was 2 or 12, disease type information was 
taken from SMR06 ICD10 codes when available.   
Treatment Operation code opcode2 and opcode2b 
Working 
variable OPCS4 codes Raw QPI NA 




Definition 1,2,3,4,9 Derived QPI 
OPCS4 codes grouped according to major 
operation/palliative operation/bypass/stoma 
formation/missing 
Patient demographic Age   
Working 
variable NA Derived QPI Date of diagnosis minus date of birth  
Patient demographic Sex Sex 
Working 
variable NA Raw SMR06 NA 
Disease information 
Extended risk 
stage   
Working 
variable NA Derived QPI 
T3/4N0 = risk stage 1; T1-3N1=risk stage 2; T4N1, T1-3N2, 
T4N2 = risk stage 3. 
Patient demographic Social deprivation simd2016_sc_quintile 
Working 




Patient demographic Charlson score quan_morbidity 
Working 
variable NA Derived SMR01 
Index created by giving patients a score of 1 for each specific 
co-morbidity related to an episode of inpatient care from 
the year before diagnosis until death or last follow up (not 
including malignancy). These conditions are: acute 
myocardial infarction, chronic heart failure, peripheral 
vascular disease, cerebrovascular disease, dementia, COPD, 
rheumatoid disease, peptic ulcer disease, mild liver disease, 
diabetes with no complications, diabetes with 
complications, hemi or paraplegia, renal disease, moderate 
to severe liver disease, HIV. These scores were adjusted 
using quan weightings (x 2 for dementia and mod/sever liver 
disease, x4 for HIV). 
Patient demographic Charlson group charlson_group 
Working 
variable NA Derived SMR01 
Patients with no significant conditions given a grouping of 
zero, those with one are in group 1 and those with more 
than one are in group 2. 





regimens at their first 
cycle of chemotherapy 
after major surgery 









fluorouarcil  Derived ChemoCare 
This is derived from the individual medications prescribed 
for an individual patient. There is a variable "regimen" in the 
raw data but regimens which include the same drugs may 
have different names within different ChemoCare systems.  
Regimen calculated names therefore derived using the 
actual drugs received.  
First regimen   first_regimen 
Working 
variable NA Derived ChemoCare 
This is the first regimen (calculated) received after major 
surgery for patients with stage II/III CRC. 
Patient demographic Location location 
Working 
variable NA Derived ChemoCare 
The location of the ChemoCare prescription by Cancer 
Network. The North of Scotland covers Tayside, Grampian 
and the Highlands.   
Treatment    
Treatment time in 
weeks total_weeks 
Working 
variable NA Derived ChemoCare 
Based on the number of cycles of treatment received in the 
adjuvant setting. Cycles are either 2 weekly or 3 weekly 
depending on the medications used in each cycle. Two or 
three weeks are added to this variable to account for the 




Treatment    
Indicator of if 
patient received 
over 3 months of 
treatment over3m 
Working 
variable NA Derived ChemoCare 
Derived from treatment time in weeks. If treatment time is 
13 weeks or over the patient is categorised as having over 3 
months of treatment (code=1). If a patient has less than 13 
weeks i.e. up to 12 weeks and 6 days, the patient is coded as 
having less than 3 months of treatment (code=0). 
Patient demographic 
Age group (under 
70 versus 70+) age_group 
Working 
variable NA Derived   
Age_group=0 if age at diagnosis is 70 years or less and Age 
group =1 if age at diagnosis is over 70 
Patient demographic SCOT eligibility SCOTelig 
Working 
variable NA Derived 
QPI and 
Chemocare 
Patients were deemed “SCOT eligible” if they had stage II 
disease with high risk features or stage III CRC and 
commenced treatment with fluoropyrimidine-oxaliplatin 
doublet chemotherapy within 11 weeks of major CRC 
surgery. SCOT ineligible=0, SCOT eligible=1. 
Disease information 
Duke's stage (QPI 
raw) 
dukes_original (in raw 
database called dukes) 
Working 
variable NA raw QPI   
Disease information 
Duke's stage (QPI 
raw) dukes 
Working 
variable NA derived QPI 
Original variable renamed dukes_original. Dukes convered 
to a byte variable with the following labels:  1 ="Dukes A" 2 
="Dukes B" 3= "Dukes C1" 4 ="Dukes C2" 5= "Dukes 
D" 96= "Not applicable" 99 ="Not recorded" 
Disease information 
Colorectal stage 
derived from QPI 
TNM dukes_derived_qpi 
Cohort 
Definition 2 and 3 Derived QPI 
Colorectal stage derived from TNM staging. 1 ="Dukes A" 2 
="Dukes B" =3 "Dukes C" 
4 ="Dukes D". When this information is missing, it is derived 
directly from the "dukes" variable (TNM assumed to be 
more reliable than raw dukes).  
Disease information T-stage (raw) 
finalt_original (called 
finalt in raw database) 
Working 
variable NA raw QPI NA 
Disease information T-stage (derived) finalt 
Working 
variable NA derived QPI 
Original variable renamed finalt_original. Finalt converted to 
a byte variable with the following labels: 1=T0, 2=T1, 3=T2, 
4=T3, 5=T4, 6=T4a, 7=T4b, 8=Tx, 9=Tis, 96=not applicable, 
99=not recorded (including missing) 
Disease information N-stage (raw) 
finaln_original (called 
finaln in raw database) 
Working 
variable NA raw QPI NA 
Disease information N-stage (derived) finaln 
Working 
variable NA Derived QPI 
Original variable renamed finaln_original. Finaln converted 
to a byte variable with the following labels: 1=N0, 2=N1, 
3=N1a, 4=N1b, 5=N1c, 6=N2, 7=N2a, 8=N2b, 9=NX, 96=not 
applicable, 99=not recorded (including missing) 
Disease information M-stage (raw) finalm_original 
Working 




Disease information M-stage (derived) finalm 
Working 
variable NA Derived QPI 
Original variable renamed finalm_original. Finalm converted 
to a byte variable with the following labels: 1=M0, 2=M1, 
3=M1a, 4=M1b, 5=M1c, 6=Mx, 96=not applicable, 99=not 
recorded (including missing) 
Disease information     
Working 










variable NA Derived SMR06 
Original variable (stage_colorectal) converted to a numerical 











variable NA Derived SMR06 
Derived from stage_clinical_t. 1=1/1a/1b/1b/1m/is. 











variable NA Derived SMR06 
Derived from stage_clinical_n. 0=0, 1=1/1a/1b/1b/1m/is. 










variable NA Derived SMR06 




stage (raw) stage_pathologic_t 
Working 
variable NA raw SMR06 NA 
Disease information 
Pathological T-
stage (derived) path_stage_t 
Working 
variable NA Derived SMR06 
Derived from stage_pathologic_t. 1=1/1a/1b/1b/1m/is. 




stage (raw) stage_pathologic_n 
Working 
variable NA raw SMR06   
Disease information 
Pathological N-
stage (derived) path_stage_n 
Working 
variable NA Derived SMR06 
Derived from stage_pathologic_n. 0=0, 




stage (raw) stage_pathologic_m 
Working 
variable NA raw SMR06   
Disease information 
Pathological M-
stage (derived) path_stage_m 
Working 
variable NA Derived SMR06 





Disease information Final T-stage finalt_SMR 
Working 
variable NA Derived SMR06 
Clinical t stage (clinical_stage_t) used. When this is missing, 
path_stage_t used. Also, clinical_stage_t_replaced with 
path_stage_t if path_stage_t upgrades/worse grade than 
clinical staging.  
Disease information Final N-stage finaln_SMR 
Working 
variable NA Derived SMR06 
Clinical n stage (clinical_stage_n) used. When this is missing, 
path_stage_n used. Also, clinical_stage_t_replaced with 
path_stage_n if path_stage_n upgrades/worse grade than 
clinical staging.  
Disease information Final M-stage finalm_SMR 
Working 
variable NA Derived SMR06 
Clinical m stage (clinical_stage_m) used. When this is 
missing, path_stage_m used. Also, 
clinical_stage_m_replaced with path_stage_m if 





variable NA Derived SMR06 






Definition 2 and 3 Derived SMR06 
Overall stage derived from SMR. Derived TNM stage 
(stage_derived) used as baseline. If this information is 
missing, dukes_derived fills in the missing variables.  
Disease information TNM T stage finalt_cohort 
Working 
variable NA Derived 
SMR06 & 
QPI 
Used to specify extended risk stage. TNM staging from QPI 
used.  1=finalt1/2/9, 2=finalt3, 3=finalt4, 4=finalt5/6/7, 
9=finalt5/96/99. Any missing variables in QPI replaced if 
SMR06 not missing. 
Disease information TNM N stage finaln_cohort 
Working 
variable NA Derived 
SMR06 & 
QPI 
Used to specify extended risk stage. TNM staging from QPI 









Figure 14-15 OS Kaplan-Meier curve by risk stage 
 





Figure 14-17 OS Kaplan-Meier curve by SCOT eligibility 
 





Figure 14-19 OS Kaplan-Meier curve by regimen 
 





Figure 14-21 OS Kaplan-Meier curve by age group 
 





Figure 14-23 OS Kaplan-Meier curve by disease site 
 





Figure 14-25 OS Kaplan-Meier curve by SIMD 
 





Figure 14-27 OS Kaplan-Meier curve by Charlson group 
 





Figure 14-29 OS Kaplan-Meier curve by location 
 





Figure 14-31 OS Kaplan-Meier curve by sex 
 
Figure 14-32 CRC Kaplan-Meier curve by sex 









































































































































































































































































































Figure 14-34 Plot of residuals for time series (national overall cohort) 
 







Figure 14-36 Plot of residuals for time series (national SCOT eligible cohort) 
 






Figure 14-38 Plot of residuals for time series (national SCOT ineligible cohort) 
 
Figure 14-39 Plot of partial residuals for time series (national SCOT ineligible cohort) 
 





Logistic regression overall 1.84 
Logistic regression SCOT eligible 1.50 





15 Appendix 6 Comparison of impact frameworks 
As discussed in Chapters 1 and 3, research impact frameworks can be used to 
structure data collection for impact evaluation, as well as communicating the 
results of an evaluation. Below, six different frameworks that were identified 
from a review of the literature (Chapter 3) are used to describe the impact of 
the SCOT trial. 
15.1 Payback framework 
A description of the payback framework was first published in in the 1990s (15). 
The framework consists of a modified logic model (see Figure 3-3) alongside a 
list of five impact categories (Figure 15-1). This was initially developed to 
evaluate health services research.  
 
Figure 15-1 Payback framework categories of impact.  Taken from (15) 
 
Stage 0: Topic/Issue Identification 
In the early 2000s it was known that adjuvant fluoropyrimidine-oxaliplatin 
doublet chemotherapy provided a survival benefit for patients with stage II and 
stage III colorectal cancer. The standard treatment was six months duration 




problem with this treatment was the high rate of toxicity, in particular 
peripheral neuropathy that accompanied this duration of therapy 
Interface A: Project specification and selection 
Professor Jim Cassidy (oncologist) and Mr Jim Paul (CTU statistician) at the 
University of Glasgow identified this was an issue and developed a clinical trial 
idea to explore this concept further. In the meantime, other clinicians and trial 
groups in a number of countries worldwide were also developing clinical trials to 
address this concern.  
Stage 1: Inputs to research  
The SCOT trial was developed by the University of Glasgow CTU. A successful 
funding application was made to the Medical Research Council and the trial was 
awarded £2.4 million in investment in 2006. A decision was made to open the 
SCOT trial in multiple centres and both in the UK and internationally. Other 
funding was invested from CRUK, NIHR, the Swedish Cancer Society and Interreg 
for the purposes of this trial.  
Stage 3: Research process 
The SCOT trial opened in 2008 and recruited patients until 2013. In total, 6,144 
patients registered for the trial, 6,088 were randomised and 6,065 provided 
consent for their data to be used.  
Stage 3: Primary outputs from research 
The SCOT trial findings met the pre-specified end-point showing that 3 months 
of treatment was non-inferior to 6 months of treatment for the overall trial 
population. Pre-planned subgroup analysis showed that there was an unexpected 
differences in outcome depending on the regimen selected by the treating 
physician. A post-hoc analysis showed differences in outcome for stage III 
patients dependent on the size of the tumour and nodal involvement.  




The dissemination of the SCOT trial findings provide examples of the first 
payback in the framework, “knowledge”. The findings were initially 
disseminated in June 2017 at the ASCO conference by Professor Tim Iveson, the 
trial principal investigator. The results were also discussed at the ESMO 
conference in September 2017 and published in full in the Lancet Oncology in 
April 2018. Results to patients specifically with high-risk stage II disease were 
presented separately at ESMO 2018. The SCOT trial was the largest contributor 
to the International Duration of Adjuvant treatment (IDEA) collaboration and 
these collaboration results were disseminated initially at ASCO 2017 and ESMO 
2017. The full publication of primary results was published in the New England 
Journal of Medicine in March 2018. Results for high-risk stage II patients were 
presented at ASCO 2019, ESMO 2019 and published in full in the Journal of 
Clinical Oncology in December 2020. Finally, overall survival results for IDEA 
were disseminated at ASCO 2020 and published in full in the Lancet Oncology in 
November 2020.  
Stage 4: Secondary outputs: policy making/product development 
This stage overlaps with category three, benefits from informing policy and 
product development. The main impact on policy from the SCOT trial has been 
on clinical guidelines from medical professional bodies. The survey undertaken 
for this thesis (Chapter 5) outlined which guidelines clinicians use in practice. 
Out of this list of guidelines, the NICE guidelines, Japanese and NCCN guidelines 
have been updated since the dissemination of the SCOT trial and IDEA 
collaboration findings and have specifically cited one or both of these trial 
findings as the basis for their recommendations.  
Stage 5: Adoption by practitioners and public 
The results of the survey (Chapter 5) and real world prescribing data analysis 
(Chapters 7 and 8) have demonstrated that the SCOT trial findings have been 
adopted into practice by clinicians.  




It is predicted that the practice change outlined above will lead to health 
benefits for patients who will experience less toxicity from a shorter duration of 
treatment. There are also cost benefits from the perspective of the healthcare 
services providing this treatment.  
Stock or reservoir of knowledge 
The impact of this trial must be evaluated in the context of other knowledge. 
For example, the results of the SCOT trial will be adopted and used within the 
context of the finding of the IDEA collaboration and each of the other five trials 
that contributed. The SCOT trial findings will build on previous knowledge from 
clinical trials conducted prior to SCOT (Chapter 1).  
Categories of impact 
Using the list of categories of payback, those not picked up by using the logic 
model include: 
Better targeting of future research: The results of the SCOT trial will impact on 
future clinical trials investigating chemotherapy in the neoadjuvant or adjuvant 
setting. For example, the UK based POLEM trial has used 3 months of CAPOX as 
its standard adjuvant arm (336). Also, there is a major parallel work stream of 
translational work (TransSCOT) currently in progress using translational samples 
collected from patients in the SCOT trial (260). 
Staff development and educational benefits: This PhD is using patient level data 
from the SCOT trial and has provided the opportunity for further research in this 
context. Individual patient level data is being used for the purposes of 
contributing to a separate higher degree (OCTOPUS project, University of 
Manchester (349)). Specifically related to health economics, anonymised patient 
level data is being used as a teaching resource on an educational course at the 
University of Glasgow.  
Economic benefits from a healthy workforce and reduction in working days lost: 
As described in Chapter 6, if the SCOT trial findings are implemented and 




patients will return to work sooner, providing significant monetary benefits at a 
societal level.  
15.2 Research utilisation ladder 
This framework focuses on the utilisation of research results by decision makers 
and others in society and aligns with “user” focused definitions of research 
impact (see Chapter 1). The utilisation of research is considered a process 
consisting of several stages. In their article describing the research utilisation 
ladder, Landry et al (204) created a modified version of Knott and Wildavsky’s 
scale (1980) of research utilisation (image below) and used this scale to assess 
the impact of social science research. In their study, the scale is used to survey 
over 2,000 social science researchers regarding how they self-assess their 
research is used in practice. In the survey, the authors also collected details 
regarding the research in question and the action of the researchers to promote 
research use. A Likert scale was used to ask researchers of how well they rate 
the utilisation of their research and these results were converted into a binary, 
quantifiable result. Specifically, each rung on the ladder is assigned a zero score 
if the survey participant answers negatively on the Likert scale or a one score if 
the participant answers in a positive manner. The details collected regarding 
research and its use are used as co-variates in a regression model to predict 
which researchers/what type of research is likely to climb highest on the 
knowledge utilisation ladder and which stages/rungs of the ladder may present 
barriers to research impact. Below, this framework is applied to the SCOT trial 





Figure 15-2 Landry's ladder of knowledge utilisation  Taken from (204) 
 
Stage 1: Evidenced via conference presentations and publications of the SCOT 
trial results. (This would score 1).  
Stage 2: The survey reported in Chapter 5 shows that clinicians are aware of the 
SCOT trial findings. (This would score 1). 
Stage 3: The SCOT trial findings have been cited in the NICE guidelines and other 
professional guidelines internationally. (This would score 1). 
Stage 4: The survey results showed that practitioners were making efforts to use 
the SCOT trial results in their own practice. (This would score 1). 
Stage 5: Again, the survey in this thesis (Chapter 3) shows that the SCOT trial 
and IDEA collaboration did influence the practice change described by survey 
participants. (This would score 1). 
Stage 6: Both the survey (Chapter 3) and administrative database analysis 
(Chapter 6) demonstrate that the SCOT trial findings have changed practice. 




15.3 Research Impact Framework 
The Research Impact Framework (RIF) was developed by researchers (2006) at 
the London School of Hygiene and Tropical Medicine (LSHTM). These authors 
recognised that there was an increasing requirement for academics to describe 
the impact of the research they carry out, but that this usually performed on an 
ad hoc basis, making it difficult to learn from and to make comparisons between 
these evaluations. Their aim was to provide a framework specifically for health 
researchers who have had no training in impact evaluation, to enable them to 
evaluate the impact of their work.  
The authors developed their framework firstly by drawing on previous literature 
to identify four main areas of research impact that would form the basis of their 
framework. This information was used to develop an interview guide, which was 
subsequently used to question researchers at LSHTM regarding the impact of 
their work. Through these interviews the authors developed, alongside the 
primary researchers themselves, impact narratives around seven health services 
and policy research projects and around four more basic research projects from 
the performed by researchers at the departments of Epidemiological and Public 
Health and Infectious and Tropical Disease. They also conducted four case 
studies using secondary data such as reports and previous impact evaluations. 
Thematic analysis of interview transcripts was performed and the results were 
used to build the RIF. Specifically, 27 categories of impact were identified from 
the interview transcripts and other sources, grouped under four themes. In some 
instances, these categories were divided further into sub-categories, which 
represented more specific examples of impact or potential impact that may 
arise from health research. The four main themes were: research impact, policy 
impact, service impact and societal impact. This framework went through 
further iteration and validation through discussion with LSHTM researchers and 
by testing the framework using LSHTM researchers and research projects. A 
summary of the framework is provided below. The impact areas, categories and 





Figure 15-3 Five main impact areas included in the Research Impact Framework  Taken from 
(99) 
 
Description of research project/programme 
The topic area is research into adjuvant treatment for patients with colorectal 
cancer. The research under evaluation is a phase III multi-centre, international 
trial conducted in six countries. The budget to perform this research is outlined 
in Error! Reference source not found. Appendix 4.  
Research-related impact 
The problem that the SCOT trial addressed was the high level of toxicity, in 
particular neuropathy, from the previous standard duration of adjuvant 
chemotherapy given to patients with high risk stage II and stage III colorectal 
cancer. Due to the high incidence of CRC globally, thousands of patients were 
being treated with six months of treatment and experiencing toxicity each year. 
The research method used to investigate the merits of a shorter treatment 
duration was a large phase III clinical trial and the findings from this trial were 




Chapter 1). The SCOT trial contributed to a global research network (IDEA) and 
provided the opportunity for collaboration and pooling of results. Professor Jim 
Cassidy and laterally, Professor Tim Iveson were the chief investigators of this 
trial and both worked closely alongside the lead statistician Mr Jim Paul. The 
trial was developed and managed by the CRUK Glasgow Clinical Trials Unit.  
Policy impact 
The level of policy impact of the SCOT trial was local, national, and 
international and the type of policy was mainly clinical guidelines. Specifically, 
the SCOT trial has been cited in the 2020 NICE guidelines. The IDEA 
collaboration, to which it was the largest contributor, has been cited in 
Japanese and NCCN guidelines.  
Service impact 
The SCOT trial has impacted on the health service. As shown in Chapter 6, there 
has been a change in practice corresponding with the SCOT trial findings, leading 
to a reduction in the duration of adjuvant chemotherapy delivered. Chapter 6 
has demonstrated that shorter duration of treatment is a cost-effective strategy 
and that it will be cost-saving.  
Societal impact 
Although difficult to measure, it is expected that using shorter treatment in the 
adjuvant setting for CRC will benefit the health of patients by reducing the 
toxicity related to longer treatment, without significantly compromising survival 
outcomes. Macroeconomic impacts are likely to be seen at a societal level if 
patients given shorter treatment return to work, leisure and caring duties 
sooner. 
Specific categories/sub-categories relevant to the SCOT trial: 
Area Category Sub-category 
Research related 
impacts 
Type of problem/knowledge 
addressed 





    
Addressing research gaps and 
testing new hypotheses 
  Publications and papers Publications in scientific journals 
    Technical reports 
    
Citation of research publications 
by other researchers 
  
Research networks and user 
involvement   
  Research leadership   
  Communication 
Formal academic 
talks/presentations 
    Guidelines 
Policy Impact Level of policy making Local/National/International 
  Type of policy Guidelines 
  Nature of policy influence Instrumental 
Service Impacts Evidence based practice   
  
Cost-containment and cost-
effectiveness   
Societal impact Health status   
  
Macroeconomic/related to the 
economy Healthy workforce outcomes 
    Value of health gain 
 
15.4 Montague and Valentim (modified CAHS) 
Montaague and Valentim have described the development of a novel impact 
framework based on a combination of the Canadian Academy of Health Sciences 
(CAHS) framework and the Bennett and Rockwell theory of action. The CAHS 
framework was developed using the Payback framework and the five main 
impact categories of the CAHS closely align with those from the Payback model 
(Advancing knowledge, building capacity, informing decision-making, health 
impacts, and broad socio-economic impacts). The CAHS framework consists of a 
logic model and the five impact categories are populated with 60 impact 
indicators. A full report (2007) of who and how the CAHS framework was 
developed, alongside a full list of the indicators included is publicly available 
(21). 
Montague and Valentim suggest that there are challenges to using the CAHS 
framework in practice and that it is not straightforward to link impacts and tell 
a story of how impact has occurred. Recognising this challenge, they call on the 




from a chain of events. The authors apply the 60 indicators of impact from the 
CAHS framework to the seven stages in the Bennett hierarchy to produce a new 
framework to evaluate the impact of health research. Montague and Valentim 
apply their framework to evaluate the impact of a cancer trial. This work was 
commissioned by the Canadian Cancer Society, Canada’s largest health charity, 
which wanted to better evaluate the impact of their investments.  
The image below shows the chain of results (left hand column) along with typical 
indicators of impact corresponding to each stage in the theory of change (right 
hand column). A summary of the main indicators of SCOT trial impact according 
to these stages is provided in the table below. In addition, a diagram of these 
indicators of impact occurring over time is provided in line with the diagram 






Figure 15-4 Framework for research impact assessment.  Taken from (193) 






Indicator of impact 
7. End 
outcomes 
Measures of impact on 
overall problem, 
ultimate goals, side 
effects, social and 
economic 
consequences 
Chapter 6 shows that the trial findings have 
confirmed shorter treatment to be cost-effective 
in most situations. The budget impact analysis 
predicts the likely cost savings at the health 
service budget level if implementation occurs. 
Wider, society level economic impacts include the 
reduction in productivity loss due to an earlier 
return to work for patients who are treated with 




are likely to be affected at a population level, 
specifically a reduction in toxicity and longer- 




Measures of adoption 
of new practices and 
behaviour over time 
Review of real world prescriptions provide a 
robust indication of uptake of trial results 





Measures of individual 
and group changes in 
knowledge, abilities, 
skills and aspirations 
Again, the survey in Chapter 5 has captured this 
to some extent.  
4. Reactions What participants and 
clients say about the 
program, satisfaction, 
interest, strengths and 
weaknesses 
Clinician, patient, and policy maker reactions to 
the trial results. This can be demonstrated 
through formal publication of conference 
discussions and the survey such as the one 




The characteristics of 
program participants 
and clients, number, 
nature of involvement 
and background 
Dissemination of trial findings in the academic 




on what the program 
actually offers 
Running of the trial and the trial results.  
1. Inputs Resources expended, 
number and types of 
staff involved, time 
expended 
The financial and time investment by funders and 












Figure 15-5 Montague and Valentim's framework applied to the SCOT trial.  Adapted from (193) 









Other researchers use primary 
data and patient specimens 
(TransSCOT) to conduct 
further research 
Clinicians and patients become 
aware of and discuss trial 
results 
Clinicians use the 
results in practice 
Practice change leads to cost-
savings for the healthcare system 
and reduced toxicity for patients 
Results presented at 
conferences and published 
in journals 





15.5 Weiss’s logic model (modified United way 
framework) 
In his 2005 essay, Anthony Weiss raises a call to arms to medical researchers and 
funders to change the way the impact of medical research is evaluated. He 
argues for a shift away from an outputs based approach that focuses on 
publication counts and journal impact factors and a move to an outcomes based 
approach that evaluates how research brings us one step closer to the real goal 
for any medical research – to improve disease. He adapts a logic model 
described in a report by not for profit organisation United Way, which was 
developed in 1996 to better evaluate the impact of programs of work performed 
by human service, research and charitable institutions. Weiss adapts this logic 
model and applies it to medical research (image below) and describes ways in 
which impact at each level of the logic model could be evaluated and the 
challenges to impact occurring and its evaluation at each stage. In particular, 
Weiss highlights that a barrier to research impact often occurs between the 
publication of research results and the application of those results into practice, 
the “efficacy-effectiveness gap”. Although a simple model, this is still 
considered a type of impact framework. How this framework could be applied to 





Figure 15-6 Anthony Weiss's logic model Taken from (202) 
 
Inputs Project specific financial investment from funders, CTU investment, and 
input of time and effort from clinicians and patients enrolled in SCOT. 
Clinical research projects The SCOT trial is performed in six countries over 5 
years.  
Publications documenting results of science The results of the SCOT trial are 
first disseminated at ASCO 2017 and the full publication is in April 2018. Updated 
results were communicated at ASCO 2020 and the SCOT trial has contributed to 




Key clinical decision makers become aware of scientific evidence The survey 
results reported in Chapter 5 demonstrate that a large number of clinicians were 
aware of the SCOT trial results. It is impossible to know how representative this 
sample is of clinicians generally but the large number and resounding result 
regarding SCOT trial and IDEA collaboration awareness indicate that it is likely 
most clinicians working in this field will have some idea of the SCOT trial 
findings.  
Implementation of change in clinical practice based on evidence In his essay, 
Anthony Weiss suggests that one of the most robust ways to understand if 
research results are used in practice is to analyse real world prescribing records. 
The results in Chapter 8 demonstrate that it is highly likely the SCOT trial results 
influenced the duration of adjuvant chemotherapy given to patients in Scotland.  
Improvement in patient well-being (function) It can be hypothesised that with 
a proven reduction in treatment duration that the incidence of toxicity and side 
effects from treatment seen in the SCOT trial are likely to also be demonstrated 
in the real world setting. Also, the SCOT trial showed there was no clinically 
significant difference in survival outcomes between using six versus three 
months of treatment. Longer follow up data would be required to confirm if this 
was also the case in a real world setting. Also, better collection of toxicity and 
patient reported outcomes would be necessary to demonstrate if a 
corresponding reduction in harm from treatment occurred.  
15.6 Healthcare research impact matrix 
The final framework considered was that from Cruz-Riveria and colleagues 
(2018) from the Centre for Patient Reported Outcomes at the University of 
Birmingham. This matrix was developed by reviewing the existing literature to 
find examples of methodological frameworks and summarising the synthesising 
these frameworks and the impact metrics included within each framework. The 
structure of the matrix was based on frameworks including Payback (15), the RIF 
(203)and Anthony Weiss’s logic model (202). The final matrix is displayed below. 
The authors group their impact categories into temporal groups, short, mid and 
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 Re: Assessing the “real life” impact of the SCOT trial results in Scotland: Have 
prescribing practices changed after publication of this trial and if so at what rate 
have they changed? 
 
Thank you for your Caldicott application received on 17/07/2019 regarding your proposed 
Research Project.  
 
I have reviewed this application and can confirm that I am happy to approve this 
application on behalf of the Caldicott Guardian. 
 
Please note that this approval only covers access to NHSGGC patients. 
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